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ABSTRACT 
 
Identification of differential expressions of proteins in proteomic profiles of 
biological samples shows great potential as a valuable technique for the early diagnosis 
of various diseases. An important challenge in modern protein profiling approaches is to 
reduce the complexity of the samples by limiting the number of proteins that need to be 
evaluated for distinction in the expression between normal and deceased cells.  In this 
research, an affinity based approach for the enrichment of nucleotide and nucleoside 
binding proteins from a complex cell proteome has been developed. To achieve this goal, 
new N
6
-biotinylated-8-azido-adenosine probes (AdoRs) have been designed and 
synthesized to photolabel the nucleotide and nucleoside binding proteins. These probes 
contain a reactive group that forms a covalent bond with the target proteins, as well as a 
biotin tag for affinity enrichment using avidin chromatography. Further, a mass 
spectrometric protein profiling approach is employed to quantitatively identify small 
variations in expression of nucleoside and nucleotide binding proteins in samples of 
interest.  
Mouse neuroblastoma N18TG2 cell proteome has been used as a model system for 
the development of the LC-MS/MS based proteomic analysis of these affinity enriched 
protein fractions. Upon enrichment, the photolabeled proteome exhibited an 
approximately four-fold abundance of nucleoside and nucleotide binding proteins over
xi 
 
nonlabeled proteome. The approach was extended to compare the proteomic profiles of 
nucleotide and nucleoside binding proteins in cancerous (Hey) and non-cancerous (T-80) 
human ovarian cell proteome. Certain proteins that were not detected in cell lysate were 
also identified in labeled proteome, thereby demonstrating the strength of our approach in 
enriching low abundant proteins. 
To substantiate the qualitative analysis, we have employed the Stable Isotope 
Labeling in Amino Acid Cell Culture (SILAC) for the quantitative study of the protein 
expression in cancerous and non-cancerous human ovarian cells. A modest panel of 
proteins with differential expressions in these cell lines was identified, a few of which 
have been correlated to various forms of cancer. Vimentin, stress induced 
phosphoprotein-1, and heat shock protein 90 that were identified to have altered 
expressions in these cell lines are among some of the proteins associated with ovarian 
cancer. 
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CHAPTER 1 
INTRODUCTION 
 
One of the major goals of molecular biology is to explore how biological systems 
work. One of the approaches in this direction is to explore the connections between all 
the genes and proteins and establish biological pathways based on their products. 
Therefore, the isolation and characterization of individual genes and proteins from 
various biological sources in order to reduce the complex systems into individual 
components has been the major focus of the research over the last 50 years. This 
approach involves gathering information from individual components for complex 
system. With the great advancements in technology for larger scale investigations, the 
study of more complex systems such as the genome and proteome of a biological system 
has become feasible. It exhibits a potential for research in understanding the connections 
between individual components and link them to biological processes in a comprehensive 
manner. However, this all-inclusive approach is constantly challenged by the complexity 
of the biological systems and needs to be optimized for practical solutions.  
 
1.1. Global Approaches for Research in System Biology 
In the post-genomic era, a multitude of novel high-throughput technologies have 
been developed to accomplish the assessment of thousands of biological molecules at 
once. This has laid the foundation of various “-omics” platforms such as genomics, 
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epigenomics, transcriptomics, proteomics, and metabolomics.
1
 Figure 1.1 represents the 
link between various biomolecules and the corresponding “-omics” branch associated 
with their studies. 
The systems-level information provided by each “-omics” platform offers an 
unmatched insight into the complexity of a biological system and have immensely 
assisted scientiﬁc discoveries and their clinical applications over the past decade. The 
success of “-omics” boosted by bioinformatics, genome-sequencing, and high-throughput 
genome-wide experimentation have led to some characterization of most components of a 
substantial number of organisms. This success has shifted the focus of research from 
molecules to networks.
2
  
 
Figure 1.1: “-omics” Approaches for Cell Function Analysis 
With advances in experimental protocols cost for such experiments has decreased 
and scientists have applied multiple “-omics” platforms to investigate the same biological 
systems.
3,4
 These studies will be critically useful for biologists as molecular changes at 
numerous levels can potentially be evaluated simultaneously to move one step closer to 
the primary goals of “systems biology”, i.e. to understand how biological systems work 
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to create various phenotypes.
5,6 
The vast stratum of the heterogeneous biological 
information has been benefitted by the network information of interacting molecules for 
the interpretation of these multiple “-omics” datasets for its integration into a more 
complete and consistent representation. Advances in tandem mass spectrometry have 
been an important source to provide data for the integration of transcriptomics with 
quantitative proteomics data, where proteomics data can be a source for the information 
for the changes on the gene products as a consequence of the transcriptional changes.
7
 
With the introduction of the “-omics”, this approach has emerged as one of the 
dominant methods to evaluate the behavior of a system. The discovery of the new 
molecular mechanisms has evolved as a key goal of the top-down systems biology. It 
uses an interactive cycle which embraces generations of experimental data, subsequent 
data analysis and data integration to establish correlations between concentrations of 
molecules. The newly recognized correlation will lead to the hypotheses concerning co- 
and inter-regulation of groups of those molecules. These hypotheses envisage new 
associations, which can be further examined by new experiments or traditional 
biochemical analyses.
8
 The major strengths of top-down systems biology are that this 
approach is potentially complete (i.e. genome-wide) and it addresses the metabolome, 
ﬂuxome, transcriptome, and proteome.9 
Modern technologies which have potential to perform parallel analyses may 
provide prospects to identify distinguishing patterns (signatures or portraits) for the 
diagnosis of diseases like cardiovascular disease, Alzheimer’s disease, and different types 
of cancers. The omic-derived patterns can also serve as platforms to predict response to 
therapies and discover new biomarkers linked to the disease in question. The 
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identification of new biomarkers for the rapid mapping of uncharacterized genomes may 
prove clinically meaningful towards future diagnostics strategies, which could turn out to 
be the most significant outcome of the application of top-down system biology. 
  
1.2. Need for Alternative Approaches for Progress in Proteomics 
As an example of complexity faced in using a top-down system biology approach, 
the number of proteins in human proteome range in the low millions.
10,11,12
 Disparities as 
a result of environmental and biological factors like gender, age, weight, ethnicity, 
temperature, humidity, pulmonary infection, and certain allergens can affect these 
numbers greatly.
13
 Moreover, the range for proteins with relatively high-abundance and 
relatively low-abundance may vary by a factor of 10
21
 or more making the identification 
of changes in concentration of the individual proteins a major challenge.
14,15
 Various 
fractionation techniques dependent upon differences in structural and/or physical 
properties have been employed to reduce the complexity of human proteome sample.
16,17
  
In the field of proteomics, several well established procedures exist to resolve and 
analyze complex protein mixtures derived from biological samples. Moreover, the vibrant 
nature of the proteome creates a major challenge for the resolution of these changes. The 
field of activity based proteomics has evolved greatly in last two decades for the 
proteomic analysis of physiologically important protein targets. This approach centers 
around the enrichment of the distinct sets of proteins by making use of various tags for 
detection and isolation purposes.
18
 Activity based protein profiling (ABPP) which 
involves the isolation of certain families of proteins or enzymes from complex protein 
samples have been successfully used for such studies.
19,20
 The major advantage of the 
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ABPP is the specificity based on activity of a protein or enzyme, rather than its 
abundance in the samples to be tested.
21
 Mass spectrometry based proteomics analysis 
has significantly evolved in recent years to quantify small changes in samples of interest 
and to identify new biomarkers for early diagnosis of diseases. The ABPP methodology 
has evolved from the analysis of relatively small protein sets toward the comprehensive 
analysis of more complex protein samples in cells, tissues, or organisms.
22
 This new 
approach to proteomics is focused on the use of activity based probes (ABPs) as a means 
to tag, enrich and isolate distinct sets of proteins based on their enzymatic activity. Due to 
the enormous potential of integrative “-omics”, attempts to design experiments which can 
analyze the heterogeneous data have gained immense interest. These new technologies 
generate an extraordinary large amount of data and that poses a challenge to the analysis 
of the results. Thus the key to a successful application will depend on properly designed 
experiments, dependable statistical data analysis, and appropriate interpretation of the 
data. 
 
1.3. Motivation 
Proteins are vital components of living systems as they are involved in the 
metabolic pathways of cells. Hence, malfunctioning proteins can be linked to various 
human diseases. Detection of differences between proteomic profiles is essential in 
developing new diagnostic strategies for the early detection of disease or in identifying 
novel proteins targets for the development of new drugs for the treatment of disease.
23
  
However, the identification of differences between proteomic profiles from normal and 
diseased tissues (or cells) is a challenging task resulting both from the complexity of the 
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human proteome and the potential of relatively minor, but important, differences in 
profiles. Issues like differential mRNA splicing, proteolysis, and post-translational 
modifications serve to increase the complexity of the human proteome, which only 
increases the challenge in defining differences between proteomic profiles. The capability 
to identify increasingly smaller amounts of protein from ever more complex mixtures is a 
principal driving force in proteomics today.
22,23
 The major challenge for modern 
proteomic profiling approaches is to develop innovative strategies to maximize the use of 
the existing information and available technology for the diagnosis and treatment of 
various human diseases. The ultimate goal of the research detailed in this thesis was to 
design and implement a set of ABPP probes to address these challenges. My focus has 
been ABPP probes specifically targeted against proteins that bind the adenine nucleosides 
and nucleotides (collectively referred to as adenine ribose derivatives, AdoRs). 
A very large number of proteins in the human proteome bind to certain nucleic 
acids or cofactors comprised of nucleoside or nucleotides. Hence, the nucleic acid-
binding proteome potentially creates the leading domain for the development of various 
ABPP probes.
21
 Because of their metabolic centrality, the number of proteins and 
enzymes that would bind an AdoR is large and the defective expression of AdoR-binding 
proteins correlate to a number of human diseases including cancer, cardiovascular 
disease, obesity, and other metabolic defects.  Examples of the aberrant expression of 
various AdoR-binding proteins linked to physiological disorders are listed in Table 1.1. 
The hypothesis is that proteomic profiles of AdoR-binding proteins will yield new 
biomarkers for the study, early diagnosis, and assessment of diseases and report new 
targets for the development of novel therapeutics.  
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Table 1.1: Aberrant Expression of AdoR-Binding Proteins in Various Diseases 
AdoR-Binding Protein 
Expression 
Defects 
Disease 
Adenosine deaminase Decrease 
Severe combined 
immunodeficiency (SCID
24
) 
Adenosine deaminase Decrease Leukemia
25
 
Adenosine A2B receptor Increase Invasive breast cancer
26
 
Adenosine A3 receptor Increase Colon cancer
27
 
Adenylate kinase Increase Stomach cancer
28
 
AMP deaminase Increase Colon
 
cancer
29
 
ATP-dependent protein 
kinases 
Increase or 
Decrease 
Numerous cancers
30,31,32
 
CREB
e
 Complex Numerous cancers
33
 
ecto-5’-nucleotidase 
(CD73) 
Increase Numerous cancers
34,35
 
Ser/Thr kinase  Increase Numerous cancers
36,37
 
AMP-activated protein 
kinase (AMPK)  
Mutation Heart disease
38
 
DNA methyltransferase-
1 (SAM-dependent)  
Increase 
Schizophrenia and bipolar 
disorder
39
  
ATP-binding cassette 
(ABC) transporters  
Increase 
Multi-drug resistant cancer 
40
 
 
Methylthioadenosine 
phosphorylase 
Decrease Liver, pancreatic cancer 
Nucleoside diphosphate 
kinase (Nm23) 
Decrease Highly metastatic cancers
41
 
Phosphatidylinositol 3-
kinase (ATP-dependent) 
Increase Numerous cancers 
Poly(ADP-ribose) 
polymerase-1 (PARP-1) 
Increase or 
Decrease 
Numerous cancers
42
 
S-Adenosylmethionine 
decarboxylase
f
 
Increase Numerous cancers 
Acyl-CoA synthetase Increase 
Idiopathic dilated  
cardiomyopathy
43
 
Adenosine deaminase Decrease Heart failure 
Adenosine A2A receptor Decrease Heart failure 
Adenosine A2B receptor Decrease Heart failure 
Adenosine A3 receptor Decrease Heart failure 
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Adenylate kinase Decrease Heart failure 
Adenylyl cyclase Decrease Mycocardial infarction 
AMP-activated protein 
kinase (AMPK) 
Mutation Heart disease 
AMP deaminase Mutation Heart failure 
ATP-dependent protein 
kinases 
Increase 
Myocardial ischemia/Heart 
failure
44
 
Creatine kinase Decrease 
Myocardial ischemia/Heart 
failure 
Nucleoside diphosphate 
kinase 
Increase Cardiac hypertrophy
45
 
3-Phosphoglycerate 
kinase 
Decrease Heart failure 
S-Adenosylmethionine 
decarboxylase 
Increase Numerous cancers
46,47
 
 
1.4. Contributions of this Research 
The goal of this project is to develop ABPP probes targeted specifically against 
AdoR-binding proteins and then use our probes to extend the ABPP strategy to identify 
potential biomarkers in diseased biological samples. The overall research can be 
summarized as shown in Figure 1.2 and can be subdivided into three main objectives; 
synthesis of ABPP probe, optimization and validation of the use of AdoR probes against 
purified proteins and cell proteome (N18TG2 cells), and comparative analysis of proteome 
of interest using mass spectrometry. 
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Figure 1.2: Research Summary 
1.4.1. Design and Synthesis of a Series of Biotinylated Photoaffinity ABPP Probes 
Targeted Against AdoR-Dependent Proteins 
The biotinylated azido-AdoR analogs that can be covalently linked to the 
nucleotide binding proteins by exposure to UV light were synthesized and the resulting 
covalent protein-probe conjugates were isolated by avidin affinity chromatography. The 
AdoR probes are designed to include a photolabile azide moiety for the covalent 
attachment to the target AdoR-binding proteins upon UV irradiation. The covalent 
attachment is required to ensure the attachment of probe to the targeted family of proteins 
even after the removal of UV light. The probe also includes a biotin tag for the 
enrichment of the probe-protein conjugates using avidin affinity chromatography. The 
enrichment of the AdoR binding proteins is crucial to the detection and analysis of any 
change in their amounts as they may be present in very low abundance compared to other 
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cell proteins and may not be detected in the shadow of highly abundant proteins due to 
the limitations of the mass spectrometric instruments. The synthesis of the probe is 
designed so that extended linker lengths, varying positions of the photoactivatable moiety 
and slight modifications on modifiable 5’-group of ribose moiety can generate a panel of 
biotinylated azido-adeonsine analogs designed to profile proteomes for AdoR-dependent 
proteins. 
1.4.2. Optimization and Validation of the Use of AdoR-Specific Probes against a 
Set of Purified Proteins and Cell Proteome  
A number of proteins that bind AdoR are commercially available, one example 
being calf intestinal adenosine deaminase (cADA). As an intermediate proof-of-concept 
before exposing the ABPP probes to cell homogenates, labeling conditions were 
optimized and validated against purified cADA and other control proteins. Following the 
successful labeling of cADA with a synthesized ABPP probe, a series of AdoR-binding 
protein profiles from proteomes derived from mouse neuroblastoma N18TG2 cells, non-
cancerous ovarian cells (T80), and ovarian cancer cells (Hey) were generated. The 
analysis of treated proteome subjected to affinity chromatography, followed by SDS-
PAGE, and Western blotting of the ABPP labeled proteome using anti-biotin HRP 
conjugated antibody resulted in reproducible pattern of proteins in the labeled and non-
labeled fractions. 
1.4.3. Proteomic Profiling with the Mass Spectrometry for Qualitative and 
Quantitative Analysis  
The fractions from affinity chromatography from the mouse neuroblastoma 
N18TG2 cells, non-cancerous ovarian cells (T80), and ovarian cancer cells (Hey) were 
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subjected to mass spectrometry-based proteomic analysis for identifying the ABPP 
labeled proteome. The potential biomarkers were quantified and analyzed for the ovarian 
cell lines using Stable Isotope Labeling of Amino Acids in Cell Culture (SILAC) 
approach. 
 
1.5. Outline of the Dissertation 
The dissertation is organized into six chapters. In Chapter 2, the background for 
the synthesis of the probe, the identification of biomarkers, the evolution of the field of 
ABPP, proteomics, and various proteomic tools is explained in detail. The focus of 
Chapter 3 is the experimental design and data for the synthesis of adenine nucleoside 
analogs as activity based probes for AdoR-binding proteins. The proof-of-concept 
detailing our labeling of cADA and the analysis of probe-labeled cADA is outlined in 
Chapter 4.  The probe-based enrichment of AdoR-binding proteins from the whole cell 
extract of N18TG2 cells is also described in Chapter 4. The use of our AdoR probes for the 
comparative analysis of two ovarian cancer cell lines, T-80 cells (non-cancerous, human 
ovarian cells) and Hey cells (cancerous human ovarian cells), with emphasis on 
quantification of changes in proteomic profiles is detailed in Chapter 5. The concluding 
remarks about the success in identifying important biomarkers belonging to the AdoR-
binding proteome and an analysis of the future direction for the research described in this 
dissertation is contained within Chapter 6. 
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CHAPTER 2 
BACKGROUND AND RELATED WORK 
 
In this chapter, a brief introduction of the various concepts, techniques, and tools 
that are foundation for the research described in this dissertation are presented. 
Specifically, the overall concepts of biomarkers, activity based protein profiling, and 
proteomics that have been utilized in this research are discussed. Also, the various tools 
for proteomics analysis, including protein database search engines, and processing 
software are described. 
 
2.1. Biomarkers 
A biomarker is a molecular or biological characteristic that is an indicator of a 
biological condition. They can be independently measured and assessed in body fluids 
and tissues as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention.
1
 Biomarkers have an important 
role in explaining the link between exposure to environmental factors, the progress of 
chronic human diseases, and the detection of subgroups that are at increased risk for 
diseases.  Biomarkers are used in many scientific fields such as medicine, cell biology, 
genetics and toxicology etc. Biomarkers discovery can be largely classified into 
proteomics (for protein biomarkers), genomics (for mRNA, genes, and gene products), 
RNA profiling (for changes in RNA), or metabolomics (for small metabolites and other 
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small molecules). Universal characteristic changes in complex organ functions and in 
biological structures can also serve as biomarkers. Some very common examples of 
biomarkers that have been used in pre-clinical research and clinical diagnosis for a 
considerable time are body temperature which is a standard biomarker for fever, 
cholesterol values that serve as biomarker for coronary and vascular disease, and C-
reactive protein (CRP) as a biomarker for inflammation. 
Biomarkers can be categorized as disease biomarkers and toxicity biomarkers, 
which appear, disappear, or express changes in concentration in response to the presence 
and severity of a diseased state, and in response to drugs, respectively. Alternatively, the 
biomarkers can be classified as diagnostic biomarkers, prognostic biomarkers and 
predictive biomarkers. A diagnostic biomarker is used to detect a given disease in an 
individual. These markers are presumed to have high specificity and sensitivity. For 
example, the presence of Bence–Jones protein in urine remains one of the strongest 
diagnostic indicators of multiple myeloma.
2
 A prognostic biomarker is used to predict the 
likely course of the disease. It also helps in the prediction of the recurrence of the disease. 
Hence, detection of a prognostic biomarker dictates the pace of the therapy. As an 
example, in testicular teratoma, the levels of human chorionic gonadotropin
3
 and alfa-
fetoprotein
4
 can discriminate two groups with different survival rates. A predictive 
biomarker serves to envisage the response to a drug before treatment is started. These 
markers identify whether an individual would, or would not respond to a particular 
treatment. The array-type experiments have led to the prediction of clinical outcome from 
the molecular characteristics of a patient’s tumor using these biomarkers.5 
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Advancements in genomic and proteomic tools have led to an overwhelming 
number of DNAs, RNAs and proteins being identified as potential biomarkers under 
investigation. For instance, thousands of transcripts have been characterized from 
numerous samples using microarrays for finding the RNA-type biomarkers. The 454 
sequencing method,
6
 which is capable of conducting parallel sequencing for very large 
number of samples have led to the discovery of genetic markers.
7
 The discovery of these 
new biomarkers has postulated that a single-biomarker analysis is usually inadequate to 
conclude a particular condition. Hence, it is being substituted by multi-parametric 
analysis of genes and/or proteins.
5
 For example, the 70-gene-panel microarray study of 
survival prediction became the first multi-gene panel test to be approved by the FDA for 
predicting breast cancer relapse and led to the development of MammaPrint® (Agendia, 
Amsterdam, The Netherlands).
8
 An incredible growth in the application of gene-
expression profiling over the past decade, has led to understanding of pathogenesis and 
has contributed to the discovery of a large number of diagnostic markers.
9
 The 
progression in mass spectrometry and protein and DNA arrays technologies, as well as 
expansion in thorough understanding of the human genome have facilitated concurrent 
assessment of thousands of proteins and genes in single experiments, and has led to 
renewed interest in discovering novel biomarkers. 
Proteomic-pattern profiling is a recent and highly accepted approach to biomarker 
discovery. Figure 2.1 represents a sample proteomic profile for the appearance or 
disappearance of few proteins in diseased biological samples from various patients (1-5) 
as compared against the normal healthy sample (N). These changes in expression of 
certain proteins can serve as markers for the corresponding diseases. The rationale behind 
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the growing popularity of the proteomics approach over the genomics is that the mRNA 
information does not reveal the function of all proteins, which are the functional 
components within organisms. For example, complete information about the sub-
fractions of post translationally modified proteins structure and effect of factors like 
changes in pH on the binding properties of proteins cannot be derived from genomic data 
alone. The patterns of expression of the proteins can be assessed by mass spectrometry, 
and used in combination with mathematical algorithms for the diagnosis.
5
 Mass-
spectrometry-based methods of proteomic analysis have improved in recent years. The 
conversion to increased throughput and more-reliable data within complex biological 
samples such as tissues, serum, urine, plasma and body fluids have greatly exploited  the 
sophisticated technology for higher mass accuracy, higher sensitivity, and shorter cycling 
times.
10,11,12 
  
 
Figure 2.1: Protein Profiling Patterns to Demonstrate Changes in Composition of 
Constituent Proteins under Conditions of Stress or Disease 
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A potential biomarker of a disease can be defined as a protein molecule that 
possesses the following features.
13
 
 A biomarker is a protein whose expression depends on a particular pathological 
condition, and presence or absence or small variations in its relative abundance may 
be a sign of the disease. 
 A biomarker should serve as a parameter to reveal the severity of a disease and its 
progression stage. 
 A biomarker should be detectable in biological fluids such as urine, saliva, blood 
serum or in case of cancer, in the tissue from biopsy. 
 A biomarker should be easily detected with confidence in a relatively short time 
period from very small amount of samples, and the overall procedure should be 
inexpensive. 
 The expression of a biomarker should be comparable under a variety of conditions 
between the biological models during the time course. 
The primary focus of proteomics, and activity based protein profiling is to search 
for new biomarkers of a disease that can be used in clinical diagnosis.
14
 The aim of this 
research is to find such new biomarkers among the nucleotide binding proteins, for the 
early diagnosis of various types of cancers. 
 
2.2. Activity Based Protein Profiling 
Activity Based Protein Profiling (ABPP) is a powerful technique, which involves 
the use of activity and/or affinity-based probes (ABPs) to identify proteins in native 
biological systems, to study protein function on a proteome-wide scale. Figure 2.2 shows 
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a schematic representation of ABPP. One of the major strengths of the ABPP is its 
dependence on activity in contrast to the abundance of proteins in a complex proteome. It 
has been used to identify novel protein targets for the treatment of various diseases, the 
function of uncharacterized proteins,
15,16
 novel biomarkers, selective enzyme 
inhibitors,
17,18,19,20
 and “off-target” proteins for drugs.  
The foundation of the ABPP involves the application of chemical probes that can 
react with mechanistically-related classes of enzymes at the active site.
21
 Some common 
electrophiles and protein-reactive natural products have also been employed as activity-
based probes (ABPs).
22
 Generally, ABPP probes target a large, but convenient fraction of 
the enzyme proteome, which shares similar catalytic features. The size of the enzyme 
subset, however, can range from a few proteins to several hundred.
22
 A representative 
structure of an ABP is shown in Figure 2.2, as adapted from Cravatt et.al.
22
 
 
Figure 2.2: Activity Based Protein Profiling (ABPP) 
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The activity-based probes (ABPs) are normally small organic molecules to label a 
specific enzyme family, and are composed of the following components, as shown in 
Figure 2.3.  
1. A recognition unit which structurally and/or functionally resembles the natural 
substrate of the target enzyme family, and directs the ABP to the target enzymes. 
2. A reactive group that enables the irreversible covalent attachment of the probe to the 
enzyme at the active site. Azide and acetylenes are among the commonly used 
reactive groups used in ABPs.  
3. A tag that facilitates the detection and/or purification of the enzyme-probe conjugate. 
Some commonly used tags are fluorophores, radioactive labels, epitope tags, and 
biotin. 
4. A linker that chemically attaches the reactive group to the tag. 
The foundation of the ABPP lies in the coalition between the organic chemistry, 
and enzymology.
22, 23
 The inhibition of the serine hydrolases, cholinesterase 
chymotrypsin, and trypsin by diisopropyl ﬂuorophosphate, in the beginning of 1950s was 
instrumental for the design of ABPP probes.
24,25,26,27
 ABPP probes have been successfully 
employed to generate profiles of various enzyme classes including hydrolases,
28
 
proteases,
17, 28,29,30, 31
 metalloproteases,
30
  phosphatases,
32
 P450s,
33,34,35
 
glycosidases,
36,37,38
 oxidoreductases, and kinases.
39,40, 41
 Variations in ABPP design have 
evolved significantly in the past few decades to widen the utility of this strategy. One of 
the earliest applications of ABPP to proteomics was reported in 1970s by Stroming and 
group who conducted gel electrophoresis analysis on whole cells or membrane fractions 
using radiolabeled penicillin G for penicillin binding proteins (PBPs).
42,43,44
 These studies 
24 
 
were limited by the fact that information regarding the protein sequence and genomics 
could not be derived at that time. Earlier attempts to generate proteomic profiles of 
nucleotide-binding proteins have employed probes based on 5’-p-fluorosulfonylbenzoyl 
adenosine (FSBA), an affinity label for adenosine/adenylate-binding sites designed and 
extensively explored by Colman and coworkers.
41
  
 
Figure 2.3: Activity Based Probes (ABPs) 
The primary focus of this dissertation is an attempt towards the development of an 
ABPP approach to quantitatively identify the adenine nucleosides binding proteins, 
collectively referred to as adenine ribose derivatives, AdoRs, and families of related 
proteins that exist in their active state. Adenine nucleotides and nucleosides have a wide 
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range of functions in the cell. They are important in cell signaling pathways, DNA 
synthesis, and in the cellular energy balance. Adenosine is an endogenous purine 
nucleoside that modulates many physiological processes, and plays an important role in 
biochemical processes, such as energy transfer as adenosine triphosphate (ATP) and 
adenosine diphosphate (ADP) as well as in signal transduction as cyclic adenosine 
monophosphate (cAMP). Adenosine receptors are widely distributed throughout the body 
including the heart, central nervous system, lymphocytes, and kidneys, which undergoes 
cellular signaling involving adenosine. These cell signaling processes are mediated 
through binding interactions of adenosine with four known adenosine receptor subtypes 
A1, A2A, A2B, and A3.
45
 There are a large number of proteins that have binding 
interactions with adenosine analogs, and approximately 10% the human proteome binds 
to some form of adenosine containing cofactor. An estimated 60 ATP binding protein 
families including protein kinases, with structurally distinct binding motifs have been 
reported.
22, 46
  
Our approach involves an adenine nucleoside analogue to study proteomic 
profiles of AdoR-binding proteins using mass spectrometry. Earlier attempts to generate 
proteomic profiles of nucleotide-binding purified proteins have employed probes based 
on 5’-p-fluorosulfonylbenzoyl adenosine (FSBA), an affinity label for 
adenosine/adenylate-binding sites.
47,48
 The ﬂuorosulfonyl moiety of 5’-FSBA, is an 
electrophile that can react with nucleophilic amino acid residues with elimination of the 
ﬂuoride to form a covalent adduct that occupies, the position of the γ-phosphate of ATP.   
A new ABPP probe is designed with the modification of nucleoside base rather than 5’-
hydroxyl of the ribose, to curtail the proteome from cancer cells with enrichment of 
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adenine binding proteins. This would generate proteomic profiles of adenine binding 
proteins in closely related cells to identify new biomarkers.  
 
2.3. Proteomics for Biomarkers Discovery 
2.3.1. Relation between Genome and Proteome 
The proteome is the entire complement of proteins, which can vary with time and 
diverse necessities, or stresses that a cell or organism undergoes.
22, 49
 A proteome is much 
more complex than a genome as the number of protein coding genes in the human 
genome is fairly smaller than proteins in the human proteome.
50
 In other words, genome 
may be treated as “static” whereas the proteome is “dynamic”, and is subject to changes 
not only on the cell type but also on its surroundings at a particular time. Due to 
processes such as alternative mRNA splicing, RNA editing, and post-translational protein 
modifications, there is often no analytical relationship between mRNA abundances and 
the quantity of the corresponding functional protein present within a biological sample, 
the direct measurement of protein expression can more precisely point to cellular 
dysfunction underlying the progress of a disease. Thus, proteomics, the study of various 
proteomes is instrumental in characterizing cells and tissues of interest that cannot be 
completely illustrated by genome alone.
51,52
  
2.3.2. Proteomics 
Proteomics was established in early 1980s as a set of methodologies to resolve 
protein sequences on a large scale. The critical objective of proteomics is to explore each 
single protein through physiological processes, which is of great significance in 
understanding pathological states. Proteomic research is usually conducted by taking a 
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speciﬁc subset of proteins from two or more different biological systems (e.g., healthy 
cells and infected cells) in a comparative study. Conventionally, the protein subset of 
choice is isolated from the rest of the proteome, typically by one or two dimensional gel 
electrophoresis or immunoprecipitation, to determine the abundance levels.
53
 This 
approach has greatly progressed by the introduction of mass spectrometry (MS) 
instruments. 
Figure 2.4 shows a flowchart representation of proteomic analysis using mass 
spectrometry as adapted from Kocher and coworkers.
54
 This technology has evolved 
immensely with several disciplines, including ultra-sensitive methods for protein 
separation, bioinformatics, and spectroscopy being integrated for analysis of proteomes. 
In spite of great advancement in this technology, one of the major challenges in 
proteomics includes understanding the proteins function(s) and interaction of protein 
network(s).  
In the past few decades, proteomics has emerged as a tool to link between genes 
and proteins, and their functions. The long term objective is to find biomarkers of various 
diseases, leading to the design of new, more efficient, personalized therapies. The 
underlying principle behind the concept is that pathogenic mechanisms cause changes in 
protein expressions, and the profiles of the proteome from different stages of a disease 
may help provide a set of new targets for the treatment of these diseases. Proteomics can 
be applied to study the global changes in protein expression, also known as expression 
proteomics and to study the systematic protein–protein interactions through the isolation 
of protein complexes known as cell-map proteomics.
55
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Figure 2.4: Flowchart - Representation of Proteomic Analysis using Mass Spectrometry 
2.3.3. Classification of Proteomics Approaches 
Modern proteomics can broadly be classified into the following categories.
13
  
 Quantitative Proteomics: This branch of proteomics aims at simultaneous 
quantification (by mass spectrometry) of level differences between many proteins in 
different samples instead of the measurement of the absolute concentrations. Each 
protein and its pathophysiology is evaluated using various methods, with “normal” 
and “pathological” values analyzed using advance statistical analysis on large 
populations of controls and patients. These analyses are generally accompanied by 2D 
gel electrophoresis and western blot analysis to minimize any false positives. 
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 Structural Proteomics: This branch of proteomics aims at providing information 
necessary to understand the relationship between protein sequence, structure, 
mechanism of action and function. The primary significance of this technique lies in 
the fact that structural knowledge of protein domains responsible for biological 
activity is the initial point for the drug design. The most frequently used approaches 
involve X-ray crystallography, nuclear magnetic resonance spectrometry (NMR) and 
electron microscopy (EM). 
 Functional Proteomics: This branch of proteomics aims at identification and 
characterization of proteins to understand their role in biochemical reactions that 
control the functioning of cells and organisms. It focuses on the interactions of one 
protein with other proteins, nucleic acids and small molecules to reveal the regulatory 
mechanisms of biochemical pathways in conditions that most closely resemble the 
natural surroundings. 
 Clinical Proteomics: This branch of proteomics aims at early and more accurate 
diagnosis and administration of effective treatment for personalized treatment of a 
pathological condition. It is accomplished by diagnostics, and identification of new 
drugs and drug targets as well as vaccines for prevention of diseases. 
 Experimental Bioinformatics: It entails the design at the interface of experimental, 
and bioinformatics methods to generate new information from proteomics 
experiments. The combined genomic and proteomic advances have resulted in 
outburst of biological data. This field of science focuses on coordinating the 
interdisciplinary results with the sophistication of the automated systems to provide 
researchers the opportunity to avail the information in an insightful manner. 
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2.3.4. Tools for Proteomics Analysis 
In conventional proteomics approaches, complex protein samples are separated by 
isoelectric point and molecular weight using 2-dimensional gels. Although, the 2D gels 
can be employed to study the changes in protein expression patterns in given samples, 
they cannot be used to establish the identity of each individual protein which have shown 
differential expression. To ascertain which protein is changing, isolation of the individual 
protein spots, followed by proteolysis and analysis of the mass of each peptide by Matrix-
assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry is 
required. The measured peptide masses are searched against the predicted mass values for 
theoretical digestion of proteins in a sequence database, and the protein is identified by a 
statistically significant number of matches.
56,57,58,59
 Multidimensional Protein 
Identification Technology (MudPIT) created by the Yates laboratory abolishes gel 
separations.
60,61
 As an alternative to 2D gel separation, biochemical fractions containing 
many proteins are directly proteolyzed and the enormous number of peptides generated, 
are separated by 2-dimensional liquid chromatography before entering the mass 
spectrometer. This technique automates the analysis of even very complex samples such 
as whole cell lysates. Recent studies have identified 1,000 to 2,000 proteins in a single 
fraction with MudPIT. The procedure employs tandem mass spectrometry so that, after 
the mass of a peptide is measured, the peptide is fragmented using a collision-induced 
dissociation cell and the masses of the fragmentation products are determined. 
Considerable computational effort can typically transform this data into an amino acid 
sequence. Thus one peptide is often sufficient to identify a protein, a sensitivity 
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advantage that enables identification of minor proteins in a biological fraction that cannot 
be visualized on 2-dimensional gels.  
The statistical relevance of peptide identification is determined by calculating the 
probability that the tandem mass spectrum is a random match to a sequence of the same 
molecular weight in the database. Typically, the predicted fragmentation patterns from 
database sequences are compared to the observed tandem mass spectrum fragmentation 
pattern to determine how closely the sequence fits the spectrum. The probability of a 
random match is calculated based on the frequency of occurrence of fragment ions in the 
database. By using this approach, a statistical confidence is assigned to the match. The 
validity of the algorithm is supported by a number of studies that used MudPIT to 
identify proteins from nuclear envelope,
62
 heart compartments,
63
 red blood cell 
membrane,
64
 ovarian cancer cells,
65
 and others.
66
  
2.3.4.1. Database Search Engines 
A. SEQUEST 
SEQUEST® is a registered trademark of the University of Washington. Sequest 
identifies each tandem mass spectrum individually. This software evaluates protein 
sequences from a database to figure out the identified peptides that may be generated 
from a sample. The mass spectrum provides the peptide's intact mass which is used by 
Sequest for the information to establish the set of candidate peptides sequences. This can 
then be compared to the spectrum by including those peptides which are close to the mass 
of the observed peptide ion. For each candidate peptide, Sequest assigns a theoretical 
tandem mass spectrum, and matches these theoretical spectra to the tandem mass 
spectrum observed by the use of cross correlation. The candidate sequence with the best 
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matching theoretical tandem mass spectrum is reported as the best identification for this 
spectrum. 
B. MASCOT 
Mascot® is a registered trademark of Matrix Science Ltd.  
(http://www.matrixscience.com/search_intro.html). It integrates all of the proven 
methods of searching i.e. Peptide Mass Finger Print, sequence query, and MS/MS ion 
search. The experimental mass values and calculated peptide mass or fragment ion mass 
values obtained, are then compared by applying cleavage rules to the entries in a all-
inclusive primary sequence database. By application of a proper scoring algorithm, the 
closest match or matches are identified. If the "unknown" protein is present in the 
sequence database, it is pulled out for a precise entry. If the sequence of the unknown 
protein is absent in the database, the entries for equivalent proteins from connected 
species with closest homology are considered for an entry. 
C. X! TANDEM 
X! Tandem is an open source software that can match tandem mass spectra with 
peptide sequences for protein identification. All X! Series search engines are employed to 
calculate statistical confidence (expectation values) for all of the individual spectrum-to-
sequence assignments. It involves the reassembly of all of the peptide assignments in a 
data set onto the recognized protein sequences for assigning the statistical confidence. 
The aim is to establish that the assembly and alignment is non-random. Therefore, there 
is often no need for separate assembly and statistical analysis software, such as 
PeptideProphet and ProteinProphet. 
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2.3.4.2. Database Processing Softwares 
A. SCAFFOLD 
Scaffold is a proteomic software/tool designed to confidently identify proteins in 
biological samples. Using output from SEQUEST, Mascot, or X! Tandem, Scaffold 
validates, organizes, and interprets mass spectrometry data. This can be utilized to easily 
manage large amounts of data, compare samples, and search for protein modifications.  
Scaffold offers both a high-level overview of the results and a detailed look at supporting 
data, facilitating both top-down and bottom-up analysis. 
B. MAXQUANT 
MaxQuant is a quantitative proteomics software package designed for analyzing 
large mass spectrometric data sets. It is specifically aimed at high-resolution mass 
spectrometry (MS) data. Currently, Thermo LTQ-Orbitrap and LTQ-FT-ICR instruments 
are supported and Mascot is used as a search engine. Mann and coworkers have 
explained the step-by-step protocol for using MaxQuant on stable isotope labeling by 
amino acids in cell culture (SILAC) data obtained with double or triple labeling.
67
 
MaxQuant is used to automatically assemble a matrix of SILAC ratios with rows 
corresponding to proteins and columns to different 'samples' or 'conditions' facilitating 
cross-experiment comparison of protein ratios. Thus, for the most part it is preferable to 
evaluate data from different samples together in one MaxQuant project which facilitate 
comparison of quantitative information directly, and for reliable control of protein false 
discovery rate (FDR).
67
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CHAPTER 3 
SYNTHESIS OF THE PHOTOAFFINITY PROBE 
 
The first step in the enrichment of the adenosine binding proteome using ABPP is 
to outline the structure of the photoaffinity labeling probe. This chapter describes the 
earlier use of AdoR probes in proteomic applications and the concepts that were 
considered for the design and synthesis of the probe. 
 
3.1. Fuzzy Recognition of Ligand Binding Sites 
The protein-ligand interactions for specific proteins may drastically alter due to 
certain modifications involving hydrogen bonding atoms on purine base, as suggested by 
some studies.
1,2,3
 However, an elaborate study of adenosine with protein complexes it has 
been shown that the hydrogen-bonding is not critical.
4
 As demonstrated in a study of 
protein-adenylate complexes by Moodie and Co.
4,5
, there are no conserved hydrogen 
binding patterns for recognition of adenine. This concept of fuzzy recognition can be 
explained in terms of steric and electrostatic conditions of a ligand which can be fulfilled 
by many different arrays of the protein residues.
4
 It is believed that a common local motif 
for the adenine binding sites exist among the proteins with different folds.
6,7 
Based on the 
structural analysis of atomic interactions between the purine base of ATP and proteins, it 
has been demonstrated that a large structural diversity subsist for purine base detection.
8
 
Proteins with entirely different folds may take up similar recognition for binding 
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substrates.
6,7,9,5
 This concept of fuzzy structural motifs have been reinforced by many 
studies in various protein ligand complexes.
10,11
  
It can be envisioned from these studies that modifications on the adenine moiety 
do not necessarily disrupt all binding interactions with the target proteins. Hence, 
substituents on the purine base may possibly recruit different subclasses of proteins. 
From these studies, it can be postulated that adenosine analogs modified at the purine 
base can be used as a tool to search for nucleotide binding proteins in a large proteome. 
The proteome enriched in nucleotide binding proteins can then be analyzed to identify 
protein profiling patterns of nucleotide binding proteins which may otherwise be difficult 
to detect. With these concepts in mind, we have developed our AdoR probes for 
photolabeling of adenosine binding proteome. 
 
3.2. Applications of Adenosine Analogs  
Changes in binding interactions of adenosine to adenosine receptors and 
adenosine binding proteins can be introduced by small modifications in the adenosine 
structure. Not surprisingly, adenosine analogs with modified structure have abundance of 
literature evidences.
12,13
 Adenosine analogs have a broad range of interesting biological 
activities with an immense potential for therapeutic applications.
14
 A large variety of 
possible substituents in adenosine analogs improved their selectivity and specificity 
towards their main biological targets and therefore have been comprehensively explored 
for a number of therapeutic applications. For example, adenosine analogs containing N
6
-
bicyclo substituents have been reported to be potent and selective A1 adenosine receptor 
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agonists.
15,16
 Another example includes a N
6
-, C2- and 5’-modified adenosine analogs as 
A3 adenosine receptor agonist.
17
  
 
3.3. Adenosine Analogs as ABPP Probes 
The ATP analogs have been successfully used to probe nucleoside triphosphate 
binding sites of a wide variety of proteins, including protein kinases, ATPases, 
cytoskeletal proteins, and enzymes involved in polynucleotide synthesis and repair.
18
 For 
example, 5'-p-fluorosulfonylbenzoyladenosine (FSBA) and 8-azidoadenosine 5'-
monophosphate (N3-AMP) has been used as affinity labels to analyze the feedback 
control for amidotransferase in E. coli by targeting the purine nucleotide sites,
19,20
 
diazirine containing adenosine triphosphate probe has been used to detect tropomysin 
inside the actomyosin complex,
21
 N
6
-(6-bromoacetamidohexyl)-AMP·PCP has been used 
as affinity label for glyceraldehyde-3-phosphate dehydrogenase and myokinase,
22
 8-azido 
adenosine monophosphate analogos have been used for photoaffinity labeling of protein 
kinase from bovine brain,
23
 fructose-1,6- bisphosphatase,
24
 and rubisco activase.
25,26 
Figure 3.1 represents some adenosine derivatives that have been employed in affinity 
labeling of nucleoside binding proteins. 
Roberta Colman and coworkers have been greatly involved in generating a large 
selection of chemical tools for the analysis of nucleotide-binding proteins.
19,27,28,29,30
 
These probes usually contained one photolytic, alkylating or acylating groups.
30
  The 
reported nucleotide-based afﬁnity labels have been more or less divided into three 
categories based on the position of the incorporated labeling group:
31
 
a) modiﬁcations on the nucleoside base,  
44 
 
b) modiﬁcations of the 5’-hydroxyl of the ribose, and  
c) other modiﬁcations of the ribose moeity. 
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Figure 3.1: Structure of Various Affinity Probes for ATP Binding Proteins 
 
One of the earliest nucleotide probe that has emerged from these efforts for 
incorporation of the labeling moiety on the 5’-hydroxyl is 5’-p-ﬂuorosulfonylbenzoyl 
adenosine (5’-FSBA)19,31 with the structure shown in Figure 3.1. The ﬂuorosulfonyl 
moiety of 5’-FSBA is an electrophile that reacts with nucleophilic amino acid residues to 
form a covalent adduct occupying the position of the γ-phosphate of ATP.19 Thus, a 
speciﬁc reaction with the lysine amino groups in protein kinases is possible. 5’-FSBA 
reacts with a variety of nucleotide-binding proteins by sulfonylation of predominantly 
lysine amino groups and tyrosine hydroxyls.
31
 Although, 5’-FSBA has been successfully 
employed for photolabeling of nucleotide-binding proteins, the molecule lacks a clear-cut 
site for attaching a reporter tag such as biotin, often needed for the target enrichment and 
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identiﬁcation from proteomes.31 Recently, 5’-FSBA has been employed as a LC/MS 
based proteomic tool for kinase profiling such as ALK5, CDK2
32,33,34
 and Fn3K-related 
proteins
35
 in order to map peptide labeling sites and to identify physiological substrates of 
a Drosophila p-21 activated kinase.
36
 
Although, FSBA is typically used for individual proteins, a few proteome-wide 
approaches have been recently described. Moore and coworkers
37
 have demonstrated the 
application of FSBA and FSBG as chemical probes in the identification of nucleotide 
binding proteins in cell proteomes. They identified 14 FSBA-modified proteins in 
proteomic analysis of human DG75 B cells, human Jurkat T cells and Lck-deficient 
Jurkat T cells (JCaM1). The majority of the proteins were chaperones, kinases and other 
ATP binding proteins. In another application of FSBA as an activity based probe for 
purine nucleotide binding sites in human Jurkat cells, 185 FSBA-labeled sites were 
identified for sulfonylbenzoyladenosine (SBA) modified peptides.
38
 A synthetic ATP 
analog, 5'-rho-fluorosulfonylbenzoylad-enosine (FSBA) has been recently used as an 
affinity/activity-based probe for nucleotide-binding sites on a proteome-wide scale in 
human Jurkat cells.
38
 Though, affinity labels modified at the 5’-hydroxyl of the ribose 
have been employed to target nucleotide binding proteins on a proteome-wide scale, to 
the best of our knowledge the nucleoside base modified affinity labels have not been 
explored in this domain. Due to extensive involvement of purine nucleotide binding 
proteins in varied biological processes, discrete subsets of nucleotide binding proteins can 
serve a more comprehensive analysis of cell proteome. This dissertation aims at the 
attempts to use nucleoside base modified affinity labels for enrichment of nucleotide 
binding proteome. 
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3.4. General Synthetic Protocols for Adenosine Analogs  
Most common modification in adenosine analogs that are responsible for the 
inhibition of diverse adenosine receptors are typically in the N
6
-, C8- and 5’-positions. 
Preparation of the N
6
-substituted adenosines generally involves SNAr processes, starting 
from purine derivatives bearing a leaving group such as an alkyl sulfonyl,
39
 an 
imidazolyl,
40,41
 a sulfone,
41
 an activated phenoxy,
42
  or a halogen in the 6-position. 
Substitution of the 6-halopurine is the most popular method to synthesize N
6
-substituted 
adenosine derivatives.
43,44,45,46
 Another approach to synthesize N
6
-substituted adenosine 
involves mono- and di-alkylations of the 6-amino group of the adenosine.  N
6
-
monoalkyladenosine derivatives have been prepared by reductive alkylation with 
aldehyde and sodium cyano-borohydride in aceteic acid.
47,48
 Alkyl bromides in presence 
of a strong base have also been employed to generate series of mono- and di-alkylated 
adenosine analogs.
48,49
  Recently, an efficient synthesis of N
6
-substituted adenosine and 
2’-deoxyadenosine from corresponding inosine using 1H-benzotriazol-1-yloxy-
tris(dimethylamino) phosphonium hexafluorophosphate (BOP) and Hunigs base was 
reported.
50
 The reaction proceeds via the formation of an intermediate phosphonium salt 
and was found to be highly compatible with various functional groups. 
Similarly, C8-substitution is commonly carried out starting from C8-bromopurines, 
and C8-chloropurines which are reacted with heteronucleophiles via nucleophilic 
substitution reactions. Although this chemistry proved to be reliable, the selective 
introduction of two different substituents in positions N
6
 and C8 constitute a major 
challenge in the synthesis of these adenosine analogs. 
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3.5. Design and Synthesis of N6-Biotinylated-8-azido Adenosine  
Due to the important role of adenosine in biological processes, one of the main 
objectives is to design and synthesize activity-based profiling reagents 1a and 1b shown 
in Figure 3.2 for the identification of AdoR-binding proteins and to use these probes to 
profile AdoR-binding proteins in cancer-related proteomes. The aberrant expression of 
individual AdoR-binding proteins has been linked to a number of cancers and other 
human diseases. In initial studies, the 2’ and 3’ hydroxyls of ribose moiety in probe 1a 
were protected in order to confine the number of proteins that can bind AdoRs. The 
results from proteomic profiling of with probes 1a and 1b were compared to evaluate the 
effect of the hydroxyl groups of the ribose. The overall design of these AdoR probes 
includes the following components: 
1. Reactive group: a photolabile azide which generate an electrophilic nitrene upon UV 
irradiation for covalent attachment of the probe to the target proteins  
2. Tag: a biotin group for the detection and isolation of probe-protein conjugates using 
anti-biotin antibody and avidin affinity chromatography 
3. Binding group: an adenosine ring that provides selectivity towards proteins with a 
binding pocket for adenosine (expected to be AdoR dependent proteins) 
4. Linker: 1,6-diaminohexane that links the AdoR moiety to the biotin tag 
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Figure 3.2: Design of the ABPP Photoaffinity Probe 
 
For the success of the underlined study, the synthesis of adenine analogs has to be 
relatively straightforward and flexible. The primary design of the probe includes an azide 
group on the purine ring at position C8 and the biotin tag at position N
6
 attached in such a 
way that it does not drastically alter the binding properties of the purine to its target 
proteins (Figure 3.2). Therefore, the 8-azido derivative was synthesized with the biotin 
tag on the N
6
- position of the purine ring connected through a carbon chain linker. For the 
synthesis of compounds 1a and 1b, multiple synthetic approaches have been developed. 
3.5.1. Initial Synthetic Approaches 
The first synthetic approach involved the introduction of the N
6
-modification 
followed by a C8-modification as shown in scheme 1 of Figure 3.3. The three hydroxyl 
groups of the inosine were protected using acetic anhydride and DMAP in anhydrous 
dichloromethane to give triacetyl derivative 2 in 95% yield. Next, following a reported 
procedure, compound 2 was then converted to 6-chloropurine 3 with thionyl chloride.
51
  
N-boc-1,6-hexanediamine was used to substitute the C6-chloro group to yield compound  
4 in 62%yield. Compound 4 was also synthesized by a one-step synthesis utilizing BOP 
49 
 
according to a literature procedure reported by Wan et.al resulting in 74% yield.
50
 All 
attempts to brominate compound 4 in C8-position using Br2/AcONa/AcOH, N-
bromosuccinimide, and Br2/Na2HPO4/H2O did not provide the desired product 7a. As 
inferred by 
1
H NMR, the bromination caused the partial loss of the ribose moiety. 
Unfortunately, all attempts in which the N
6
-linker has been introduced prior to the C8- 
bromination step were unsuccessful due to the poor yields and difficult purification 
procedures. 
As an alternative route to synthesize 8-azido-N
6
-biotinylated adenosine, the order 
of the substitution at positions N
6
 and C8 was reversed. This approach involved the 
azidation at the C8-position followed by the N
6
-modification as shown in scheme 2 of 
Figure 3.3. The triacetyl derivative 2 was first brominated at C8-position using a 
saturated bromine solution in 10% sodium phosphate to give 5 in 93% yield.
52
 Then, the 
bromo in C8-position was substituted by an azido group to give 6 in 78% yield. All the 
attempts to convert compound 5 or 6 to N
6
-substituted adenosine analogs 7a or 7b 
respectively were not practical. As followed by LCMS, the reaction of 5 with BOP did 
not resulted in the desired product whereas the reaction of 6 provide product in <10%  
yield for the desired product 7b. A number of approaches to improve the overall yield by 
the use of different solvent systems and variations in temperature met with very little 
success. 
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Figure 3.3: Initial Synthetic Approaches 
 
 
51 
 
3.5.2. Final Synthetic Approach 
One of the synthetic challenges towards the preparation of the desired probes 1a 
and 1b was the introduction of the azido group in the base. In previous literature reports, 
various synthetic protocols for this transformation have been reported for close analogs of 
adenosine, nevertheless the majority of these 8-azido-adenosine analogs have not been 
further modified. For the preparation of compounds 1a and 1b, however, follow-up 
reactions to introduce the linker-biotin moiety did not work without an unwanted reaction 
with the azide in C8-position. In order to secure the amounts of probes 1a and 1b 
required for the bioanalytical experiments, a synthetic route was envisioned using 
combinations of the transformations which have been shown in the first two synthetic 
approaches to be reliable. Figure 3.4 represents the synthetic scheme employed for 
successful synthesis of probes 1a and 1b. 
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Figure 3.4: Final Synthetic Approach 
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The C8-bromo derivative 5 was first converted to the 6,8-dichloro derivative 8 in 
93% yield using thionyl chloride under reflux conditions.
53
 The C6-position of the 
dichloro compound 8 was then selectively substituted with mono-N-Boc-1,6-
diaminohexane at -10˚C to give 9 in 66% yield. A small amount of product in which the 
substitution occured in C8-positon, has also been observed by LC-MS analysis. For the 
azidation of the C8-chloro, the reaction was tried with sodium azide, trimethylsilylazide 
and cesium azide (upto 10 equivalents). The reaction gave best results when refluxed 
with a combination of cesium azide and trimethylsilyl azide in dioxane to provide 
compound 10 in 79% isolated yield.  To avoid issues during the purification, the progress 
of the azidation reaction was carefully monitored by LC-MS until the chloro derivative 9 
was completely consumed. 
The assignment of the site of the amino substitution was based on the comparison 
of 10 to the product 7b formed via BOP coupling conditions both by NMR and HPLC 
analysis. The structure of the intermediate 10 was identical to compound 7b. The overall 
yield for the synthesis was higher and purification was more efficient in this approach 
and hence this scheme was implemented for preparing the probes. 
The N-Boc group was deprotected using trifluoro acectic acid to give amine 11 
which was then coupled without purification with biotin using EDCI/DMAP coupling 
conditions to yield the desired N
6
-biotinylated-azido adenosine analog 12. Finally, the 
acetyl group in C5'-position was selectively hydrolyzed using ammonia solution in 
MeOH at -40˚C to furnish C5’-hydroxyl to yield 1a. In contrast, treatment of triacetoxy 
derivative 12 with 2N methylamine solution in MeOH at room temperature globally 
deprotected the ribose to yield photoaffinity probe 1b. Some amount of the mono 
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acetylated product was observed during the purification by HPLC column. All these 
derivatives were collected as pure compounds. Methylamine solution was found to be an 
appropriate reagent as the 8-azido group was not affected even at room temperature for 
prolonged period of time. Application of commonly used mild bases for deprotection 
resulted in undesired products. For example, the treatment of compound 12 with 
NH3/MeOH at room temperature led to the substitution of the 8-azido group by an amine, 
while treatment with NH4OH/MeOH provided the 8-methoxy-substituted adenosine 
analog. Reaction conditions using K2CO3 resulted in a product with hydroxyl in C8-
position determined by mass spectrometry.  
 
3.6. Preparation of Modified Nucleotide Probes 
3.6.1. Materials 
All reagents and solvents were purchased from commercial sources and used 
without further purification. All reactions were run under an Argon atmosphere unless 
otherwise indicated. Prior to use of solvents in reactions, they were purified by passing 
the degassed solvents through a column of activated alumina and transferred by an oven-
dried syringe or cannula. Thin layer chromatography was performed on Merck TLC 
plates (silica gel 60 F254). Spots were visualized under UV (254 or 356 nm) light. 
Preparative column chromatography was performed on silica gel (230-400 mesh), 
suspended in CH2Cl2. 
1
H NMR and 
13
C NMR were recorded on a Varian Inova 400 (400 
MHz) or a Bruker Avance DPX-250 (250 MHz) instrument. The purification of 
designated compounds was carried out using reverse phase HPLC system (Waters Prep 
LC 4000 system with Waters 996 photo-diode array detector, Agilent column Eclipse 
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XDB-C18, 5 µm, 9.4 mm x 250 mm). Compounds were eluted using a gradient elution of 
A: B (95:5 to 0:100) over 40 min at a flow rate of 5.0 mL/min, where solvent A was H2O 
(0.05% TFA) and solvent B was CH3CN (0.05% TFA). The HRMS data were measured 
on an Agilent 6210 Series MSD/TOF with electrospray ionization. The LC/MS data were 
measured on an Agilent 1100 LC/MSD-VL with electrospray ionization.  
3.6.2. Preparation of N6-Biotinylated-8-azido Probes 
NH
N
N
O
N
O
AcO
OAcOAc
Ac2O, DMAP, dry DCM
0oC, rt, 8 h,95%
NH
N
N
O
N
O
HO
OHOH
2Inosine  
Acetic acid 3,4-diacetoxy-5-(6-oxo-1,6-dihydro-purin-9-yl)-tetrahydro-furan-2-
ylmethyl ester (2): To a solution of inosine (9.00 g, 33.6 mmol) and DMAP (408 mg, 
3.36 mmol) in dry DCM (200 mL) at 0
o
C was added Ac2O (31.7 mL, 336 mmol). After 2 
hrs of stirring at 0°C and then at room temperature for 6 hrs, the reaction mixture was 
quenched with cold water (10 mL). The reaction mixture was washed with saturated 
solution of sodium bicarbonate (3 X 150 mL) followed by brine (2 X 150 mL). The DCM 
layer was dried over anhydrous sodium sulfate and concentrated to a pale yellow oil and 
subjected to flash column chromatography (0-5% MeOH in DCM) to give 2 (12.6 g, 95 
%) as white solid. Rf = 0.4 (CH2Cl2/CH3OH, 90/10, v/v). The spectral data was identical 
to the literature values.
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N
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AcO
OAcOAc
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Acetic acid 4-acetoxy-2-acetoxymethyl-5-(8-bromo-6-oxo-1,6-dihydro-purin-9-yl)-
tetrahydro-furan-3-yl ester; compound with methane (5): The 2’,3’,5’-Tri-O-acetyl-
8-bromoinosine 3 was synthesized following the literature procedure
52
. To a solution of 2 
(5.00 g, 12.6 mmol) in dioxane (200 mL) at room temperature was added aqueous Br2 
solution (5 mL in 200 mL 10% w/v Na2HPO4 aqueous solution). The solution was stirred 
at room temperature for 3 days; the reaction mixture was replenished for bromine with 
another 60 mL (freshly prepared) aqueous bromine solution and stirred for another 3 
days. The reaction was quenched with slow addition of 2 N NaHSO3 in ice bath with 
stirring until the disappearance of yellow color of bromine. The solution was extracted 
with DCM (3 × 200 mL). The DCM extract was dried over anhydrous sodium sulfate, 
concentrated to a pale yellow oil and subjected to flash column chromatography (0-3% 
MeOH in DCM) to give 5 (5.5 g, 92%) as white solid. Rf = 0.5 (CH2Cl2/CH3OH, 90/10, 
v/v). The spectral data was identical to the literature values.
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Acetic acid 4-acetoxy-5-acetoxymethyl-2-(6,8-dichloro-purin-9-yl)-tetrahydro-furan-
3-yl ester (8): To a solution of 5 (2.5 g, 5.60 mmol) in dry DCM (25 mL) at 40
o
C was 
added dry DMF (45 µL, 0.56 mmol) and thionyl chloride (1.33 g, 11.2 mmol). The 
solution was refluxed for 4 hours and then cooled to the room temperature. The reaction 
was quenched with cold water and pH of the solution was adjusted to neutral with 
saturated sodium bicarbonate in ice bath. The product was extracted with DCM (3 × 50 
mL). The DCM extract was dried over anhydrous sodium sulfate , concentrated to a pale 
yellow oil and subjected to flash column chromatography (0-2% MeOH in DCM) to give 
8 (2.19 g, 93 %) as white solid. Rf = 0.6 (CH2Cl2/ CH3OH, 95/5, v/v). 
1
H NMR  (400 
MHz, CDCl3) δ 8.73 (s, 1H), 6.26 (t, J = 5.1 Hz, 1H), 6.16 (d, J = 4.6 Hz, 1H), 5.80 (t, J 
= 5.7 Hz, 1H), 4.44 - 4.39 (m, 2H), 4.28 (dd, J = 11.8, 5.5 Hz, 1H), 2.17 (s, 3H), 2.14 (s, 
3H), 2.07 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ170.2, 169.4, 169.3, 152.0, 151.8, 
150.0, 144.0, 130.8, 87.7, 80.2, 71.8, 70.1, 62.7, 20.5, 20.4, 20.3. 
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8 9  
Acetic acid 4-acetoxy-5-acetoxymethyl-2-[6-(6-tert-butoxycarbonylamino-
hexylamino)-8-chloro-purin-9-yl]-tetrahydro-furan-3-yl ester (9): To a solution of 8 
(500 mg, 1.12 mmol) in dry DCM (5 mL) at -10
o
C was added anhydrous DIPEA (157 
µL, 1.12 mmol) and mono-N-Boc-1,6-hexandiamine (266 mg, 1.23 mmol). The solution 
was stirred for 3 hours and then allowed to stir at room temperature overnight. The 
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reaction mixture was washed with water and the product was extracted with DCM (3 × 
20 mL). The DCM extract was dried over anhydrous sodium sulfate, concentrated to a 
pale yellow oil and subjected to reverse phase HPLC column chromatography (30-100% 
Acetonitrile in H2O) and subjected to freeze drying to give 9 (463 mg, 66 %) as white 
solid. Rf = 0.55 (CH2Cl2/ CH3OH, 95/5, v/v). 
1
H NMR (400 MHz, CDCl3) δ 8.40 (s, 1H), 
6.05 (d, J = 5.3 Hz, 1H), 5.90 (t, J = 5.6 Hz, 1H), 5.73 (s, 1H, NH), 5.52 (t, J=5.3 Hz, 
1H), 4.74 (s,1H, NH), 4.37 (m, 1H), 4.29 (m, 2H), 3.47 (m, 1H), 3.43 (m, 1H), 2.99 (m, 
2H), 2.02 (s, 3H), 1.94 (s, 3H), 1.93 (s, 3H), 1.56 (m, 2H), 1.39-1.27 (m, 15H). 
13
C NMR 
(101 MHz, CDCl3) δ 170.4, 169.8, 156.4, 154.9, 152.8, 148.3, 143.3, 131.9, 85.4, 80.5, 
79.2, 71.5, 70.2, 63.1, 42.8, 40.1, 30.3, 29.3, 29.1, 28.5, 25.9, 20.8, 20.7, 20.5. HRMS 
m/z calculated: 627.2540 observed: 627.2547  
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Acetic acid 4-acetoxy-5-acetoxymethyl-2-[8-azido-6-(6-tert-butoxycarbonylamino-
hexylamino)-purin-9-yl]-tetrahydro-furan-3-yl ester (10): To a solution of 9 (463 mg, 
0.73 mmol) in dioxane (10 mL) was added CsN3 (647 mg, 3.65 mmol) and trimethylsilyl 
azide (480 µL, 3.65 mmol). The solution was refluxed for 3 days. The reaction was 
followed every 24 hours by LC-MS until the peak of the chloro derivative 9 completely 
disappeared providing the desired product 10. The reaction mixture was washed with 
water and the product was extracted with DCM (3 × 25ml). The DCM extract was dried 
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over anhydrous sodium sulfate, concentrated to a pale yellow solid and subjected to flash 
column chromatography (0-3% MeOH in DCM) to give 10 ( 369 mg, 79 %)  as white 
solid. Rf = 0.55 (CH2Cl2/ CH3OH, 95/5, v/v). 
1
H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 
6.13 (d, J = 5.8 Hz, 1H), 5.88 (t, J = 5.8 Hz, 1H), 5.52 (bd, 2H), 4.58 (s, 1H, NH), 4.46 
(bd, J = 10.8 Hz, 1H), 4.32 (m, 2H), 3.54 (m, 1H), 3.44 (m, 1H), 3.07 (m, 2H), 2.10 (s, 
3H), 2.02 (s, 3H), 1.99 (s, 3H), 1.64 (m, 2H), 1.47 – 1.35 (m, 15H). 13C NMR (101 MHz, 
CDCl3) δ 170.3, 169.6, 169.5, 156.2, 153.7, 152.9, 148.8, 146.3, 123.5, 84.9, 80.4, 79.0, 
71.1, 70.0, 62.7, 42.7, 40.0, 29.9, 29.3, 28.3, 25.9, 25.7, 20.5, 20.4, 20.3. HRMS m/z 
calculated: 634.2943 observed: 634.2955 
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rt, 4 h, 81%
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Acetic acid 4-acetoxy-5-acetoxymethyl-2-[8-azido-6-(6-tert-butoxycarbonylamino-
hexylamino)-purin-9-yl]-tetrahydro-furan-3-yl ester (11): A solution of 9 (369 mg, 
0.58 mmol) in 9:1 dry DCM:TFA (3.7 mL) was stirred at room temperature for 4 hours. 
The reaction was followed by LC-MS for complete deprotection of N-Boc group and 
formation of the desired product. The reaction was quenched with triethyl amine (2 ml) 
and extracted with  DCM (3 × 15 mL). The DCM extract was dried over anhydrous 
sodium sulfate and concentrated to pale yellow solid 11 (251 mg, 81%). Rf = 0.45 
(CH2Cl2/CH3OH, 90/10, v/v). Attempts to purify product using flash column 
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chromatography resulted in significant loss of product and hence crude product was 
directly subjected to the next step without further purification.  
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11 12  
Acetic acid 4-acetoxy-2-acetoxymethyl-5-(8-azido-6-{6-[5-(2-oxo-hexahydro-
thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-hexylamino}-purin-9-yl)-tetrahydro-
furan-3-yl ester (12): To a solution of biotin (115 mg, 0.47 mmol), EDCI·HCl (90 mg, 
0.47 mmol), and DMAP (86 mg, 0.70 mmol) in dry DMF (5 mL) was slowly added a 
solution of crude 11 (251 mg, 0.47 mmol) in dry DCM (5 mL) and a solution was stirred 
at room temperature for 8 hours. 20 mL water was added and the product extracted with 
DCM (3 × 20 mL). The DCM extract was dried over anhydrous sodium sulfate and 
concentrated to a pale yellow solid and subjected to reverse phase column 
chromatography (30-100% acetonitrile in H2O) to give 12 (256 mg, 72%) after freeze- 
drying. Rf = 0.3 (CH2Cl2/CH3OH, 90/10, v/v).
 1
H NMR (400 MHz, CDCl3) δ 8.37 (s, 
1H), 6.3 (bs, 1H), 6.28 (m,1H), 6.17 (d, 5.5 Hz, 1H), 5.95 (t, J = 5.7 Hz, 1H), 5.62 (m, 
1H), 4.54 – 4.46 (m, 2H), 4.41 (d,5.9 Hz, 1H), 4.37 (m, 2H), 4.30 (m, 1H), 3.56 – 3.46 
(m, 2H), 3.20 (m, 2H), 3.12 (dd, J = 11.0, 7.1 Hz, 1H), 2.87 (dd, J = 12.0, 4.7 Hz, 1H), 
2.69 (d, J = 12.0 Hz, 1H), 2.20 (m, 2H), 2.11 (s, 3H), 2.02 (s, 6H), 1.75 – 1.61 (m, 6H), 
1.44 (m, 2 H), 1.41-1.25 (m, 6H). 
13
C NMR (101 MHz, CDCl3) δ 174.2, 170.6, 170.1, 
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169.9, 164.5, 153.3, 151.8, 150.5, 146.2, 129.6, 86.0, 80.1, 71.8, 70.0, 62.9, 62.2, 60.6, 
55.6, 43.5, 40.6, 39.5, 39.3, 35.7, 29.1, 28.7, 27.9, 26.0, 25.9, 25.6, 20.7, 20.6, 20.5. 
HRMS m/z calculated: 760.3195 observed: 760.3186 
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12 1a  
Acetic acid 4-acetoxy-5-(8-azido-6-{6-[5-(2-oxo-hexahydro-thieno[3,4-d]imidazol-6-
yl)-pentanoylamino]-hexylamino}-purin-9-yl)-2-hydroxymethyl-tetrahydro-furan-3-
yl ester (1a): To a solution of 12 (100 mg, 0.13 mmol) in MeOH (5 mL) was slowly 
added  ammonia and the solution was stirred at -40˚C for 2 hours. The reaction mixture 
was diluted with MeOH and immediately concentrated under vacuum to give a  foamy 
solid (73 mg), which was purified by HPLC column (20-80% acetonitrile in H2O) 
followed by freeze drying to give 1a (57 mg, 61%). Rf = 0.25 (CH2Cl2/CH3OH, 90/10, 
v/v).
 1
H NMR (400 MHz, CDCl3) δ 8.43 (s, 1H), 6.78 (d, J = 30.1 Hz, 1H), 6.57 (s, 2H), 
6.45 (d, J = 8.3 Hz, 1H), 5.67 – 5.58 (m, 1H), 5.51 (d, J = 5.2 Hz, 1H), 4.49 (s, 1H), 4.28 
(s, 2H), 3.89 (dd, J = 44.4, 11.4 Hz, 2H), 3.51 (d, J = 28.2 Hz, 2H), 3.10 (s, 3H), 2.76 
(dd, J = 67.9, 10.8 Hz, 2H), 2.18 (s, 2H), 2.11 (s, 6H), 1.61 (s, 6H), 1.46 – 1.21 (m, 8H).. 
13
C NMR (101 MHz, CDCl3) δ 173.4, 170.3, 169.6, 164.1, 154.1, 152.9, 149.0, 145.7, 
123.9, 85.2, 79.8, 71.4, 70.6, 62.9, 61.7, 60.1, 55.6, 42.8, 40.5, 39.05, 38.99, 35.8, 29.3, 
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29.0, 28.1, 28.0, 26.1, 25.6, 20.6, 20.4. HRMS m/z calculated: 718.3090 observed: 
718.3082 
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12 1b  
5-(2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoic acid {6-[8-azido-9-(3,4-
dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ylamino]-hexyl}-
amide (1b): The solution of 12 (100 mg, 0.13 mmol) in 2N methylamine solution (0.5 
mL) was stirred at room temperature for 4 hours. The reaction mixture was concentrated 
immediately under vacuum to give a foamy solid (54 mg ), which was purified by HPLC 
column (20-80% acetonitrile in H2O) followed by freeze drying to give 1b (43 mg, 52%) 
along with small amount of monoacetyl derivative. Rf = 0.1 (CH2Cl2/CH3OH, 90/10, 
v/v).
 1
H NMR (400 MHz, MeOD) δ 8.34 (s, 1H), 6.17 (d, J = 7.5 Hz, 1H), 4.77 (dd, J = 
7.4, 5.4 Hz, 1H), 4.62 (s, 2H), 4.49 (m, 1H), 4.32 – 4.26 (m, 2H), 4.16 (m, 1H), 3.82 (m, 
1 H), 3.24 – 3.08 (m, 4H), 2.91 (dd, J = 12.4, 4.5 Hz, 1H), 2.87 (bs, 1H), 2.67 (d, J = 12.7 
Hz, 1H), 2.19 (t, J = 7.4 Hz, 2H), 2.04-1.97 (m, 2H), 1.75 – 1.61 (m, 4H), 1.50 – 1.28 (m, 
10 H), 1.10 (t, J = 6.6 Hz, 2H). 
13
C NMR (101 MHz, CDCl3) δ 174.2, 164.7, 152.3, 
151.7, 150.7, 146.5, 118.2, 86.0, 80.5, 71.7, 70.0, 63.0, 62.4, 60.9, 55.3, 43.7, 40.6, 39.4, 
38.0, 35.6, 29.2, 28.7, 27.7, 26.0, 25.9, 25.6. HRMS m/z calculated: 634.2878 observed: 
634.2870. 
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CHAPTER 4 
PROOF OF CONCEPT: THE USE OF THE 8-AZIDO-N
6
-BIOTINYLATED 
ADENOSINE TO LABEL ADENOSINE DEAMINASE AND THE ADOR-
BINDING PROTEINS FROM THE SOLUBLE PROTEOME DERIVED FROM 
MOUSE NEUROBLASTOMA N18TG2 CELLS 
 
4.1 Overview 
Following the successful synthesis of AdoR-based probe 1a, our first goal was to 
use 1a to label AdoR-binding proteins in a complex cell proteome from the mouse 
neuroblastoma N18TG2 cells. The soluble proteome derived from the N18TG2 cells was 
treated with probe 1a under UV light with wavelength higher than 295nm.
1
 The treated 
proteome was evaluated by SDS-PAGE followed by Western analysis using anti-biotin 
HRP conjugate antibody that would show all the proteins labeled with our biotinylated 
AdoR probe. The outcome from this experiment was a large number of proteins 
visualized when using the anti-biotin antibody, indicating significant labeling with probe 
1a. The high degree of proteome labeling with probe 1a suggested that a number of 
experimental variables need to be optimized including UV irradiation time, total 
protein/probe ratio, amount of antibody used per SDS-gel, and antibody incubation time 
to make best use of the probe. To establish optimum conditions for the use of 1a, we used 
a commercially available purified AdoR-binding protein, calf intestinal adenosine 
deaminase (cADA, EC 3.5.4.4). Our rationale was to gain experience with the AdoR-
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probes with a purified AdoR-binding protein, a simpler system, before using our ABPP 
probes in a more complex milieu - a proteome.   
 
4.2 Photolabeling of Adenosine Deaminase and other Purified Proteins 
4.2.1 Materials and Methods 
cADA was from EMD Calbiochem. Anti-biotin antibody HRP conjugate was 
from Sigma Aldrich. SuperSignal West Pico Chemiluminescent Substrate and CL-
XPosure film were from Thermo Scientific.  PVDF membrane was from Millipore.  
Probe 1a was synthesized as described earlier (in Chapter 3) and dissolved in 1:1 
methanol:water as a 1 mM probe solution.  
cADA (2 µM) in cold PBS solution stored at 4˚C was treated with 10 µM probe 
1a in PBS buffer for a total volume of 500 µl in a quartz cuvette. The solution was 
exposed to UV light for variable amount of time and then diluted with cold PBS solution 
to a final volume of 1.0 mL.  The diluted solution was concentrated using a 10 kDa 
ultrafilter to remove unreacted probe from the probe-labeled cADA. Protein (2 µg) was 
loaded in each well of a 10% SDS gel from samples treated for different time periods and 
the gel was run for 30 minutes. The gel was electroblotted to a PVDF membrane at 70 V 
for 60 minutes at 4˚C. The membrane was then blocked using 5% non-fat dry milk in 
Tris-buffered saline Tween 20 (TBST) buffer for 1 hour at room temperature followed by 
incubation with the anti-biotin antibody HRP conjugate (Sigma) in 1:5000 dilution in 20 
ml 1% non-fat dry milk in TBST buffer at 4°C overnight. The membrane was washed 
with TBST (3 × 20 mL) for 10 minutes each. The membrane was then developed using 
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SuperSignal West Pico Chemiluminescent Substrate and exposed to CL-XPosure Film 
for 1 minute.  
A few non-AdoR binding proteins like concanavalin A (conA) and anit-apoptotic 
protein Bcl-XL were evaluated for probe 1a labeling. All three proteins, i.e cADA, conA, 
and Bcl-xL were treated with probe 1a in 1:1 concentration ratio. All solutions were 
exposed to UV light for 2 minutes and then diluted with cold PBS solution to a final 
volume of 1.0 ml. Protein (2 µg) was loaded in each well of a 10% SDS mini-gel (8.3 cm 
× 7 cm × 1mm) for each tested protein and the gel was run for 30 minutes. The gel was 
electroblotted to a PVDF membrane at 70 V for 60 minutes at 4˚C. The membrane was 
then blocked using 5% non-fat dry milk in Tris-buffered saline Tween 20 (TBST) buffer 
for 1 hour at room temperature followed by incubation with the anti-biotin antibody HRP 
conjugate in 1:5000 dilution in 20 ml 1% non-fat dry milk in TBST buffer at 4°C 
overnight. The membrane was washed with TBST (3 × 20 mL) for 10 minutes each. The 
membrane was then developed using SuperSignal West Pico Chemiluminescent Substrate 
and exposed to CL-XPosure Film.  
4.2.2 Discussion and Results 
Western analysis of cADA treated with probe 1a is shown in Figure 4.1.a.  In 
Figure 4.1, lane 1 is the cADA without any added probe, lane 2 shows cADA with added 
probe 1a without UV irradiation, and lanes 3-8 shows cADA with added probe 1a with an 
increase in UV irradiation time, from 15 s to 300 s (keeping all the experimental variables 
constant).  These data show no labeling of cADA with probe 1a in the absence of UV 
irradiation and that the extent of probe 1a labeling is complete after 2 minutes of UV 
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irradiation. We fixed the UV irradiation time at 2 minutes, based on the outcome of these 
experiments.  
 
Figure 4.1: Labeling of cADA (2 µM) with Probe 1a (10 µM). a: The effect of 
irradiation time on the labeling cADA with probe 1a:  lane 1 represents control cADA 
without any probe, and lanes 2-7 represent cADA irradiated with UV light for 0 to 300 
seconds).  b:  Inhibition of cADA labeling by nebularine, lanes 1-6 show the decrease in 
cADA labeling by probe 1a with an increase in the concentration of nebularine, from 
molar ratios of nebularine/cADA of 0 to 800. c: Inhibition of cADA labeling by 8-azido 
adenosine, lanes 1-6 shows the decrease in cADA labeling by probe 1a with an increase 
in the concentration of 8-azidoadenosine, from molar ratios of 8-azidoadenosine/cADA 
from molar ratios 8-azidoadenosine/cADA of 0 to 100. 
 
The data from Figure 4.1.a establish that probe 1a is labeling cADA.  However, 
is probe 1a binding at the cADA active? We chose to address this question by 
determining if nebularine (purine riboside), a known cADA competitive inhibitor (KD 8-
20 µM),
2-5
 can inhibit the labeling of cADA by probe 1a. As shown in Figure 4.1.b, 
nebularine does decrease the probe 1a labeling of cADA in a concentration-dependent 
manner. We also examined the affect of 8-azidoadenosine on the labeling of cADA by 
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probe 1a. 8-Azidoadenosine also inhibits the labeling of cADA by probe 1a in a 
concentration-dependent fashion (Figure 4.1.c). 
We also demonstrated that nebularine, a competitive inhibitor of cADA with a KD 
of 8-20 µM for adenosine deaminase
2,3,4,5
 and 8-azido adenosine  inhibits probe 1a 
binding in a concentration-dependent manner, indicating that probe 1a is labeling cADA 
at the active site. Although, the fact that the inhibition by such strong inhibitor takes 
place only at much higher concentration than reported, can be attributed to the covalent 
attachment of probe 1a at active site prior to possession of the active site by the inhibitor. 
Shown in lanes 1-6 in Figure 4.1.b is the decreasing labeling effect of probe 1a when 
nebularine is present in more than 20 times concentration than the probe 1a. Lanes 1-5 in 
Figure 4.1.c shows decreasing labeling effect of probe 1a when 8-azido adenosine is 
present in more than 10 times concentration than the probe 1a. This observation can be 
interpreted as a competition from known substrates of cADA with probe 1a for binding 
sites.  
To establish the specificity of labeling by probe 1a, a few non-AdoR binding 
proteins like concanavalin A (conA) and anit-apoptotic protein Bcl-XL were evaluated for 
probe 1a labeling and no labeling was observed as shown in Figure 4.2.a. In order to 
demonstrate the effect of non-AdoR azido analogues as probes to bind cADA, probe A 
(Figure 4.2.b) was synthesized and tested for labeling cADA.  No labeling was observed 
for either conA or Bcl-XL, as expected. These experiments establish that the probe 1a has 
specificity for AdoR-binding proteins and non-AdoR azido probes have no labeling effect 
on cADA. From the information established about approximate protein concentration, 
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protein-to-probe ratio and time and intensity of irradiation, the labeling experiments for 
the soluble proteome from the N18TG2 cells were designed.  
 
 
Figure 4.2: The Specificity of Labeling. a: Potential labeling of non-AdoR binding 
proteins with probe 1a, lanes 1-3 represent the labeling of cADA, conA and Bcl-xL with 
probe 1a (2 µM protein incubated with 2 µM probe 1a and then exposed to UV light).  b: 
Potential labeling of cADA with a non-AdoR-based probe, lane 1 (control), labeling of 
cADA with probe 1a (2 µM cADA incubated with 2 µM probe 1a and then exposed to 
UV light) and lane 2, treatment of cADA with probe A (2 µM cADA incubated with 2 
µM probe A and then exposed to UV light). 
 
4.3 Proteomic Profiling of N18TG2 cells with Probe 1a By Western Blot Analysis 
Given our success in using probe 1a to specifically label cADA while not labeling 
non-AdoR proteins, we then initiated proteomic profiling experiments with probe 1a 
using mouse neuroblastoma N18TG2 cells, cells routinely cultured in the Merkler 
laboratory
6
 for other projects. Preliminary experiments with the soluble N18TG2 cell 
proteome resulted in a very high number of proteins labeled by the probe 1a. So the 
optimization for N18TG2 cell proteome was conducted with the parameters established in 
successfully labeling cADA with probe 1a. 
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Western Blot analysis, using the anti-biotin antibody, for the optimization of 
irradiation time on labeling N18TG2 cell proteome with probe 1a is shown in Figure 4.3. 
In this experiment, the independent N18TG2 cell proteome fractions were treated with 10X 
probe concentration in the time intervals between 0 to 4 minutes. The experiment showed 
that the optimal time required to get a convenient fraction of the N18TG2 cell proteome 
labeled is about 2 minutes, similar to the optimum irradiation time we observed in 
labeling cADA with probe 1a (Figure 4.1.a). All further studies were conducted with 
these parameters kept constant. 
 
Figure 4.3: Effect of Irradiation Time on Labeling the Soluble N18TG2 Cell 
Proteome with probe 1a. Protein, (20 µM, calculated assuming an average protein 
molecular weight of 50 kDa. was incubated with 200 µM probe 1a.  Lanes 1-7 represent 
UV irradiation for 0 to 240 sec and lane 8 represents the biotinylated molecular weight 
markers. 
 
Proteomes were prepared from 5-6 × 10
7
 confluent cells by homogenization in 
protease inhibitor cocktail followed by centrifugation to prepare the soluble proteomic 
sample (supernatant) and the membrane-bound proteomic fraction (pellet). The 
experiment was initiated utilizing the soluble N18TG2 proteome. Endogenous avidin-
binding proteins were removed from the soluble N18TG2 proteome by incubation with 
monomeric avidin-beads to eliminate false negatives. Following removal of the 
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endogenous avidin-binding proteins, a 10-fold molar excess of the probe 1a was added in 
the dark and then the soluble proteome/probe mixture was exposed to UV for 2 minutes 
and immediately diluted with cold PBS buffer. Optimization experiments showed that 
[probe 1a]/protein] ratio = 10 yielded the best profiles. Unreacted probe 1a was removed 
in the dark by ultrafiltration using 10 kDa filters and the sample then applied to an avidin 
column. Non-biotinylated proteins were eluted from the avidin column using PBS 
fractions until UV absorbance of the PBS Wash reached background generating the "PBS 
Wash" sample. The biotinylated protein•probe 1a conjugates were eluted from the 
column by a first washing with 2 mM biotin in PBS (the "Biotin Wash") followed by 0.1 
M glycine pH 2.8 (the "Regeneration Wash") until UV absorbance reached background. 
The three different washes were reduced to equal volume using 10 kDa Millipore ultra 
centrifuge filters, boiled with SDS loading buffer and subjected to SDS-PAGE analysis 
(Figure 4.6.a). Proteins were electro-transferred from the polyacrylamide gel to a 
polyvinylidene difluoride (PVDF) membrane, the membrane was blocked with non-fat 
dry milk (NFDM), the blocked membrane was incubated with goat anti-biotin•horse 
radish peroxidase (HRP) conjugate in 1:5000 dilution in 20 ml 1% NFDM, which will 
bind to the primary anti-biotin  antibody. The protein•probe 1a conjugates were 
visualized using a SuperSignal West Pico Chemiluminescent HRP Substrate from 
Thermo Scientific using manufactures protocol (Figure 4.6.b). Following the success in 
detection of labeled proteome with anti-biotin•horseradish peroxidase (HRP) conjugate, 
the identification of labeled proteome was conducted using liquid chromatography-
tandem mass spectrometry analysis (LC-MS/MS). The procedure for proteomic profiling 
can be summarized into a flowchart as shown in Figure 4.4. 
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Figure 4.4: Protocol for Proteomic Profiling with our AdoR-Based Probes 
 
4.3.1 Materials and Methods 
Fetal bovine serum (FBS) was purchased from Atlanta Biologicals, donor equine 
serum was purchased from Thermo Scientific (Waltham, MA), and DMEM (Dulbecco’s 
Modified Eagle Medium) and penicillin/streptomycin were purchased from Mediatech 
Cellgro. Mouse neuroblastoma N18TG2 cells were purchased from DSMZ (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH). PVDF (Polyvinylidene 
fluoride) membrane was purchased from Millipore (Billerica, MA). Tween-20, were 
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purchased from Sigma-Aldrich. SuperSignal chemiluminescent detection system was 
purchased from Pierce. All other reagents and cell culture supplies were of the highest 
quality available from commercial suppliers. Probe 1a was synthesized as described 
earlier (in Chapter 3), and dissolved in 1:1 methanol:water as a 10 mM probe solution. 
4.3.1.1 Cell Culture  
N18TG2 cells were grown at 37˚C at 5% CO2 in DMEM supplemented with 100 
µM 6-thioguanine, 100 I.U./mL penicillin, 1.0 mg/mL streptomycin and 10% FBS in 225 
cm
2
 culture dishes. Cultures were grown to 85-90% confluence, washed with PBS and 
released from the culture dishes by trypsinization. Cells were collected by centrifugation, 
rinsed with PBS, and re-pelleted to remove the supernatant. 
4.3.1.2 Cell Lysis 
Cells were thawed on a shaker to bring them to room temperature and treated with 
800 µl of Lysis Buffer containing 20 mM cold Tris-HCl (pH 7.4), 2 mM MgCl2, 1 mM 
EDTA, 1 mM EGTA, 150 mM NaCl, 1% (v/v) Triton X-100, and 1% (v/v) of a protease 
inhibitor cocktail (Sigma). Cells were then sonicated using a microprobe model 50 sonic 
dismembrator (fisher scientific) for 30 s interval followed by 30 s cooling for a total of 5 
minutes on ice and centrifuged for 5 minutes at 13,200 rpm. Supernatant containing the 
soluble cell proteome was analyzed for protein concentration via the Bradford Dye 
Binding Assay
7
 using BSA as standard. 
4.3.1.3 Removal of Endogenous Avidin-binding Proteins  
Endogenous avidin binding proteins were eliminated from the soluble proteome 
using Pierce
®
 Monomeric Avidin Kit # 20227. The protocol we use follows the 
manufacturer's instructions with a few minor modifications that optimize the separation 
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efficiency. All solutions (PBS, biotin blocking solution, and regeneration buffer) were 
brought to room temperature. A disposable column was filled with 2 mL of resin slurry 
(equivalent to 1 mL of resin) and the stored PBS (from the resin) was allowed to flow 
through the column. The non-reversible biotin-binding sites on the column were blocked 
using manufacturer’s instructions (Pierce® Monomeric Avidin Kit). 
Avidin is a tetrameric protein and the biotin-avidin interactions are one of the 
strongest protein-ligand interactions known with a Kdissocitaion = 10
-15 
M
-1
. The monomeric 
form of this protein has a lower affinity with Kd = 10
-8 
M
-1
, which is sufficiently strong 
enough for the affinity column for purification of our biotinylated protein•probe 
conjugates, but has the advantage of using milder conditions to elute the bound proteins. 
Hence, we employed monomeric avidin beads from Pierce for separation of biotinylated 
proteome from the non-biotinylated proteome.  The avidin affinity column separates the 
biotinylated proteins from rest of the proteome.  Since the photoaffinity probe 1a contains 
a biotin, all the proteins that are covalently labeled with the probe will possess a bound 
biotin.  The non-biotinylated/non-labeled proteins should have little to no affinity for 
avidin. Hence, they can be easily eluted from the avidin column with PBS and are 
collected as “PBS Wash”.  A concentrated biotin solution (2 mM) poses competition to 
the biotinylated/ labeled proteins at the binding sites on avidin column and should elute 
the biotinylated proteins that are relatively weakly bound to the column and these are 
collected as “Biotin Wash”.  The relatively tightly bound proteins that cannot be eluted 
by 2 mM biotin solution and are eluted only under conditions that disrupted the biotin-
avidin interaction. This was attained using a 2.8 M glycine solution. At such a low pH, 
the avidin structure is altered and biotin-avidin interactions are weakened, resulting in 
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elution of all the biotinylated/labeled proteins from the column termed as “Regeneration 
Wash”. 
 
Figure 4.5: Affinity Chromatography Protocol 
Once the pH is returned to 7.0-8.0, the avidin structure is recovered and biotin-
avidin interactions are restored. Hence, the avidin column can be regenerated for reuse by 
adjusting the pH back to 7. The monomeric avidin beads can be reused upon regeneration 
for approximately ten applications, as described in the manufacturer's instructions. One 
column was used only for one specific cell line and the columns were used until the 
recovery of total protein was higher than 75% in total of all the fractions. A schematic 
diagram for the protocol for collection of various washes is shown in Figure 4.5. 
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4.3.1.4 Loading the Protein Sample 
The column was placed in a clean test tube and the test tube was labeled “Flow 
through (FT)”. The crude protein sample was added to the center of the disk. The sample 
in centrifuge tube was washed with PBS and added to the column to assure all the protein 
is transferred. PBS was added to bring the total load volume to 1 mL. When the sample 
reached the top of the avidin, it was allowed to incubate at room temp in the column for 
15 minutes. The collected fractions were capped, and kept on ice throughout the 
separation procedure. 
4.3.1.5 PBS Wash - Removal of the Non-bound Protein 
The avidin column was placed in a new test tube labeled “PBS w1”. PBS (2 mL) 
was added and the first fraction was collected. The PBS addition was repeated in new test 
tubes labeled “PBS w2…w3…w4” until no protein was detected by the Bradford dye 
binding assay. It is important to note that at this stage the PBS Wash fraction is the 
protein of interest. 
4.3.1.6 Biotin Wash - Removal of the Weakly Bound Proteins  
The avidin column was placed in a new test tube labeled “Biotin w1”. Biotin 
blocking and elution buffer (2 mL) was added and the first fraction was collected. The 
biotin blocking and elution buffer addition was repeated in new test tubes labeled “Biotin 
w2…w3” until no protein detected by the Bradford dye binding assay. It is important to 
note that at this stage the Biotin Wash fraction is NOT the protein of interest. 
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4.3.1.7 Regeneration Wash - Removal of Tightly Bound Biotinylated Proteins and 
Regeneration of the Avidin Column 
The avidin column was placed in a new test tube labeled “Reg. wash”. 
Regeneration buffer (2 mL) was added and the first fraction was collected. The 
regeneration buffer addition was repeated in new test tubes labeled “Regeneration 
w2…w3” until no protein detected by the Bradford dye binding assay. It is important to 
note that at this stage the Regeneration Wash fraction is NOT the protein of interest. The 
column was washed by placing the column over a waste container and adding 8 mL of 
PBS to pass through the column. The bottom of the column was capped and filled with 2-
3 mL of PBS and stored in the cold room. 
4.3.1.8 Recovery of Endogenous Avidin Binding Proteins Removed Proteome 
The PBS-w fractions were pipetted into a 10kD cutoff ultrafilter (approximate 
initial volume of 15 mL) and centrifuged for approximately 20 minutes at 13,000 rpm at 
4°C to reduce the volume to 500-600 µL. The concentrated sample from the ultrafilter 
was transferred into a 1.5 mL Eppendorf tube and labeled as N18TG2 “endogenous avidin 
binding proteins removed PBS w” and stored at -80°C 
The concentration of endogenous avidin binding proteins removed was 
determined using the Bradford dye binding assay and the amount of protein recovered 
from the avidin column was calculated. A large majority of the total crude protein, ~95% 
of the total, protein was recovered in the PBS Wash. We expected this result as most 
proteins would not be labeled with our AdoR-based probe. 
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4.3.1.9 UV Irradiation to Label the AdoR-binding Proteins with the Probe 
The endogenous avidin binding proteins removed proteome was diluted with cold PBS 
(at 4˚C) to 1 mL total volume in a quartz cuvette with final protein concentration ranging 
from 20-40 µM (based on average molecular weight of proteins to be 50 kD) as desired. 
The probe 1a (10 × protein concentration) was then added to proteome and the sample 
was placed in front of the UV light beam (Oriel Instruments housing with Osram 150 W 
XBO xenon short-arc lamp, light source fitted with a Schott filter WG295 to eliminate 
UV lights below 295 nm). The sample was irradiated for total 2 minutes with mixing the 
sample after 30 s and 90 s with the pipette tip and immediately diluted with cold PBS 
solution to 2 mL volume. The solution was concentrated using a 10 kDa cutoff ultrafilter 
(Millipore) to remove any non-reacted probe from the labeled proteome. The flow 
through from the tube was discarded and the filtered protein on top was loaded on the 
affinity column. The steps from Section 4.4.1.5 to 4.4.1.8 were repeated with the volume 
of washes adjusted to the volume of avidin beads (Pierce
®
 Monomeric Avidin Kit 
#20227, following the detailed instructions available at the Pierce website). It is 
important to note that at this stage the Biotin Wash and Regeneration Wash are the 
desired protein fractions. All the fractions, PBS Wash, Biotin Wash, and Regeneration 
Wash, were concentrated in 3 different 10 kDa ultrafilters at 4°C to reduce the final 
volume to approximately 100 µL. The protein concentration of all three samples was 
determined using the Bradford dye binding assay and the amount of protein recovered 
from the avidin column was calculated. 
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4.3.1.10 Sample Preparation for SDS Gel Analysis 
An aliquot of approximately 50 µl of each sample with equal concentration of 
protein (~1 mg/mL) was prepared. To all samples, 10 µL of 5X Laemmli Buffer 
containing 60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, and 
0.01% bromophenol blue was added and boiled for 5 minutes. The samples were brought 
to room temperature and stored at -20°C if the SDS gel was not run on the same day. The 
SDS gel with 10-20 µg of total protein in each lane and Western Blot with 5 µg total 
protein in each lane were run for proteomic profiling. 
4.3.1.11 1D Gel Electrophoresis for Western Blot Analysis 
Approximately, 10µg of total protein from labeled and unlabeled fractions were 
subjected to electrophoretic separation on a 10% SDS-PAGE minigel at 120 V for 45 
minutes. The gel was electroblotted onto a PVDF membrane at 70 V for 90 minutes at 
4˚C. The membrane was then blocked using 5% non-fat dry milk in TBST buffer for 1 
hour. at room temperature followed by incubation with an anti-biotin antibody HRP 
conjugate (Sigma # A4541) in 1% non-fat dry milk in TBST buffer at 4˚C overnight. The 
membrane was washed with TBST (3 × 20 mL) for 10 minutes each. The membrane was 
then developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific #34080) and exposed to CL-XPosure Film (Thermo Scientific # 34091). 
4.3.2 Discussion and Results 
The patterns of Figure 4.6.a are exactly as expected. The non-biotinylated 
molecular weight markers were visualized upon Coomassie staining (Figure 4.6.a, lane 
1), but not in Western Blot (Figure 4.6.b, lane 1), whereas the biotinylated-protein 
molecular weight markers were visible only after Western Blot analysis (Figures 4.6.a 
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and 4.6.b, lane 11).  The majority of the proteins in the N18TG2 proteome do not bind 
probe 1a, and are eluted with PBS. A number of proteins are prominently stained with 
Coomassie Blue (Figure 4.6.a, lanes 2-4), yet nothing is exposed in the Western Blot 
when visualized with the anti-biotin HRP conjugate (Figure 4.6.b, lanes 2-4). The 
protein•probe 1a conjugates that are relatively weakly bound to the avidin column are 
eluted with the Biotin Wash.  The SDS-PAGE lanes representing the Biotin Wash are 
blank upon Coomassie staining (Figure 4.6.a, lanes 5-7), but the protein•probe 1a 
conjugates present in the Biotin Wash are visualized with anti-biotin HRP conjugate 
(Figure 4.6.b, lanes 5-7).  The protein•probe 1a conjugates most tightly bound to the 
avidin column are eluted with the Regeneration Wash.  There are proteins visible in the 
Regeneration Wash when stained with Coomassie Blue (Figure 4.6.a, lanes 8-10) and 
with the anti-biotin HRP conjugate (Figure 4.6.b, lanes 8-10).  Experiments were carried 
out in triplicate.  My results demonstrate that the profiles are reproducible, with the same 
pattern of bands being observed from repeat profiles from separately prepared N18TG2 
cells (Figures 4.6.a and 4.6.b), and that addition of nebularine before UV exposure 
restrain the formation of the protein•probe 1a conjugates, as seen in the Western Blots. 
We observe a 2-3 fold decrease in labeling by using probe 1a.  Figure 4.7 demonstrates 
the effect on PBS Wash, Biotin Wash and Regeneration Wash fractions from two parallel 
experiments for labeling of the N18TG2 cell proteome, one of which was treated with 10 
fold nebularine prior to addition of Probe 1a.  The extent of nebularine inhibition differs 
from protein-to-protein and may provide an estimate for the dynamic range for probe 1a 
labeling for a particular protein (Figure 4.7). This was not explored in further details as it 
was out of the scope of this research.  
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Figure 4.6: Proteomic Profile of N18TG2 Cell Proteome (Generated using Probe 1a). 
Duplicate SDS-gels were run a.  stained using Coomassie blue, b. visualized via Western 
Blot analysis using anti-biotin antibody HRP conjugate. Lane 1 is MW standards, lanes 
2-4 are the PBS Wash, lanes 5-7 are the Biotin Wash, lane 8-10 are the Regeneration 
Wash, and lane 11 is biotinylated MW standards. 
 
 
Figure 4.7: Effect of Nebularine on Proteomic Profile of N18TG2 Cell Proteome. 
Lanes 2-4 are the PBS Wash, lanes 3-4 are the Biotin-Wash, lanes 5-6 are the 
Regeneration Wash, and lane 7 is biotinylated MW standards. (- indicates absence of 
Nebularine, + indicates addition of Nebularine prior to addition of Probe 1a) 
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4.4 Proteomic Profiling of N18TG2 Cells with Probe 1a using LC-MS/MS 
Analysis 
4.4.1 Materials and Methods 
All reagents and supplies were of the highest quality available from commercial 
suppliers. Iodoacetamide (IAA), dithiothreitol (DTT), SDS, glacial acetic acid and 
Formic acid were from Sigma-Aldrich. TPCK treated trypsin was from AB SCIEX Pte. 
Ltd. 
4.4.1.1 In Solution Protein Digestion for LC-MS/MS Analysis 
In solution trypsin digestion was employed to facilitate the identification of 
proteins in each of the proteomic washes:  PBS Wash, Biotin Wash, and Regeneration 
Wash. Due to technical and instrumental problems observed in our analyses of the   
protein digests from the washes, a series of experiments were performed to optimize the 
conditions. The major problem was detergent interference from the protein samples. To 
eliminate this problem, in gel protein digestion was successfully employed for LC-
MS/MS sample preparation. 
4.4.1.2 1D Gel Electrophoresis for Protein Digestion for LC-MS/MS Analysis 
A small portion of the protein sample from the avidin column described in 
Section 4.4.1.11 was employed for protein identification from the different proteomic 
wash samples. Approximately, 20µg of protein from labeled and unlabeled fractions were 
subjected to electrophoretic separation on a 10% SDS-PAGE minigel at 120V for 30 
minutes. The migration was stopped after the front had moved by about 3 cm into the 
separating gel so that the bands of a prestained molecular weight marker were visible and 
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separated in the 20-250 kDa range. The SDS-PAGE gel was stained using Comassie blue 
staining protocol and complete lanes of the cell proteome were cut out for MS analysis. 
4.4.1.3 In-gel Protein Digestion with Trypsin for LC-MS/MS Analysis 
Gel slices were excised from the SDS-PAGE gels using a clean scalpel for each 
lane to avoid any contamination between samples. The gel slices were transferred to 
Eppendorf tubes washed with acetonitrile and dried under nitrogen. The gel pieces were 
all washed with 50% acetonitrile (ACN) in distilled water with agitation for 15 minutes 
each for 2-3 times and covered with neat ACN for 10 minutes. The gels were rehydrated 
with 100 mM ammonium bicarbonate (ABC) for 5 minutes followed by addition of 
acetonitrile to give 1:1 ratio of ABC/ACN and agitated for another 15 minutes. The gels 
were left in this solution for 6-12 hours to destain completely. The gel pieces were 
reduced using 45 mM dithiothreitol (DTT) at 55˚C for 30 minutes. The reducing agent 
was then replaced by freshly prepared 100 mM iodoacetamide (IAA) for 
carbamidomethylation in dark at room temperature for 30 minutes. The gel pieces were 
washed with 50% acetonitrile/50 mM ABC with agitation for 15 minutes each for 3 times 
or untill the gel pieces were completely colorless. In-gel proteolytic cleavage with 
sequencing grade trypsin (Promega, Madison, WI), 12.5 mg/mL in 50 mM ABC was 
performed overnight at 37°C, with a total protein to trypsin ratio of approximately 20:1. 
The supernatant from the gels was transferred to another Eppendorf tube and the action of 
trypsin was stopped by adding 5% acetic acid to get final concentration of 0.5% acetic 
acid. The gel pieces were then washed with 1:1 ACN/water containing 0.01% formic acid 
with vortexing for 15 minutes. The supernatant was then combined with the trypsin 
digest. Digests were desalted using reverse phase C18 mini columns that have an 
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estimated loading capacity equal to 30-60µg. The peptides were eluted from the 
microcolumns with 90% acetonitrile. The elute from the columns was recovered and the 
volume of the trypsin digest was reduced by evaporation on a vacuum pump. The final 
volume was adjusted to 40 µl with 0.1% formic acid. 5µl of protein digest sample were 
injected on a 10cm X 75µm i.d. reversed-phase column packed with 5 mm, 300 A˚ C18 
material (New Objective, Woburn, MA), and separated by a nanoflow liquid 
chromatography using 90-min linear gradients from 2 to 40% ACN at 250nL/min.  
4.4.1.4 Database Search 
Tandem mass spectrometric analysis was accomplished with an LTQ Orbitrap XL 
(Thermo) mass spectrometer. Orbitrap survey scans were acquired at a mass resolving 
power of 60000 at m/z 400. The top 10 most abundant ions were selected for 
fragmentation in the LTQ ion trap. Raw ﬁles were processed in MASCOT version 2.2.2 
(Matrix Science, Boston, MA) search algorithm against a composite IPI mouse (version 
3.35, number of entries is 51490 × 2) protein sequence database containing both forward 
and randomized sequences. Constant modiﬁcation of cysteine by carbamidomethylation 
and the variable modiﬁcation of methionine oxidation, N-terminal protein acetylation, N-
terminal peptide and lysine carbamoylation, and phosphorylation of serine and threonine 
were specified as variable modifications were employed. Mascot was searched with a 
fragment ion mass tolerance of 0.80 Da and a parent ion tolerance of 15.0 ppm assuming 
the digestion enzyme trypsin with the possibility of one missed cleavage. In general, 
probability-based MOWSE (MOlecular Weight SEarch) scores corresponding to a 
significance threshold of P<0.05 were considered for peptide identification in addition to 
manual validation of the MS/MS data. 
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4.4.2 Discussion and Results 
The isolated proteins from both labeled and non-labeled fractions were identified 
by tandem mass spectrometry using trypsin digest of an entire lane from SDS-PAGE gel. 
The identification of proteins from an entire excised lane from the PBS Wash (similar to 
lane 2-3 in Figure 4.6.a) and Regeneration Wash (similar to lane 6-7 in Figure 4.6.a) 
revealed a panel of total 383 proteins comprising 166 unique AdoR-binding proteins 
(only present in Regeneration Wash) from searches against the mouse International 
Protein Index (IPI) database using Mascot search engine. A few examples of highly 
labeled AdoR-binding proteins from the N18GT2 cell proteome were 40S ribosomal 
protein S12, peroxiredoxin-2, 60S ribosomal protein L12, D-3-phosphoglycerate 
dehydrogenase, Stress-induced-phosphoprotein 1, ATP synthase subunit O, 
mitochondrial, Poly(rC)-binding protein 1, Glycyl-tRNA synthetase, Cullin-associated 
NEDD8-dissociated protein 1, 40S ribosomal protein S3, 40S ribosomal protein S9, 
Importin subunit beta-1, 40S ribosomal protein S19, Polyadenylate-binding protein 1, 
40S ribosomal protein S10, Putative uncharacterized protein, ATP synthase subunit d, 
mitochondrial, 40S ribosomal protein S17, KH type splicing regulatory protein KSRP, 
ADP/ATP translocase 1, Calnexin, eukaryotic translation initiation factor 3 subunit I, 
Electron transfer flavoprotein subunit alpha, mitochondrial, 60S ribosomal protein L13, 
Histone H2A.J, dihydropyrimidinase-related protein 2 etc. based on spectral count 
analysis by Scaffold. The proteins that were labeled are shown in Table 4.1 while the 
proteins that were not labeled at all are shown in Table 4.2. The columns P1, P2 and P3 
in Table 4.1 and Table 4.2 represents the spectral counts observed corresponding to the 
identified proteins in PBS Wash (non-labeled proteome) whereas columns R1, R2 and R3 
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represents the spectral counts observed corresponding to the identified proteins in 
Regeneration Wash (labeled proteome). 
The gene ontology data determined using the panther protein classification 
system revealed a 4-fold enrichment of the AdoR-binding proteins in the Regeneration 
Wash relative to PBS Wash (35% Vs 8.1%) as shown in Figure 4.8. It is important to 
mention that this methodology is developed to enrich the nucleotide or nucleoside 
binding proteins in a large, complex proteome sample. A four-fold enrichment in this 
data is averaged over the proteins that are identified in labeled vs non-labeled proteome 
fractions. The enrichment corresponding to individual proteins varies and certain proteins 
that are not identified in whole cell proteome are also identified in significant amount.  
The analysis by protein pathways among PBS Wash (non-labeled) and Regeneration 
Wash (labeled) proteome fractions indicates that the proteins involved in Huntington’s 
disease, Ubiquitin proteasome pathway, PDGF signaling pathway, pyrimidine 
metabolism and ATP synthesis have greatly enriched in the Regeneration Wash (Figure 
4.9). 
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Figure 4.8 Classification by Protein Class - Shows a four-fold increase in nucleotide 
binding proteins in Regeneration Wash (labeled cell proteome) compared to PBS Wash 
(non-labeled cell proteome). 
 
Thus, this technology enables an efficient and scalable pipeline to generate 
reproducible proteomic profiles from a small sample with enrichment of nucleotide 
binding proteins. Western Blot analysis of a few proteins identified by LC-MS/MS 
analysis of the Regeneration Wash (labeled) and the PBS Wash (non-labeled) using 
specific primary and secondary antibodies yielded the comparable results. For example, 
when anti-fructose bisphosphate aldolase A was used as primary antibody it showed a 
band in Western Blot of all three PBS Wash samples but not in Regeneration Wash 
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samples as expected from LC-MS/MS analysis. Similarly, anti stress-induced-
phosphoprotein1 antibody showed a band in Western Blot of all three Regeneration Wash 
samples but not in PBS Wash samples. So it was established that probe 1a can 
successfully be used to photolabel AdoR binding proteins in a specific manner and hence 
AdoR proteins can be enriched from the cell proteome using the Activity Based Protein 
Profiling AdoR probe 1a and its analogues.  
 
Figure 4.9 Classification by Pathways Involved 
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Table 4.1: Proteins Labeled by Probe 1a in N18TG2 Cell Proteome (P-1 to P-3 
represent PBS Wash and R-1 to R-3 represent Regeneration Wash samples) 
Identified Proteins (383)  Spectral Counts for Proteins using 
Scaffold 
P-1  P-2  P-3  R-1  R-2  R-3  
40S ribosomal protein S12  0  0  0  39  53  47  
Peroxiredoxin-2  0  3  0  32  28  34  
60S ribosomal protein L12  0  8  4  27  24  28  
D-3-phosphoglycerate dehydrogenase  0  0  0  30  28  25  
Stress-induced-phosphoprotein 1  0  0  0  27  25  24  
ATP synthase subunit O, 
mitochondrial  
0  0  0  29  30  22  
Poly(rC)-binding protein 1  0  2  0  28  22  13  
Glycyl-tRNA synthetase  0  0  0  20  25  16  
Cullin-associated NEDD8-dissociated 
protein 1  
0  0  0  24  28  9  
40S ribosomal protein S3  0  0  0  24  20  15  
40S ribosomal protein S9  0  0  0  9  24  12  
Importin subunit beta-1  0  0  0  19  19  10  
40S ribosomal protein S19  0  0  0  15  15  19  
Polyadenylate-binding protein 1  0  2  0  21  15  10  
40S ribosomal protein S10 0 0 0 15 17 10 
Putative uncharacterized protein 0 0 0 9 16 6 
ATP synthase subunit d, 
mitochondrial 
0 0 0 18 15 8 
40S ribosomal protein S17 0 0 0 15 16 12 
KH type splicing regulatory protein 
KSRP 
0 0 0 12 18 12 
ADP/ATP translocase 1 0 3 4 12 10 7 
Calnexin 0 2 0 12 16 6 
Eukaryotic translation initiation factor 
3 subunit I 
0 0 0 13 9 6 
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Table 4.1 (contd.) 
Electron transfer flavoprotein subunit 
alpha, mitochondrial 
0 0 0 16 13 10 
60S ribosomal protein L13 0 0 0 11 11 11 
Histone H2A.J 0 0 4 13 7 9 
Dihydropyrimidinase-related protein2 0 0 0 11 12 12 
Isoform 1 of Poly(rC)-binding protein 
2 
0 3 1 11 8 11 
40S ribosomal protein S18 0 0 0 10 9 8 
60S ribosomal protein L23 0 2 2 11 8 8 
LOC100039355 protein 0 0 0 11 9 6 
60S acidic ribosomal protein P2 0 0 0 9 9 7 
Putative uncharacterized protein 0 0 0 13 5 12 
60S ribosomal protein L23a 0 2 2 10 9 9 
adaptor protein complex AP-1, beta 1 
subunit 
0 0 0 16 11 3 
Spermidine synthase 0 0 0 16 10 2 
Prohibitin-2 0 2 5 9 10 4 
Phosphoribosylaminoimidazole 
carboxylase, phosphoribosyl 
aminoribosylaminoimidazole, 
succinocarboxamide synthetase, 
isoform CRA_a 
0 0 0 8 11 6 
40S ribosomal protein S3a 0 0 0 8 9 4 
40S ribosomal protein S7 0 2 2 8 10 3 
60S ribosomal protein L31 0 0 0 9 8 6 
40S ribosomal protein S13 0 0 0 6 7 7 
Eukaryotic translation initiation factor 
3 subunit F 
0 0 0 8 13 1 
Histone H2B type 1-F/J/L 0 0 0 10 8 4 
phosphoribosylglycinamide 
formyltransferase 
0 0 0 13 9 4 
Dynactin subunit 2 0 0 0 7 10 8 
Crmp1 protein 0 0 0 6 8 9 
similar to ribosomal protein S25 0 0 0 8 7 10 
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Table 4.1 (contd.) 
V-type proton ATPase subunit E 1 0 0 0 9 6 7 
Exportin-2 0 0 0 6 9 2 
Tubulin alpha-1A chain 0 0 0 8 6 9 
Ribosomal protein L21 0 1 1 10 2 6 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial 
0 0 0 7 8 4 
Heat shock protein 75 kDa, 
mitochondrial 
0 0 0 9 9 5 
60S ribosomal protein L31 0 0 0 9 8 6 
 
 
Table 4.2: Proteins Not-Labeled by Probe 1a in N18TG2 Cell Proteome (P-1 to P-3 
represent PBS Wash samples, R-1 to R-3 represent Regeneration Wash samples) 
Identified Proteins (383)  Spectral Counts for Proteins using 
Scaffold 
P-1 P-2 P-3  R-1  R-2  R-3  
Malate dehydrogenase, 
mitochondrial  
41  36  39  0  0  0  
Calreticulin  33  36  32  0  0  0  
Eukaryotic initiation factor 4A-I  26  25  23  0  6  0  
Protein disulfide-isomerase A3  26  33  24  0  0  0  
Fructose-bisphosphate aldolase A  23  36  38  0  2  0  
Transketolase  21  19  22  0  2  0  
Prothymosin alpha  18  25  22  0  0  0  
Citrate synthase, mitochondrial  16  22  17  0  0  0  
Guanine nucleotide-binding protein 
subunit beta-2-like 1 
16 19 18 0 0 0 
Putative uncharacterized protein 15 17 9 0 0 0 
Aconitate hydratase, mitochondrial 13 19 9 0 0 0 
Isoform Long of 9-3-3 protein 
beta/alpha 
13 16 15 0 0 0 
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Table 4.2 (contd.) 
Isoform 1 of Acidic leucine-rich 
nuclear phosphoprotein 32 family 
member E 
13 13 8 0 2 0 
Staphylococcal nuclease domain-
containing protein 1 
12 13 9 0 0 0 
Bifunctional purine biosynthesis 
protein PURH 
11 13 11 0 0 0 
Superoxide dismutase [Cu-Zn] 11 13 8 0 0 0 
Phosphoglycerate kinase 1 10 9 13 0 0 0 
Phosphoglycerate mutase 1 10 12 8 0 0 0 
sepiapterin reductase 8 9 3 0 0 0 
Isoform Mitochondrial of Fumarate 
hydratase, mitochondrial 
8 4 4 0 0 0 
10 kDa heat shock protein, 
mitochondrial 
7 12 10 0 0 0 
Proliferation-associated protein 2G4 7 10 8 0 0 0 
Adenylate kinase isoenzyme 2, 
mitochondrial 
7 6 6 0 0 0 
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CHAPTER 5 
QUALITATIVE AND QUANTITATIVE COMPARATIVE PROTEOMICS 
ANALYSIS FOR HUMAN OVARIAN CANCER CELL LINES – T-80 (NORMAL) 
VERSUS HEY (CANCEROUS) 
 
5.1 Overview 
Establishing the proof of concept for photolabeling of cell proteome using probe 
1a in N18TG2 cell proteome, which resulted in reproducible protein profiles within 
labeled and non-labeled domains and considerable enrichment of nucleotide binding 
proteins in labeled proteome as compared to the non-labeled proteome, the next goal was 
to utilize this methodology to compare the protein profiles of closely related cell lines.  
To demonstrate the utility of this analytical method to discover disease elated 
biomarkers, we analyzed proteome from two closely related cell lines, T-80 cells (non-
cancerous human ovarian cells) and Hey cells (cancerous human ovarian cells) to identify 
small variances in their protein profiles. Both cell lines were identically grown in RPMI 
1640 media and protein extracts were analyzed in the same manner as N18TG2 cells by 
labeling with photoaffinity probe followed by avidin affinity chromatography to isolate 
the labeled proteome. The changes in protein profile of labeled and non-labeled proteome 
were analyzed by Western Blot analysis and LC-MS/MS analysis in the same manner as 
for N18TG2 cells. The methods of analysis thus far were mainly focused on identifying 
the differences in expression of various cell proteins in normal versus diseased cells. To 
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further classify proteins which can be assigned as biomarkers, it is important to establish 
the quantitative changes that can be indicative of a certain condition(s). 
Therefore, the next step of the research involved the quantification of the 
identified proteins using Stable isotope labeling by amino acids in cell culture (SILAC) 
to compare proteomic profiles of two human-ovarian cell lines, T-80 cells (non-
cancerous) versus Hey cells (cancerous). SILAC followed by the use of nano-scale liquid 
chromatography coupled to electrospray ionization mass spectrometry has been 
employed for protein identification and quantification. The analysis of the protein 
mixture with a known heavy/light ratio showed reliable quantification using Maxquant. 
Finally, the Western Blot analysis of some of the identified proteins of interest using 
relevant antibodies for the ovarian cancer cell lines under study yielded data in 
concurrence with those obtained by proteomic analysis of the same samples by SILAC 
approach. 
 
5.2 Stable Isotope Labeling of Amino Acids in Cell Culture (SILAC) 
SILAC is a simple accurate and powerful approach widely used in mass 
spectrometry (MS)-based quantitative analysis of proteomes.
1,2
 SILAC labels complete 
cellular proteomes through incorporation of non-radioactive stable isotope-containing 
amino acids in newly synthesized proteins. Cells are grown in a specifically formulated 
culture medium with “heavy” amino acids containing a substituted stable isotope, such as 
arginine with six 
13
C atoms and four 
15
N atoms and/or lysine with six 
13
C atoms. Cells 
grown in this medium incorporate the heavy amino acids usually after five cell doublings. 
Since the peptides are isotopically distinctive, the light and heavy labeled peptides are 
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noticeably distinguishable by mass spectrometry. A small percentage of the sample is 
removed early on to check incorporation of the heavy amino acids and a growth of 5-8 
doubling times is recommended for a high incorporation. Samples should be mixed 
immediately after the cells are grown.  
Trypsin that cleaves at the carboxyl-termini of lysine and arginine residues is 
frequently used as proteolytic enzyme in proteomics workflows as it is a very aggressive 
yet specific protease.
3
 Therefore, SILAC using arginine and lysine as labeling amino 
acids combined with trypsin digestion is an ideal array wherein all peptides except the C-
terminal peptide of a protein are, technically quantifiable.
4
 As isotope-labeled 
13
C6 L-
lysine or 
13
C6, 
15
N4 L-arginine are biochemically identical to their natural analogs, there 
is no effect on cell morphology, signaling or growth rates. Also, the light and heavy 
amino acids are chemically identical and thus co-elute in SDS-PAGE and HPLC 
separation.  Typically two cell populations are grown identically with one comprising of 
natural amino acids (“light”) and other comprising of heavy isotopes of amino acids 
(“heavy”) to quantify differential changes in a particular protein(s) in the large proteome. 
The heavy and light cells can be treated for desired modifications, drug testing etc. The 
altered proteins can be enriched with various enrichment techniques. After enrichment of 
the desired proteins followed by proteolysis, pairs of equivalent precursor peptides can be 
correlated and quantified for their intensities using mass spectrometry-based relative 
protein quantification methods. When light and heavy cell populations are mixed, they 
remain distinguishable by MS, and protein abundances are determined from the relative 
MS signal intensities.  
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SILAC provides precise quantitative contrast between two proteomes without any 
chemical derivatization or manipulation. Figure 5.1 is a schematic representation of 
SILAC. It demonstrates the exemplary peaks for change in mass of the trypsin cleaved 
peptide with labeled lysine or arginine. As isotope-labeled 
13
C6 L-Lysine or 
13
C6 
15
N4 L-
arginine are biochemically identical to their natural analogs, there is no effect on cell 
morphology, signaling or growth rates. Typically two cell populations are grown 
identically with one comprising of natural amino acids (“light”) and other comprising of 
heavy isotopes of amino acids (“heavy”) to quantify differential changes in a particular 
proteome. When light and heavy cell populations are mixed, they remain distinguishable 
by MS, and protein abundances are determined from the relative MS signal intensities. 
SILAC provides accurate relative quantification without any chemical derivatization or 
manipulation and enables development of well-designed functional assays in proteomics. 
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Figure 5.1: Schematic Representation of SILAC 
 
The major applications of SILAC are as follows: 
 Quantitative analysis of relative changes in protein abundance from different cell 
treatments. 
 Quantitative analysis of proteins for which there are no antibodies available. 
 Protein expression profiling of normal versus disease cells. 
 Identification and quantification of hundreds to thousands of proteins in a single 
experiment. 
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5.3 SILAC Labeling for Comparative Analysis of Hey and T-80 Cells 
A double labeling SILAC approach where stable isotope labeled “heavy” lysine 
and arginine (Lys “6” and Arg “10” corresponding to a mass shift in 6 and 10 Da for 
lysine and arginine, respectively) replaced “light” lysine and arginine (Lys “0” and Arg 
“0”) in the ovarian cancer cell line growth media.  After metabolic labeling of all proteins 
(approximately 6 cell doublings), the samples were processed for mass spectrometric 
analysis. Normal T80 ovarian cells were grown in normal growth media whereas ovarian 
cancer (HEY) cells were grown in growth media supplemented with “heavy” 13C6 and 
15
N4- arginine and 
13
C6-lysine. 
5.3.1 Materials and Methods 
T-80 cells, derived from large T antigen/ hTERT immortalized normal ovarian 
surface epithelial cells, and Hey cells originally derived from peritoneal deposit of a 
patient with moderately differentiated papillary cystadeno carcinoma of the ovary were 
kindly provided by Dr. Meera Nanjundan (Department of Cell Biology, Microbiology 
and Molecular Biology, University of South Florida). SILAC RPMI media (cat# 89982) 
and 
13
C6, 
15
N4-arginine (cat# 89990) were purchased from Pierce. Fetal bovine serum 
(FBS) was purchased from Atlanta Biologicals. PVDF membrane was purchased from 
Millipore. Tween-20 was purchased from Sigma-Aldrich. SuperSignal chemiluminescent 
detection system was purchased from Pierce. Monomeric Avidin Kit/beads (cat # 20227) 
were purchased from Pierce. Probe 1a and 1b were synthesized as described earlier (in 
Chapter 3), and dissolved in 1:1 methanol:water as a 10 mM probe solution. All other 
reagents and cell culture supplies were of the highest quality available from commercial 
suppliers. 
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The schematic diagram for proteomic analysis of Hey and T-80 cells for 
comparative analysis is shown in Figure 5.2. All samples were prepared in triplicates. 
5.3.1.1 Cell Culture 
T-80 cells were grown in “light” SILAC RPMI 1640 medium, and Hey cells were 
grown in “heavy” SILAC RPMI 1640 medium supplemented with 8% fetal bovine serum 
and 1% penicillin-streptomycin (from Thermofisher) in 225 cm
2
 culture dishes at 37˚C 
and 5% CO2 according to supplier instructions. Cultures were gown to 85-90% 
confluency, washed with PBS and trypsinized. While growing these cells, the cells were 
washed with PBS before passaging to next cycle in order to remove any traces of trypsin 
during the culturing time. This was done as the growth of the cells is very slow in 
presence of traces of trypsin. Cells were collected by centrifugation, rinsed with PBS, and 
re-pelleted before removal of supernatant. A 1:1 mixture of light and heavy cells was 
analyzed for heavy to light ratio (H/L ratio) by mass spectrometry after 6 doublings to 
ensure complete isotope labeling. The pelleted cells were stored at -80˚C until further 
investigation. 
5.3.1.2 Cell Lysis 
Both T-80 (light) and Hey (heavy) Cells were thawed on a shaker to bring them to 
room temperature. Approximately 10
6
-10
7
 cells from both cell lines i.e. T-80 and Hey 
cells were treated with 800 µl of Lysis Buffer containing 20 mM Tris-HCl (pH 7.4), 2 
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1% (v/v) Triton X-100, and 1% 
(v/v) of a commercially available protease inhibitor cocktail (Sigma). Cells were then 
sonicated using a microprobe sonicator for 5 minutes on ice and centrifuged for 5 minutes 
@ 13.2 (x1000 rpm). Supernatant containing the soluble cell proteome was analyzed for 
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protein concentration via Bradford Dye Binding Assay
5
 using BSA as standard. 
Equimolar concentration of both T-80 and Hey cell proteome were mixed to get an 
approximately 20mg/ml total concentration. 
5.3.1.3 Removal of Endogenous Avidin Binding Proteins 
Endogenous avidin binding proteins were eliminated from the soluble proteome 
using the Pierce® Monomeric Avidin Kit. Initially detailed instructions manual available 
for the product was followed and a few changes were introduced later to enhance and 
optimize the separation efficiency. All solutions (PBS, biotin blocking solution and 
regeneration buffer) were brought to room temperature. A disposable column was filled 
with 2ml of resin slurry (eqv. to 1ml resin) and the stored PBS (from the resin) was 
allowed to flow through the column. The non-reversible biotin-binding sites on the 
column were blocked using manufacturer’s instructions. PBS Wash and Regeneration 
Wash were collected as presented earlier (in Chapter 4).  
5.3.1.4 Photolabeling of Proteome and Sample Preparation for Mass Spectrometry 
Approximately 10mg of protein (1:1 mixture from both cell lines) was incubated 
on the Pierce® Monomeric Avidin column (2 ml) for 30 minutes for the removal of 
endogenous avidin binding proteins from the soluble proteome. 2mg of the non-avidin 
binding proteome (PBS Wash) from the column for both cell lines were treated with 
probe 1a in presence of UV light using UV filter for wavelength > 295nm for 2 minutes. 
The labeled proteome was immediately washed through 10kD Millipore ultracentrifuge 
filters using PBS to remove any unbound probe and prevent further unspecific labeling. 
Labeled proteome was then isolated from non-labeled proteome using Pierce® 
Monomeric Avidin Kit. Approximately 2 mg treated protein samples were loaded to the 
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center of the disk of a 1ml avidin column and washed with PBS till no protein was 
detected using Bradford Dye Binding Assay.
5
 The column was further washed with 2mM 
biotin solution to remove loosely bound proteome till no absorbance was observed using 
Bradford dye binding assay.
5
 Finally, the column was washed with 0.1 M glycine, pH 2.8 
solution to elute the strongly bound proteome from the avidin column. The fractions 
containing protein were combined and labeled as PBS Wash (or non-labeled proteome), 
Biotin Wash, and Regeneration Wash (or labeled proteome). Protein samples were 
analyzed for concentration using Bradford dye binding assay
5
 and equal amount (in mg) 
for each sample wash from cells lines to be compared were boiled with sample buffer for 
5 minutes (detailed procedure same as Section 4.3). 
5.3.1.5 1D Gel Electrophoresis for Western Blot 
Approximately, 10µg of protein from labeled and unlabeled fractions of 1:1 
mixture from both cell lines were subjected to electrophoretic separation on a 10% SDS-
PAGE minigel at 120 V for 45 minutes. The gel was electroblotted to a PVDF membrane 
at 70 V for 90 minutes at 4˚C. The membrane was then blocked using 5% non-fat dry 
milk in TBST buffer for an hour at room temperature followed by incubation with an 
anti-biotin antibody HRP conjugate (Sigma) in 1% non-fat dry milk in TBST buffer at 
4˚C overnight. The membrane was washed with TBST (3X20ml) for 10 minutes each. 
The membrane was then developed using SuperSignal West Pico Chemiluminescent 
Substrate, and exposed to CL-XPosure film. 
5.3.1.6 1D Gel Electrophoresis for Protein Digestion 
Approximately, 30µg of protein from labeled and unlabeled fractions from 1:1 
mixture from both cell lines were subjected to electrophoretic separation on a 10% SDS-
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PAGE minigel at 120V for 30 minutes. The migration was stopped after the front had 
moved by about 3 cm into the separating gel so that the bands of a prestained molecular 
weight marker were visible and separated in the 20-250 kDa range. The SDS-PAGE gel 
was stained using Coomassie blue staining protocol and complete lanes of the cell 
proteome were cut for MS analysis (Detailed procedure same as Section 4.3). 
5.3.1.7 In-gel Protein Digestion with Trypsin 
Gel slices excised from SDS-PAGE gels using clean scalpel for each lane to avoid 
any contamination were transferred to the Eppendorf tubes washed with acentonitrile and 
dried under nitrogen. The gel pieces were all washed with 50% acetonitrile in distilled 
water with vortexing for 15 minutes each for 2-3 times and covered with neat acetonitrile 
for 10 minutes. The gels were rehydrated with 100 mm ammonium bicarbonate (ABC) 
for 5 minutes followed by addition of acetonitrile to give 1:1 ratio of ABC/ACN and 
vortexed for another 15 minutes. The gels were left in this solution for 6-12 hours to 
destain completely. The gel pieces were reduced using 45mM dithiothreitol (DTT) at 
55˚C for 30 minutes. The reducing agent was then replaced by freshly prepared 100mM 
iodoacetamide (IAA) for carbamidomethylation in dark at room temperature for 30 
minutes. The gel pieces were washed with 50% ACN/50mM ABC with vortexing for 15 
minutes each for 3 times or till the gel pieces were completely colorless. In-gel 
proteolytic cleavage with sequencing grade trypsin (Promega, Madison, WI), 12.5ng/µl 
in 50mM ABC was performed with protein to enzyme ratio around 20:1 overnight at 
37˚C. The supernatant from the gels was transferred to another eppendorf tube and the 
action of trypsin was stopped by adding 5% HAc to get final concentration of 0.5% HAc. 
The gel pieces were then washed with 1:1 ACN/water containing 0.01% formic acid with 
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vortexing for 15 minutes. The supernatant was then combined with the trypsin digest. 
Digests were desalted using reverse phase C18 mini columns which have an estimated 
loading capacity equal to 30-60µg. The peptides were eluted from the microcolumns with 
90% acetonitrile. The elute from the columns was recovered and the volume of the 
trypsin digest was reduced by evaporation on a vacuum pump. The final volume was 
adjusted to 40µl with 0.1% formic acid. 5µl of protein digest sample were injected on a 
10cm X 75µm i.d. reversed-phase column packed with 5 mm, 300 A˚ C18 material (New 
Objective, Woburn, MA) and separated by a nanoflow liquid chromatography using 90-
min linear gradients from 2 to 40% ACN at 250nL/min. using a hybrid linear ion trap-
Orbitrap mass spectrometer (LTQ Orbitrap XL, Thermo, San Jose, CA) equipped with a 
nanoelectrospray ionization source and operated with the Xcalibur (version 2.0) data 
acquisition software. 
5.3.1.8 Database Searching 
MS/MS data generated by data-dependent acquisition via the LTQ-Orbitrap were 
extracted against the IPI_human_random-v3.54 database (for Hey and T-80 cell 
proteome) protein databases containing both forward and randomized sequences using 
the Mascot (version 2.2.1; Matrix Science, Boston, MA) search algorithm.  Separate 
Mascot searches were performed using a fragment ion mass tolerance of 0.60 Da and a 
parent ion tolerance of 10 ppm.  Iodoacetamide derivative of cysteine was specified in 
Mascot as a fixed modification. Oxidation of methionine, acetylation of aspargine  and 
+6 on K (
13
C6) and +10 on R (
13
C6,
15
N4) were specified as variable modifications in the 
database search. The Mascot multidimensional protein identification technology 
(MudPIT) scoring system was used for all analyses of mixtures (the unlabeled sample 
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was analyzed with standard scoring) with significance threshold at p = 0.05 and minimum 
ion score equal to 9.  
5.3.1.9 Protein Identification 
A. Scaffold Analysis 
The software program Scaffold (version Scaffold 3, Proteome Software Inc., 
Portland, OR) was then employed to compile and validate tandem MS-based peptide and 
protein identifications.  Peptides identified with greater than 95.0% probability as 
determined by the Peptide Prophet algorithm
6
 were accepted.  Proteins identified with 
greater than 99.0% probability were accepted and excluded single peptide-based 
identifications. This filtering criteria established a false positive identification rate 
[(number of randomized peptide sequences identified/total number of peptides identified) 
x 100%] of ~ 0% for the IPI_human proteome data set based on the reported decoy 
database search strategy. The accepted proteins were analyzed through the use of IPA, 
(Ingenuity® Systems, www.ingenuity.com) and Panther (pantherdb.org). 
B. Maxquant Analysis 
Raw MS/MS files from LTQ-orbitrap were analyzed by Maxquant (version 
1.2.0.13) supported by Andromeda as the database search engine for peptide 
identification. MS/MS spectra were searched against a concatenated non-redundant 
Uniprot decoy database. Protein sequences of common contaminants like trypsin and 
keratins were used in “contaminants.fasta” database to remove any contaminants from the 
observed data. Peptide tolerance of 20ppm, lysine (+6) and arginine (+10) as special 
amino acids and minimum ratio count as 1 along with default settings for other 
parameters were used for peptide quantification. Bioinformatics analysis of Maxquant/ 
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Andromeda work flow output and the analysis of the abundances of the identified 
proteins were performed with the Perseus module (available with the Maxquant suite). 
Peptides and proteins with false discovery rate (FDR) of less than 1% and at least 2 
unique peptides were accepted as hits. The summary file containing summary 
information for all the raw files processed with a single MaxQuant run such as MaxQuant 
parameters, information of the raw file contents, and statistics on the peak detection is 
attached as appendices. Based on this file a quick overview can be gathered on the quality 
of the data in the raw file. The accepted proteins were analyzed through the use of IPA, 
(Ingenuity® Systems, www.ingenuity.com) and Panther (pantherdb.org). 
5.3.2 Discussion and Results 
A total of 327 proteins were identified using Scaffold. The average of spectrum 
counts from triplicate runs for labeled, non-labeled and whole cell lysate were 
calculated and the difference between the labeled and non-labeled was determined. The 
proteins enriched in labeled and non-labeled fractions were subjected to Gene Ontology 
(GO) data using panther database analysis. The classification based on Protein Class 
shown in Figure 5.2 indicates an enrichment of nucleotide binding proteins in labeled 
proteome. This was similar to the experiment discussed earlier (in Chapter 4). Though 
we have shown the concept of enrichment of nucleotide binding proteins earlier in 
N18TG2 cells, it was important to test it with Hey cells and T-80 cells as well. 
TUBB Tubulin beta chain, TUBB2C Tubulin beta-2C chain, TUBA1A Tubulin 
alpha-1A chain, TUBA1B Tubulin alpha-1B chain, and TUBB3 Tubulin beta-3 chain are 
among the top 5 proteins that were completely labeled and hence entirely absent in PBS 
Wash (non-labeled fraction). The beta-tubulins are microtubule components encoded by a 
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multigene family, which generates slightly different proteins with complex expression 
patterns. In tumoral tissues, most isotypes demonstrate an altered expression in specific 
tumor types or related to tumoral characteristics. Therefore, interactions which involve 
beta-tubulin binding, microtubule dynamics alteration, and cell division blockage are the 
target of several widely used anticancer drugs activity. The expression of these drug 
targets in tumoral and normal cells could be of fundamental importance for therapy 
outcome. The expression patterns for the complex beta-tubulin have not been well 
described in human cells. Enrichment of these proteins in labeled proteome can serve as a 
platform to study the very small changes in their expressions as biomarkers for tumor 
cells.
7
 CLTC Isoform 1 of clathrin heavy chain 1, which is also exclusively present in 
labeled proteome fraction has also been shown to express significantly higher in 
hepatocellular carcinoma (HCC). It is important to mention here that this protein cannot 
be detected significantly in whole cell lysate or non-labeled fractions (spectral counts less 
than 2).  
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Figure 5.2: Identified Protein Classes: Labeled, non-labeled and whole cell lysate 
proteome from Hey and T-80 cells using probe 1a 
 
Entries marked in bold in Table 5.1 are some of the identified proteins that have 
not been detected in whole cell lysate or non-labeled fractions but shows significant 
spectral count data in labeled proteome. This emphasizes the importance for affinity-
based enrichment in analysis of such proteins in a complex protein sample.
8
 It is 
important to note that this approach is not aimed to purify AdoR-binding proteins but to 
enrich AdoR-binding proteins and interacting partners in order to generate reproducible 
proteome profiles that will enhance cancer biomarker discovery.  ATP5A1 ATP synthase 
subunit alpha, mitochondrial is another protein found exclusively in labeled proteome. 
The exon 3 of the alpha subunit of ATP synthase has been reported to be involved in 
duplication of four nucleotides involved in colorectal cancer.
9
 A decrease in the 
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expression of ATP5B has been indicative of various cancers including lung, liver, kidney 
colon carcinomas.
10,11  
It has been reported that
 
the decrease in appearance of ATP5A1  
may be involved in development of resistance to 5-fluorouracil in colon cancer cells.
9
  
 
Table 5.1: Spectral Count Data from Scaffold Analysis for Hey and T-80 Cells used 
in SILAC Quantification 
 Protein 
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1 TUBA1A Tubulin 
alpha-1A chain 
1 86 81 75 1 1 1 
2 TUBB2C Tubulin 
beta-2C chain 
45 75 95 77 1 1 1 
3 TUBB3 Tubulin beta-3 
chain 
29 61 75 63 1 1 1 
4 CLTC Isoform 1 of 
Clathrin 
 heavy chain 1 
3 29 25 14 1 1 1 
5 DYNC1H1 
Cytoplasmic dynein 1 
 heavy chain 1 
1 26 25 27 1 1 1 
6 TCP1 T-complex 
protein 1 subunit 
 Alpha 
1 26 18 20 1 1 1 
7 ATP5A1 ATP 
synthase subunit alpha,  
Mitochondrial 
14 19 15 18 1 1 1 
8 ATP1A1 Isoform Long 
of Sodium/potassium- 
transporting ATPase 
subunit alpha-1 
2 18 12 17 1 1 1 
9 LGALS1 Galectin-1 5 15 15 12 1 0 1 
10 GNB2L1 Guanine 
nucleotide-binding 
protein subunit beta-
2-like 1 
1 15 13 14 1 1 1 
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Table 5.1 (contd.) 
11 CAND1 Isoform 1 of 
Cullin-associated 
NEDD8- 
dissociated protein 1 
1 15 7 8 1 1 1 
12 PSMD2 26S 
proteasome non-
ATPase  
regulatory subunit 2 
1 14 9 13 1 1 1 
13 RPS12 ribosomal 
protein S12 
3 14 11 10 1 1 1 
14 PHGDH D-3-
phosphoglycerate  
Dehydrogenase 
2 13 11 12 1 1 1 
15 ASNS Asparagine 
synthetase glutamine-
hydrolyzing 
1 11 15 16 1 1 1 
16 XPO1 Exportin-1 1 11 11 13 1 1 1 
17 LDHB L-lactate 
dehydrogenase B chain 
9 11 11 12 1 3 3 
18 COPG Coatomer 
subunit gamma 
1 11 7 10 1 1 1 
19 HIST1H1C Histone 
H1.2 
1 11 8 7 1 1 1 
20 CCT3 chaperonin 
containing TCP1,  
subunit 3 isoform b 
1 11 11 4 1 1 1 
21 RPS3 40S ribosomal 
protein S3 
1 10 12 9 1 1 1 
22 IPO7 Importin-7 1 10 8 8 1 1 1 
23 CSE1L Isoform 1 of 
Exportin-2 
3 10 7 4 1 1 0 
24 EPRS Bifunctional 
aminoacyl-tRNA  
Synthetase 
1 9 11 9 1 1 1 
25 RARS isoform 
complexed of arginyl-
tRNA synthetase, 
cytoplasmic 
1 9 9 7 1 1 1 
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Table 5.1 (contd.) 
26 PRDX4 
Peroxiredoxin-4 
1 9 7 1 1 4 2 
27 SLC25A5 ADP/ATP 
translocase 2 
2 8 9 7 1 1 1 
28 PPP1CC Isoform 
Gamma-1 of  
Serine/threonine-
protein phosphatase 
 PP1-gamma catalytic 
subunit 
3 8 7 7 1 1 1 
29 EIF4A1 Eukaryotic 
initiation factor 4A-I 
6 8 5 4 1 1 1 
30 GNB2 Guanine 
nucleotide-binding 
protein G(I)/G(S)/G(T) 
subunit beta-2 
1 8 5 1 1 1 0 
31 PCBP1 Poly(rC)-
binding protein 1 
1 8 6 1 1 2 1 
32 SURF4 isoform 1 of 
surfeit locus protein 4 
1 7 8 10 1 1 1 
33 LARS Leucyl-tRNA 
synthetase, 
cytoplasmic 
1 7 8 8 1 1 1 
34 RPL30 60S ribosomal 
protein L30 
1 7 6 7 1 1 1 
35 CCT5 T-complex 
protein 1 subunit 
epsilon 
1 7 6 5 1 1 1 
36 IPO5 importin 5 3 7 6 5 1 1 1 
Entries in bold represent the proteins identified in labeled proteome that were not 
detected in whole cell lysate. 
 
We also validated our results by performing Western Blots for selected AdoR-
binding proteins whose expression is significantly modified in Hey ovarian cancer cells. 
The Western Blot analysis for the expression of Hsp 60 and Hsp 90 in subsample of the 
initial cell lysate that was used for proteomic analysis but was removed prior to trypsin 
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digestion using HRP conjugate (Cell Signaling technology), resulted in the expected 
observation that was in agreement with the proteomic data. 
Upon analysis of the AdoR-binding proteome using ingenuity software, 
approximately 58 “differentially expressed” proteins that corresponded to a relatively 
low false positive rate (FPR) of <1% were identified. The results from this analysis 
demonstrate that this is a competent method to identify several Ador-binding proteins 
relevant to our hypothesis. Out of 58 mapped proteins in T-80 and Hey cells that show 
ratio values 1 standard deviation away from the median value of the dataset (at <1% 
FPR data set), 31% were associated with biological processes implicated in cancer 
(p=5.3•10-6). Table 5.2 lists all the proteins that expresses differently in Hey versus. T-
80 cells and have been associated with various types of cancers. Proteins that have been 
correlated to ovarian cancer are marked in bold. The information provide a prospective 
to exploit this methodology in order to advance our knowledge of protein-related 
changes using multidimensional separation techniques prior to tandem mass 
spectrometric analysis. 
Table 5.2: Functions Annotations of Proteins Expressing Changes in Hey versus. 
T-80 Cells (using Ingenuity Systems) 
Type of Cancer p-Value Names of Identified Proteins Number 
of 
Identified 
Proteins 
tumorigenesis  5.33E-06 ALDH1A3, EIF4A1, FLNA, 
FLNC, HSP90AA1, HSPA5, 
HSPB1, KRT18, KRT8, NCL, 
NPM1, P4HB, PHGDH, 
PRDX1, PRDX2, STIP1, 
TGM2, VIM 
 18 
carcinoma 3.01E-05 EIF4A1, FLNA, FLNC, 
HSP90AA1, HSPA5, KRT18, 
NCL, NPM1, P4HB, STIP1, 
VIM 
 11 
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Table 5.2 (Contd.) 
Cancer  3.99E-05 ALDH1A3, EIF4A1, FLNA, 
FLNC, HSP90AA1, HSPA5, 
HSPB1, KRT18, KRT8, NCL, 
NPM1, P4HB, PHGDH, 
PRDX1, STIP1, VIM 
 16 
Tumor 1.44E-04 EIF4A1, FLNA, FLNC, 
HSP90AA1, HSPA5, KRT18, 
NCL, NPM1, P4HB, PRDX2, 
STIP1, TGM2, VIM 
 13 
digestive organ 
tumor 
6.66E-04 HSP90AA1, HSPA5, KRT18, 
P4HB, STIP1, VIM 
 6 
liver cancer 7.46E-04 HSP90AA1, HSPA5, NPM1, 
PHGDH, PRDX1 
 5 
chemosensitivity of 
tumor cells 
1.68E-03 TGM2  1 
metastasis of 
papillary thyroid 
carcinoma 
1.68E-03 VIM  1 
cholangiocarcinoma 2.68E-03 HSP90AA1, VIM  2 
Carney complex 
type 1 
3.35E-03 VIM  1 
prostatic tumor 3.36E-03 FLNA, FLNC, HSP90AA1, 
NCL 
 4 
head and neck 
tumor 
5.68E-03 HSP90AA1, HSPA5, KRT18, 
VIM 
 4 
breast cancer 7.41E-03 ALDH1A3, EIF4A1, 
HSP90AA1, KRT18, KRT8, 
P4HB 
 6 
mesothelioma 8.08E-03 HSP90AA1, VIM  2 
bone tumor 1.03E-02 HSP90AA1, NPM1  2 
large cell lung 
carcinoma 
1.17E-02 EIF4A1  1 
plasmacytoma 1.17E-02 NPM1  1 
non-small cell lung 
cancer 
1.61E-02 EIF4A1, HSP90AA1, VIM  3 
transformation of 
fibroblasts 
1.63E-02 NPM1, PRDX1  2 
squamous cell 
tumor 
1.68E-02 HSP90AA1, HSPA5, NPM1  3 
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Table 5.2 (contd.) 
prostatic carcinoma 1.71E-02 FLNA, FLNC, NCL  3 
prostate cancer 2.03E-02 FLNA, FLNC, HSP90AA1, 
NCL 
 4 
follicular adenoma 2.32E-02 PRDX2  1 
gastrointestinal 
tumor 
2.53E-02 HSP90AA1, P4HB  2 
transformation of 
eukaryotic cells 
3.18E-02 HSP90AA1, NPM1, PRDX1  3 
bladder carcinoma 3.30E-02 HSP90AA1  1 
cervical cancer 3.60E-02 HSP90AA1, HSPB1  2 
ovarian cancer 3.90E-02 HSP90AA1, STIP1, VIM  3 
skin squamous cell 
carcinoma 
3.95E-02 HSPA5  1 
adenocarcinoma 3.97E-02 EIF4A1, HSP90AA1, VIM  3 
skin tumor 4.60E-02 HSP90AA1, HSPA5  2 
nasopharyngeal 
carcinoma 
4.75E-02 HSP90AA1  1 
 
Differential abundance of proteins associated with ovarian cancer biology is of 
particular interest. Upon quantitative analysis of the SILAC labeled peptides pairs 
which are used as surrogate markers for protein expression or activity alterations, we 
found several interesting proteins that were present at different abundance levels in 
ovarian cancer cells compared to normal cells.  For example, proteins, vimentin, HSP90 
(Heat Shock Protein 90), and stress induced phosphoprotein 1 (STIP1; HSP70/HSP90 
organizing protein) identified from the SILAC analysis have been associated with 
ovarian cancer (p=3.9•10-3). Vimentin and STIP1 have both been recently proposed as 
biomarkers of ovarian cancer and HSP90 is currently a drug target for treatment of 
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ovarian carcinoma.
12,13,14
 Peroxiredoxin 1 and peroxiredoxin 2 which are found from 
this data  have been associated with different forms of cancer including lung, breast and 
prostate cancer.
15,16
 Although, peroxiredoxin have not been correlated to ovarian cancer 
directly, it can be a potential biomarker for ovarian cancer. A modest panel of 
biomarkers for ovarian cancer cells has been generated in one global-scale analysis 
which has been corroborated by several individual studies investigating ovarian cancer. 
The extensive list of AdoR-binding proteins that show altered expression or activity can 
provide a high impact proteome dataset that can be used for future clinical validation in 
human ovarian cancer patients in order to access biomarker sensitivity and specificity 
for improved prognosis and diagnosis of this disease. Table 5.3 and Table 5.4 lists the 
proteins up-regulated and down-regulated in Hey cells compared to T-80 cells by 
Ingenuity System Analysis and literature information. 
 
Table 5.3: Fold Change Up-Regulated in Hey Cells Compared to T-80 Cells (using 
Ingenuity Systems) 
Molecules  Exp. Value  Type of cancer associated  
HIST1H1B  9.918  Several 
NCL  7.727   
VIM  7.311  cancer, thyroid cancer, head and neck 
cancer, metastasis, Carney complex type 1, 
scleroderma, endometriosis, cerebral 
amyloid angiopathy, bile duct cancer, 
cholangiocarcinoma, cervical carcinoma, 
colon cancer, colon carcinoma, liver 
cancer, papillary thyroid cancer, papillary 
thyroid carcinoma, uterine cancer  
STIP1  5.657  cancer, colon cancer, colon carcinoma  
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Table 5.3 (contd.) 
HIST1H1D  4.199  Several 
HIST1H1E  4.112  Several 
NPM1  4.112  acute myeloid leukemia, cancer, tumor, 
lymphoid cancer, lymphomagenesis, 
hematological neoplasia, bone cancer, oral 
squamous cell carcinoma, neoplasia, 
tumorigenesis  
MVP  4.084  breast cancer, colon cancer 
HIST1H1C  4.056  Several 
RPS12  3.811  Several 
 
 
Table 5.4: Fold Change Down-Regulated in Hey Cells Compared to T-80 Cells 
(using Ingenuity Systems) 
Molecules  Exp. Value  Type of cancer associated  
HSPB1  5.134  Cancer, liver cancer, hepatocellular 
carcinoma, basal-cell carcinoma, skin 
cancer, skin squamous cell carcinoma, 
breast cancer, cervical cancer, cervical 
adenocarcinoma, carcinoma  
EIF4A1  4.627  breast cancer, cancer, infiltrating duct 
breast carcinoma, lung adenocarcinoma, 
non-small cell lung cancer, non-small-cell 
lung carcinoma, lung cancer, large cell 
lung carcinoma  
KRT18  3.364  oral cancer, mucoepidermoid carcinoma, 
metastatic colorectal cancer, breast cancer, 
cancer  
RPS5  3.317  Several 
PRDX2  3.249   
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Table 5.4 (contd.) 
HSP90AA1  3.204  cancer, lung cancer, breast cancer, head 
and neck cancer, ovarian cancer, prostate 
cancer, liver cancer, osteosarcoma, 
multiple myeloma, squamous-cell 
carcinoma, sarcoma, bladder carcinoma, 
prostatic neoplasm, soft tissue sarcoma, 
renal cancer, melanoma metastases, 
colorectal cancer, gastrointestinal stromal 
tumor, nasopharyngeal carcinoma, 
melanoma, mesothelioma, non-small cell 
lung cancer, adult solid tumor, small 
intestine cancer, malignant cutaneous 
melanoma, cervical neoplasm, fallopian 
tube cancer, lymphoid cancer, ovarian 
carcinoma, cervical cancer, colon 
carcinoma, gastric cancer, colon cancer, 
bile duct cancer, cholangiocarcinoma, 
Huntington's disease, liver neoplasia, 
hepatocellular carcinoma, lung 
adenocarcinoma, Waldenstrom's 
macroglobulinemia, bronchiolo-alveolar 
adenocarcinoma  
ALDH1A3  3.204  breast cancer  
HSPA5  3.182  liver cancer, hepatocellular carcinoma, 
cancer, brain cancer, skin cancer, skin 
squamous cell carcinoma  
FLNA  2.949   
FLNC  2.828   
 
A proteomic profile shift in the normal log(2) distribution curve for change in 
expression of proteins in cell lysate and labeled proteome is shown in Figure 5.3. The X-
axis of the graph represents the log(2) of the ratios of heavy (in cancerous) to light (in 
non-cancerous) isotopes of identified proteins and Y-axis represents the number of 
proteins in the corresponding ratio intervals in the cell lysate and labeled proteome 
fraction respectively using Maxquant. The graph shows that a large number of proteins 
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have unaltered expression levels in cell lysate i.e. have a ratio close to one as expected in 
normal distribution. The data from Figure 5.3 further supports that the expression of 
heavy to light proteins in cell lysate is significantly different from that in the labeled 
proteome and hence useful in evaluating changes in expression of proteins that may not 
be identified in whole cell lysate. Some proteins for which the change in ratio in cell 
lysate and labeled proteome can be calculated are listed in Table 5.5. The complete list of 
identified proteins is attached in Appendix 2. 
 
Figure 5.3: Ratio Distribution of Proteins in Heavy versus Light (H/L) Ovarian 
Cells 
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Table 5.5: Ratio of Average of Labeled versus Cell Lysate Proteins (Probe 1a) 
Protein Descriptions Cell-Lysate Proteome Labeled Proteome Labele
d/Cell 
Lysate 1 2 3 1 2 3 
Macrophage-capping 
protein  
27.96 44.09 29.47 150.20 40.21 123.51 3.09 
X-ray repair cross-
complementing protein 5  
1.38 1.44 1.27 1.32 9.05 1.65 2.94 
Activated RNA 
polymerase II 
transcriptional coactivator 
p15  
0.17 0.20 0.19 0.45 0.96 0.07 2.63 
Protein-glutamine gamma-
glutamyltransferase 2  
53.41 15.49 42.33 157.36 33.55 101.78 2.63 
Protein S100-A11  2.18 2.77 2.26 3.56 6.72 3.40 1.90 
Chloride intracellular 
channel protein 4  
2.07 1.86 1.70 1.31 4.93 1.61 1.39 
Glyceraldehyde-3-
phosphate dehydrogenase  
1.51 1.53 1.56 1.87 2.08 1.83 1.26 
Heat shock protein HSP 
90-beta  
1.16 1.30 1.27 1.20 2.02 1.24 1.19 
Uncharacterized protein  0.71 0.63 0.97 0.41 1.46 0.73 1.13 
Isoform Short of 14-3-3 
protein beta/alpha  
1.31 1.41 1.38 1.13 1.85 1.60 1.12 
Heat shock protein beta1  0.01 0.02 0.03 0.03 0.02 0.02 1.05 
Alpha-enolase  0.35 0.26 0.43 0.26 0.48 0.35 1.05 
Peptidyl-prolyl cis-trans 
isomerase B  
1.20 1.29 1.26 0.66 2.02 1.22 1.04 
Uncharacterized protein  0.95 0.95 0.97 0.75 1.28 0.96 1.04 
Isoform 2 of Heat shock 
protein HSP 90-alpha  
1.87 2.12 2.18 1.77 2.78 1.84 1.04 
Moesin  1.62 1.76 1.86 1.29 2.27 1.74 1.01 
Transitional endoplasmic 
reticulum ATPase  
1.30 1.39 1.42 0.75 2.37 1.01 1.01 
Chloride intracellular 
channel protein 1  
0.94 1.01 0.45 0.27 1.36 0.75 1.00 
Obg-like ATPase 1  1.17 1.17 1.41 1.08 1.45 1.20 1.00 
Actin, cytoplasmic 2  0.94 0.94 0.96 0.76 0.97 1.10 0.99 
Isoform 2 of Annexin A2  2.32 2.42 2.50 1.85 2.92 2.32 0.98 
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Table 5.5 (contd.) 
Protein disulfide-
isomerase A3  
0.90 0.80 0.89 0.55 1.12 0.87 0.98 
Peptidyl-prolyl cis-trans 
isomerase A  
1.34 1.31 1.46 1.21 1.58 1.21 0.97 
Annexin A5  1.15 1.22 1.21 0.89 1.52 1.03 0.96 
14-3-3 protein zeta/delta  1.44 1.49 1.41 1.12 1.51 1.51 0.95 
Nucleoside diphosphate 
kinase  
1.16 1.33 1.22 0.92 1.59 1.02 0.95 
Eukaryotic initiation factor 
4A-I  
1.10 1.33 1.13 0.76 1.57 1.04 0.95 
High mobility group 
protein B1  
0.75 0.70 0.93 0.33 1.28 0.57 0.92 
14-3-3 protein epsilon  0.05 0.07 0.11 0.03 0.13 0.05 0.92 
Protein DJ-1  0.71 0.68 0.73 0.54 0.87 0.53 0.91 
Calreticulin  0.93 0.83 0.94 0.25 1.23 0.97 0.91 
L-lactate dehydrogenase B 
chain  
1.05 1.02 1.08 0.90 0.95 1.02 0.91 
Annexin A1  1.84 1.87 1.88 1.32 2.11 1.58 0.90 
Pyruvate kinase isozymes 
M1/M2  
0.58 0.62 0.63 0.15 0.87 0.60 0.89 
Galectin-1  0.63 0.81 0.80 0.14 1.04 0.81 0.89 
Heat shock cognate 71 
kDa protein  
1.74 1.70 1.79 1.23 1.84 1.53 0.88 
78 kDa glucose-regulated 
protein  
1.21 1.24 1.33 0.70 1.32 1.29 0.88 
Isoform 2 of Tropomyosin 
alpha-3 chain  
0.83 0.81 0.95 0.31 1.18 0.73 0.86 
Adenylyl cyclase-
associated protein 1  
0.96 1.10 1.04 0.76 0.91 0.95 0.85 
Triosephosphate isomerase  0.69 0.63 0.64 0.33 0.73 0.58 0.83 
Profilin-1  0.78 0.83 0.82 0.62 0.83 0.51 0.81 
Ezrin  0.45 1.05 0.46 0.15 0.91 0.50 0.80 
Alpha-actinin-4  1.41 1.65 1.52 0.90 1.41 1.24 0.78 
L-lactate dehydrogenase A 
chain  
0.65 0.70 0.82 0.50 0.52 0.58 0.74 
14-3-3 protein theta  0.72 0.64 0.75 0.26 0.82 0.47 0.73 
Nucleophosmin  2.26 2.39 2.43 1.23 2.31 1.60 0.73 
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Table 5.5 (contd.) 
Uncharacterized protein  0.88 0.81 0.85 0.34 1.10 0.37 0.71 
Putative heat shock protein 
HSP 90-beta 4  
1.53 1.56 1.55 0.80 1.73 0.63 0.68 
Heat shock 70 kDa protein 
6  
1.19 1.23 1.30 0.63 1.03 0.79 0.66 
Phosphoglycerate mutase  0.60 0.74 0.66 0.48 0.57 0.25 0.65 
Fructose-bisphosphate 
aldolase A  
0.46 0.52 0.60 0.15 0.57 0.30 0.64 
Isoform 2 of Protein 
disulfide-isomerase A6  
0.78 0.80 0.76 0.10 0.94 0.34 0.59 
Glucose-6-phosphate 
isomerase  
0.44 0.42 0.29 0.14 0.44 0.08 0.58 
Phosphoglycerate kinase   0.78 0.90 1.01 0.21 0.81 0.51 0.57 
Polyubiquitin-C  1.19 1.28 1.28 0.56 0.71 0.86 0.57 
Elongation factor 2  0.60 0.64 0.62 0.12 0.52 0.42 0.56 
Ubiquitin-like modifier-
activating enzyme 1  
0.60 0.56 0.52 0.35 0.16 0.39 0.54 
Protein SET  0.98 0.73 1.87 0.15 1.08 0.70 0.54 
Isoform C of Prelamin-
A/C  
1.53 1.57 1.72 0.63 0.87 0.91 0.50 
Histone H2B  0.77 0.74 0.70 0.05 0.67 0.36 0.49 
Nucleolin  3.24 2.80 2.97 0.98 2.36 1.07 0.49 
Protein disulfide-
isomerase  
0.65 0.61 0.68 0.11 0.40 0.44 0.49 
Peroxiredoxin-6  0.80 0.82 0.77 0.17 0.75 0.25 0.49 
Proliferating cell nuclear 
antigen  
0.38 0.52 0.63 0.10 0.56 0.09 0.49 
Heterogeneous nuclear 
ribonucleoproteins A2/B1  
1.73 1.53 1.87 0.77 0.99 0.68 0.48 
Heat shock 70 kDa protein 
1A/1B  
0.25 0.12 0.37 0.06 0.18 0.08 0.44 
Transgelin-2  0.34 0.37 0.37 0.09 0.29 0.09 0.43 
Small nuclear 
ribonucleoprotein Sm D1  
1.12 1.20 1.22 0.25 0.51 0.59 0.38 
Actinin alpha 1 isoform b  1.05 1.10 0.69 0.15 0.48 0.44 0.37 
Talin-1  0.77 0.71 0.89 0.22 0.46 0.18 0.37 
Histone H2A type 2-A  0.66 0.74 0.66 0.03 0.32 0.31 0.32 
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Table 5.5 (contd.) 
14-3-3 protein gamma  0.47 0.46 0.51 0.13 0.16 0.13 0.29 
Importin subunit beta-1  0.55 0.61 0.63 0.06 0.37 0.08 0.28 
Uncharacterized protein  0.61 0.56 0.28 0.21 0.09 0.11 0.28 
Uncharacterized protein  0.48 0.53 0.51 0.08 0.23 0.08 0.26 
Glutathione S-transferase  0.21 0.26 0.27 0.07 0.07 0.06 0.26 
Ras GTPase-activating-like 
protein IQGAP1  
0.44 0.15 0.48 0.10 0.10 0.08 0.25 
Heterogeneous nuclear 
ribonucleoprotein A1  
1.15 1.16 1.21 0.10 0.69 0.10 0.25 
Uncharacterized protein  1.67 4.65 0.93 0.38 0.80 0.59 0.24 
Vinculin  0.38 0.37 0.36 0.07 0.07 0.07 0.18 
Adenylate kinase 2, 
mitochondrial  
2.01 1.62 1.74 0.07 0.33 0.52 0.17 
Isoform 2 of 
Heterogeneous nuclear 
ribonucleoprotein K  
1.38 1.32 1.30 0.22 0.14 0.32 0.17 
Heterogeneous nuclear 
ribonucleoprotein U  
0.58 1.11 1.41 0.06 0.06 0.35 0.15 
Polypyrimidine tract 
binding protein 1  
1.49 1.53 1.58 0.16 0.11 0.28 0.12 
Heterogeneous nuclear 
ribonucleoprotein Q  
1.22 1.43 1.32 0.15 0.23 0.09 0.12 
Superoxide dismutase 
[Mn], mitochondrial  
2.88 6.56 3.31 0.10 0.17 0.97 0.10 
Heterogeneous nuclear 
ribonucleoprotein H  
1.39 1.38 1.44 0.06 0.08 0.06 0.05 
Heterogeneous nuclear 
ribonucleoprotein F  
0.90 5.33 5.94 0.03 0.20 0.04 0.02 
 
 Macrophage-capping protein,
17
 X-ray repair cross-complementing protein,
18
 
activated RNA polymerase II transcriptional coactivator p15, glutamine gamma-
glutamyltransferase 2
19,20,21
 are few proteins for which the literature suggests to be 
involved in various forms of cancer. In this study, these have shown significantly 
different expression ratios for Hey/T-80 cell proteome in cell lysate compared to 
labeled proteome. These potential cancer biomarkers are enriched in labeled proteome 
and hence changes in their expressions can be detected in more efficient manner.  
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With the successful implementation of the enrichment of nucleotide binding 
proteins for studying the patterns of protein expressions in normal versus diseased 
ovarian cancer cells using probe 1a, the study was continued with the completely 
deprotected analogue of probe 1a. The completely deprotected ribose adenosine 
derivative, probe 1b, was used in a similar manner to label the proteome from Hey and 
T-80 cells and analyze the proteomic patterns between the two cell lines. As expected 
with the deprotected probe, a significantly higher number of proteins were identified 
and with enrichment of nucleotide binding proteins in labeled proteome. Figure 5.4 
shows the gene ontology data for protein classes in labeled and non-labeled proteome 
versus cell lysate in photolabeling and affinity enrichment experiment with probe 1b. 
 
Figure 5.4:  Protein Classes in Labeled, Non-Labeled and Whole Cell Lysate 
Proteome in Hey and T-80 Cells using Probe 1b 
 
129 
 
The comparison of the identified proteins from Hey and T-80 cell proteome 
labeled with probe 1b indicated a list of new proteins that shows an altered expression in 
two cell lines. HMGA1(High mobility group protein HMG-I/HMG-Y),
22,23
 Human 
isoform 7 and 15 of fibronectin,
24,25,26,27
 glutamine gamma-glutamyltransferase,
28,29,30,31,32
 
14-3-3 protein theta,
33,34,35
 are some of the significant proteins that are highlighted in the 
labeled proteome. It is interesting to mention that HMGA1, fibronectin and glutamine 
gamma-glutamyltransferase have been correlated to ovarian cancers.
27,32,36,37  
From this data it can be concluded that the enrichment of nucleotide-binding 
proteins using photolabeling with N
6
-biotinylated 8-azido adenosine analogues followed 
by affinity isolation may serve as a platform to identify some novel biomarkers that 
cannot be identified by proteomics in whole cell lysates. In some cases, it has been 
observed that the proteins are identified in whole cell lysate as well as the enriched 
proteome. But the ratio of change can be detected more precisely in labeled proteome as 
compared to whole cell lysate. This change in ratio of expression can also be due to 
possible change in the nucleoside binding properties of the protein in cancer cells. This 
indicates the potential for this approach is not limited to identifying low abundant 
proteins but can be extended to understand the changes in structure of the proteins in 
cancer proteome. Some proteins for which the change in ratio in cell lysate and labeled 
proteome can be calculated are listed in Table 5.6. The complete list of identified 
proteins is attached at the end of this dissertation in Appendix-3. 
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Table 5.6: Ratio of Average of Labeled versus Cell Lysate Proteins (Probe 1b) 
Protein 
Descriptions 
Cell Lysate Proteome Labeled Proteome Labeled/ 
Cell 
Lysate 1 2 3 1 2 3 
Isoform 2 of 
Elongation factor 
1-delta  
0.48 0.27 0.05 1.14 1.16 1.28 4.45 
T-complex protein 
1 subunit beta  
Chaperonin 
containing TCP1, 
subunit 2 (Beta) 
0.45 0.47 0.36 0.77 0.96 1.90 2.85 
B-cell receptor-
associated protein 
31   
0.49 0.67 0.56 1.79 1.04 1.50 2.50 
 Poly(RC) binding 
protein 2  Poly(rC)-
binding protein 2  
Poly(RC) binding 
protein 2, isoform 
CRA_b   
0.67 0.17 0.53 0.96 0.90 1.12 2.15 
Cathepsin D   1.20 1.23 1.10 1.63 3.94 1.65 2.04 
14-3-3 protein 
epsilon  Isoform 
SV of 14-3-3 
protein epsilon   
0.05 0.07 0.11 0.15 0.15 0.15 2.01 
Cell division 
control protein 42 
homolog   
0.36 0.17 0.89 0.80 0.86 0.82 1.74 
Chloride 
intracellular 
channel protein 1   
0.94 1.01 0.45 1.23 1.24 1.30 1.58 
HLA class I 
histocompatibility 
antigen, B-42 alpha 
chain  HLA class I 
histocompatibility 
antigen, B-7 alpha 
chain  HLA cla 
0.02 0.03 0.02 0.02 0.03 0.05 1.57 
Ezrin   0.45 1.05 0.46 0.99 0.94 1.10 1.55 
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Table 5.6 (contd.) 
Obg-like ATPase 1  
Isoform 3 of Obg-like 
ATPase 1 
1.17 1.17 1.41 1.30 1.31 3.17 1.54 
Lamin-B1  
Uncharacterized 
protein   
0.34 0.32 0.08 0.36 0.37 0.42 1.53 
Moesin   1.62 1.76 1.86 2.58 2.69 2.68 1.52 
Hypoxia up-regulated 
protein 1   
0.81 1.12 0.66 1.43 1.04 1.35 1.48 
Cytochrome c  
Uncharacterized 
protein   
2.15 2.64 2.49 3.44 3.65 3.44 1.45 
Heat shock 70 kDa 
protein 1A/1B   
0.25 0.12 0.37 0.37 0.34 0.35 1.44 
Isoform 2 of 
Heterogeneous 
nuclear 
ribonucleoprotein K   
1.38 1.32 1.30 1.84 1.80 1.97 1.41 
Rab GDP dissociation 
inhibitor beta GDP 
dissociation inhibitor2   
0.71 0.63 0.97 1.17 0.97 0.95 1.35 
Abhydrolase domain-
containing protein 10, 
mitochondrial   
4.07 3.84 6.57 4.87 10.63 3.94 1.34 
Adipocyte plasma 
membrane-associated 
protein  Isoform 2 of 
Adipocyte plasma 
membrane-associated 
protein   
0.51 0.52 0.70 0.61 0.83 0.85 1.33 
Alpha-enolase   0.35 0.26 0.43 0.44 0.46 0.49 1.33 
Adenylate kinase 2, 
mitochondrial  
Isoform 2 of 
Adenylate kinase 2 
2.01 1.62 1.74 2.04 2.07 2.81 1.29 
Heterogeneous 
nuclear 
ribonucleoprotein U  
Isoform 
0.58 1.11 1.41 1.26 1.42 1.27 1.27 
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Table 5.6 (contd.) 
Isoform Short of 14-3-3 
protein beta/alpha   
1.31 1.41 1.38 1.57 1.64 1.72 1.21 
Isoform 2 of 
Tropomyosin alpha-3 
chain Tropomyosin3 I 
0.83 0.81 0.95 1.04 0.90 1.16 1.20 
Calnexin   0.71 0.73 0.70 0.97 0.77 0.77 1.18 
Ras-related protein Rab-
1B  Ras-related protein 
Rab-1A  Putative Ras-
related protein Rab-1C   
3.93 1.96 4.43 1.14 4.52 6.41 1.17 
Talin-1  Talin 1   0.77 0.71 0.89 0.91 0.87 0.93 1.15 
Protein DJ-1   0.71 0.68 0.73 0.73 0.77 0.91 1.14 
Aminopeptidase N   22.83 28.08 32.45 36.59 22.77 35.65 1.14 
Filamin-A  Isoform 2 of 
Filamin-A r 
0.75 0.67 0.71 0.78 0.82 0.83 1.14 
Calreticulin   0.93 0.83 0.94 1.01 1.06 0.98 1.13 
Isoform 1 of Voltage-
dependent anion-
selective channel protein 
2  Isofor 
1.99 2.13 2.24 2.23 2.31 2.63 1.13 
Alpha-actinin-4  Alpha 
actinin 4 short isoform   
1.41 1.65 1.52 1.68 1.72 1.74 1.12 
Proteasome activator 
complex subunit 2   
0.61 0.56 0.28 0.50 0.55 0.57 1.11 
Elongation factor 1-
gamma  r|E7E 
0.88 0.81 0.85 0.98 0.88 0.91 1.10 
 Protein disulfide-
isomerase  r|F5H 
0.65 0.61 0.68 0.70 0.70 0.71 1.09 
Capping protein (Actin 
filament) muscle Z-line, 
beta  Isoform 2 of F-
actin-capping protein 
0.62 0.69 0.63 0.67 0.78 0.66 1.08 
Peroxiredoxin-1   0.86 0.86 0.91 0.92 0.96 0.97 1.08 
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Table 5.6 (contd.) 
Triosephosphate 
isomerase  Isoform 2 of 
Triosephosphate 
isomerase   
0.69 0.63 0.64 0.68 0.72 0.72 1.08 
Glucose-6-phosphate 
isomerase  Glucose-6-
phosphate isomerase   
0.44 0.42 0.29 0.45 0.40 0.39 1.08 
Serpin H1  
Uncharacterized protein  
Uncharacterized protein  
0.02 0.03 0.02 0.02 0.02 0.03 1.08 
Spectrin alpha chain, 
brain  ncharacterized 
protein  Isoform 3 of 
Spectrin alpha chain, 
brain   
0.23 0.55 0.56 0.49 0.48 0.46 1.07 
Annexin A1  Annexin 
A1 (Fragment)   
1.84 1.87 1.88 1.92 2.00 2.08 1.07 
 Peroxiredoxin-6   0.80 0.82 0.77 0.90 0.84 0.79 1.05 
 Heterogeneous nuclear 
ribonucleoproteins 
A2/B1  Isoform A2 of 
Heterogeneous nuclear 
ribonucleoproteins 
A2/B1   
1.73 1.53 1.87 1.76 1.80 1.84 1.05 
 Splicing factor, proline- 
and glutamine-rich  
Isoform Short of 
Splicing factor, proline- 
and glutamine-rich   
1.36 1.61 1.67 1.64 1.69 1.55 1.05 
Cytoskeleton-associated 
protein 4   
1.01 0.95 0.91 0.98 0.98 1.05 1.05 
Isoform 2 of Protein 
disulfide-isomerase A6  
Uncharacterized protein   
0.78 0.80 0.76 0.76 0.83 0.87 1.05 
Transmembrane emp24 
domain-containing 
protein 10   
1.41 1.26 1.25 1.44 1.15 1.51 1.05 
78 kDa glucose-
regulated protein   
1.21 1.24 1.33 1.28 1.37 1.29 1.04 
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Table 5.6 (contd.) 
Actinin alpha 1 isoform b  
Alpha-actinin-1  Isoform 
2 of Alpha-actinin-1   
1.05 1.10 0.69 0.99 0.96 1.01 1.04 
Peroxiredoxin-5, 
mitochondrial  Isoform 
Cytoplasmic+peroxisoma
l of Peroxiredoxin-5, 
mitochondrial   
1.50 1.40 1.74 1.56 1.65 1.58 1.03 
Nucleophosmin  Isoform 
2 of Nucleophosmin   
2.26 2.39 2.43 2.24 2.58 2.48 1.03 
 Polypyrimidine tract 
binding protein 1  
Isoform 2 of 
Polypyrimidine tract-
binding protein 1   
1.49 1.53 1.58 1.47 1.66 1.60 1.03 
Beta-2-microglobulin   0.09 0.09 0.05 0.09 0.04 0.11 1.02 
 Profilin-1   0.78 0.83 0.82 0.76 0.85 0.87 1.02 
Histone H3.2   0.71 0.74 0.76 0.80 0.77 0.69 1.02 
Elongation factor Tu, 
mitochondrial   
2.16 2.39 2.43 2.54 2.31 2.26 1.02 
Fructose-bisphosphate 
aldolase A   
0.46 0.52 0.60 0.53 0.54 0.55 1.02 
Isoform C of Prelamin-
A/C  Lamin A/C  Isoform 
ADelta10 of P 
1.53 1.57 1.72 1.63 1.62 1.65 1.02 
 Complement component 
1 Q subcomponent-
binding protein, 
mitochondrial   
1.92 2.43 1.87 1.66 2.62 2.02 1.01 
 Protein disulfide-
isomerase A3  Protein 
disulfide isomerase 
family A, member 3, 
isoform CRA_b   
0.90 0.80 0.89 0.85 0.86 0.93 1.01 
Phosphoglycerate mutase    0.60 0.74 0.66 0.63 0.69 0.71 1.01 
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Table 5.6 (contd.) 
Malate dehydrogenase, 
mitochondrial   
1.58 1.44 1.38 1.34 1.62 1.49 1.01 
Heterogeneous nuclear 
ribonucleoprotein A3  
Isoform 2 of nuclear 
ribonucleoprotein A3   
2.62 2.58 2.78 2.52 2.61 2.87 1.00 
Peptidyl-prolyl cis-trans 
isomerase B   
1.20 1.29 1.26 1.25 1.26 1.24 1.00 
Chloride intracellular 
channel protein 4   
2.07 1.86 1.70 1.84 1.80 1.97 1.00 
Phosphoglycerate kinase 
1  Phosphoglycerate 
kinase  
Phosphoglycerate kinase 
r|E7ERH5 
0.78 0.90 1.01 0.85 0.94 0.90 1.00 
Heat shock 70 kDa 
protein 6  Putative heat 
shock 70 kDa protein 7   
1.19 1.23 1.30 1.20 1.21 1.29 0.99 
NADH-cytochrome b5 
reductase 3  Isoform 2 of 
NADH-cytochrome b5 
reductase 3  
1.11 1.20 1.24 1.06 1.24 1.23 0.99 
Vinculin  Isoform 1 of 
Vinculin   
0.38 0.37 0.36 0.36 0.38 0.37 0.99 
Elongation factor 2  0.60 0.64 0.62 0.54 0.65 0.65 0.99 
Heterogeneous nuclear 
ribonucleoprotein A1   
1.15 1.16 1.21 1.16 1.15 1.16 0.98 
Annexin A5  1.15 1.22 1.21 1.18 1.16 1.19 0.98 
Brain acid soluble 
protein 1  Isoform 2 of 
Brain acid soluble 
protein 1   
0.52 0.51 0.53 0.45 0.57 0.51 0.98 
 High mobility group 
protein B1  High-
mobility group box 1   
0.75 0.70 0.93 0.75 0.79 0.78 0.98 
Actin, cytoplasmic 2   0.94 0.94 0.96 0.90 0.92 0.96 0.98 
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Table 5.6 (contd.) 
Ubiquitin-like modifier-
activating enzyme 1   
0.60 0.56 0.52 0.54 0.54 0.56 0.97 
 Non-POU domain-
containing octamer-
binding protein     
1.09 1.62 1.74 1.51 1.41 1.39 0.97 
 14-3-3 protein zeta/delta  
r 
1.44 1.49 1.41 1.26 1.52 1.40 0.96 
 Transgelin-2   0.34 0.37 0.37 0.38 0.40 0.26 0.96 
 Peptidyl-prolyl cis-trans 
isomerase A  Peptidyl-
prolyl cis-trans 
isomerase  
Peptidylprolyl isomerase 
A (Cyclophilin A) O 
1.34 1.31 1.46 1.29 1.32 1.34 0.96 
 Isoform 2 of Annexin 
A2  Putative annexin 
A2-like protein r 
2.32 2.42 2.50 2.32 2.31 2.31 0.96 
 Heat shock cognate 71 
kDa protein   
1.74 1.70 1.79 1.58 1.73 1.68 0.96 
Protein S100-A6   1.71 1.85 1.78 1.63 1.70 1.77 0.95 
X-ray repair cross-
complementing protein 6  
1.30 1.43 1.28 1.43 1.23 1.14 0.95 
Thioredoxin-dependent 
peroxide reductase, 
mitochondrial   
1.64 2.20 1.79 1.79 1.72 1.81 0.95 
14-3-3 protein gamma   0.47 0.46 0.51 0.48 0.46 0.41 0.95 
Ras-related protein Rap-
1b  
0.73 0.76 0.70 0.69 0.67 0.70 0.94 
Endoplasmin   0.76 0.74 0.68 0.64 0.69 0.72 0.94 
Protein disulfide-
isomerase A4   
0.32 0.27 0.32 0.29 0.28 0.29 0.94 
Spectrin beta chain, 
brain 1  Isoform Short of 
Spectrin beta chain, 
brain 1   
0.24 0.13 0.60 0.20 0.39 0.31 0.93 
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Table 5.6 (contd.) 
Nucleoside diphosphate 
kinase  Isoform 3 of 
Nucleoside diphosphate 
kinase B   
1.16 1.33 1.22 1.19 1.02 1.12 0.90 
 Tumor protein D52-like 
2  Tumor protein D52-
like 2  Isoform 3 of 
Tumor protein D54   
2.22 1.90 1.68 1.92 1.43 1.87 0.90 
 60 kDa heat shock 
protein, mitochondrial   
4.07 4.23 4.20 3.50 3.84 3.83 0.89 
 ATP synthase subunit b, 
mitochondrial  ATP 
synthase, H+ 
transporting, 
mitochondrial F0 
complex, subunit B1   
1.47 1.79 1.73 1.43 1.43 1.58 0.89 
 Ras GTPase-activating-
like protein IQGAP1   
0.44 0.15 0.48 0.10 0.41 0.43 0.89 
Isoform 2 of Heat shock 
protein HSP 90-alpha  
Full-length cDNA clone 
CS0CA P007YF18 of T 
1.87 2.12 2.18 1.85 1.81 1.80 0.88 
Cofilin-1  Co 0.95 0.95 0.97 0.79 0.88 0.87 0.88 
 Protein-glutamine 
gamma-
glutamyltransferase 2   
53.41 15.49 42.33 26.26 31.11 40.67 0.88 
 14-3-3 protein theta   0.72 0.64 0.75 0.55 0.63 0.64 0.86 
 Actin, alpha cardiac 
muscle 1  Actin, alpha 
skeletal muscle  Actin, 
aortic smooth muscle   
0.94 1.00 0.97 0.76 0.86 0.83 0.84 
Glyceraldehyde-3-
phosphate 
dehydrogenase  
Glyceraldehyde-3-
phosphate 
dehydrogenase  
Glyceraldehyde-3-
phosphate dehydrog 
1.51 1.53 1.56 0.98 1.45 1.44 0.84 
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Table 5.6 (contd.) 
Histone H4   0.77 0.89 0.88 0.69 0.65 0.73 0.82 
Vesicle-trafficking 
protein SEC22b   
0.89 1.17 2.30 1.13 1.16 1.21 0.80 
Heat shock protein HSP 
90-beta  Putative heat 
shock protein HSP 90-
beta-3   
1.16 1.30 1.27 1.00 0.98 1.00 0.80 
ATP synthase subunit 
beta, mitochondrial  
ATP synthase subunit 
beta   
1.76 2.02 1.89 1.39 1.52 1.58 0.79 
Elongation factor 1-
alpha 1  Putative 
elongation factor 1-
alpha-like 3  EEF1A1 
protein   
0.90 0.89 0.95 0.72 0.73 0.72 0.79 
Adenylyl cyclase-
associated protein 1  
Isoform 2 of Adenylyl 
cyclase-associated 
protein 1   
0.96 1.10 1.04 1.01 0.26 1.18 0.79 
Polyubiquitin-C   1.19 1.28 1.28 0.92 1.07 0.95 0.78 
Keratin, type I 
cytoskeletal 18   
0.72 0.77 0.80 0.64 0.59 0.57 0.78 
Isoform 2 of 
Procollagen-lysine,2-
oxoglutarate 5-
dioxygenase 2  
9.34 5.50 15.56 5.26 5.25 13.05 0.77 
Protein SET  Isoform 2 
of Protein SET  p 
0.98 0.73 1.87 0.86 0.95 0.89 0.75 
Glutathione S-
transferase P   
0.21 0.26 0.27 0.21 0.27 0.07 0.75 
Myosin, light 
polypeptide 6, alkali, 
smooth muscle and non-
muscle, isoform CRA_c  
Myosin light  
0.48 0.53 0.51 0.36 0.40 0.38 0.75 
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Table 5.6 (contd.) 
Serine/threonine-protein 
phosphatase 2A 65 kDa 
regulatory subunit A 
alpha isoform   
0.72 0.83 0.78 0.69 0.72 0.33 0.75 
Nucleolin NCL protein   3.24 2.80 2.97 2.09 2.62 2.04 0.75 
Heat shock protein beta-
1   
0.01 0.02 0.03 0.02 0.01 0.02 0.72 
Leucine-rich PPR motif-
containing protein, 
mitochondrial   
2.13 1.76 10.39 4.41 2.82 2.98 0.72 
KH domain-containing, 
RNA-binding, signal 
transduction-associated 
protein 1  Isoform 2 
7.60 1.12 1.34 2.60 2.03 2.33 0.69 
Lysosome-associated 
membrane glycoprotein 
1  
1.16 1.45 1.60 0.97 0.97 0.96 0.69 
Stress-70 protein, 
mitochondrial   
7.10 3.21 3.02 2.94 3.26 2.88 0.68 
Voltage-dependent 
anion-selective channel 
protein 1   
2.15 2.26 2.53 1.40 1.72 1.58 0.68 
Prohibitin  Uncha 2.74 2.79 2.58 1.88 1.99 1.56 0.67 
Heterogeneous nuclear 
ribonucleoprotein H  
Heterogeneous nuclear 
ribonucleoprotein H2  
1.39 1.38 1.44 0.89 0.97 0.95 0.67 
Pyruvate kinase 
isozymes M1/M2  
Isoform M1 of Pyruvate 
kinase isozymes M1/M2  
0.58 0.62 0.63 0.40 0.34 0.46 0.66 
Putative heat shock 
protein HSP 90-beta 4   
1.53 1.56 1.55 0.94 1.02 0.97 0.63 
Superoxide dismutase 
[Mn], mitochondrial  
Superoxide dismutase  
Superoxide dismutase  
2.88 6.56 3.31 2.60 2.59 2.59 0.61 
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Table 5.6 (contd.) 
Proliferating cell nuclear 
antigen   
0.38 0.52 0.63 0.25 0.13 0.53 0.59 
Heterogeneous nuclear 
ribonucleoprotein Q  
Isoform 2 of 
Heterogeneous nuclear 
ribonucleoprotein Q   
1.22 1.43 1.32 0.75 0.76 0.68 0.55 
Plectin  Isoform 2 of 
Plectin  Isoform 6 of 
Plectin OS=Homo s 
6.71 14.22 16.14 6.04 8.21 5.93 0.54 
Importin subunit beta-1   0.55 0.61 0.63 0.09 0.39 0.39 0.49 
Prohibitin-2   2.73 2.85 2.70 1.26 1.38 1.29 0.47 
Aspartyl/asparaginyl 
beta-hydroxylase   
2.58 5.91 2.71 1.70 1.90 1.54 0.46 
Macrophage-capping 
protein  r|E7ENU 
27.96 44.09 29.47 12.64 15.89 16.06 0.44 
Tubulin beta-4B chain   0.73 0.74 0.79 0.38 0.32 0.27 0.43 
L-lactate dehydrogenase 
A chain  L-lactate 
dehydrogenase  Isoform 
2 of L-lactate 
dehydrogenase A chain  
G 
0.65 0.70 0.82 0.28 0.51 0.12 0.42 
60S ribosomal protein 
L6  60S ribosomal 
protein L6   
1.24 1.44 1.40 0.79 0.34 0.29 0.35 
Myosin-9  Isoform 2 of 
Myosin-9   
0.55 0.52 0.58 0.13 0.31 0.13 0.35 
Uncharacterized protein  
HLA class I 
histocompatibility 
antigen, A-3 alpha chain  
0.07 0.04 0.03 0.01 0.02 0.01 0.32 
Vimentin   4.72 14.70 16.09 2.44 2.31 2.34 0.20 
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CHAPTER 6 
CONCLUSION AND FUTURE PROSPECTS OF THE PROJECT 
 
In this dissertation we have described an activity/affinity based approach for the 
enrichment of nucleotide and nucleoside binding proteins from a complex cell proteome. 
The application of this approach has demonstrated that the nucleotide binding proteins 
were enriched by a factor of four in labeled proteome (Regeneration Wash) as compared 
to non-labeled proteome (PBS Wash) in mouse neuroblastoma N18TG2 cells and human 
ovarian Hey and T-80 cells (cancerous an non-cancerous) when compared to complex 
cell lysates respectively. Also, certain proteins that were not detected in cell lysate have 
been identified in labeled proteome that reflects the strength of this approach to enrich 
low abundant protein. The proteomic profiles that were generated from various cell lines 
showed reproducible profiles in triplicate experiments. Hence, it can be concluded that 
the N
6
-biotinylated-8-azido-adenosine can be used to enrich nucleotide and nucleoside 
binding proteins from complex cell proteome which can enhance the efficiency of 
relative quantification of individual proteins in a complex proteome.  
Application of SILAC labeling combined with activity/affinity based approach to 
study proteomic profiles of human ovarian cells, normal and cancerous, uncovered 
diverse patterns of protein reactivity by screening the cell proteomes with N
6
-
biotinylated-8-azido-adenosine probe in Hey Cells (cancerous ovarian cells) Vs T-80 
cells (non-cancerous ovarian cells). This approach combines the identification as well as 
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quantification of differentially expressed proteins in proteome under investigation. 
Several of these identified proteins have been reported as potential biomarkers for 
different forms of cancer in literature reports and a few have even been correlated to 
ovarian cancer. A modest panel of other proteins for which there is no literature evidence 
for their role in cancer or their potential as cancer biomarkers have also been identified. 
These identified proteins can serve as potential biomarkers and provide further insights 
into the biochemical basis of ovarian cancer. The relevant biomarkers from diseased 
samples can be analyzed by biochemical assays to further support the data. 
The research holds an abundant potential to explore discrete subsets of nucleotide 
binding proteins from a complex cell proteome and to quantify changes in protein 
expressions for low abundant proteins, otherwise not detected in quantities to analyze 
with confidence. This approach is not limited to search for cancer biomarkers only. Due 
to extensive involvement of nucleotide binding proteins in other physiological disorders, 
this approach can be extended to generated protein profiles of cell lines from varied 
sources. The identified protein biomarkers can then be further tested for finding 
biomarkers for diagnosis and prognosis of the disease in question. 
 A series of biotinylated azido-AdoR analogs can be generated to target different 
subsets of nucleotide binding proteins for affinity chromatography and LC-MS/MS 
analysis. The following scheme shows a set of potential AdoR analogs for extension of 
this research.  
148 
 
 
 
Figure 6.1: Examples of Potential AdoR Analogs 
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APPENDIX 1 
N18TG2 Cells- Scaffold Analysis 
 
Identified Proteins Accession Number Non-Labeled Proteome Labeled Proteome Celll Lysate Proteome 
1 2 3 1 2 3 1 2 3 
40S ribosomal protein S12 IPI00225634  0 0 0 39 53 17 0 0 0 
Peroxiredoxin-2 IPI00117910 0 3 0 32 28 34 8 6 10 
D-3-phosphoglycerate dehydrogenase IPI00225961 0 0 0 30 28 25 15 15 13 
ATP synthase subunit O, mitochondrial IPI00118986 0 0 0 29 30 22 0 0 0 
Poly(rC)-binding protein 1 IPI00128904 0 2 0 28 22 13 3 4 2 
60S ribosomal protein L12 IPI00849793 0 8 4 27 24 28 11 9 9 
Stress-induced-phosphoprotein 1 IPI00121514 0 0 0 27 25 24 7 4 4 
Cullin-associated NEDD8-dissociated protein 1 IPI00896727 0 0 0 24 28 9 8 7 4 
40S ribosomal protein S3 IPI00134599 0 0 0 24 20 15 8 6 6 
Polyadenylate-binding protein 1 IPI00124287  0 2 0 21 15 10 0 0 0 
Glycyl-tRNA synthetase IPI00112555 0 0 0 20 25 16 9 8 7 
Importin subunit beta-1 IPI00323881  0 0 0 19 19 10 7 7 9 
ATP synthase subunit d, mitochondrial IPI00230507  0 0 0 18 15 8 0 0 0 
Electron transfer flavoprotein subunit alpha, mitochondrial IPI00116753 0 0 0 16 13 10 4 4 6 
adaptor protein complex AP-1, beta 1 subunit IPI00346965  0 0 0 16 11 3 0 0 0 
Spermidine synthase IPI00136912 0 0 0 16 10 2 0 0 0 
40S ribosomal protein S19 IPI00113241  0 0 0 15 15 19 5 6 5 
40S ribosomal protein S10 IPI00112448  0 0 0 15 17 10 0 0 0 
40S ribosomal protein S17 IPI00465880  0 0 0 15 16 12 4 6 3 
40S ribosomal protein S14 IPI00322562  0 0 0 14 24 12 0 0 0 
Putative uncharacterized protein IPI00123292  0 0 0 14 16 6 16 18 17 
Eukaryotic translation initiation factor 3 subunit I IPI00269613 0 0 0 13 14 6 0 0 0 
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Histone H2A.J IPI00153400  0 0 4 13 7 9 18 21 20 
Putative uncharacterized protein IPI00117569  0 0 0 13 5 12 16 18 17 
phosphoribosylglycinamide formyltransferase IPI00230612 0 0 0 13 9 4 3 2 4 
KH type splicing regulatory protein KSRP IPI00876559 0 0 0 12 18 12 0 0 0 
ADP/ATP translocase 1 IPI00115564 0 3 4 12 10 7 4 3 6 
Calnexin IPI00119618 0 2 0 12 16 6 6 7 6 
60S ribosomal protein L13 IPI00224505  0 0 0 11 11 11 5 6 4 
Dihydropyrimidinase-related protein 2 IPI00114375 0 0 0 11 12 12 0 0 0 
Isoform 1 of Poly(rC)-binding protein 2 IPI00127707  0 3 1 11 8 11 10 8 6 
60S ribosomal protein L23 IPI00139780 0 2 2 11 8 8 3 5 3 
LOC100039355 protein IPI00469918  0 0 0 11 9 6 1 1 3 
40S ribosomal protein S18 IPI00317590  0 0 0 10 9 8 5 5 5 
60S ribosomal protein L23a IPI00461456  0 2 2 10 9 9 2 4 2 
Histone H2B type 1-F/J/L IPI00114642  0 0 0 10 8 4 18 20 15 
Ribosomal protein L21 IPI00315548  0 1 1 10 2 6 0 0 0 
26S protease regulatory subunit 6A IPI00133206  0 0 0 10 7 2 2 4 2 
60S acidic ribosomal protein P2 IPI00139795 0 0 0 9 9 7 0 0 0 
Prohibitin-2 IPI00321718 0 2 5 9 10 4 6 5 4 
60S ribosomal protein L31 IPI00123007  0 0 0 9 8 6 4 2 3 
V-type proton ATPase subunit E 1 IPI00119115 0 0 0 9 6 7 0 0 0 
Heat shock protein 75 kDa, mitochondrial IPI00132762 0 0 0 9 9 5 3 1 2 
60S ribosomal protein L6 IPI00313222  0 2 2 9 3 3 4 9 6 
Uridine 5'-monophosphate synthase IPI00121552 0 0 0 9 9 0 0 0 0 
proteasome 26S  ATPase subunit 4 IPI00828513 0 0 0 9 9 0 2 3 2 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 IPI00475154  0 0 0 9 7 0 0 0 0 
G1 to S phase transition 1 isoform 1 IPI00230355  0 0 0 9 6 0 0 0 0 
Phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoribosylaminoimidazole, succinocarboxamide 
synthetase, isoform CRA_a 
IPI00624863 0 0 0 8 11 6 0 0 0 
40S ribosomal protein S3a IPI00331345 0 0 0 8 9 4 6 8 4 
40S ribosomal protein S7 IPI00136984 0 2 2 8 10 3 6 8 7 
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Eukaryotic translation initiation factor 3 subunit F IPI00120914 0 0 0 8 13 1 0 0 0 
similar to ribosomal protein S25 IPI00115992  0 0 0 8 7 10 1 1 3 
Tubulin alpha-1A chain IPI00110753 0 0 0 8 6 9 95 102 111 
Envelope protein IPI00406960 0 0 0 8 8 4 4 5 3 
Protein dpy-30 homolog IPI00117168 0 0 0 8 8 4 0 0 0 
Exportin-1 IPI00395038 0 0 0 8 7 2 4 5 5 
Isoform 1 of Importin-5 IPI00626994 0 0 0 8 10 0 0 0 0 
111 kDa protein IPI00228113  0 0 0 8 6 4 0 0 0 
26S proteasome non-ATPase regulatory subunit 14 IPI00113262 0 0 0 8 9 0 0 0 0 
Dynactin subunit 2 IPI00116112 0 0 0 7 10 8 0 0 0 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
IPI00153660 0 0 0 7 8 4 3 3 2 
Eif3b protein IPI00229859 0 0 0 7 8 4 0 0 0 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa 
subunit 
IPI00117705  0 0 0 7 9 5 0 0 0 
60S ribosomal protein L35 IPI00263879 0 0 0 7 6 6 0 0 0 
60S ribosomal protein L27 IPI00122421 0 0 0 7 3 3 0 0 0 
Tubulin beta-3 chain IPI00112251 0 0 0 7 4 2 5 6 8 
40S ribosomal protein S13 IPI00125901 0 0 0 6 7 7 0 0 0 
Crmp1 protein IPI00312527  0 0 0 6 8 9 0 0 0 
Exportin-2 IPI00112414 0 0 0 6 14 2 6 3 5 
Isoform Smooth muscle of Myosin light polypeptide 6 IPI00354819  0 0 0 6 6 6 3 3 3 
Cytochrome c oxidase subunit 5A, mitochondrial IPI00120719 0 1 1 6 8 4 0 0 0 
60S ribosomal protein L22 IPI00222546 0 1 0 6 6 6 3 3 2 
26S proteasome non-ATPase regulatory subunit 11 IPI00222515 0 0 0 6 8 4 0 0 0 
Importin-7 IPI00331444 0 0 0 6 8 2 0 0 0 
60S acidic ribosomal protein P0 IPI00314950 0 3 3 6 3 1 11 13 9 
Histone H1.4 IPI00223714 0 0 0 6 4 7 6 3 4 
ATP synthase subunit delta, mitochondrial IPI00453777 0 0 0 6 8 3 0 0 0 
Importin subunit alpha-2 IPI00124973 0 0 0 6 6 3 0 0 0 
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Isoform 1 of Glucosidase 2 subunit beta IPI00115680  0 0 0 6 4 5 0 0 0 
26S protease regulatory subunit S10B IPI00125971 0 0 0 6 5 4 1 1 2 
myosin light chain, regulatory B-like IPI00109044  0 0 0 6 4 4 0 0 0 
Ras-related protein Rab-21 IPI00337980 0 0 0 6 0 8 0 0 0 
Ras-related protein Rab-11B IPI00135869  0 0 0 6 6 0 0 0 0 
UDP-glucose ceramide glucosyltransferase-like 1 IPI00762897 0 0 0 6 3 0 0 3 1 
Isoform 1 of Transcription intermediary factor 1-beta IPI00312128 0 0 0 6 4 0 0 0 0 
Electron transfer flavoprotein subunit beta IPI00121440  0 0 0 5 11 5 0 0 0 
Galectin-1 IPI00229517 0 0 0 5 6 9 0 0 0 
40S ribosomal protein S20 IPI00323819 0 0 0 5 8 4 0 0 0 
Small nuclear ribonucleoprotein Sm D1 IPI00322749 0 0 0 5 8 4 5 2 2 
Isoform 1 of Small glutamine-rich tetratricopeptide repeat-containing 
protein alpha 
IPI00116331  0 0 0 5 6 0 0 0 0 
ATP synthase subunit gamma, mitochondrial IPI00313475  0 0 0 5 2 6 0 0 0 
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial IPI00338536 0 0 0 5 6 2 0 0 0 
Putative uncharacterized protein IPI00136883  0 0 0 5 7 0 16 18 17 
Isoform 2 of Neutral alpha-glucosidase AB IPI00115679  0 0 0 5 2 1 0 0 0 
Isoform 1 of Splicing factor 3B subunit 3 IPI00122011 0 0 0 5 5 0 0 0 0 
cytoplasmic activation/proliferation-associated protein 1 isoform c IPI00121515  0 0 0 5 6 0 0 0 0 
Isoform SERCA2B of Sarcoplasmic/endoplasmic reticulum calcium ATPase 
2 
IPI00338964  0 0 0 5 3 2 0 0 0 
Ras-related protein Rab-2A IPI00137227 0 0 0 5 4 0 0 0 0 
Isoform 1 of Plasminogen activator inhibitor 1 RNA-binding protein IPI00471475  0 0 0 5 0 2 0 0 0 
Methionyl-tRNA synthetase, cytoplasmic IPI00461469 0 0 0 5 3 0 6 2 4 
Putative uncharacterized protein IPI00380130  0 0 0 4 6 5 16 18 17 
Dynein light chain roadblock-type 1 IPI00315225  0 0 0 4 8 6 0 0 0 
Prohibitin IPI00133440 0 0 4 4 4 4 3 0 0 
39S ribosomal protein L12, mitochondrial IPI00118963 0 0 0 4 5 8 0 0 0 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 IPI00309035 0 0 0 4 4 5 0 0 0 
Isoform 1 of ATP-dependent RNA helicase DDX39 IPI00123878 0 0 0 4 4 2 4 2 2 
ATP synthase subunit b, mitochondrial IPI00341282 0 0 0 4 4 1 0 0 0 
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Tubulin beta-2C chain IPI00169463 0 2 2 4 4 2 8 9 5 
similar to ribosomal protein S26 IPI00261455  0 2 2 4 3 2 0 0 0 
Isoform 1 of Eukaryotic translation initiation factor 3 subunit K IPI00120322 0 0 0 4 6 3 0 0 0 
Eukaryotic translation initiation factor 3 subunit H IPI00128202 0 0 0 4 0 1 0 0 0 
40S ribosomal protein S21 IPI00132950 0 0 0 4 6 2 0 0 0 
V-type proton ATPase subunit B, brain isoform IPI00119113 0 0 0 4 9 0 0 0 0 
poly(rC) binding protein 3 IPI00411074  0 0 0 4 4 4 0 0 0 
Synaptic vesicle membrane protein VAT-1 homolog IPI00126072 0 0 0 4 6 2 0 0 0 
glutaminase isoform 1 IPI00464317 0 0 0 4 5 0 0 0 0 
UPF0568 protein C14orf166 homolog IPI00132456 0 0 0 4 3 4 0 0 0 
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit IPI00130185 0 0 3 4 4 0 0 0 0 
Isoform 1 of Eukaryotic translation initiation factor 4 gamma 1 IPI00421179  0 0 0 4 4 3 0 0 0 
Argininosuccinate synthase IPI00134746  0 1 0 4 5 0 19 13 12 
Rab5B IPI00116563  0 0 0 4 4 2 0 0 0 
39S ribosomal protein L10, mitochondrial IPI00132412 0 0 0 4 4 2 0 0 0 
Importin subunit alpha-7 IPI00649329  0 0 0 4 4 2 0 0 0 
Asparaginyl-tRNA synthetase, cytoplasmic IPI00223415  0 0 0 4 4 0 2 2 1 
ADP/ATP translocase 2 IPI00127841 0 0 0 4 2 1 0 0 0 
Small nuclear ribonucleoprotein Sm D3 IPI00119224 0 0 0 4 2 0 0 0 0 
Ubiquilin-2 IPI00387416  0 0 0 4 3 0 0 0 0 
Isoform 1 of SUMO-activating enzyme subunit 1 IPI00129105  0 0 0 4 4 0 0 0 0 
Isoform 1 of Mitochondrial import receptor subunit TOM34 IPI00165694  0 0 0 4 3 0 0 0 0 
Exportin-T IPI00116741  0 0 0 4 3 0 0 0 0 
Isoform 2 of E3 ubiquitin-protein ligase HUWE1 IPI00453613  0 0 0 4 2 0 0 0 0 
Cytochrome b5 reductase 3 IPI00110885  0 0 0 4 2 0 0 0 0 
Novel protein silmilar to ribosomal protein L32 IPI00128267  0 0 0 4 0 2 0 0 0 
60S ribosomal protein L5 IPI00308706  0 0 0 4 0 0 3 3 2 
Eukaryotic translation initiation factor 3 subunit C IPI00321647 0 0 0 4 0 0 0 0 0 
40S ribosomal protein S4, X isoform IPI00331092 0 0 0 3 5 4 2 4 0 
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Proteasome activator complex subunit 3 IPI00113660 0 3 0 3 4 3 0 0 0 
transportin 1 isoform 1 IPI00221523  0 0 0 3 5 2 0 0 0 
Ribose-phosphate pyrophosphokinase IPI00318204  0 0 0 3 3 1 0 0 0 
Putative uncharacterized protein IPI00270326 0 0 0 3 4 4 16 18 17 
Tetratricopeptide repeat protein 1 IPI00130475 0 0 0 3 2 2 0 0 0 
similar to ribosomal protein L24 IPI00134202  0 2 0 3 2 2 0 0 0 
C-1-tetrahydrofolate synthase, cytoplasmic IPI00122862 0 0 0 3 4 1 0 0 0 
Nuclease-sensitive element-binding protein 1 IPI00120886  0 2 0 3 0 2 0 0 0 
TBC1 domain family member 15 IPI00110247 0 0 0 3 2 2 0 0 0 
RuvB-like 1 IPI00133985  0 0 0 3 0 0 0 0 0 
UBX domain-containing protein 1 IPI00123589 0 0 0 3 0 0 0 0 0 
Importin-9 IPI00130158  0 0 0 3 0 0 0 0 0 
SEC31-like 1 IPI00377592  0 0 0 3 0 0 0 0 0 
40S ribosomal protein S15a IPI00230660  0 0 0 2 2 7 0 0 0 
60S ribosomal protein L30 IPI00222549  0 4 3 2 2 2 0 0 0 
60S acidic ribosomal protein P1 IPI00113377  0 0 4 2 2 2 8 7 7 
Cytochrome b-c1 complex subunit 1, mitochondrial IPI00111885  0 4 4 2 3 0 0 0 0 
Myosin-9 IPI00123181 0 0 0 2 4 4 3 3 1 
Ras-related protein Rap-1b IPI00407954 0 1 2 2 2 4 0 0 0 
26S proteasome non-ATPase regulatory subunit 2 IPI00123494 0 0 0 2 6 1 0 0 0 
Isoform 2 of 40S ribosomal protein S24 IPI00402981  0 0 0 2 0 7 0 0 0 
Ubiquitin carboxyl-terminal hydrolase 5 IPI00113214  0 0 0 2 3 4 2 3 4 
Isoform 1 of Titin IPI00756257 0 0 0 2 2 2 0 0 0 
26S protease regulatory subunit 8 IPI00135640  0 0 0 2 3 0 0 0 0 
26S proteasome non-ATPase regulatory subunit 1 IPI00267295  0 0 0 2 6 0 0 0 0 
ATP synthase subunit e, mitochondrial IPI00111770 0 0 0 2 3 4 0 0 0 
40S ribosomal protein S30 IPI00399483  0 0 0 2 2 3 0 0 0 
Isoform 1 of Nuclear autoantigenic sperm protein IPI00130959  0 1 0 2 2 0 0 0 0 
26S protease regulatory subunit 4 IPI00133428 0 0 0 2 3 3 0 0 0 
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Ras-related protein Rab-7a IPI00408892 0 4 0 2 1 0 0 0 0 
Putative uncharacterized protein IPI00133066  0 0 0 2 3 2 16 18 17 
40S ribosomal protein S15 IPI00319231  0 2 0 2 2 0 4 1 4 
Isoform 1 of Elongation factor Tu, mitochondrial IPI00274407  0 0 0 2 2 2 6 2 6 
Cytochrome b-c1 complex subunit 2, mitochondrial IPI00119138 0 2 0 2 4 0 0 0 0 
40S ribosomal protein S27-like protein IPI00124709  0 0 0 2 2 4 0 0 0 
Phosphate carrier protein, mitochondrial IPI00124771  0 0 0 2 2 4 1 4 4 
ATP synthase-coupling factor 6, mitochondrial IPI00125460 0 0 0 2 2 4 0 0 0 
Leucyl-tRNA synthetase, cytoplasmic IPI00453819 0 0 0 2 4 2 1 2 4 
Acetyl-CoA acetyltransferase, mitochondrial IPI00154054 0 0 0 2 5 0 4 4 2 
Isoform 1 of Deoxyhypusine hydroxylase IPI00224991 0 0 0 2 4 1 0 0 0 
Isoform 3 of Septin-9 IPI00515330 0 0 0 2 1 0 0 0 0 
Ribonuclease inhibitor IPI00313296 0 0 0 2 4 0 0 0 0 
hypothetical protein isoform 2 IPI00265107  0 0 3 2 0 0 5 4 10 
Isoform Long of Delta-1-pyrroline-5-carboxylate synthetase IPI00129350  0 0 0 2 4 0 1 3 3 
Arsenical pump-driving ATPase IPI00624501 0 0 0 2 4 0 0 0 0 
Leucine-rich PPR motif-containing protein, mitochondrial IPI00420706  0 0 0 1 5 2 0 0 0 
Basic leucine zipper and W2 domain-containing protein 2 IPI00387337 0 0 0 1 4 0 0 0 0 
Eukaryotic translation elongation factor 1 epsilon-1 IPI00133928 0 0 0 1 3 0 0 0 0 
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial IPI00132042 0 1 0 1 5 0 0 0 0 
Isoform 2 of Dynamin-1-like protein IPI00172221  0 0 0 1 3 0 0 0 0 
Aspartyl-tRNA synthetase, cytoplasmic IPI00122743  0 0 0 1 4 0 0 0 0 
Ras-related protein Rab-1B IPI00133706 0 0 0 1 3 1 0 0 0 
Hexokinase-2 IPI00114342 0 0 0 1 2 1 0 0 0 
Isoform CW17 of Splicing factor 1 IPI00116284  0 0 0 1 1 0 0 0 0 
Pyrroline-5-carboxylate reductase 3 IPI00153234  0 0 0 1 2 0 0 0 0 
Isoform 1 of Filamin-A IPI00131138  0 0 0 1 2 0 0 0 0 
Ubiquitin carboxyl-terminal hydrolase 14 IPI00270877  0 0 0 1 2 0 0 0 0 
kinesin light chain 1 isoform 1D IPI00403890  0 0 0 1 0 0 0 0 0 
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Ubiquitin carboxyl-terminal hydrolase isozyme L1 IPI00313962  0 16 17 0 0 0 14 14 15 
Isoform 1 of Rab GDP dissociation inhibitor beta IPI00122565  0 10 12 0 0 0 13 6 8 
Nucleoside diphosphate kinase A IPI00131459 0 3 11 0 0 0 7 5 7 
Profilin-1 IPI00224740  0 8 3 0 0 0 8 5 6 
Calcyclin-binding protein IPI00115650 0 0 0 0 7 6 1 4 1 
Peroxiredoxin-6 IPI00555059  0 5 4 0 2 0 6 5 6 
Myb-binding protein 1A IPI00331361 0 5 3 0 0 0 7 6 7 
Argininosuccinate lyase IPI00314788 0 8 4 0 0 0 4 3 6 
Isoform 2 of Transcription elongation factor A protein 1 IPI00121887 0 5 5 0 0 0 0 0 0 
Aldose reductase IPI00223757 0 0 6 0 0 0 6 7 4 
radixin isoform a IPI00653921 0 4 4 0 0 0 0 0 0 
Ubiquitin-conjugating enzyme E2 N IPI00165854  0 2 4 0 0 0 0 0 0 
Annexin A2 IPI00468203  0 5 3 0 0 0 0 0 0 
Isoform 1 of Ubiquitin-conjugating enzyme E2 variant 1 IPI00113257 0 4 4 0 0 0 0 0 0 
Adenosylhomocysteinase IPI00230440 0 7 0 0 0 0 0 0 0 
Isoform 1 of Eukaryotic translation initiation factor 2A IPI00119806  0 6 1 0 0 0 0 0 0 
Copper transport protein ATOX1 IPI00117379 0 4 1 0 0 0 0 0 0 
Isoform 2 of Transcription factor BTF3 IPI00131186  0 0 7 0 0 0 0 0 0 
Glucose-6-phosphate isomerase IPI00228633  0 0 7 0 0 0 6 15 9 
Putative uncharacterized protein IPI00132089 0 3 1 0 0 0 16 18 17 
Tyrosyl-tRNA synthetase IPI00314153 0 1 2 0 0 0 0 0 0 
Prefoldin subunit 2 IPI00119545 0 0 0 0 3 2 0 0 0 
40 kDa peptidyl-prolyl cis-trans isomerase IPI00132966 0 2 3 0 0 0 0 0 0 
40S ribosomal protein S28 IPI00137736  0 3 2 0 0 0 0 0 0 
Reticulon 4 IPI00275539  0 0 0 0 2 3 0 0 0 
MARCKS-related protein IPI00281011 0 2 2 0 0 0 0 0 0 
similar to QM protein IPI00112024 0 2 2 0 0 0 0 0 0 
similar to ribosomal protein L38 IPI00138302  0 0 0 0 0 1 0 0 0 
Isoform 1 of Coiled-coil domain-containing protein 47 IPI00310518  0 0 0 0 5 0 0 0 0 
157 
 
Isoform 1 of A-kinase anchor protein 12 IPI00123709  0 2 0 0 0 1 0 0 0 
Isoform 1 of V-type proton ATPase catalytic subunit A IPI00407692 0 0 0 0 3 0 0 0 0 
Isoform 1 of C-terminal-binding protein 1 IPI00128155  0 0 0 0 4 0 0 0 0 
Brain acid soluble protein 1 IPI00129519 0 4 0 0 0 0 4 2 3 
COP9 signalosome complex subunit 3 IPI00131870 0 0 0 0 4 0 0 0 0 
Copine-3 IPI00266752 0 0 0 0 3 0 0 0 0 
Thimet oligopeptidase IPI00322150 0 4 0 0 0 0 0 0 0 
28 kDa heat- and acid-stable phosphoprotein IPI00352475 0 4 0 0 0 0 0 0 0 
titin isoform N2-A IPI00604969  0 0 0 0 0 1 0 0 0 
COP9 signalosome complex subunit 4 IPI00131871  0 2 0 0 0 0 0 0 0 
Dihydrofolate reductase IPI00230042 0 2 0 0 0 0 0 0 0 
Eukaryotic translation initiation factor 6 IPI00115862 0 2 0 0 0 0 0 0 0 
Lysosomal membrane glycoprotein 1, isoform CRA_a IPI00469218  0 3 0 0 0 0 0 0 0 
Vesicle-fusing ATPase IPI00656325  0 0 0 0 2 0 0 0 0 
Isoform 2 of tRNA (cytosine-5-)-methyltransferase NSUN2 IPI00850580  0 3 0 0 0 0 0 0 0 
Bifunctional aminoacyl-tRNA synthetase IPI00339916  0 0 0 0 2 0 0 0 0 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 IPI00120716 0 0 0 0 2 0 0 0 0 
DNA-(apurinic or apyrimidinic site) lyase IPI00224152 0 2 0 0 0 0 0 0 0 
Microtubule-associated protein 1B IPI00130920  1 15 8 14 10 6 12 9 11 
Elongation factor 1-gamma IPI00318841 1 0 0 12 15 18 6 5 7 
Lon protease homolog IPI00319518  1 0 1 4 11 3 8 12 7 
Clathrin heavy chain 1 IPI00169916  1 9 6 2 2 0 7 6 6 
Transaldolase IPI00124692 1 3 4 0 0 0 4 1 4 
Protein canopy homolog 2 IPI00135512 1 4 2 0 0 0 3 2 0 
Isoform 1 of Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial IPI00459725  1 3 2 0 0 0 0 0 0 
Gamma-enolase IPI00331704 1 0 2 0 0 0 0 0 0 
Peroxiredoxin-1 IPI00121788 2 2 0 36 39 27 7 10 10 
Isoform 1 of Heterogeneous nuclear ribonucleoprotein K IPI00223253  2 0 2 21 16 14 11 7 13 
Nucleosome assembly protein 1-like 1 IPI00123199 2 4 2 15 14 7 8 8 8 
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Arginyl-tRNA synthetase, cytoplasmic IPI00315488 2 2 2 8 10 2 6 4 6 
MCG22130, isoform CRA_b IPI00468771  2 3 2 8 4 7 0 0 0 
Peroxiredoxin-4 IPI00116254  2 2 1 7 10 4 3 2 1 
Ras-related protein Rab-1A IPI00114560 2 2 1 7 6 7 6 6 4 
Valyl-tRNA synthetase IPI00130353 2 0 2 4 4 0 3 5 3 
Transforming protein RhoA IPI00315100  2 2 2 1 1 0 0 0 0 
Beta-actin-like protein 2 IPI00221528 2 2 3 1 0 1 0 0 0 
Myristoylated alanine-rich C-kinase substrate IPI00229534 2 0 2 1 2 4 0 0 0 
Rab GDP dissociation inhibitor alpha IPI00323179 2 14 7 0 0 0 2 3 2 
Threonyl-tRNA synthetase, cytoplasmic IPI00468688 2 6 4 0 0 0 0 0 0 
Glutathione S-transferase P 1 IPI00555023 2 6 2 0 0 0 4 2 4 
14-3-3 protein eta IPI00227392 2 5 6 0 0 3 8 9 6 
Seryl-aminoacyl-tRNA synthetase, isoform CRA_b IPI00225307 2 7 4 0 0 0 5 4 7 
Actin-related protein 3 IPI00115627 2 4 5 0 0 0 0 0 0 
Putative uncharacterized protein IPI00122815  2 5 1 0 3 0 16 18 17 
6-phosphogluconate dehydrogenase, decarboxylating IPI00466919  2 5 5 0 0 0 0 0 0 
FK506-binding protein 4 IPI00230139 2 4 4 0 1 0 2 3 4 
Isoform 1 of Obg-like ATPase 1 IPI00111981  2 4 4 0 0 1 0 0 0 
Isoform 1 of Methionine adenosyltransferase 2 subunit beta IPI00468802  2 2 1 0 0 0 0 0 0 
Isoform 2 of Acidic leucine-rich nuclear phosphoprotein 32 family 
member B 
IPI00113536  2 7 2 0 0 0 2 0 2 
IgE-binding protein IPI00116996  2 6 3 0 0 0 0 0 0 
High mobility group protein B2 IPI00462291 2 2 2 0 0 0 0 0 0 
Nuclear migration protein nudC IPI00132942 2 2 2 0 0 0 0 0 0 
Isoform 1 of 60 kDa heat shock protein, mitochondrial IPI00308885 3 8 4 107 104 57 36 39 35 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A 
alpha isoform 
IPI00310091 3 3 4 22 19 7 6 4 4 
similar to Protein disulfide isomerase associated 6 IPI00854971 3 14 8 2 5 3 0 0 0 
lysyl-tRNA synthetase isoform 1 IPI00469103  3 9 1 2 2 2 2 0 0 
Transgelin-2 IPI00125778 3 6 5 0 4 3 18 10 17 
Nucleolin IPI00317794 3 11 4 0 2 0 19 19 15 
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Protein DJ-1 IPI00117264  3 5 6 0 0 0 7 7 4 
Histidine triad nucleotide-binding protein 1 IPI00108189 3 6 7 0 0 0 6 6 4 
protein disulfide isomerase associated 4 IPI00271951 3 5 2 0 0 0 0 0 0 
Tubulin beta-5 chain IPI00117352 4 35 18 109 94 70 86 75 82 
Dihydropyrimidinase-related protein 3 IPI00122349  4 6 1 34 33 21 7 13 11 
78 kDa glucose-regulated protein IPI00319992 4 11 9 13 16 18 42 30 36 
Alanyl-tRNA synthetase, cytoplasmic IPI00321308 4 6 0 13 30 7 11 9 11 
20 kDa protein IPI00857345 4 6 3 13 9 9 0 0 0 
Nucleophosmin IPI00127415  4 6 6 8 8 5 14 16 16 
ADP-ribosylation factor 2 IPI00135730  4 6 5 8 6 6 0 0 0 
Actin, alpha skeletal muscle IPI00110827  4 7 6 4 6 2 0 0 0 
Actin, cytoplasmic 1 IPI00110850 4 2 4 4 4 3 207 191 164 
Ran-specific GTPase-activating protein (Fragment) IPI00321978 4 2 4 2 6 6 2 3 2 
Hypoxia up-regulated protein 1 IPI00123342 4 8 6 2 2 0 0 0 0 
Farnesyl pyrophosphate synthetase IPI00120457 4 7 2 2 2 2 5 2 3 
Putative uncharacterized protein IPI00399961  4 2 3 2 2 0 16 18 17 
Rho GDP-dissociation inhibitor 1 IPI00322312 4 10 8 0 0 0 8 8 8 
Acidic leucine-rich nuclear phosphoprotein 32 family member A IPI00314736 4 5 6 0 0 0 0 0 0 
Malate dehydrogenase, cytoplasmic IPI00336324 4 6 9 0 0 0 13 18 14 
Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial IPI00132653 4 4 4 0 0 0 0 0 0 
Histidyl-tRNA synthetase, cytoplasmic IPI00116991  4 6 5 0 0 0 0 0 0 
Ornithine aminotransferase, mitochondrial IPI00129178 4 6 2 0 0 0 3 2 2 
Prostaglandin E synthase 3 IPI00127989  4 5 2 0 2 0 9 14 11 
Nascent polypeptide-associated complex subunit alpha, muscle-specific 
form 
IPI00111831  4 7 3 0 0 0 0 0 0 
Actin-related protein 2 IPI00177038  4 3 1 0 0 0 0 0 0 
Isoform B of Cytosolic acyl coenzyme A thioester hydrolase IPI00125939  4 0 0 0 0 0 0 0 0 
T-complex protein 1 subunit eta IPI00331174 5 3 4 20 31 15 28 23 21 
Isoform 1 of Tryptophanyl-tRNA synthetase, cytoplasmic IPI00113738  5 8 5 1 0 1 0 0 0 
Stathmin IPI00551236  5 12 8 0 0 0 0 0 0 
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Phosphoserine aminotransferase IPI00115620  5 5 3 0 0 0 0 0 0 
Eukaryotic peptide chain release factor subunit 1 IPI00312468 5 6 4 0 0 0 0 0 0 
T-complex protein 1 subunit theta IPI00469268 6 4 2 19 29 20 13 11 4 
Serine hydroxymethyltransferase IPI00454008 6 6 9 0 0 0 7 2 1 
Isoform 1 of Protein SET IPI00111560  6 6 8 0 0 0 6 4 4 
Aspartate aminotransferase, mitochondrial IPI00117312 6 2 5 0 0 0 0 0 0 
Programmed cell death protein 5 IPI00116120 6 0 0 0 0 0 0 0 0 
ATP synthase subunit alpha, mitochondrial IPI00130280 7 13 10 51 49 31 18 21 16 
T-complex protein 1 subunit epsilon IPI00116279 7 3 4 20 25 18 15 8 7 
Transitional endoplasmic reticulum ATPase IPI00622235 7 6 4 16 23 5 21 25 18 
Heterogeneous nuclear ribonucleoprotein A/B IPI00117288  7 6 8 7 5 8 19 18 19 
Asparagine synthetase [glutamine-hydrolyzing] IPI00116966 7 5 3 5 6 4 11 6 7 
Isoform 2 of Cell division control protein 42 homolog IPI00113849 7 6 10 5 6 0 0 0 0 
Proliferating cell nuclear antigen IPI00113870 7 9 4 1 0 0 4 3 3 
10 kDa heat shock protein, mitochondrial IPI00263863 7 12 10 0 0 0 0 0 0 
Proliferation-associated protein 2G4 IPI00119305 7 10 8 0 0 0 6 6 5 
Adenylate kinase isoenzyme 2, mitochondrial IPI00269076  7 6 6 0 0 0 4 3 3 
Tubulin alpha-1B chain IPI00117348 8 18 21 92 85 75 0 0 0 
heat shock protein 9 IPI00880839 8 16 11 35 39 28 21 22 19 
Triosephosphate isomerase IPI00467833 8 23 20 1 2 0 7 7 7 
sepiapterin reductase IPI00129164 8 9 3 0 0 0 0 0 0 
Isoform Mitochondrial of Fumarate hydratase, mitochondrial IPI00129928  8 4 4 0 0 0 0 0 0 
14-3-3 protein epsilon IPI00118384 9 13 9 2 4 2 22 14 17 
Fatty acid synthase IPI00113223 10 4 7 42 53 22 19 15 18 
T-complex protein 1 subunit delta IPI00116277 10 3 4 30 33 20 9 13 7 
T-complex protein 1 subunit gamma IPI00116283 10 6 9 23 29 16 15 13 10 
Endoplasmin IPI00129526 10 12 10 22 29 18 26 21 22 
40S ribosomal protein SA IPI00123604  10 10 12 10 7 7 10 8 7 
Isoform HSP105-alpha of Heat shock protein 105 kDa IPI00123802  10 13 5 9 14 7 8 5 4 
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Phosphoglycerate kinase 1 IPI00555069 10 14 13 0 0 0 6 7 8 
Phosphoglycerate mutase 1 IPI00457898 10 12 8 0 0 0 12 12 16 
Heat shock 70 kDa protein 4 IPI00331556 11 17 13 1 2 0 10 12 12 
Bifunctional purine biosynthesis protein PURH IPI00330303  11 13 11 0 0 0 1 3 4 
Superoxide dismutase [Cu-Zn] IPI00130589 11 13 8 0 0 0 8 7 8 
T-complex protein 1 subunit zeta IPI00116281 12 8 9 12 12 7 12 11 10 
Staphylococcal nuclease domain-containing protein 1 IPI00123129 12 13 9 0 0 0 0 0 0 
Aconitate hydratase, mitochondrial IPI00116074 13 19 14 0 0 0 9 6 11 
Isoform Long of 14-3-3 protein beta/alpha IPI00230682 13 16 15 0 0 0 11 9 9 
Isoform 1 of Acidic leucine-rich nuclear phosphoprotein 32 family 
member E 
IPI00130016  13 13 8 0 2 0 4 4 3 
Cofilin-1 IPI00890117 14 26 12 21 25 34 0 0 0 
Isoform 1 of 14-3-3 protein theta IPI00408378  14 16 11 5 8 7 14 13 16 
Isoform 1 of T-complex protein 1 subunit alpha B IPI00459493 15 9 8 19 27 23 7 11 8 
14-3-3 protein gamma IPI00230707 15 24 19 2 4 0 17 15 15 
Putative uncharacterized protein IPI00467841  15 17 14 0 0 0 16 18 17 
Heat shock protein HSP 90-alpha IPI00330804 16 32 33 10 18 18 31 36 33 
Citrate synthase, mitochondrial IPI00113141 16 22 17 0 0 0 11 6 7 
Guanine nucleotide-binding protein subunit beta-2-like 1 IPI00317740 16 19 18 0 0 0 10 8 8 
ATP citrate lyase IPI00126248  17 20 18 4 15 4 25 19 17 
Elongation factor 1-alpha 1 IPI00307837 18 24 22 136 167 90 87 105 93 
Prothymosin alpha IPI00224784  18 25 22 0 0 0 0 0 0 
GTP-binding nuclear protein Ran IPI00134621 19 22 25 3 5 4 16 17 14 
Ubiquitin-like modifier-activating enzyme 1 IPI00123313 19 30 25 1 13 4 25 17 19 
ATP synthase subunit beta, mitochondrial IPI00468481 21 32 30 104 112 72 55 64 54 
Transketolase IPI00137409 21 19 22 0 2 0 7 6 5 
T-complex protein 1 subunit beta IPI00320217 23 15 13 29 40 22 18 19 15 
Fructose-bisphosphate aldolase A IPI00221402  23 36 38 0 2 0 23 26 18 
Elongation factor 2 IPI00466069 26 26 37 45 48 30 75 81 84 
L-lactate dehydrogenase A chain IPI00319994  26 32 41 23 26 22 41 49 46 
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Eukaryotic initiation factor 4A-I IPI00118676 26 25 23 0 6 0 24 29 22 
Protein disulfide-isomerase A3 IPI00230108 26 33 24 0 0 0 22 24 23 
mesotrypsin IPI00742417  27 14 22 6 0 5 0 0 0 
Eukaryotic translation initiation factor 5A-1 IPI00108125 29 17 27 4 2 6 19 24 10 
14-3-3 protein zeta/delta IPI00116498 33 32 36 11 16 8 24 26 30 
Calreticulin IPI00123639 33 36 32 0 0 0 14 19 19 
Glyceraldehyde-3-phosphate dehydrogenase IPI00273646  36 25 23 120 116 74 141 165 149 
Isoform M2 of Pyruvate kinase isozymes M1/M2 IPI00407130 37 37 33 50 55 36 61 45 60 
Heat shock cognate 71 kDa protein IPI00323357 40 48 43 55 62 44 110 92 98 
Malate dehydrogenase, mitochondrial IPI00323592 41 36 39 0 0 0 34 35 35 
Peptidyl-prolyl cis-trans isomerase IPI00554989 46 86 73 2 5 2 93 88 88 
Actin, cytoplasmic 2 IPI00874482 54 60 72 72 72 38 0 0 0 
MCG18238 IPI00229080 75 80 74 107 99 71 119 127 113 
Alpha-enolase IPI00462072 79 90 84 6 4 0 153 143 143 
Histone H3.2  0 0 0 0 0 0 64 67 53 
Isoform 5g of Peripherin  0 0 0 0 0 0 43 47 34 
Histone H2A type 2-C  0 0 0 0 0 0 22 20 24 
11 kDa protein  0 0 0 0 0 0 14 14 17 
Phosphatidylethanolamine-binding protein 1  0 0 0 0 0 0 14 12 14 
Vimentin  0 0 0 0 0 0 15 13 8 
Heterogeneous nuclear ribonucleoprotein H  0 0 0 0 0 0 10 11 9 
40S ribosomal protein S8  0 0 0 0 0 0 10 9 10 
Isoform 1 of Non-POU domain-containing octamer-binding protein  0 0 0 0 0 0 12 10 5 
Isoform Pl-VDAC1 of Voltage-dependent anion-selective channel protein 1  0 0 0 0 0 0 8 7 9 
similar to 40S ribosomal protein S14 isoform 1  0 0 0 0 0 0 7 9 8 
hypothetical protein LOC666586  0 0 0 0 0 0 8 7 6 
Isoform 3 of Heterogeneous nuclear ribonucleoproteins A2/B1  0 0 0 0 0 0 8 5 6 
60S ribosomal protein L7  0 0 0 0 0 0 6 5 7 
small inducible cytokine subfamily E, member 1  0 0 0 0 0 0 6 5 7 
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60S ribosomal protein L15  0 0 0 0 0 0 6 5 7 
annexin A6 isoform b  0 0 0 0 0 0 5 7 5 
Cytoplasmic dynein 1 heavy chain 1  0 0 0 0 0 0 6 3 7 
Isoform 1 of AP-2 complex subunit beta-1  0 0 0 0 0 0 5 6 4 
similar to Bifunctional aminoacyl-tRNA synthetase  0 0 0 0 0 0 6 5 4 
Macrophage migration inhibitory factor  0 0 0 0 0 0 6 5 4 
complement component 1, q subcomponent binding protein  0 0 0 0 0 0 5 6 3 
60S ribosomal protein L4  0 0 0 0 0 0 6 4 3 
Fascin  0 0 0 0 0 0 4 3 6 
Isoform 1 of Heterogeneous nuclear ribonucleoprotein A3  0 0 0 0 0 0 5 6 2 
Probable ATP-dependent RNA helicase DDX5  0 0 0 0 0 0 6 4 3 
Phosphoribosyl pyrophosphate synthetase-associated protein 2  0 0 0 0 0 0 5 4 4 
Gag  0 0 0 0 0 0 7 4 2 
Adenine phosphoribosyltransferase  0 0 0 0 0 0 4 4 4 
hypothetical protein  0 0 0 0 0 0 4 6 2 
hypothetical protein  0 0 0 0 0 0 5 4 3 
Isoform 2 of F-actin-capping protein subunit beta  0 0 0 0 0 0 4 3 5 
Adenylyl cyclase-associated protein 1  0 0 0 0 0 0 3 4 4 
Isoform 2 of Spectrin alpha chain, brain  0 0 0 0 0 0 4 2 5 
poly A binding protein, cytoplasmic 2  0 0 0 0 0 0 3 3 4 
Splicing factor, proline- and glutamine-rich  0 0 0 0 0 0 4 3 3 
Heterogeneous nuclear ribonucleoprotein L  0 0 0 0 0 0 3 4 3 
Cytochrome c, somatic  0 0 0 0 0 0 3 4 2 
Protein ARMET  0 0 0 0 0 0 3 3 3 
TAR DNA-binding protein 43  0 0 0 0 0 0 3 3 3 
Isoform 2 of ATP-dependent RNA helicase A  0 0 0 0 0 0 2 3 4 
similar to ribosomal protein L10a  0 0 0 0 0 0 4 1 4 
Lamin-B1  0 0 0 0 0 0 5 3 1 
60S ribosomal protein L8  0 0 0 0 0 0 4 4 1 
164 
 
60S ribosomal protein L10  0 0 0 0 0 0 3 3 2 
ATP-dependent RNA helicase DDX3X  0 0 0 0 0 0 2 4 2 
S-methyl-5'-thioadenosine phosphorylase  0 0 0 0 0 0 3 3 2 
Serine/threonine-protein phosphatase PP1-beta catalytic subunit  0 0 0 0 0 0 1 3 3 
Proteasome subunit alpha type-4  0 0 0 0 0 0 4 1 2 
Eukaryotic translation initiation factor 2 subunit 1  0 0 0 0 0 0 2 3 2 
NADPH--cytochrome P450 reductase  0 0 0 0 0 0 5 2 0 
40S ribosomal protein S9  0 0 0 0 0 0 2 3 1 
5'(3')-deoxyribonucleotidase, cytosolic type  0 0 0 0 0 0 4 1 1 
Proteasome subunit beta type-4  0 0 0 0 0 0 2 2 1 
Multisynthetase complex auxiliary component p38  0 0 0 0 0 0 3 0 2 
29 kDa protein  0 0 0 0 0 0 2 0 3 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial 
 0 0 0 0 0 0 1 2 1 
Isoform 2 of Spectrin beta chain, brain 1  0 0 0 0 0 0 1 3 0 
Ras-related protein Rap-1A  0 0 0 0 0 0 2 0 2 
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial  0 0 0 0 0 0 0 3 1 
Eukaryotic translation initiation factor 3 subunit M  0 0 0 0 0 0 0 1 3 
Lupus La protein homolog  0 0 0 0 0 0 0 2 1 
ELAV (Embryonic lethal, abnormal vision, Drosophila)-like 4  0 0 0 0 0 0 3 0 0 
CPN10-like protein  0 0 0 0 0 0 0 2 0 
Isoform 2 of Importin-5  0 0 0 0 0 0 0 0 2 
Putative gag-pol protein  0 0 0 0 0 0 2 0 0 
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APPENDIX 2 
Ratio of Heavy and Light Proteins from SILAC Experiment with Probe 1a 
NaN represent the proteins for which ratio cannot be calculated using Maxquant Analysis.  
Proteins are adjusted so that the proteins with greater difference in expression in Cell Lysate Vs Labeled Proteome are Listed First. 
 
Protein Descriptions 
 
Ratio H/L Cell Lysatae Ratio H/L Labeled Proteome Ratio H/L Non-labeled Proteome 
1 2 3 1 2 3 1 2 3 
Proteasome activator complex subunit 1  
Uncharacterized protein   
0.319 NaN NaN 0.058 0.227 0.127 NaN NaN NaN 
 F-actin-capping protein muscle Z-line, alpha 2 OS 0.577 NaN NaN 0.192 0.470 0.177 NaN NaN NaN 
Calponin-2  Calponin 2, isoform CRA_a  
Uncharacterized protein   
0.688 NaN NaN 0.066 0.054 0.051 NaN NaN NaN 
Serine/threonine-protein phosphatase  
Serine/threonine-protein phosphatase  Isoform 
Gamma-2 of Serine/threonine-protein 
0.973 1.024 1.019 0.225 NaN 0.259 0.215 0.948 1.115 
Superoxide dismutase [Cu-Zn]  Uncharacterized 
protein   
1.013 1.066 1.072 0.208 0.525 NaN NaN NaN NaN 
Heterogeneous nuclear ribonucleoprotein Q  Isoform 2 
of Heterogeneous nuclear ribonucleoprotein Q  
GN=SYNCRIP; Isoform 3 of Heterogen 
1.218 1.433 1.322 0.148 0.228 0.087 0.110 0.143 NaN 
Eukaryotic initiation factor 4A-III   1.287 1.217 1.430 0.144 NaN 0.909 NaN NaN NaN 
Translationally-controlled tumor protein  
Uncharacterized protein  TPT1 protein |Q5 
1.369 NaN NaN 1.817 2.044 1.853 NaN NaN NaN 
DNA-(apurinic or apyrimidinic site) lyase  
Uncharacterized protein  GN=APEX1  
1.443 NaN NaN 1.768 2.036 1.887 NaN NaN NaN 
Peroxiredoxin-5, mitochondrial  Isoform 
Cytoplasmic+peroxisomal of Peroxiredoxin-5, 
mitochondrial  GN=PRDX5; Uncharacterized protein 
OS= 
1.499 1.400 1.744 0.125 NaN 0.278 NaN NaN NaN 
ATP synthase subunit beta, mitochondrial  ATP 
synthase subunit beta   
1.759 2.023 1.890 0.075 NaN 0.183 0.038 0.206 0.280 
Macrophage-capping protein  Uncharacterized protein 
|E7ENU 
27.962 44.087 29.468 150.200 40.212 123.510 NaN NaN NaN 
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Protein-glutamine gamma-glutamyltransferase 2  
Uncharacterized protein  GN=TGM2  
53.410 15.492 42.327 157.360 33.553 101.780 1.964 2.009 2.174 
Uncharacterized protein  Ubiquitin carboxyl-terminal 
hydrolase isozyme L1  Uncharacterized protein  GN 
NaN NaN NaN NaN 15.037 12.621 NaN NaN NaN 
Protein S100-A13   NaN NaN NaN NaN 2.829 1.957 NaN NaN NaN 
Oligoribonuclease, mitochondrial  Isoform 2 of 
Oligoribonuclease, mitochondrial  GN=REXO2; 
Uncharacterized protein  GN=REXO2  
NaN NaN NaN NaN 2.241 11.495 NaN NaN NaN 
Uncharacterized protein  Tubulin-specific chaperone A  
Uncharacterized protein |E5R 
NaN NaN NaN NaN 0.321 0.746 NaN NaN NaN 
Threonyl-tRNA synthetase, isoform CRA_a  
Uncharacterized protein  Threonyl-tRNA synthetase, 
cytoplasmic   
NaN NaN NaN 2.036 1.667 1.396 NaN NaN 1.206 
Uncharacterized protein  SMT3 suppressor of mif two 
3 homolog 3 (Yeast), isoform CRA_d  
NaN NaN NaN 1.118 1.435 1.245 NaN NaN NaN 
SH3 domain-bindin NaN NaN NaN 0.943 0.814 0.741 NaN NaN NaN 
Phosphatidylethanolamine-bindin NaN NaN NaN 0.872 1.348 0.995 NaN NaN NaN 
Prothymosin alpha  Isoform 2 of Prothymosin alpha NaN NaN NaN 0.841 1.294 0.977 NaN NaN NaN 
Isoform 3 of Importin-5  Uncharacterized protein  
Isoform 2 o 
NaN NaN 1.366 0.833 1.032 1.062 0.066 0.059 0.068 
Acidic leucine-rich nuclear phosphoprotein 32 family 
member E  Acidic (Leucine-rich) nuclear 
phosphoprotein 32 family, member E |E9PPH5 
NaN NaN 0.188 0.790 1.012 0.610 NaN NaN NaN 
Tropomyosin alpha-4 chain  Isoform 2 of Tropomyosin 
alpha-4 chain  GN=TPM4 
NaN NaN NaN 0.625 1.451 1.014 NaN NaN NaN 
Myotrophin  Myotrophin  Uncharacterized protein   NaN NaN NaN 0.612 0.486 0.703 NaN NaN NaN 
Ubiquitin-conjugating enzyme E2 variant 1  Ubiquitin-
conjugating enzyme E2 variant 1  HCG2044781  GN 
NaN NaN NaN 0.610 1.120 0.141 NaN NaN NaN 
Hepatoma-derived growth factor (High-mobility group 
protein 1-like)  Hepatoma-derived growth factor  
Hepatoma-derived gr 
NaN NaN NaN 0.534 1.163 1.077 NaN NaN NaN 
Acidic leucine-rich nuclear phosphoprotein 32 family 
member B  Isoform 2 of Acidic leucine-rich nuclear 
phosphoprotein 32 family member B  
GN=ANP32B;|Q5T6W 
NaN NaN NaN 0.452 3.798 0.531 NaN NaN NaN 
Fructose-bisphosphate aldolase C  Fructose-
bisphosphate aldolase  Fructose-bisphosphate 
aldolase  GN=A 
NaN NaN NaN 0.438 0.671 0.193 NaN NaN NaN 
Thioredoxin  Thioredoxin   NaN NaN NaN 0.420 0.270 NaN NaN NaN NaN 
167 
 
Proteasome subunit beta type-3   NaN NaN NaN 0.256 NaN 0.870 NaN NaN NaN 
Peptidyl-prolyl cis-trans isomerase FKBP1A  FK506 
binding protein 1A, 12kDa  FK506 binding protein12  
NaN NaN NaN 0.248 0.185 0.174 NaN NaN NaN 
Uncharacterized protein  Protein phosphatase 1 
regulatory subunit 12A  Uncharacterized protein   
NaN NaN NaN 0.197 0.128 NaN NaN NaN NaN 
Transaldolase  Transaldolase   NaN NaN NaN 0.183 1.032 0.583 NaN NaN NaN 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1  
Uncharacterized protein  
NaN NaN NaN 0.163 0.176 0.524 NaN NaN NaN 
Proteasome subunit alpha type-5   NaN NaN NaN 0.134 NaN 0.137 NaN NaN NaN 
High mobility group protein HMG-I/HMG-Y   NaN NaN NaN 0.129 0.660 0.180 NaN NaN NaN 
DnaJ homolog subfamily C member 8 NaN NaN NaN 0.097 0.728 0.593 NaN NaN NaN 
Thioredoxin reductase 1, cytoplasmic  Isoform 6 of 
Thioredoxin reductase 1, cytoplasmic  GN=TXNRD1; 
Uncharacterized protein omo sap 
NaN NaN NaN 0.073 0.256 0.076 NaN NaN NaN 
Isoform A of Protein CutA  Isoform C of Protein CutA  
GN=CUTA; Uncharacterized 
NaN NaN NaN 0.068 0.035 0.072 NaN NaN NaN 
14-3-3 protein eta   NaN NaN NaN 0.063 0.103 0.126 NaN NaN NaN 
Alpha-1-antiproteinase precursor NaN NaN NaN 0.030 0.012 0.022 NaN 0.123 0.333 
Beta-casein - Bos taurus (Bovine). NaN NaN NaN 0.024 0.011 0.066 0.031 0.017 0.014 
Alpha-S1-casein - Bos taurus (Bovine). NaN NaN NaN 0.018 0.028 0.028 0.011 0.007 0.006 
Cysteine dioxy NaN NaN NaN 0.015 0.018 0.016 NaN NaN NaN 
 Trans NaN NaN NaN 0.013 NaN 0.016 NaN NaN NaN 
Uncharacterized protein  Isoform 5 of 
Serine/threonine-protein kinase WNK1  GN=WNK1; 
Isoform 4 of Serine/threonine-protein kinase WNK1  
0.001 0.001 0.068 0.000 0.001 0.001 0.002 0.001 0.002 
Uncharacterized protein  Trypsin-1  Protease 0.003 0.010 0.005 NaN NaN NaN 0.066 NaN NaN 
Heat shock protein beta-1  Uncharacterized protein   0.013 0.022 0.026 0.032 0.016 0.016 0.033 0.004 0.025 
Serpin H1  Uncharacterized protein  0.020 0.027 0.025 0.043 NaN 0.034 NaN NaN NaN 
Keratin, type II cytoskeletal ,KRT1 Keratin, type II 
cytoskeletal 1 
0.021 0.019 0.028 0.011 0.019 0.015 0.010 0.008 0.017 
HLA class I histocompatibility antigen, B-42 alpha chain  
HLA class I histocompatibility antigen, B-7 alpha chain  
HLA cla 
0.021 0.032 0.016 NaN NaN NaN NaN NaN NaN 
 Isoform 2 of Tropomyosin beta chain  GN=TPM2; 
Isoform 3 of Tropomyosin beta chain  GN=TPM2 
0.025 0.027 0.015 0.053 0.110 0.019 NaN NaN NaN 
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Pachytene checkpoint protein 2  0.028 0.046 0.043 NaN NaN NaN NaN NaN NaN 
Alpha-2-HS-glycoprotein precursor 0.033 0.043 0.067 0.019 0.019 0.003 NaN NaN NaN 
Keratin, type I cytoskeletal 10  GN=KRT10 PE=1 SV=6 0.034 0.022 0.006 0.008 0.009 0.009 0.019 0.013 0.015 
Uncharacterized protein  Isoform 3 of Myosin-10 
|P35580-2|MYH1 
0.034 0.048 0.033 NaN NaN NaN NaN NaN NaN 
Bovine serum albumin precursor 0.037 0.021 0.024 0.013 0.003 0.006 0.033 NaN 0.062 
14-3-3 protein epsilon  Isoform SV of 14-3-3 protein 
epsilon  GN=YWHAE 
0.047 0.065 0.113 0.026 0.130 0.050 NaN NaN NaN 
Aldehyde dehydro 0.066 0.070 0.075 NaN NaN NaN 0.045 0.042 0.047 
Uncharacterized protein  HLA class I histocompatibility 
antigen, A-3 alpha chain  Uncharacterized protein omo 
sapi 
0.072 0.038 0.031 0.028 NaN NaN NaN NaN NaN 
Isoform 2 of Protein-L-isoaspartate(D-aspartate) O-
methyltransferase  P 
0.080 0.466 0.477 0.084 NaN 0.091 NaN NaN NaN 
D-3-phosphoglycerate dehydrogenase  
Phosphoglycerate dehydrogenase  Uncharacterized 
protein  GN=PHGDH P 
0.084 0.040 0.048 NaN NaN NaN 0.063 0.184 0.039 
Uncharacterized protein  Beta-2-micro 0.093 0.088 0.052 NaN NaN NaN NaN NaN NaN 
Keratin, type I cytoskeletal 9   0.095 0.034 0.158 0.025 0.014 0.011 0.030 0.015 0.036 
Thioredoxin domain-containing protein 5  TXNDC5 
protein  HCG1811539, isoform CRA_b  GN=MUTED 
PE=2 SV 
0.128 0.680 NaN NaN NaN NaN NaN NaN NaN 
  0.132 0.073 NaN 0.126 NaN NaN NaN NaN NaN 
Trans-Golgi network integral membrane protein 2  
Uncharacterized protein  Isoform TGN48 of Trans-
Golgi network int 
0.137 0.772 NaN NaN NaN NaN NaN NaN NaN 
Importin-9   0.138 NaN 0.103 NaN NaN NaN NaN NaN 0.065 
Protein disulfide-isomerase TMX3  Uncharacterized 
protein   
0.165 NaN NaN NaN NaN NaN NaN NaN NaN 
Activated RNA polymerase II transcriptional 
coactivator p15   
0.168 0.203 0.192 0.447 0.961 0.074 NaN NaN NaN 
Poly(rC)-bindin 0.190 NaN NaN NaN NaN NaN 1.358 1.143 1.615 
Nuclear pore complex protein Nup93   0.191 0.427 1.061 NaN NaN NaN NaN NaN NaN 
Uncharacterized protein   0.198 NaN 0.199 0.372 NaN NaN 1.324 0.882 1.506 
Copine-1  Uncharacterized protein  Copine I  
Uncharacterize 
0.199 0.101 0.359 NaN 0.362 0.116 NaN NaN NaN 
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Aldose reductase  Uncharacterized protein   0.205 NaN 0.138 NaN NaN NaN NaN NaN NaN 
 Si 0.210 NaN 0.235 NaN NaN 0.421 NaN NaN NaN 
  0.214 0.261 0.267 0.066 0.069 0.055 NaN NaN NaN 
Protein FAM3C  Uncharacterized protein   0.215 0.083 0.094 NaN NaN NaN NaN NaN NaN 
Kinectin  Isoform 2 of Kinectin  Uncharact 0.223 NaN 0.342 NaN NaN NaN NaN 0.071 0.425 
Spectrin alpha chain, brain  Uncharacterized protein  
Isoform 3 of Spectrin alpha chain, brain  GN= 
0.226 0.552 0.556 0.051 NaN 0.096 NaN 1.145 0.090 
Isoform B of Bifunctional 3-phosphoadenosine 5-
phosphosulfate synthase 2  Bifunctional 3-phospho 
0.229 0.275 0.164 NaN NaN NaN NaN NaN NaN 
 Spectrin beta chain, brain 1  Isoform Short of Spectrin 
beta chain, brain 1  GN=SPTBN1; Isoform 2 of Spectrin 
beta chain, brain 1  
0.237 0.131 0.599 NaN NaN NaN 0.081 0.409 0.062 
Heat shock 70 kDa protein 1A/1B  Uncharacterized 
protein  GN=HSPA1A PE=3 SV 
0.250 0.119 0.367 0.056 0.185 0.083 0.147 NaN 0.130 
Lon protease homolo 0.282 NaN NaN NaN NaN NaN NaN NaN NaN 
Phosphoribosyl pyrophosphate synthase-associated 
protein 2  Uncharacterized protein o 
0.289 0.088 0.094 NaN NaN NaN NaN NaN NaN 
Lamina-associated polypeptide 2, isoform alpha  
Lamina-associated polypeptide 2, isoforms 
beta/gamma  Thymopoietin, isof 
0.311 NaN NaN NaN NaN NaN NaN NaN NaN 
 Protein disulfide-isomerase A4   0.319 0.270 0.320 NaN NaN 0.156 NaN NaN NaN 
 Trans 0.342 0.369 0.373 0.089 0.293 0.086 NaN NaN NaN 
 Lamin-B1  Uncharacterized protein   0.345 0.322 0.082 NaN NaN NaN NaN NaN NaN 
Alpha-enolase   0.345 0.263 0.434 0.262 0.478 0.351 0.124 NaN 0.107 
Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, 
mitochondrial   
0.357 0.114 0.121 NaN NaN NaN NaN NaN NaN 
Annexin A11  Uncharacterized protein   0.362 NaN 0.308 NaN NaN NaN NaN NaN NaN 
Uncharacterized protein  Cell division control protein 
42 homolo 
0.364 0.171 0.888 NaN NaN NaN NaN NaN NaN 
Filamin-C  Isoform 2 of Filamin-C  GN=FLNC 0.377 0.691 0.705 NaN NaN NaN 0.074 0.047 0.072 
Vinculin  Isoform 1 of Vinculin   0.380 0.374 0.364 0.069 0.072 0.066 NaN NaN NaN 
Proliferatin 0.381 0.523 0.630 0.096 0.559 0.089 NaN NaN NaN 
Prefoldin subunit 3  Uncharacterized protein   0.412 NaN NaN NaN NaN 1.396 NaN NaN NaN 
Fatty acid synthase   0.431 0.290 0.436 NaN NaN NaN 0.099 1.973 0.080 
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Ras  0.435 0.152 0.475 0.099 0.095 0.076 NaN 0.057 0.168 
Histone H1.2  Histone H1.3   0.437 0.451 0.502 0.030 0.303 NaN 3.240 6.379 1.318 
  0.441 0.421 0.288 0.140 0.445 0.080 NaN NaN NaN 
Exportin-1   0.442 1.052 0.946 NaN NaN 0.116 NaN NaN NaN 
Ezrin  Uncharacterized protein   0.447 1.045 0.461 0.152 0.913 0.499 NaN NaN NaN 
T-complex protein 1 subunit beta  Uncharacterized 
protein  Chaperonin containing TCP1, subunit 2 (Beta), 
isoform CRA_c O 
0.451 0.468 0.355 0.859 NaN 0.609 NaN NaN NaN 
Fructose-bisphosphate aldolase A   0.460 0.524 0.602 0.150 0.567 0.299 NaN NaN NaN 
14-3-3 protein  0.468 0.459 0.506 0.134 0.156 0.132 NaN NaN NaN 
Uncharacterized protein  Myosin, light polypeptide 6, 
alkali, smooth muscle and non-muscle, isoform CRA_c  
Myosin light  
0.475 0.525 0.509 0.084 0.230 0.075 0.184 0.187 0.572 
Uncharacterized protein  Isoform 2 of Elongation 
factor 1-delta >t 
0.480 0.274 0.051 NaN NaN NaN 1.479 2.211 1.659 
Actin, cytoplasmic 1  Uncharacterized protein  
Uncharacteriz 
0.482 0.452 0.508 NaN NaN NaN NaN NaN NaN 
T-complex protein 1 subunit gamma  Uncharacterized 
protein >s 
0.484 0.806 0.963 NaN NaN NaN 0.138 0.174 0.097 
B-cell receptor-associated protein 31  Uncharacterized 
protein  GN=BCAP31 P 
0.492 0.673 0.564 NaN NaN NaN NaN NaN NaN 
Krt79 Keratin 79 0.503 NaN 0.115 NaN NaN NaN NaN NaN NaN 
 ADP-ribosylation factor-like protein 1  
Uncharacterized protein  GN=ARL1 PE=2 SV 
0.509 0.773 NaN NaN NaN NaN NaN NaN NaN 
Adipocyte plasma membrane-associated protein  
Isoform 2 of Adipocyte plasma membrane-associated 
protein  GN=APMAP 
0.510 0.517 0.697 NaN NaN NaN NaN NaN NaN 
Cytochrome b5 type B  Uncharacterized protein   0.517 0.583 0.531 NaN NaN NaN NaN NaN NaN 
Brain acid soluble protein 1  Isoform 2 of Brain acid 
soluble protein 1  GN=BASP1 
0.520 0.513 0.526 NaN NaN NaN NaN NaN NaN 
Uncharacterized protein  Keratin, type II cytoskeletal 8  
GN=KRT8 PE=1 SV=7 
0.539 0.562 0.567 0.016 NaN NaN 0.039 0.123 0.066 
Peptidyl-prolyl cis-trans isomerase FKBP4   0.543 0.504 NaN NaN NaN 0.531 NaN NaN NaN 
Myosin-9  Isoform 2 of Myosin-9  GN=MYH9 0.550 0.521 0.585 0.064 NaN 0.061 0.103 0.295 0.144 
Importin subunit beta-1  Uncharacterized protein   0.551 0.611 0.625 0.058 0.369 0.082 0.139 0.135 0.404 
Keratin, type II cytoskeletal 2 epidermal KRT2 Keratin, 0.551 0.029 0.631 0.022 0.010 0.025 0.017 0.018 0.032 
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type II cytoskeletal 2 epidermal 
Ribonuclease inhibitor   0.568 0.612 0.124 NaN NaN NaN 0.907 0.612 0.823 
 Pyruvate kinase isozymes M1/M2  Isoform M1 of 
Pyruvate kinase isozymes M1/M2  
0.578 0.620 0.629 0.152 0.872 0.603 0.296 0.725 0.499 
Heterogeneous nuclear ribonucleoprotein U  Isoform 
Short of Heterogeneous nuclear ribonucleoprotein U  
GN=HNRNPU; Uncharacterized prote 
0.584 1.111 1.412 0.056 0.059 0.348 0.116 0.640 0.871 
Phospho 0.598 0.742 0.661 0.476 0.574 0.250 NaN NaN NaN 
Elongation factor 2  Uncharacterized protein 
|F5GZG3|F5GZG3 
0.602 0.641 0.624 0.117 0.516 0.420 0.116 0.086 0.094 
Endoplasmic reticulum resident protein 29  
Uncharacterized protein   
0.603 0.788 0.650 0.148 NaN 0.171 NaN NaN NaN 
Ubiquitin-like modifier-activating enzyme 1  
Uncharacterized protein  GN=UBA1 PE 
0.604 0.560 0.519 0.351 0.163 0.393 NaN NaN NaN 
Nicotinamide phosphoribosyltransferase  
Uncharacterized protein   
0.606 0.608 NaN NaN NaN NaN NaN NaN NaN 
Nicotinate-nucleotide pyrophosphorylase 
[carboxylatin 
0.610 0.516 0.512 NaN NaN NaN NaN NaN 0.198 
Nucleosome assembly protein 1-like 1  
Uncharacterized protein  GN=NAP1L1  
0.612 0.649 0.693 NaN NaN NaN NaN 0.716 0.669 
Uncharacterized protein  Proteasome activator 
complex subunit 2  GN=PSME2  
0.615 0.562 0.281 0.205 0.092 0.110 NaN NaN NaN 
Uncharacterized protein  Capping protein (Actin 
filament) muscle Z-line, beta  Isoform 2 of F-actin-
capping protein 
0.623 0.693 0.632 NaN NaN 0.165 NaN NaN NaN 
 Keratin, type I cytoskeletal 14   0.629 NaN NaN NaN NaN NaN NaN 0.096 NaN 
  0.631 0.809 0.804 0.135 1.043 0.812 1.023 1.160 1.286 
Histone H3.1  Histone H3.1t  Histone cluster 2, H3, 
pseudogene 2 |Q6NXT2| 
0.650 0.904 0.789 NaN NaN NaN NaN NaN NaN 
Protein disulfide-isomerase  Uncharacterized protein 
|F5H 
0.651 0.609 0.682 0.110 0.395 0.444 0.069 0.147 0.060 
L-lactate dehydrogenase A chain  L-lactate 
dehydrogenase  Isoform 2 of L-lactate dehydrogenase 
A chain  G 
0.655 0.701 0.820 0.504 0.518 0.581 0.282 0.338 0.221 
Tubulin beta chain  Uncharacterized protein 
|Q5JP53|Q5JP53 
0.660 0.649 0.673 NaN NaN NaN 0.955 0.972 0.929 
Histone H2A type 2-A  Histone H2A type 2-C   0.661 0.744 0.662 0.026 0.324 0.308 NaN NaN NaN 
Isoform 2 of Eukaryotic translation initiation factor 5A-
1  Eukaryotic translati 
0.661 0.177 NaN 0.171 0.769 0.603 NaN NaN NaN 
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ADP-ribosylation factor 3  ADP-ribosylation factor 1  
Uncharacterized protein |F5H3A6 
0.663 0.604 NaN NaN NaN NaN NaN NaN NaN 
UV excision repair protein RAD23 homolog B  RAD23 
homolog B (S. cerevisiae), isoform CRA_a  
Uncharacterized protein 
0.667 NaN 0.726 NaN NaN NaN NaN NaN NaN 
Poly(RC) binding protein 2  Poly(rC)-binding protein 2  
Poly(RC) binding protein 2, isoform CRA_b  GN= 
0.671 0.175 0.535 NaN NaN NaN NaN 1.208 0.322 
Tubulin alpha-1B chain  Tubulin alpha-4A chain 
|A8MUB1|A8M 
0.682 0.739 0.727 0.157 0.330 0.200 0.600 1.037 0.875 
Triosephosphate isomerase  Isoform 2 of 
Triosephosphate isomerase   SV=1 
0.687 0.634 0.639 0.329 0.726 0.576 NaN NaN NaN 
Exportin-2  Isoform 3 of Exportin-2  Uncharacterized 
protein 
0.697 0.672 0.623 0.221 NaN 0.372 NaN NaN NaN 
Catenin alpha-1  Uncharacterized protein |F5GXI1|F5 0.698 0.669 0.853 0.104 NaN NaN 0.114 0.055 0.076 
Protein DJ-1   0.706 0.684 0.727 0.537 0.866 0.531 NaN NaN NaN 
Uncharacterized protein  Rab GDP dissociation 
inhibitor beta  GDP dissociation inhibitor 2  GN=GDI2 
PE=2  
0.706 0.626 0.967 0.406 1.461 0.730 NaN NaN NaN 
Calnexin  Uncharacterized protein   0.708 0.726 0.701 NaN NaN NaN 0.048 0.023 0.042 
Histone H3.2   0.710 0.740 0.761 NaN NaN NaN NaN NaN NaN 
Keratin, type I cytoskeletal 18  Uncharacterized protein   0.722 0.773 0.802 0.036 NaN NaN 0.082 0.126 0.133 
14-3-3 protein theta  Uncharacterized protein   0.724 0.644 0.751 0.259 0.816 0.471 NaN NaN 0.074 
Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform  Uncharacterized 
protein  Uncharecterized protein 
0.724 0.831 0.777 0.961 NaN 0.555 0.060 0.037 0.072 
Tubulin beta-4B chain   0.726 0.744 0.788 0.092 NaN NaN 0.848 1.288 0.940 
Ras-related protein Rap-1b  Uncharacterized protein 
|A 
0.726 0.759 0.699 0.087 NaN NaN NaN NaN NaN 
Lactoylglutathione lyase  Isoform 2 of 
Lactoylglutathione lyase  GN=GLO1 
0.730 0.713 0.643 NaN NaN 0.792 NaN 1.194 NaN 
T-complex protein 1 subunit eta  Chaperonin 
containing TCP1, subunit 7 (Eta), isoform CRA_c  
Uncharacterized protein  
0.734 0.731 0.738 NaN NaN NaN 0.109 0.608 0.547 
Keratin, type II cuticular Hb4  GN=KRT8 0.745 NaN 0.847 NaN NaN NaN NaN NaN NaN 
Krt4 Keratin, type II cytoskeletal 4 0.745 NaN 0.847 NaN NaN NaN 0.174 0.221 NaN 
Filamin-A  Isoform 2 of Filamin-A |A6NDY9|A6NDY 0.748 0.675 0.714 0.304 NaN 0.291 0.049 0.038 0.070 
 Histone 0.749 0.695 0.926 0.325 1.282 0.566 NaN NaN NaN 
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Histone H2A.Z  Histone H2A.V  Histone H2A  Histone 
H2A omo 
0.750 0.739 0.342 NaN NaN NaN NaN NaN NaN 
Endoplasmin  Uncharacterized protein   0.757 0.737 0.682 0.128 NaN NaN 0.068 0.107 0.117 
Talin-1  Talin 1   0.767 0.709 0.886 0.218 0.463 0.183 0.051 0.025 0.052 
Histone H4   0.767 0.890 0.876 NaN 0.042 NaN NaN NaN NaN 
Histone H2B  Histone H2B  Histone H2B type 1-K   0.770 0.739 0.698 0.052 0.673 0.361 0.089 NaN NaN 
Profilin-1   0.777 0.828 0.821 0.618 0.830 0.511 NaN NaN NaN 
Phosphoglycerate kinase 1  Phosphoglycerate kinase  
Phosphoglycerate kinase  
0.779 0.902 1.012 0.209 0.810 0.508 NaN NaN NaN 
Isoform 2 of Protein disulfide-isomerase A6  
Uncharacterized protein  GN=PDIA6  
0.784 0.803 0.763 0.104 0.942 0.340 0.071 0.046 0.052 
Isoform 2 of Heterogeneous nuclear ribonucleoprotein 
A/B  Isoform 3 of Heterogeneous nuclear ribo 
0.787 0.849 NaN 0.024 0.118 0.185 NaN NaN NaN 
Peroxiredoxin-6   0.800 0.824 0.775 0.168 0.752 0.249 NaN NaN NaN 
Hypoxia up-regulated protein 1  Uncharacterized 
protein  
0.806 1.118 0.658 NaN NaN NaN NaN NaN NaN 
Si 0.818 9.606 1.957 NaN NaN NaN NaN NaN NaN 
Isoform 2 of Tropomyosin alpha-3 chain  Tropomyosin 
3  I 
0.834 0.811 0.946 0.312 1.176 0.729 NaN NaN NaN 
Malate dehydrogenase  Malate dehydrogenase, 
cytoplasmic  Malate dehydrogenase |B9A0 
0.850 NaN 0.175 0.687 2.073 0.776 NaN NaN NaN 
T-complex protein 1 subunit epsilon  Uncharacterized 
protein  
0.855 1.634 0.773 NaN NaN NaN 0.697 0.691 0.545 
Peroxiredoxin-1   0.864 0.865 0.911 NaN NaN NaN 1.686 1.469 1.389 
Isoform 2 of AP-2 complex subunit beta  Adaptor-
related protein complex 2, beta 1 subunit, isoform  
0.878 0.858 NaN NaN NaN NaN NaN 0.296 NaN 
Uncharacterized protein  Elongation factor 1-gamma  
Uncharacterized protein |E7E 
0.884 0.806 0.847 0.342 1.102 0.368 0.473 0.145 0.621 
Mitochondrial fission 1 protein   0.891 0.963 1.003 NaN NaN NaN NaN NaN NaN 
Vesicle-traffickin 0.893 1.166 2.299 NaN NaN NaN NaN NaN NaN 
Hetero 0.897 5.335 5.937 0.030 0.204 0.044 0.876 1.345 0.802 
Beta-actin-like protein 2   0.897 0.934 0.921 NaN NaN 1.031 NaN NaN NaN 
T-complex protein 1 subunit alpha  T-complex protein 
1 subunit alpha  T-complex protein 1 subunit alpha   
0.898 0.841 0.858 NaN NaN NaN 0.518 0.544 0.162 
Elongation factor 1-alpha 1  Putative elongation factor 
1-alpha-like 3  EEF1A1 protein  GN=EEF1A1 P 
0.900 0.887 0.951 0.038 NaN 0.108 1.190 1.244 1.031 
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Astrocytic phosphoprotein PEA-15  Phosphoprotein 
enriched in astrocytes 15   
0.902 0.561 NaN NaN 0.920 1.124 NaN NaN NaN 
Protein disulfide-isomerase A3  Protein disulfide 
isomerase family A, member 3, isoform CRA_b  
Uncharacterized protein 
0.904 0.802 0.890 0.548 1.116 0.872 NaN NaN NaN 
Clathrin heavy chain 1  Isoform 2 of Clathrin heavy 
chain 1  GN=CLTC 
0.909 1.157 1.323 0.134 NaN NaN 0.948 1.195 1.123 
  0.911 0.876 0.958 NaN 0.946 0.345 NaN NaN NaN 
Calreticulin  Uncharacterized protein   0.927 0.829 0.941 0.254 1.231 0.971 NaN NaN NaN 
Actin, alpha cardiac muscle 1  Actin, alpha skeletal 
muscle  Actin, aortic smooth muscle  GN=ACTA2 PE=1 
SV= 
0.936 1.000 0.975 NaN NaN 5.558 NaN NaN NaN 
Chloride intracellular channel protein 1   0.936 1.009 0.447 0.273 1.358 0.753 0.050 0.042 0.019 
Actin, cytoplasmic 2  Uncharacterized protein   0.944 0.937 0.965 0.757 0.968 1.096 0.629 1.217 1.033 
Uncharacterized protein  Cofilin-1  Uncharacterized 
protein  Co 
0.953 0.955 0.971 0.747 1.279 0.963 0.158 0.453 0.108 
Histone H3.3   0.955 0.757 0.917 NaN NaN NaN NaN NaN NaN 
Adenylyl cyclase-associated protein 1  Isoform 2 of 
Adenylyl cyclase-associated protein 1  GN=CAP1; 
Adenylyl cyclase-associated protein OS= 
0.956 1.099 1.040 0.756 0.914 0.946 NaN NaN NaN 
26S protease regulatory subunit 6B  Isoform 2 of 26S 
protease regulatory subunit 6B  GN=PSMC4 
0.956 1.060 0.960 NaN NaN NaN NaN 1.738 NaN 
Ras-related protein Rab-6A  Isoform 2 of Ras-related 
protein Rab-6A   S 
0.958 NaN NaN NaN NaN NaN NaN NaN NaN 
UMP-CMP kinase  Uncharacterized protein   0.960 NaN NaN 1.014 NaN NaN NaN NaN NaN 
 Exocyst complex component 1  Isoform 2 of Exocyst 
complex component 1   
0.973 NaN NaN NaN NaN NaN NaN NaN NaN 
 Protein SET  Isoform 2 of Protein SET  Uncharacterized  0.979 0.734 1.873 0.146 1.082 0.696 NaN NaN NaN 
 40S ribosomal protein S7  Uncharacterized protein   0.996 1.183 NaN NaN NaN NaN NaN NaN NaN 
 Cytoskeleton-associated protein 4   1.009 0.952 0.915 NaN NaN NaN NaN NaN NaN 
 60S acidic ribosomal protein P1   1.018 1.198 1.251 NaN NaN 0.200 NaN NaN NaN 
 40S ribosomal protein S3  Uncharacterized protein  1.020 1.036 0.990 NaN NaN NaN 1.017 1.065 0.745 
 Actinin alpha 1 isoform b  Alpha-actinin-1  Isoform 2 
of Alpha-actinin-1   
1.052 1.100 0.695 0.148 0.483 0.436 NaN NaN 0.127 
 Coronin-1C_i2 protein  Coronin-1C  Uncharacterized 
protein   
1.053 1.113 1.009 0.907 NaN 0.879 NaN NaN NaN 
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 L-lactate dehydro 1.053 1.023 1.076 0.898 0.948 1.016 0.780 0.938 0.524 
 Ran  1.059 11.003 NaN NaN NaN NaN NaN NaN NaN 
 60S ribosomal protein L22   1.080 1.220 1.154 NaN NaN NaN NaN NaN NaN 
 60S ribosomal protein L23  Uncharacterized protein   1.086 1.172 NaN NaN NaN NaN NaN NaN NaN 
 Non-POU domain-containing octamer-binding protein  
Uncharacterized protein  GN=N 
1.089 1.622 1.736 NaN 0.104 NaN NaN NaN NaN 
 Eukaryotic initiation factor 4A-I   1.104 1.330 1.126 0.760 1.569 1.038 0.021 0.008 0.028 
 Uncharacterized protein  NADH-cytochrome b5 
reductase 3  Isoform 2 of NADH-cytochrome b5 
reductase 3 omo sapie 
1.113 1.202 1.238 NaN NaN NaN NaN NaN NaN 
 Small nuclear ribonucleoprotein Sm D1   1.116 1.196 1.216 0.255 0.512 0.590 NaN NaN NaN 
 Uncharacterized protein  Sodium/potassium-
transporting ATPase subunit alpha-1  ATPase, Na+/K+ 
transporting, alpha 1 
1.135 1.088 1.091 248.500 NaN NaN NaN NaN NaN 
 Transformin 1.144 NaN NaN NaN NaN NaN NaN NaN NaN 
 Annexin A5  Uncharacterized protein 1.149 1.220 1.211 0.887 1.523 1.034 NaN NaN NaN 
 Heterogeneous nuclear ribonucleoprotein A1  
Uncharacterized protein  GN=HN 
1.149 1.164 1.210 0.097 0.690 0.099 NaN NaN NaN 
 Nucleoside diphosphate kinase  Isoform 3 of 
Nucleoside diphosphate kinase B  GN=NME2; 
Nucleoside diphosphate kinase B   
1.158 1.329 1.222 0.922 1.587 1.017 NaN NaN NaN 
 Heat shock protein HSP 90-beta  Putative heat shock 
protein HSP 90-beta-3   
1.160 1.304 1.269 1.195 2.024 1.235 0.185 0.203 0.137 
 40S ribosomal protein S5   1.161 1.250 1.239 NaN NaN NaN 0.847 NaN 0.093 
 Actin-related protein 3  Uncharacterized protein 
|B4DTI 
1.161 1.476 1.390 1.753 NaN 1.350 NaN NaN NaN 
 Lysosome-associated membrane  1.165 1.449 1.596 NaN NaN NaN NaN NaN NaN 
 Obg-like ATPase 1  Isoform 3 of Obg-like ATPase 1   1.170 1.167 1.406 1.081 1.447 1.199 NaN NaN NaN 
 Heat shock 70 kDa protein 6  Uncharacterized protein  
Putative heat shock 70 kDa protein 7  GN=HSPA7 PE 
1.191 1.232 1.302 0.634 1.035 0.786 NaN NaN NaN 
 Polyubiquitin-C  Uncharacterized protein   1.192 1.284 1.277 0.557 0.709 0.860 0.056 0.041 0.132 
 Peptidyl-prolyl cis-trans isomerase B   1.196 1.294 1.265 0.661 2.016 1.224 NaN NaN NaN 
 Cathepsin D   1.198 1.231 1.104 NaN NaN NaN 0.134 NaN NaN 
 Tubulin alpha-1A chain  Tubulin, alpha 3, isoform 
CRA_c  Uncharacterized protein   
1.201 1.235 1.237 NaN NaN NaN 0.666 1.074 1.077 
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 60S ribosomal protein L18  Ribosomal protein L18  
Ribosomal protein L18  
1.208 NaN NaN NaN NaN NaN NaN NaN NaN 
 Endoplasmic reticulum resident protein 44   1.209 1.249 1.312 NaN NaN NaN NaN NaN NaN 
 78 kDa  1.211 1.243 1.327 0.697 1.324 1.294 0.053 0.053 0.276 
 Tropomodulin-3   1.218 1.573 1.401 NaN NaN NaN NaN NaN NaN 
 Stress-induced-phosphoprotein 1  Stress-induced-
phosphoprotein 1 (Hsp70/Hsp90-organizing protein), 
isoform CRA_b  Unc 
1.225 NaN NaN NaN NaN NaN 2.422 1.907 4.069 
 Isoform 2 of Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial  Hydroxyacyl-coenzyme A 
dehydrogenase, m 
1.230 2.074 1.418 NaN NaN NaN NaN NaN NaN 
 Apoptosis inhibitor 5  Uncharacterized protein  
Isoform 2 of Apoptosis inhibitor 5   
1.243 1.267 1.313 0.142 NaN 0.702 NaN NaN NaN 
 60S ribosomal protein L6  60S ribosomal protein L6   1.244 1.443 1.395 NaN NaN NaN NaN NaN NaN 
 Uncharacterized protein  Matrin-3  Uncharacterized 
protein  
1.276 1.318 1.217 NaN NaN 0.339 NaN NaN NaN 
 Eukaryotic translation initiation factor 3 subunit M  
Uncharacterized protein   
1.280 NaN NaN NaN NaN NaN NaN NaN NaN 
 Acidic leucine-rich nuclear phosphoprotein 32 family 
member A  Uncharacterized protein   
1.284 NaN 1.253 0.362 1.609 1.138 NaN NaN NaN 
 X-ray repair cross-complementing protein 6  
Uncharacterized protein  GN=XRCC6 
1.298 1.433 1.282 0.943 NaN NaN 0.094 NaN 0.063 
 Transitional endoplasmic reticulum ATPase   1.304 1.385 1.422 0.751 2.374 1.012 0.091 0.078 0.097 
 Isoform Short of 14-3-3 protein beta/alpha   1.307 1.406 1.379 1.130 1.848 1.603 NaN NaN NaN 
 Proteasomal ubiquitin receptor ADRM1  
Uncharacterized protein   
1.316 1.300 1.525 NaN NaN NaN NaN NaN NaN 
 Catenin beta-1  Uncharacterized protein  1.335 7.248 NaN NaN NaN NaN NaN NaN NaN 
 HCG1784554, isoform CRA_a  Eukaryotic translation 
initiation factor 3 subunit F  Uncharacterized protein 
omo sapi 
1.335 1.371 1.317 NaN NaN 0.141 NaN 0.990 0.548 
 Peptidyl-prolyl cis-trans isomerase A  Peptidyl-prolyl 
cis-trans isomerase  Peptidylprolyl isomerase A 
(Cyclophilin A) O 
1.344 1.315 1.456 1.210 1.577 1.207 NaN NaN NaN 
 Serine/arginine-rich splicing factor 7  Uncharacterized 
protein  Splicing factor, arginine/serine-rich 7, 35kDa, 
isof 
1.349 1.537 1.648 NaN NaN NaN NaN NaN NaN 
 Splicing factor, proline- and glutamine-rich  Isoform 
Short of Splicing factor, proline- and glutamine-rich  
GN=SFPQ 
1.364 1.607 1.674 NaN NaN 0.726 NaN NaN NaN 
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 X-ray repair cross-complementin 1.375 1.443 1.271 1.317 9.046 1.654 NaN NaN 0.260 
 Isoform 2 of Heterogeneous nuclear 
ribonucleoprotein K  Uncharacterized protein O 
1.378 1.323 1.295 0.223 0.142 0.319 1.388 1.115 1.775 
 Heterogeneous nuclear ribonucleoprotein H  
Uncharacterized protein  Heterogeneous nuclear 
ribonucleoprotein H2  
1.394 1.385 1.444 0.061 0.079 0.057 1.201 0.852 1.258 
 Transmembrane emp24 domain-containin 1.409 1.260 1.245 NaN NaN NaN NaN NaN NaN 
 Alpha-actinin-4  Alpha actinin 4 short isoform  
Uncharacterized protein   
1.415 1.654 1.521 0.904 1.415 1.240 0.021 0.014 0.017 
 Histone-binding protein RBBP4  Isoform 3 of Histone-
binding protein RBBP4  GN=RBBP4; Retinoblastoma 
binding protein 7  GN 
1.428 0.625 NaN NaN NaN NaN 1.552 12.933 NaN 
 26S proteasome non-ATPase regulatory subunit 1  
Isoform 2 of 26S proteasome non-ATPase regulatory 
subunit 1  GN=PSMD1 
1.435 0.990 NaN NaN NaN NaN NaN NaN NaN 
 14-3-3 protein zeta/delta  Uncharacterized protein 
|E7 
1.443 1.488 1.410 1.117 1.510 1.510 0.214 0.235 0.149 
 Basic leucine zipper and W2 domain-containing 
protein 1  Isoform 2 of Basic leucine zipper and W2 
domain-containing protein 1  GN=BZW1; Unc 
1.446 NaN NaN NaN 2.351 0.304 NaN NaN NaN 
 Calcium-binding mitochondrial carrier protein SCaMC-
1  Isoform 2 of Calcium-binding mitochondrial carrier 
protein SCaMC-1   
1.457 1.590 1.676 NaN NaN NaN NaN NaN NaN 
 Delta-1-pyrroline-5-carboxylate synthase  Isoform 
Short of Delta-1-pyrroline-5-carboxylate synthase   
1.464 1.547 1.604 NaN NaN NaN NaN NaN NaN 
 ATP synthase subunit b, mitochondrial  ATP synthase, 
H+ transportin 
1.466 1.794 1.726 NaN NaN NaN NaN NaN NaN 
 Stomatin-like protein 2  Uncharacterized protein   1.468 1.121 1.185 NaN NaN NaN NaN NaN NaN 
 Enoyl-CoA hydratase, mitochondrial   1.480 1.491 1.629 NaN NaN NaN NaN NaN NaN 
 Polypyrimidine tract binding protein 1  Isoform 2 of 
Polypyrimidine tract-binding protein 1  GN=PTBP1; 
Polypyrimidine tract-binding prot 
1.485 1.530 1.579 0.161 0.107 0.281 0.208 0.406 0.224 
 Glyceraldehyde-3-phosphate dehydrogenase  
Glyceraldehyde-3-phosphate dehydrogenase  
Glyceraldehyde-3-phosphate dehydrog 
1.510 1.534 1.560 1.875 2.081 1.829 1.184 1.934 1.077 
 Isoform C of Prelamin-A/C  Lamin A/C  Isoform 
ADelta10 of P 
1.530 1.575 1.718 0.635 0.871 0.912 0.290 0.825 NaN 
 Putative heat shock protein HSP 90-beta 4   1.531 1.563 1.549 0.797 1.725 0.630 NaN NaN NaN 
 DNA-dependent protein kinase catalytic subunit  
Isoform 2 of DNA-dependent protein kinase catalytic 
1.532 1.677 1.906 NaN NaN NaN 0.310 NaN NaN 
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subunit  GN=PRKDC; Uncharacterized p 
 ATP synthase subunit d, mitochondrial  Isoform 2 of 
ATP synthase subunit d, mitochondrial  GN=ATP5H; 
Uncharacterized protein omo sap 
1.548 1.140 1.289 NaN NaN NaN NaN NaN NaN 
 Malate dehydro 1.581 1.440 1.380 0.059 NaN 0.082 NaN NaN NaN 
 Isoform 2 of Cleavage and polyadenylation specificity 
factor subunit 6  
1.597 1.854 1.398 NaN NaN NaN NaN 0.892 NaN 
 Moesin   1.624 1.764 1.859 1.287 2.268 1.742 NaN NaN NaN 
 Importin subunit alpha-4   1.627 1.787 1.351 NaN NaN NaN NaN 7.536 0.276 
 Thioredoxin-dependent peroxide reductase, 
mitochondrial  Uncharacterized protein   
1.637 2.200 1.786 NaN NaN NaN 0.205 0.296 NaN 
 Uncharacterized protein  Transketolase  
Uncharacterized protein  Un 
1.674 4.648 0.929 0.380 0.796 0.588 1.650 13.205 1.300 
 ATP synthase subunit alpha, mitochondrial  ATP 
synthase subunit alpha   
1.702 1.860 1.760 NaN NaN NaN NaN 0.026 0.105 
 Protein S100-A6   1.709 1.853 1.781 1.560 NaN NaN NaN NaN NaN 
 Heterogeneous nuclear ribonucleoproteins A2/B1  
Isoform A2 of Heterogeneous nuclear 
ribonucleoproteins A2/B1   
1.731 1.534 1.868 0.775 0.991 0.677 NaN NaN NaN 
 Caveolin-1  Caveolin  Caveolin   1.738 NaN NaN NaN NaN NaN NaN NaN NaN 
 Heat shock cognate 71 kDa protein  Uncharacterized 
protein  GN=HSPA8  
1.743 1.704 1.786 1.232 1.843 1.526 0.725 0.634 0.985 
 Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2  Uncharacterized protein o 
1.775 8.595 11.242 NaN NaN NaN NaN NaN NaN 
 Heterogeneous nuclear ribonucleoprotein D0  Isoform 
3 of Heterogeneous nuclear ribonucleoprotein D0  
GN=HNRNPD; Uncharacterized protein 
1.787 2.119 NaN NaN 0.792 0.674 NaN NaN NaN 
 Electron transfer flavoprotein subunit alpha, 
mitochondrial  Uncharacterized protein   
1.797 2.001 1.892 NaN NaN NaN NaN NaN NaN 
 Annexin A1  Annexin A1 (Fra 1.838 1.867 1.884 1.322 2.110 1.579 NaN NaN NaN 
 Isoform 2 of Heat shock protein HSP 90-alpha  Full-
length cDNA clone CS0CAP007YF18 of T 
1.871 2.121 2.178 1.766 2.781 1.841 0.074 0.044 0.032 
 Mitochondrial 2-oxo 1.879 1.892 2.183 NaN NaN NaN NaN NaN NaN 
 Complement component 1 Q subcomponent-bindin 1.919 2.427 1.869 NaN 0.329 NaN 0.065 0.192 0.183 
 Major vault protein  Uncharacterized protein   1.936 1.906 5.665 NaN NaN NaN NaN 1.728 0.346 
 Isoform 1 of Voltage-dependent anion-selective 
channel protein 2  Isofor 
1.990 2.128 2.238 NaN NaN NaN NaN NaN NaN 
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 CD44 antigen  Isoform 5 of CD44 antigen  Isoform 1.999 1.842 NaN 3.892 6.468 5.410 NaN NaN NaN 
 Adenylate kinase 2, mitochondrial  Uncharacterized 
protein  Isoform 2 of Adenylate kinase 2, 
mitochondrial  
2.011 1.617 1.743 0.073 0.331 0.516 NaN NaN NaN 
 26S proteasome non-ATPase regulatory subunit 2  
Uncharacterized protein   
2.022 2.366 2.344 NaN NaN NaN 0.443 NaN 0.071 
 Chloride intracellular channel protein 4  
Uncharacterized protein   
2.068 1.863 1.704 1.312 4.931 1.605 NaN NaN NaN 
 Leucine-rich PPR motif-containin 2.133 1.757 10.387 NaN NaN NaN NaN NaN NaN 
 Cytochrome c  Uncharacterized protein   2.146 2.637 2.494 0.272 8.924 NaN NaN NaN NaN 
 Voltage-dependent anion-selective channel protein 1  
Uncharacterized protein  
2.154 2.262 2.526 NaN NaN NaN NaN NaN NaN 
 Elongation 2.156 2.391 2.430 NaN 3.250 NaN NaN NaN NaN 
 Protein S100-A11   2.179 2.771 2.257 3.563 6.719 3.400 NaN NaN NaN 
 Tumor protein D52-like 2  Tumor protein D52-like 2  
Isoform 3 of Tumor protein D54  GN=TPD52L2;> 
2.218 1.903 1.678 NaN NaN NaN NaN NaN NaN 
 Nucleophosmin  Isoform 2 of Nucleophosmin   SV=1 2.261 2.388 2.432 1.230 2.306 1.605 1.595 1.158 2.885 
 Isoform 2 of Annexin A2  Putative annexin A2-like 
protein |B3KRQ1|B3KRQ1_HU 
2.322 2.422 2.498 1.852 2.924 2.317 0.834 0.590 1.434 
 Uncharacterized protein  39S ribosomal protein L12, 
mitochondrial  Uncharacterized protein  GN=SLC2 
2.344 2.491 1.955 NaN NaN NaN NaN NaN NaN 
 40S ribosomal protein S12   2.371 2.873 0.995 NaN NaN NaN 8.103 7.323 2.269 
 Aspartyl/asparaginyl beta-hydroxylase  
Uncharacterized protein  GN=ASPH  
2.580 5.910 2.709 NaN NaN NaN NaN NaN NaN 
 Heterogeneous nuclear ribonucleoprotein A3  Isoform 
2 of Heterogeneous nuclear ribonucleoprotein A3  
GN=HNRNPA3; Uncharacterized protein 
2.619 2.582 2.779 NaN NaN NaN NaN NaN NaN 
 ATP-dependent DNA helicase Q1  Uncharacterized 
protein  
2.684 2.797 2.910 NaN 12.081 9.201 NaN 23.750 NaN 
 Prohibitin-2  Uncharacterized protein  2.727 2.849 2.704 NaN NaN NaN NaN NaN NaN 
 Prohibitin  Uncharacterized protein  Uncha 2.741 2.793 2.584 NaN NaN NaN NaN NaN NaN 
 Trifunctional enzyme subunit alpha, mitochondrial   2.792 2.378 2.959 NaN NaN NaN NaN NaN NaN 
 Superoxide dismutase [Mn], mitochondrial  
Superoxide dismutase  Superoxide dismutase  
2.882 6.563 3.309 0.102 0.167 0.969 NaN NaN NaN 
 Heat shock protein 75 kDa, mitochondrial  
Uncharacterized protein   
3.056 2.906 2.258 NaN NaN NaN NaN NaN NaN 
 Nucleolin  Uncharacterized protein  NCL protein   3.241 2.798 2.975 0.982 2.359 1.073 2.709 2.656 9.824 
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 Tubulin beta-8 chain  Novel protein similar to beta-
tubulin 4Q (TUBB4Q) (LOC253936) Uncharacterized 
protein O 
3.655 0.154 0.150 NaN NaN NaN 1.484 1.372 1.512 
 Ras-related protein Rab-1B  Ras-related protein Rab-
1A  Putative Ras-related protein Rab-1C  GN=RAB1C PE 
3.926 1.962 4.427 NaN NaN NaN NaN NaN 0.052 
 Abhydrolase domain-containin 4.068 3.837 6.566 NaN NaN NaN NaN NaN NaN 
 60 kDa heat shock protein, mitochondrial   4.069 4.228 4.203 NaN NaN NaN 0.102 0.203 0.385 
 Vimentin  Uncharacterized protein  Unchar 4.718 14.704 16.090 NaN 19.051 61.242 1.364 2.496 27.348 
 Isoform 2 of Isochorismatase domain-containing 
protein 2, mitochondrial |Q96AB3-3|ISOC 
5.021 19.755 5.515 NaN NaN NaN NaN NaN NaN 
 Uncharacterized protein  Uncharacterized protein 
|Q96 
5.104 5.499 NaN NaN NaN NaN 13.183 31.253 35.875 
 60S acidic ribosomal protein P0  60S acidic ribosomal 
protein P0-like  Uncharacterized protein  GN=RPL 
5.357 NaN NaN NaN NaN NaN 0.247 1.417 0.184 
 Cytoplasmic dynein 1 heavy chain 1   6.039 4.026 1.072 NaN NaN NaN 0.235 0.993 NaN 
 Glutathione S-transferase omega-1  Glutathione S-
transferase omega 1, isoform CRA_a  Glutathione S-
transferase omega  
6.095 NaN NaN NaN NaN 2.957 NaN NaN NaN 
 Plectin  Isoform 2 of Plectin  Isoform 6 of Plectin omo 
s 
6.706 14.219 16.137 NaN NaN NaN 9.528 18.255 15.345 
 Stress-70 protein, mitochondrial  Uncharacterized 
protein   
7.096 3.212 3.019 NaN NaN NaN 0.114 0.100 NaN 
 KH domain-containing, RNA-binding, signal 
transduction-associated protein 1  Uncharacterized 
protein  Isoform 2  
7.599 1.124 1.335 NaN NaN NaN NaN NaN NaN 
High mobility group protein HMG-I/HMG-Y  Isoform 
HMG-R of High mobility group protein HMG-I/HMG-Y  
GN=HMGA1; Isoform HMG-Y of High mobi 
8.586 47.652 NaN NaN NaN NaN NaN NaN NaN 
 ADP/ATP translocase 2  GN=SLC25A5  8.716 1.777 1.782 NaN NaN NaN 0.070 0.047 0.044 
 2,4-dienoyl-CoA reductase, mitochondrial  
Uncharacterized protein  GN=DECR1 PE 
8.787 NaN 8.137 NaN NaN NaN NaN NaN NaN 
Isoform 2 of Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2  Uncharacter 
9.339 5.498 15.557 NaN NaN 25.972 0.062 NaN NaN 
 PRA1 family protein 3  Uncharacterized protein   10.064 2.927 2.380 NaN NaN NaN NaN NaN NaN 
 Tripeptidyl-peptidase 1  Uncharacterized protein  10.904 2.367 2.283 NaN NaN NaN NaN 0.271 NaN 
 ATPase family AAA domain-containing protein 1  
Isoform 2 of ATPase family AAA domain-containing 
protein 1  GN=ATAD1; Uncharacterized pro 
12.125 NaN NaN NaN NaN NaN NaN NaN NaN 
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 Fragile X mental retardation syndrome-related protein 
1  Uncharacterized protein omo sapien 
13.541 1.916 1.773 NaN NaN NaN NaN NaN NaN 
 Tubulin beta-6 chain  Uncharacterized protein  
Tubulin, beta 6, isoform CRA_a   
20.213 0.834 3.256 NaN NaN NaN 1.406 10.841 1.232 
 Aminopeptidase N  Uncharacterized protein   22.827 28.080 32.453 NaN NaN NaN NaN NaN NaN 
 Mitochondrial dynamin-like 120 kDa protein  Isoform 
2 of Dynamin-like 120 kDa protein, mitochondrial  
GN=OPA1; Mitochondrial dynamin-like 
23.412 5.109 25.559 NaN NaN NaN NaN NaN NaN 
 Ganglioside-induced differentiation-associated 
protein 1  Isoform 2 of Ganglioside-induced 
differentiation-associated protein 1  GN=GDAP1 
25.188 28.194 25.353 NaN NaN NaN NaN NaN NaN 
 40S ribosomal protein S8  Ribosomal protein S8   26.144 NaN 0.894 NaN NaN NaN NaN NaN NaN 
 Keratin, type II cytoskeletal 7 |E7ES34|E7 37.304 NaN 60.926 NaN NaN NaN NaN 2.346 NaN 
 Isoform 3 of Cleavage and polyadenylation specificity 
factor subunit 7 |Q8N684-2|CPSF7_ 
NaN NaN NaN NaN NaN NaN NaN NaN 1.178 
 DNA replication licensin NaN NaN NaN NaN NaN NaN NaN NaN 0.983 
 40S ribosomal protein S2  Uncharacterized protein 
|E9PM36|E 
NaN NaN NaN NaN NaN NaN NaN NaN 0.541 
 Suppressor of G2 allele of SKP1 homolog  Isoform 2 of 
Suppressor of G2 allele of SKP1 homolog  GN=SUGT1 
NaN NaN NaN NaN NaN NaN NaN 54.671 NaN 
 NudC domain-containin NaN NaN NaN NaN NaN NaN NaN 7.539 NaN 
 Histone H1.4   NaN NaN NaN NaN NaN NaN NaN 5.865 1.317 
 Coatomer subunit beta  Coatomer protein complex, 
subunit beta 2 (Beta prime), isoform CRA_b   
NaN NaN NaN NaN NaN NaN NaN 1.060 1.045 
 Uncharacterized protein  Importin subunit alpha-7  
Uncharacterized protein |P522 
NaN NaN NaN NaN NaN NaN NaN 0.504 NaN 
 60S ribosomal protein L7a  Ribosomal protein L7a   NaN NaN NaN NaN NaN NaN NaN 0.414 0.132 
 6-phosphofructokinase type C  6-phosphofructokinase   NaN NaN NaN NaN NaN NaN NaN 0.174 0.098 
 Caprin-1  Isoform 2 of Caprin-1   NaN NaN NaN NaN NaN NaN NaN 0.134 NaN 
 Arf-GAP with SH3 domain, ANK repeat and PH 
domain-containing protein 2  Isoform 2 of Arf-GAP 
with SH3 domain, ANK repeat and PH domain-
containing protein 2  GN 
NaN NaN NaN NaN NaN NaN NaN 0.093 NaN 
 Isoform 2 of General vesicular transport factor p115  
General vesicular transport factor p115 omo sap 
NaN NaN NaN NaN NaN NaN NaN 0.071 NaN 
 UPF0663 transmembrane protein C17orf28  Isoform 2 
of UPF0663 transmembrane protein C17orf28  
GN=C17orf28; Isoform 3 of UPF0663 trans 
NaN NaN NaN NaN NaN NaN NaN 0.002 0.005 
182 
 
Histone H1.5   NaN NaN NaN NaN NaN NaN 3.387 5.623 2.508 
26S protease re NaN NaN NaN NaN NaN NaN 1.641 0.852 0.195 
Guanine nucleotide-binding protein subunit beta-2-like 
1  Uncharacterized protein omo s 
NaN NaN NaN NaN NaN NaN 1.109 3.419 1.607 
Inosine-5-monophosphate dehydrogenase 2  
Uncharacterized protein  GN=IMPDH 
NaN NaN NaN NaN NaN NaN 0.727 0.656 0.415 
Protein TFG  TRK-fused  TFG protein  Uncharacterized 
protein om 
NaN NaN NaN NaN NaN NaN 0.697 1.112 1.194 
Bifunctional aminoacyl-tRNA synthetase  
Uncharacterized protein   
NaN NaN NaN NaN NaN NaN 0.655 0.442 NaN 
Transcription intermediary factor 1-beta  Isoform 2 of 
Transcription intermediary factor 1-beta  GN=TRIM28 
NaN NaN NaN NaN NaN NaN 0.626 NaN 0.451 
 WD repeat-containing protein 65  Isoform 2 of WD 
repeat-containing protein 65  GN=WDR65; 
Uncharacterized protein  GN=WDR6 
NaN NaN NaN NaN NaN NaN 0.616 NaN 0.787 
 Neuropeptide Y receptor type 2   NaN NaN NaN NaN NaN NaN 0.564 NaN NaN 
 Interleukin enhancer-binding factor 3  
Uncharacterized protein  Isoform 3 of Interleukin 
enhancer-binding factor 3 o 
NaN NaN NaN NaN NaN NaN 0.475 0.232 1.708 
 60S ribosomal protein L30  Uncharacterized protein   NaN NaN NaN NaN NaN NaN 0.341 0.078 0.407 
 Uncharacterized protein  DNA-directed RNA 
polymerases I, II, and III subunit RPABC3  
Uncharacterized protein om 
NaN NaN NaN NaN NaN NaN 0.279 NaN 11.593 
 Nuclear mi NaN NaN NaN NaN NaN NaN 0.226 0.255 0.219 
 ATP-dependent RNA helicase A  Uncharacterized 
protein   
NaN NaN NaN NaN NaN NaN 0.206 6.367 0.568 
 Dihydropyrimidinase-related protein 2  
Uncharacterized protein   
NaN NaN NaN NaN NaN NaN 0.159 0.150 0.449 
  NaN NaN NaN NaN NaN NaN 0.145 NaN NaN 
Hsc70-interacting protein  Putative protein FAM10A4  
ST13 protein  
NaN NaN NaN NaN NaN NaN 0.095 0.057 0.203 
 Eukaryotic translation initiation factor 3 subunit A  
Uncharacterized protein   
NaN NaN NaN NaN NaN NaN 0.089 0.031 0.026 
 ADP-ribosylation factor 4  Uncharacterized protein  
ADP-ribosylation factor 5 |P840 
NaN NaN NaN NaN NaN NaN 0.055 NaN 0.070 
 Enamelin   NaN NaN NaN NaN NaN NaN 0.040 0.042 0.037 
 Uncharacterized protein >P02768-1 ALB Isoform 1 of 
Serum albumin precursor 
NaN NaN NaN NaN NaN NaN 0.038 NaN NaN 
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 Leucine-rich repeat-containin NaN NaN 28.666 NaN NaN NaN NaN NaN NaN 
 60S ribosomal protein L13   NaN NaN 15.679 NaN NaN NaN NaN NaN NaN 
 Coatomer subunit  NaN NaN 11.958 NaN NaN NaN NaN 0.376 0.311 
 Ras-related protein Rab-2A  Uncharacterized protein   NaN NaN 9.976 NaN NaN NaN NaN NaN NaN 
 Filamin B  Filamin-B  Filamin B  Isoform 2 of Filamin-B 
omo 
NaN NaN 6.139 NaN NaN NaN 0.048 0.038 0.088 
 Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial  Uncharacterized protein  Isoform 2 of 
Pyruvate dehydrog 
NaN NaN 3.234 NaN NaN NaN NaN NaN NaN 
 Neuroblast differentiation-associated protein AHNAK   NaN NaN 2.021 NaN NaN NaN NaN NaN NaN 
 ATP synthase subunit O, mitochondrial   NaN NaN 1.834 NaN NaN NaN NaN NaN NaN 
 Microtubule-actin cross-linking factor 1, isoforms 
1/2/3/5  Microtubule-actin cross-linking factor 1, 
isoform 4  Uncha 
NaN NaN 1.458 NaN NaN NaN NaN 0.262 NaN 
 Dolichyl-diphosphooli NaN NaN 1.288 NaN NaN NaN NaN NaN NaN 
 Uncharacterized protein  Nucleosome assembly 
protein 1-like 4b  Nucleosome assembly protein 1-like 
4 omo sapie 
NaN NaN 0.814 NaN NaN NaN NaN NaN 1.444 
 Pyridoxal kinase  Isoform 2 of Pyridoxal kinase  NaN NaN 0.813 NaN NaN NaN 0.109 NaN 0.440 
 Lamin-B2   NaN NaN 0.585 NaN NaN NaN NaN NaN NaN 
 Isoform 2 of Stathmin  Stathmin (Fra NaN NaN 0.492 NaN NaN NaN NaN NaN NaN 
 Isoform 2 of Septin-2  Uncharacterized protein  
Uncharacte 
NaN NaN 0.222 NaN NaN NaN 0.423 1.532 0.744 
 Importin-7   NaN NaN 0.197 NaN NaN NaN NaN 0.187 0.126 
 Isoform 8 of Titin  Isoform 2 of Titin  GN=TTN; Isoform 
7 of Titin   
NaN 54.609 NaN NaN NaN NaN NaN NaN NaN 
 Succinyl-CoA li NaN 40.771 NaN NaN NaN NaN NaN NaN NaN 
 Isoform 15 of Fibronectin  Fibronectin  Isoform 3 of 
Fibron 
NaN 36.756 32.594 NaN NaN NaN 6.333 12.048 38.273 
 Mitochondrial carrier homolo NaN 7.709 11.819 NaN NaN NaN NaN NaN NaN 
 10 kDa heat shock protein, mitochondrial  Heat shock 
10kDa protein 1 (Chaperonin 10), isoform CRA_b  Heat 
shock 10kDa  
NaN 5.587 15.935 NaN NaN NaN NaN NaN NaN 
 Isoform B of Phosphate carrier protein, mitochondrial  
Phosphate carrier protein, mitochondrial OS= 
NaN 3.210 2.861 NaN NaN NaN NaN 0.042 NaN 
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Glutamate dehydrogenase 1, mitochondrial  
Glutamate dehydrogenase  Glutamate dehydrogenase  
GN=GLUD1 PE 
NaN 3.128 2.800 NaN NaN NaN NaN NaN NaN 
Mitochondrial inner membrane protein  
Uncharacterized protein  Isoform 2 of Mitochondrial 
inner membrane protein  
NaN 2.323 1.919 NaN NaN NaN 0.003 0.008 0.010 
Isoform 2 of Vesicle-associated membrane protein-
associated proteinA    
NaN 2.034 1.971 NaN NaN NaN NaN NaN NaN 
 Neutral alpha- NaN 1.811 0.891 NaN NaN NaN 0.135 NaN 0.581 
Glutaminase kidney isoform, mitochondrial  Isoform 3 
of Glutaminase kidney isoform, mitochondrial  
GN=GLS; Isoform 2 of Glutaminase kidney i 
NaN 1.620 11.324 NaN NaN NaN NaN NaN NaN 
ATP-dependent RNA helicase DDX1  Uncharacterized 
protein   
NaN 1.549 NaN NaN NaN NaN 1.431 1.380 0.141 
 Dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase subunit 2  Ribophorin II  
Uncharacterized protein  
NaN 1.548 1.739 NaN NaN NaN NaN NaN 0.151 
 Calpain-2 catalytic subunit  Uncharacterized protein   NaN 1.536 1.443 NaN NaN NaN NaN NaN 0.131 
60S ribosomal protein L15  Ribosomal protein L15  
Ribosomal protein L15  
NaN 1.475 1.679 NaN NaN NaN NaN NaN NaN 
 60S ribosomal protein L10  60S ribosomal protein L10-
like  Ribosomal protein L10 (Fragment)  GN=RPL10 P 
NaN 1.405 1.016 NaN NaN NaN NaN NaN NaN 
U5 small nuclear ribonucleoprotein 200 kDa helicase  
Uncharacterized protein omo sa 
NaN 1.173 NaN NaN NaN NaN NaN NaN NaN 
Ras-related protein Rab-10   NaN 1.116 1.251 NaN NaN NaN NaN NaN NaN 
60S ribosomal protein L18a  Uncharacterized protein   NaN 1.071 NaN NaN NaN NaN NaN NaN NaN 
Adenine phosphoribosyltransferase  Adenine 
phosphoribosyltransferase, isoform CRA_b   
NaN 0.946 NaN NaN NaN NaN NaN NaN NaN 
Heat shock 70 kDa protein 4  Uncharacterized protein   NaN 0.942 NaN NaN NaN NaN 1.526 13.187 1.714 
Calponin-3  Uncharacterized protein   NaN 0.932 NaN NaN NaN NaN NaN NaN NaN 
Sideroflexin-1  Uncharacterized protein   NaN 0.900 NaN NaN NaN NaN NaN NaN NaN 
Archain 1, isoform CRA_a  Coatomer subunit delta  
Uncharacterized protein   
NaN 0.899 NaN NaN NaN NaN NaN NaN NaN 
Surfeit locus protein 4  Uncharacterized protein  
Surfeit 4A 
NaN 0.889 0.755 NaN NaN NaN NaN NaN NaN 
Histone H2A.x  Histone H2A type 1-B/E  Histone H2A 
type 1 
NaN 0.874 0.798 NaN NaN NaN NaN NaN NaN 
Coatomer subunit beta  Uncharacterized protein   NaN 0.829 NaN NaN NaN NaN NaN NaN NaN 
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 Kinesin-1 heavy chain   NaN 0.813 NaN NaN NaN NaN NaN 0.085 NaN 
Torsin-1A-interactin NaN 0.756 NaN NaN NaN NaN NaN NaN NaN 
Coatomer subunit epsilon  Uncharacterized protein  
Coatomer protein complex, subunit epsilon, isoform 
CRA_b omo sapi 
NaN 0.622 0.472 NaN NaN NaN NaN NaN NaN 
Protein transport protein Sec23A  Uncharacterized 
protein  GN=SEC23A  
NaN 0.569 NaN NaN NaN NaN NaN NaN NaN 
Uncharacterized protein NaN 0.535 0.145 NaN NaN NaN NaN NaN NaN 
Histone H1x   NaN 0.470 NaN NaN NaN NaN NaN NaN NaN 
ATP-dependent RNA helicase DDX3X  Uncharacterized 
protein   
NaN 0.420 0.170 NaN NaN NaN NaN NaN NaN 
Calpain small subunit 1   NaN 0.303 NaN NaN NaN NaN NaN NaN NaN 
Nuclear pore complex protein Nup155  
Uncharacterized protein  Isoform 2 of Nuclear pore 
complex protein Nup155  
NaN 0.173 0.351 NaN NaN NaN NaN NaN NaN 
 Tubulin beta-4A chain  Uncharacterized protein   NaN 0.150 NaN NaN NaN NaN NaN NaN 0.424 
 Transportin-1  Isoform 2 of Transportin-1  GN=TNPO1; 
Isoform 3 of Transportin-1  GN=TNPO1 
NaN 0.141 NaN NaN NaN NaN NaN NaN NaN 
HLA class I histocompatibility antigen, Cw-12 alpha 
chain  HLA class I histocompatibility antigen, Cw-15 
alpha chain  Ma 
NaN 0.064 NaN NaN NaN NaN NaN NaN NaN 
Krt18 Keratin, type I cytoskeletal 18 NaN 0.056 NaN NaN NaN NaN 0.017 0.018 0.001 
 Peroxiredoxin-2  Peroxiredoxin 2, isoform CRA_a   NaN 0.035 NaN NaN NaN NaN 0.062 0.050 0.117 
 Uncharacterized protein  Uncharacterized protein 
|A2A 
NaN 0.021 NaN NaN NaN NaN NaN NaN NaN 
14-3-3 protein beta/alpha   NaN NaN NaN NaN NaN 2.115 NaN NaN NaN 
Acyl-CoA-bindin NaN NaN NaN NaN NaN 1.849 NaN NaN NaN 
Serine/arginine-rich splicing factor 1  Isoform ASF-2 of 
Serine/arginine-rich splicing factor 1  GN=SRSF1; 
Isoform ASF-3 of Serine/argi 
NaN NaN NaN NaN NaN 1.421 NaN NaN NaN 
Annexin A4  ANXA4 protein  Uncharacterized protein   NaN NaN NaN NaN NaN 1.231 NaN NaN NaN 
 S-formyl NaN NaN NaN NaN NaN 1.057 NaN NaN NaN 
 V excision repair protein RAD23  NaN NaN NaN NaN NaN 0.954 NaN NaN NaN 
 roline synthase co-transcribed bacterial homolog 
protein  Uncharacterized protein omo s 
NaN NaN NaN NaN NaN 0.927 NaN NaN NaN 
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Multifunctional protein ADE2  Uncharacterized protein  
Isoform 2 of Multifunctional protein ADE2  GN=PA 
NaN NaN NaN NaN NaN 0.876 NaN NaN NaN 
  NaN NaN NaN NaN NaN 0.864 NaN NaN NaN 
Prostaglandin E synthase 3  Uncharacterized protein  
Prostaglandin E synthase 3 (Cytosolic), isoform CRA_d  
NaN NaN NaN NaN NaN 0.795 NaN NaN NaN 
Proliferation-associated protein 2G4  Uncharacterized 
protein  GN=PA2G4  
NaN NaN NaN NaN NaN 0.671 NaN NaN NaN 
Serpin B6   NaN NaN NaN NaN NaN 0.635 NaN NaN NaN 
Hsp90 co-chaperone Cdc37   NaN NaN 0.984 NaN NaN 0.584 0.123 0.071 NaN 
Uncharacterized protein  60S ribosomal protein L28 
|G5E 
NaN NaN NaN NaN NaN 0.572 NaN NaN NaN 
 Staphylococcal nuclease domain-containin NaN 0.715 NaN NaN NaN 0.510 NaN NaN NaN 
Uncharacterized protein  ATP-citrate synthase  ATP 
citrate lyase, isoform CRA_a  
NaN NaN NaN NaN NaN 0.400 NaN NaN NaN 
Capping protein (Actin filament) muscle Z-line, alpha 2  
F-actin-capping protein subunit alpha-2  
Uncharacterized p 
NaN NaN NaN NaN NaN 0.243 NaN NaN NaN 
 Proteasome subunit alpha type-3  Isoform 2 of 
Proteasome subunit alpha type-3  GN=PSMA3; 
Uncharacterized protein  GN=PSMA3  
NaN NaN NaN NaN NaN 0.206 NaN NaN NaN 
Uncharacterized protein  Isoform 2 of Spliceosome 
RNA helicase DDX39B  GN=DDX39B; Spliceosome RNA 
helicase DDX39B   
NaN NaN NaN NaN NaN 0.203 NaN NaN NaN 
Glutaminyl-tRNA synthetase  Uncharacterized protein 
|C9J165 
NaN NaN NaN NaN NaN 0.200 0.159 0.057 0.043 
Eukaryotic translation initiation factor 4H  Isoform 
Short of Eukaryotic translation initiation factor 4H   
NaN 0.144 0.131 NaN NaN 0.165 NaN NaN NaN 
 Puromycin-sensitive aminopeptidase  Uncharacterized 
protein  GN=NPEPPS  
NaN NaN NaN NaN NaN 0.162 NaN NaN NaN 
Isocitrate dehydro NaN NaN NaN NaN NaN 0.138 NaN NaN NaN 
Ran-specific GTPase-activating protein  
Uncharacterized protein  GN=RANBP1 P 
NaN NaN NaN NaN NaN 0.114 NaN NaN NaN 
Cleava NaN NaN NaN NaN NaN 0.106 NaN 9.705 NaN 
Isoform 4 of Probable ATP-dependent RNA helicase 
DDX17  Isoform 2 of Probable ATP-dependent RNA hel 
NaN NaN NaN NaN NaN 0.103 NaN NaN NaN 
Flap endonuclease 1   NaN NaN NaN NaN NaN 0.099 NaN NaN NaN 
Uncharacterized protein  Alanyl-tRNA synthetase, 
cytoplasmic   
NaN NaN NaN NaN NaN 0.092 NaN NaN NaN 
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 Poly [ADP-ribose] polymerase 1   NaN NaN NaN NaN NaN 0.092 NaN NaN NaN 
Aryl hydrocarbon receptor nuclear translocator  
Uncharacterized protein  GN=ARNT 
NaN NaN NaN NaN NaN 0.072 NaN NaN NaN 
 Protein phosphatase methylesterase 1  Isoform 2 of 
Protein phosphatase methylesterase 1  GN=PPME1 
NaN NaN NaN NaN NaN 0.060 NaN NaN NaN 
DNA repair protein complementing XP-G cells  
Uncharacterized protein  GN=ERCC 
NaN NaN NaN NaN NaN 0.038 NaN NaN NaN 
Destrin  Destrin (Actin depolymerizin NaN 0.037 NaN NaN NaN 0.023 0.233 NaN NaN 
14-3-3 protein sigma  Isoform 2 of 14-3-3 protein 
sigma  GN=SFN 
NaN 15.918 16.984 NaN 30.861 0.760 NaN NaN NaN 
Gelsolin  Gelsolin (Amyloidosis, Finnish type), isoform 
CRA_b  Uncharacterized protein  
NaN NaN NaN NaN 16.764 NaN NaN NaN NaN 
 Keratin, type I cytoskeletal 27   NaN NaN NaN NaN 14.407 NaN NaN NaN NaN 
 Lupus La protein  Uncharacterized protein   NaN NaN NaN NaN 1.821 NaN NaN NaN NaN 
Uncharacterized protein  Nascent polypeptide-
associated complex subunit alpha  G 
NaN NaN NaN NaN 1.369 NaN NaN NaN NaN 
Rab GDP dissociation inhibitor alpha  Uncharacterized 
protein  GDP dissociation inhibitor 1, isoform CRA_a 
omo sapie 
NaN NaN NaN NaN 1.261 NaN NaN NaN NaN 
 Hypoxanthine- NaN NaN NaN NaN 0.712 1.018 NaN NaN NaN 
 Isoform 3 of Nuclear autoantigenic sperm protein  
Uncharacterized protein  GN= 
NaN 0.130 NaN NaN 0.453 0.097 NaN NaN NaN 
 Catechol O-methyltransferase  Uncharacterized 
protein  Isoform Soluble of Catechol O-
methyltransferase  G 
NaN 0.509 0.479 NaN 0.446 0.455 NaN NaN NaN 
Twinkle protein, mitochondrial  Isoform 2 of Twinkle 
protein, mitochondrial  GN=PEO1; Isoform 3 of Twinkle 
protein, mitochondrial omo s 
NaN NaN NaN 1.687 NaN 1.655 NaN 60.001 NaN 
 6-phospho NaN NaN 1.533 1.227 1.424 1.115 NaN NaN NaN 
 Protein phosphatase 1 regulatory subunit 7  Isoform 2 
of Protein phosphatase 1 regulatory subunit 7  
GN=PPP1R7; Uncharacterized protein 
NaN NaN NaN 0.866 NaN NaN NaN NaN NaN 
 Mesencephalic astrocyte-derived neurotrophic factor   NaN NaN NaN 0.857 NaN NaN NaN NaN NaN 
 Uncharacterized protein  Calmodulin  Uncharacterized 
proteinA 
NaN 0.606 NaN 0.823 0.996 NaN NaN NaN NaN 
 Calcyclin-bindin NaN NaN 31.838 0.701 1.680 1.303 2.498 2.196 2.222 
 Rho  NaN 0.782 0.790 0.664 1.247 0.669 NaN NaN NaN 
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Cofilin-2  Cofilin 2 (Muscle), isoform CRA_d   NaN NaN NaN 0.594 NaN 0.588 NaN NaN NaN 
Annexin A6  Annexin A6, isoform CRA_c  
Uncharacterized protein  
NaN NaN 0.802 0.485 1.236 0.847 NaN NaN NaN 
Protein furry homolo NaN NaN NaN 0.431 NaN NaN NaN NaN NaN 
Alpha-fetoprotein precursor NaN NaN NaN 0.340 NaN NaN NaN NaN NaN 
T-complex protein 1 subunit delta  T-complex protein 1 
subunit delta  T-complex protein 1 subunit delta   
NaN 0.895 0.953 0.332 5.679 NaN 0.064 0.031 0.091 
Macrophage NaN 0.089 0.093 0.281 0.317 0.263 NaN NaN NaN 
Annexin A3  Uncharacterized protein NaN NaN NaN 0.251 NaN 0.773 NaN NaN NaN 
Putative heat shock protein HSP 90-beta 2   NaN 0.831 NaN 0.244 NaN NaN NaN NaN 0.102 
Eukaryotic translation initiation factor 6  Eukaryotic 
translation initiation factor 6   
NaN NaN NaN 0.242 NaN 0.967 NaN NaN NaN 
 Plastin-3  Uncharacterized protein  Un NaN NaN NaN 0.239 NaN NaN NaN NaN NaN 
 Proteasome subunit alpha type  Proteasome subunit 
alpha type-6  Proteasome subunit alpha type   
NaN NaN NaN 0.179 NaN NaN NaN NaN NaN 
  NaN 1.402 1.241 0.172 NaN NaN NaN NaN NaN 
Proteasome subunit alpha type-4  PSMA4 protein   NaN 0.670 NaN 0.165 NaN 0.175 NaN NaN NaN 
RAN, member RAS oncogene family, isoform CRA_c  
GTP-binding nuclear protein Ran  Uncharacterized 
protein  GN 
NaN 0.811 0.741 0.154 NaN 0.155 NaN NaN NaN 
Hetero NaN 1.637 1.435 0.127 NaN 0.845 NaN NaN NaN 
Heterogeneous nuclear ribonucleoproteins C1/C2  
Uncharacterized protein  GN 
NaN NaN NaN 0.090 NaN NaN 0.738 1.002 2.052 
Protein S100-A9   NaN NaN NaN 0.087 NaN NaN NaN 0.071 NaN 
Cullin-associated NEDD8-dissociated protein 1  Isoform 
2 of Cullin-associated NEDD8-dissociated protein 1  
GN=CAND1 
NaN 0.739 NaN 0.071 NaN NaN NaN NaN NaN 
Isoform Long of Glucose-6-phosphate 1-
dehydrogenase  Glucose-6-phosphate 1-
dehydrogenase O 
NaN NaN NaN 0.071 NaN 0.173 NaN NaN NaN 
Keratin, type II cytoskeletal 5  Uncharacterized protein   NaN NaN NaN 0.037 NaN NaN NaN NaN NaN 
 -phosphogluconate dehydrogenase, decarboxylating  
6-phosphogluconate dehydrogenase, decarboxylating  
6-phosphogluconate d 
NaN NaN NaN 0.015 NaN NaN NaN NaN NaN 
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APPENDIX 3  
Ratio of Heavy and Light Proteins from SILAC Experiment with Probe 1b 
NaN represent the proteins for which ratio cannot be calculated using Maxquant Analysis.  
Proteins are adjusted so that the proteins with greater difference in expression in Cell Lysate Vs Labeled Proteome are Listed First. 
 
Protein Descriptions Ratio H/L Cell Lysate Ratio H/L Labeled Proteome Ratio H/L Non-labeled Proteome 
1 2 3 1 2 3 1 2 3 
Uncharacterized protein  GN=RRAS2 PE=2 SV=1;Ras-
related protein R-Ras2  GN=RRAS2 PE=1 
SV=1;Uncharacterized protein   
NaN NaN NaN 31.969 4.506 4.211 4.324 NaN NaN 
Protein FAM162A  GN=FAM162A PE=1 
SV=2;Uncharacterized protein  GN=FAM162A PE=4 SV=1 
NaN NaN NaN 26.567 6.737 NaN NaN NaN NaN 
Mitochondrial import receptor subunit TOM70  
GN=TOMM70A PE=1 SV=1;Uncharacterized protein   
NaN NaN NaN 21.473 27.902 28.355 8.883 NaN 26.337 
Gelsolin  GN=GSN PE=1 SV=1;Gelsolin (Amyloidosis, 
Finnish type), isoform CRA_b  GN=GSN PE=2 
SV=1;Uncharacterized protein   
NaN NaN NaN 9.282 35.311 40.388 NaN NaN NaN 
Acyl-protein thioesterase 1  GN=LYPLA1 PE=1 
SV=1;Isoform 2 of Acyl-protein thioesterase 1  
GN=LYPLA1;Uncharacterized protein   
NaN NaN NaN 9.148 11.745 6.058 NaN NaN NaN 
GTP:AMP phosphotransferase, mitochondrial  GN=AK3 
PE=1 SV=4;Uncharacterized protein  GN=AK3 PE=3 
SV=1;Adenylate kinase 3   
NaN NaN NaN 7.080 25.786 4.289 NaN NaN NaN 
Cathepsin B  GN=CTSB PE=1 SV=3;Uncharacterized 
protein  GN=CTSB PE=3 SV=1;Uncharacterized protein   
NaN NaN NaN 6.551 14.963 NaN 4.947 6.266 NaN 
Neprilysin  GN=MME PE=1 SV=2;Uncharacterized protein  
GN=MME PE=4 SV=1;Uncharacterized protein   
NaN NaN NaN 6.127 6.041 0.978 NaN NaN NaN 
Heme-binding protein 1  GN=HEBP1 PE=1 
SV=1;Uncharacterized protein   
NaN NaN NaN 5.426 15.098 21.809 NaN NaN NaN 
Uncharacterized protein  GN=CD59 PE=4 SV=1;CD59 
glycoprotein  GN=CD59 PE=1 SV=1;Uncharacterized 
protein   
NaN NaN NaN 5.157 4.615 11.022 NaN NaN NaN 
Reticulon-4  GN=RTN4 PE=1 SV=2;Isoform 5 of Reticulon-
4  GN=RTN4;Isoform 2 of Reticulon-4  
NaN NaN NaN 4.536 2.025 2.097 NaN NaN NaN 
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GN=RTN4;Uncharacterized protein 
3-hydroxyisobutyryl-CoA hydrolase, mitochondrial  
GN=HIBCH PE=1 SV=2;Isoform 2 of 3-hydroxyisobutyryl-
CoA hydrolase, mitochondrial  
GN=HIBCH;Uncharacterized protein 
NaN NaN NaN 4.040 24.440 4.779 NaN NaN NaN 
Uncharacterized protein  GN=UCHL1 PE=4 
SV=1;Ubiquitin carboxyl-terminal hydrolase isozyme L1  
GN=UCHL1 PE=1 SV=2;Uncharacterized protein  GN 
NaN NaN NaN 3.143 3.947 3.782 NaN NaN NaN 
Quinone oxidoreductase  GN=CRYZ PE=1 
SV=1;Uncharacterized protein  GN=CRYZ PE=4 
SV=1;Crystallin, zeta (Quinone reductase), isoform CRA_a  
GN=D 
NaN NaN NaN 2.731 2.938 2.771 NaN NaN NaN 
Ras-related protein Rab-7a  GN=RAB7A PE=1 
SV=1;Uncharacterized protein  GN=RAB7A PE=3 
SV=1;Uncharacterized protein  GN=RAB7A PE=4 SV=1 
NaN NaN NaN 2.711 2.764 1.529 NaN NaN NaN 
Lupus La protein  GN=SSB PE=1 SV=2;Uncharacterized 
protein  GN=SSB PE=4 SV=1;Uncharacterized protein  
GN=SSB PE=4  
NaN NaN NaN 2.706 2.847 3.137 NaN NaN NaN 
Annexin A4  GN=ANXA4 PE=1 SV=4;ANXA4 protein  
GN=ANXA4 PE=2 SV=1;Uncharacterized protein  
GN=ANXA4 PE=2 SV=1 
NaN NaN NaN 2.295 7.106 5.575 NaN NaN NaN 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial  GN=DLST PE=1 SV=4;Uncharacterized 
protein  GN=DLST PE=2 SV=1;>tr|G 
NaN NaN NaN 2.253 2.516 2.877 NaN NaN NaN 
Protein LYRIC  GN=MTDH PE=1 SV=2;Uncharacterized 
protein  GN=MTDH PE=4 SV=1 
NaN NaN NaN 2.122 2.101 2.822 NaN NaN NaN 
Leucine-rich repeat flightless-interacting protein 1  
GN=LRRFIP1 PE=1 SV=2;Isoform 2 of Leucine-rich repeat 
flightless-interacting protein 1  GN=LRRFIP1; 
NaN NaN NaN 2.052 1.799 NaN NaN NaN NaN 
Perilipin-3  GN=PLIN3 PE=1 SV=3;Isoform 3 of Perilipin-3  
GN=PLIN3 
NaN NaN NaN 2.044 2.008 1.997 NaN NaN NaN 
Uncharacterized protein  GN=DBN1 PE=4 SV=1;Isoform 2 
of Drebrin  GN=DBN1;Drebrin  GN=DBN1 PE=1 
SV=4;Uncharacterized p 
NaN NaN NaN 1.981 2.475 2.945 NaN NaN NaN 
Aconitase 2, mitochondrial  GN=ACO2 PE=4 
SV=1;Aconitate hydratase, mitochondrial  GN=ACO2 
PE=1 SV=2;Uncharacterized protein  GN=ACO2 PE=4 SV= 
NaN NaN NaN 1.850 2.015 2.036 NaN NaN NaN 
Citrate synthase, mitochondrial  GN=CS PE=1 
SV=2;Citrate synthase  GN=CS PE=2 SV=1 
NaN NaN NaN 1.743 1.770 2.039 NaN NaN NaN 
S-formylglutathione hydrolase  GN=ESD PE=1 SV=2 NaN NaN NaN 1.671 1.846 1.712 NaN NaN NaN 
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TATA-binding protein-associated factor 2N  GN=TAF15 
PE=1 SV=1;Isoform Short of TATA-binding protein-
associated factor 2N  GN=TAF15;RNA-binding protein 
FUS OS 
NaN NaN NaN 1.617 1.750 1.744 NaN NaN NaN 
Serine/arginine-rich splicing factor 1  GN=SRSF1 PE=1 
SV=2;Isoform ASF-2 of Serine/arginine-rich splicing factor 
1  GN=SRSF1;Isoform ASF-3 of Serine/argi 
NaN NaN NaN 1.578 1.590 1.817 NaN NaN NaN 
Neuroblast differentiation-associated protein AHNAK  
GN=AHNAK PE=1 SV=2 
NaN NaN 2.021 1.547 1.712 1.804 NaN NaN NaN 
Heterogeneous nuclear ribonucleoprotein G  GN=RBMX 
PE=1 SV=3;Uncharacterized protein  GN=RBMX PE=2 
SV=1 
NaN NaN NaN 1.519 1.531 1.766 NaN NaN NaN 
Putative ubiquitin-conjugating enzyme E2 N-like  
GN=UBE2NL PE=5 SV=1;Ubiquitin-conjugating enzyme E2 
N  GN=UBE2N PE=1 SV=1;Uncharacterized protein 
OS=Homo s 
NaN NaN NaN 1.510 0.717 0.727 NaN NaN NaN 
ELAV-like protein 1  GN=ELAVL1 PE=1 SV=2 NaN NaN NaN 1.459 1.372 1.280 NaN NaN NaN 
ERO1-like protein alpha  GN=ERO1L PE=1 
SV=2;Uncharacterized protein  GN=ERO1L PE=4 
SV=1;Uncharacterized protein  GN=ERO1L PE=4 SV=1 
NaN NaN NaN 1.454 1.587 1.280 NaN NaN NaN 
Plastin-3  GN=PLS3 PE=1 SV=4;Uncharacterized protein  
GN=PLS3 PE=2 SV=1;Uncharacterized protein  GN=PLS3 
PE=4 SV=1;Un 
NaN NaN NaN 1.428 1.307 1.466 NaN NaN NaN 
Uncharacterized protein  GN=GNAI2 PE=4 SV=1;Guanine 
nucleotide-binding protein G(i) subunit alpha-2  
GN=GNAI2 PE=1 SV=3;Guanine nucleotide binding 
protein  
NaN NaN NaN 1.404 1.738 NaN NaN NaN NaN 
Annexin A6  GN=ANXA6 PE=1 SV=3;Annexin A6, isoform 
CRA_c  GN=ANXA6 PE=3 SV=3;Uncharacterized protein  
GN=ANXA6 PE=3 SV=1;>tr|B7Z582|B7Z582_H 
NaN NaN 0.802 1.361 1.331 1.273 NaN NaN NaN 
3-hydroxyisobutyrate dehydrogenase, mitochondrial  
GN=HIBADH PE=1 SV=2;3-hydroxyisobutyrate 
dehydrogenase  GN=NS5ATP1 PE=2 SV=1 
NaN NaN NaN 1.351 1.646 1.573 NaN NaN NaN 
Enhancer of rudimentary homolog  GN=ERH PE=1 
SV=1;Uncharacterized protein  GN=ERH PE=4 SV=1 
NaN NaN NaN 1.302 1.436 1.314 NaN NaN NaN 
Transforming protein RhoA  GN=RHOA PE=1 
SV=1;Uncharacterized protein  GN=RHOC PE=3 
SV=1;Rho-related GTP-binding protein RhoC  GN=RHOC 
PE=1 SV=1 
1.144 NaN NaN 1.275 1.298 1.282 NaN NaN NaN 
Guanine nucleotide-binding protein G(s) subunit alpha 
isoforms XLas  GN=GNAS PE=1 SV=2;Isoform XLas-2 of 
Guanine nucleotide-binding protein G(s) subunit alpha 
NaN NaN NaN 1.258 1.329 1.361 0.118 0.082 NaN 
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isoforms XLas  GN=G 
Transmembrane emp24 domain-containing protein 9  
GN=TMED9 PE=1 SV=2 
NaN NaN NaN 1.227 1.279 1.185 NaN NaN NaN 
Mesencephalic astrocyte-derived neurotrophic factor  
GN=MANF PE=1 SV=3 
NaN NaN NaN 1.225 1.144 1.299 NaN NaN NaN 
Hsp90 co-chaperone Cdc37  GN=CDC37 PE=1 SV=1 NaN NaN 0.984 1.222 1.099 5.360 NaN NaN NaN 
Uncharacterized protein  GN=RAB5C PE=3 SV=1;Ras-
related protein Rab-5C  GN=RAB5C PE=1 SV=2;Ras-
related protein Rab-5A  GN=RAB5A PE=1 SV=2;>sp 
NaN NaN NaN 1.210 1.510 1.397 NaN NaN NaN 
Integrin beta-1  GN=ITGB1 PE=1 SV=2;Isoform Beta-1C of 
Integrin beta-1  GN=ITGB1;Isoform Beta-1C-2 of Integrin 
beta-1  GN=ITGB1;>sp|P05556-5| 
NaN NaN NaN 1.159 1.299 1.366 NaN NaN NaN 
Vesicular integral-membrane protein VIP36  GN=LMAN2 
PE=1 SV=1;Uncharacterized protein  GN=LMAN2 PE=2 
SV=1 
NaN NaN NaN 1.154 1.146 1.219 NaN NaN NaN 
Transaldolase  GN=TALDO1 PE=1 SV=2;Transaldolase  
GN=TALDO1 PE=3 SV=1 
NaN NaN NaN 1.136 1.242 1.150 NaN NaN NaN 
Acyl-Coenzyme A dehydrogenase, very long chain, 
isoform CRA_b  GN=ACADVL PE=3 SV=1;Uncharacterized 
protein  GN=ACADVL PE=3 SV=1;Very long-chain specific 
ac 
NaN NaN NaN 1.126 1.249 1.129 NaN NaN NaN 
Tropomyosin alpha-4 chain  GN=TPM4 PE=1 
SV=3;Isoform 2 of Tropomyosin alpha-4 chain  GN=TPM4 
NaN NaN NaN 1.112 1.011 1.127 NaN NaN NaN 
Microtubule-associated protein RP/EB family member 1  
GN=MAPRE1 PE=1 SV=3 
NaN NaN NaN 1.111 1.145 1.252 NaN NaN NaN 
Hepatoma-derived growth factor (High-mobility group 
protein 1-like)  GN=HDGF PE=2 SV=1;Hepatoma-derived 
growth factor  GN=HDGF PE=1 SV=1;Hepatoma-derived 
gr 
NaN NaN NaN 1.110 1.254 0.602 NaN NaN NaN 
Single-stranded DNA binding protein 1  GN=SSBP1 PE=2 
SV=1;Single-stranded DNA-binding protein, 
mitochondrial  GN=SSBP1 PE=1 SV=1;Uncharacterized 
protein OS= 
NaN NaN NaN 1.109 1.041 1.034 NaN NaN NaN 
Lamin-B2  GN=LMNB2 PE=1 SV=3 NaN NaN 0.585 1.101 1.102 1.147 NaN NaN NaN 
Phosphatidylethanolamine-binding protein 1  GN=PEBP1 
PE=1 SV=3;Uncharacterized protein  GN=PEBP1 PE=2 
SV=1 
NaN NaN NaN 1.045 1.113 1.044 NaN NaN NaN 
Uncharacterized protein  GN=NACA PE=4 
SV=1;Uncharacterized protein  GN=NACA PE=4 
SV=1;Nascent polypeptide-associated complex subunit 
alpha  G 
NaN NaN NaN 1.036 2.204 NaN NaN NaN NaN 
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Isoform 4 of Probable ATP-dependent RNA helicase 
DDX17  GN=DDX17;Uncharacterized protein  GN=DDX17 
PE=3 SV=1;Isoform 2 of Probable ATP-dependent RNA 
hel 
NaN NaN NaN 1.031 0.829 0.595 0.235 NaN NaN 
Sialic acid synthase  GN=NANS PE=1 SV=2 NaN NaN NaN 1.029 0.979 1.170 NaN NaN NaN 
UPF0556 protein C19orf10  GN=C19orf10 PE=1 SV=1 NaN NaN NaN 1.020 1.113 1.339 NaN NaN NaN 
T-complex protein 1 subunit theta  GN=CCT8 PE=1 
SV=4;Chaperonin containing TCP1, subunit 8 (Theta), 
isoform CRA_a  GN=CCT8 PE=4 SV=1;Uncharacterized 
protein 
NaN NaN NaN 1.020 0.954 0.972 NaN NaN NaN 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit  GN=DDOST PE=1 
SV=4;Uncharacterized protein  GN=DDOST PE=4 SV=1 
NaN NaN 1.288 1.018 NaN 1.246 NaN NaN 0.433 
Eukaryotic translation initiation factor 2 subunit 1  
GN=EIF2S1 PE=1 SV=3 
NaN NaN NaN 1.016 1.104 1.375 NaN NaN NaN 
Myotrophin  GN=MTPN PE=1 SV=2;Myotrophin  
GN=DKFZp761E1322 PE=2 SV=1;Uncharacterized protein  
GN=MTPN PE=4 SV=1 
NaN NaN NaN 1.006 0.811 0.808 NaN NaN NaN 
Annexin A3  GN=ANXA3 PE=1 SV=3;Uncharacterized 
protein  GN=ANXA3 PE=3 SV=1;Uncharacterized protein  
GN=ANXA3 PE=3 SV=1;>tr|D6RA82|D6RA82_HUM 
NaN NaN NaN 0.985 1.106 1.016 NaN NaN NaN 
Ubiquitin-conjugating enzyme E2 variant 1  GN=UBE2V1 
PE=1 SV=2;Ubiquitin-conjugating enzyme E2 variant 1  
GN=UBE2V1 PE=2 SV=1;HCG2044781  GN 
NaN NaN NaN 0.968 1.091 0.981 NaN NaN NaN 
Prostaglandin E synthase 3  GN=PTGES3 PE=1 
SV=1;Uncharacterized protein  GN=PTGES3 PE=2 
SV=1;Prostaglandin E synthase 3 (Cytosolic), isoform 
CRA_d OS=Homo s 
NaN NaN NaN 0.950 NaN 1.062 0.273 0.335 NaN 
Prothymosin alpha  GN=PTMA PE=1 SV=2;Isoform 2 of 
Prothymosin alpha  GN=PTMA;Uncharacterized protein  
GN=PTMA PE=4 SV=1;>tr|B8ZZW7|B8ZZW7_HUM 
NaN NaN NaN 0.945 0.900 1.029 NaN NaN NaN 
Isoform 2 of Nucleoside diphosphate kinase A  
GN=NME1;Nucleoside diphosphate kinase A  GN=NME1 
PE=1 SV=1;Uncharacterized protein  GN=NME1 PE= 
NaN NaN NaN 0.935 1.073 0.976 NaN NaN NaN 
Membrane-associated progesterone receptor 
component 2  GN=PGRMC2 PE=1 SV=1 
NaN NaN NaN 0.902 0.892 0.994 NaN NaN NaN 
Proteasome subunit beta type-4  GN=PSMB4 PE=1 SV=4 NaN NaN NaN 0.841 1.669 0.856 NaN NaN NaN 
Proteasome subunit alpha type-7  GN=PSMA7 PE=1 
SV=1;Isoform 2 of Proteasome subunit alpha type-7  
GN=PSMA7;Uncharacterized protein  GN=PSMA7  
NaN NaN NaN 0.821 0.830 0.761 NaN NaN NaN 
Microtubule-associated protein  GN=MAP4 PE=4 NaN NaN NaN 0.801 0.656 0.801 NaN NaN NaN 
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SV=1;Microtubule-associated protein 4  GN=MAP4 PE=1 
SV=3;Isoform 6 of Microtubule-associated protein 4 
OS=Homo  
Proteasome subunit alpha type  GN=PSMA6 PE=3 
SV=1;Proteasome subunit alpha type-6  GN=PSMA6 PE=1 
SV=1;Proteasome subunit alpha type  GN=PSMA6 
NaN NaN NaN 0.800 0.773 0.656 NaN NaN NaN 
Cytochrome c oxidase subunit 4 isoform 1, mitochondrial  
GN=COX4I1 PE=1 SV=1 
NaN NaN NaN 0.761 0.929 0.847 NaN NaN NaN 
Basigin  GN=BSG PE=1 SV=2;Isoform 2 of Basigin  
GN=BSG;Basigin (Ok blood group), isoform CRA_f  
GN=BSG PE=2 SV=1;Basi 
NaN NaN NaN 0.743 0.776 0.805 NaN NaN NaN 
Prenylcysteine oxidase 1  GN=PCYOX1 PE=1 
SV=3;Uncharacterized protein  GN=PCYOX1 PE=2 
SV=1;Uncharacterized protein  GN=PCYOX1 PE=2 
SV=1;>tr| 
NaN NaN NaN 0.728 0.745 0.706 NaN NaN NaN 
Uncharacterized protein  GN=PRKCSH PE=4 
SV=1;Glucosidase 2 subunit beta  GN=PRKCSH PE=1 
SV=2;Uncharacterized protein  GN=PRKCSH PE=2 SV=1 
NaN NaN NaN 0.721 0.723 0.741 NaN NaN NaN 
Proliferation-associated protein 2G4  GN=PA2G4 PE=1 
SV=3;Uncharacterized protein  GN=PA2G4 PE=4 
SV=1;Uncharacterized protein  GN=PA2G4 PE=4  
NaN NaN NaN 0.708 0.795 0.919 NaN NaN NaN 
Nuclear mitotic apparatus protein 1  GN=NUMA1 PE=1 
SV=2;Isoform 2 of Nuclear mitotic apparatus protein 1  
GN=NUMA1 
NaN NaN NaN 0.695 0.883 0.682 NaN NaN NaN 
Uncharacterized protein  GN=DDX39B PE=4 
SV=1;Isoform 2 of Spliceosome RNA helicase DDX39B  
GN=DDX39B;Spliceosome RNA helicase DDX39B  GN=DD 
NaN NaN NaN 0.681 1.240 1.339 NaN NaN NaN 
Non-specific lipid-transfer protein  GN=SCP2 PE=1 
SV=2;Uncharacterized protein  GN=SCP2 PE=3 
SV=2;Uncharacterized protein  GN=SCP2 PE=3 SV=2; 
NaN NaN NaN 0.614 0.715 0.721 NaN NaN NaN 
High mobility group protein B2  GN=HMGB2 PE=1 
SV=2;Uncharacterized protein  GN=HMGB2 PE=4 SV=1 
NaN NaN NaN 0.605 0.683 0.548 NaN NaN NaN 
Ras-related protein Rab-11B  GN=RAB11B PE=1 
SV=4;Ras-related protein Rab-11A  GN=RAB11A PE=1 
SV=3 
NaN NaN NaN 0.594 0.853 0.723 0.144 0.137 NaN 
Uncharacterized protein  GN=VAMP2 PE=4 SV=1;Vesicle-
associated membrane protein 2  GN=VAMP2 PE=1 
SV=3;Vesicle-associated membrane protein 3   
NaN NaN NaN 0.581 0.695 0.620 NaN NaN NaN 
Reticulon-3  GN=RTN3 PE=1 SV=2;Isoform 2 of Reticulon-
3  GN=RTN3;Uncharacterized protein  GN=RTN3 PE=4 
SV=1;Isoform 4 
NaN NaN NaN 0.578 0.534 0.563 NaN NaN NaN 
Peroxiredoxin-4  GN=PRDX4 PE=1 SV=1;Uncharacterized 
protein  GN=PRDX4 PE=4 SV=1 
NaN NaN NaN 0.531 0.565 0.541 0.089 0.039 0.060 
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Fructose-bisphosphate aldolase C  GN=ALDOC PE=1 
SV=2;Fructose-bisphosphate aldolase  GN=ALDOC PE=2 
SV=1;Fructose-bisphosphate aldolase  GN=A 
NaN NaN NaN 0.492 0.465 0.390 NaN NaN NaN 
40S ribosomal protein S18  GN=RPS18 PE=1 SV=3 NaN NaN NaN 0.450 0.346 NaN 0.029 NaN 0.096 
14-3-3 protein eta  GN=YWHAH PE=1 SV=4 NaN NaN NaN 0.422 0.392 0.393 NaN NaN NaN 
Proteasome activator complex subunit 1  GN=PSME1 
PE=1 SV=1;Uncharacterized protein  GN=PSME1 PE=4 
SV=2 
0.319 NaN NaN 0.348 0.322 0.352 NaN NaN NaN 
Thioredoxin reductase 1, cytoplasmic  GN=TXNRD1 PE=1 
SV=3;Isoform 6 of Thioredoxin reductase 1, cytoplasmic  
GN=TXNRD1;Uncharacterized protein OS=Homo sap 
NaN NaN NaN 0.274 0.229 0.257 NaN NaN NaN 
Interferon-induced transmembrane protein 3  
GN=IFITM3 PE=1 SV=2;Interferon-induced 
transmembrane protein 2  GN=IFITM2 PE=1 
SV=2;Interferon-induced transmembrane 
NaN NaN NaN 0.274 0.144 0.284 NaN NaN NaN 
RAC-beta serine/threonine-protein kinase  GN=AKT2 
PE=1 SV=2;AKT2 protein  GN=AKT2 PE=2 
SV=1;Uncharacterized protein  GN=AKT2 PE=2 
SV=1;>tr|E7 
NaN NaN NaN 0.170 3.661 2.080 NaN NaN NaN 
Peptidyl-prolyl cis-trans isomerase FKBP3  GN=FKBP3 
PE=1 SV=1 
NaN NaN NaN 0.130 0.140 NaN NaN NaN NaN 
Lysosome membrane protein 2  GN=SCARB2 PE=1 
SV=2;Uncharacterized protein  GN=SCARB2 PE=4 SV=1 
NaN NaN NaN 0.091 0.031 0.129 NaN NaN NaN 
Hsc70-interacting protein  GN=ST13 PE=1 SV=2;Putative 
protein FAM10A4  GN=ST13P4 PE=5 SV=1;ST13 protein  
GN=ST13 PE=2 SV=1;>tr|F6VDH7|F6VDH7_ 
NaN NaN NaN 0.082 0.417 0.289 NaN NaN NaN 
60S ribosomal protein L5  GN=RPL5 PE=1 
SV=3;Ribosomal protein L5, isoform CRA_b  GN=RPL5 
PE=2 SV=1 
NaN NaN NaN 0.082 0.172 0.155 0.090 0.128 0.030 
Transgelin  GN=TAGLN PE=1 SV=4;Uncharacterized 
protein  GN=TAGLN PE=4 SV=1;Uncharacterized protein  
GN=TAGLN PE=4 SV=1 
NaN NaN NaN 0.067 0.048 0.027 NaN NaN NaN 
Keratin, type II cytoskeletal 5  GN=KRT5 PE=1 
SV=3;Uncharacterized protein  GN=KRT5 PE=3 SV=1 
NaN NaN NaN 0.031 0.013 0.028 0.029 0.066 0.020 
Epoxide hydrolase 1  GN=EPHX1 PE=1 SV=1 NaN NaN NaN 0.014 0.018 0.020 NaN NaN NaN 
Glyceraldehyde-3-phosphate dehydrogenase NaN NaN NaN 0.013 0.012 0.012 0.002 0.014 0.005 
Protein FAM184A  GN=FAM184A PE=2 SV=3;Isoform 3 of 
Protein FAM184A  GN=FAM184A;Isoform 2 of Protein 
FAM184A  GN=FAM184A;>tr|F8W8D6|F8W8D6_ 
NaN NaN NaN 0.009 0.025 0.041 NaN NaN NaN 
Annexin A3  GN=ANXA3 PE=1 SV=3;Uncharacterized 
protein  GN=ANXA3 PE=3 SV=1 
NaN NaN NaN 0.007 0.008 0.004 0.004 0.008 0.010 
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Isoform 2 of Importin-4  GN=IPO4;Importin-4  GN=IPO4 
PE=1 SV=2 
NaN NaN NaN NaN NaN NaN NaN NaN 0.169 
Ganglioside-induced differentiation-associated protein 1-
like 1  GN=GDAP1L1 PE=2 SV=2;Uncharacterized protein  
GN=GDAP1L1 PE=4 SV=1;Uncharacterized protein 
NaN NaN NaN NaN NaN NaN NaN NaN 0.099 
>P02663 SWISS-PROT:P02663 Alpha-S2-casein  NaN NaN NaN NaN NaN NaN NaN NaN 0.039 
NADPH--cytochrome P450 reductase  GN=POR PE=1 
SV=2;Uncharacterized protein  GN=POR PE=4 
SV=1;Uncharacterized protein  GN=POR PE=4 SV=1 
NaN NaN NaN NaN NaN NaN NaN 0.368 NaN 
WASH complex subunit 7  GN=KIAA1033 PE=1 
SV=2;Isoform 2 of WASH complex subunit 7  
GN=KIAA1033 
NaN NaN NaN NaN NaN NaN NaN 0.306 NaN 
60S ribosomal protein L9  GN=RPL9 PE=1 
SV=1;Uncharacterized protein  GN=RPL9 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN NaN 0.138 0.082 
Acyl-protein thioesterase 2  GN=LYPLA2 PE=1 
SV=1;Lysophospholipase II  GN=LYPLA2 PE=2 
SV=1;Lysophospholipase II  GN=LYPLA2 PE=2 
SV=1;>tr|Q5Q 
NaN NaN NaN NaN NaN NaN NaN 0.128 0.261 
Isocitrate dehydrogenase [NAD] subunit beta, 
mitochondrial  GN=IDH3B PE=1 SV=2;Isoform A of 
Isocitrate dehydrogenase [NAD] subunit beta, 
mitochondrial  GN=IDH3B;>sp|O43837-3|IDH3 
NaN NaN NaN NaN NaN NaN NaN 0.112 NaN 
Mesoderm-specific transcript homolog protein  
GN=MEST PE=2 SV=2;Isoform 2 of Mesoderm-specific 
transcript homolog protein  GN=MEST;Uncharacterized 
protein O 
NaN NaN NaN NaN NaN NaN NaN 0.096 0.462 
V-type proton ATPase subunit E 1  GN=ATP6V1E1 PE=1 
SV=1;Uncharacterized protein  GN=ATP6V1E1 PE=2 
SV=1;Uncharacterized protein  GN=ATP6V1E1  
NaN NaN NaN NaN NaN NaN NaN 0.087 NaN 
Dermcidin isoform 2  GN=DCD PE=2 SV=1;Dermcidin  
GN=DCD PE=1 SV=2 
NaN NaN NaN NaN NaN NaN NaN 0.057 NaN 
TBC1 domain family member 15  GN=TBC1D15 PE=1 
SV=2;Uncharacterized protein  GN=TBC1D15 PE=4 
SV=1;Isoform 2 of TBC1 domain family member 15  
NaN NaN NaN NaN NaN NaN NaN 0.054 NaN 
CAD protein  GN=CAD PE=1 SV=3;Uncharacterized 
protein  GN=CAD PE=3 SV=1 
NaN NaN NaN NaN NaN NaN NaN 0.042 0.023 
Collapsin response mediator protein 4 long variant  
GN=LCRMP PE=2 SV=1;Dihydropyrimidinase-related 
protein 3  GN=DPYSL3 PE=1 SV=1 
NaN NaN NaN NaN NaN NaN NaN 0.032 NaN 
Twinkle protein, mitochondrial  GN=PEO1 PE=1 
SV=1;Isoform 2 of Twinkle protein, mitochondrial  
GN=PEO1;Isoform 3 of Twinkle protein, mitochondrial 
NaN NaN NaN NaN NaN NaN 134.180 138.330 129.120 
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OS=Homo s 
Cytochrome b-c1 complex subunit 1, mitochondrial  
GN=UQCRC1 PE=1 SV=3 
NaN NaN NaN NaN NaN NaN 4.483 5.366 NaN 
ADP-ribosylation factor 4  GN=ARF4 PE=1 
SV=3;Uncharacterized protein  GN=ARF4 PE=3 SV=1;ADP-
ribosylation factor 5  GN=ARF5 PE=2 SV=1;>sp|P840 
NaN NaN NaN NaN NaN NaN 2.567 NaN 3.474 
Prosaposin  GN=PSAP PE=4 SV=1;Uncharacterized 
protein  GN=PSAP PE=4 SV=1;Isoform Sap-mu-9 of 
Proactivator polypeptide  GN=PSAP;>tr|C9JIZ6|C9 
NaN NaN NaN NaN NaN NaN 2.360 3.394 2.480 
Acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight 
chain  GN=ACADM PE=2 SV=1;Isoform 2 of Medium-
chain specific acyl-CoA dehydrogenase, mitochondrial  
GN=ACADM;>sp|P11310|ACADM 
NaN NaN NaN NaN NaN NaN 2.343 2.670 NaN 
Succinyl-CoA ligase [ADP/GDP-forming] subunit alpha, 
mitochondrial  GN=SUCLG1 PE=1 SV=4 
NaN NaN NaN NaN NaN NaN 1.898 2.490 1.770 
Tricarboxylate transport protein, mitochondrial  
GN=SLC25A1 PE=1 SV=2 
NaN NaN NaN NaN NaN NaN 1.697 NaN NaN 
Histone H1.5  GN=HIST1H1B PE=1 SV=3 NaN NaN NaN NaN NaN NaN 1.636 2.677 2.040 
Erlin-1  GN=ERLIN1 PE=1 SV=1;Erlin-2  GN=ERLIN2 PE=1 
SV=1;Uncharacterized protein  GN=ERLIN2 PE=4 SV=1;ER 
lipid raft  
NaN NaN NaN NaN NaN NaN 1.291 1.909 NaN 
Uncharacterized protein  GN=POLR2H PE=4 SV=1;DNA-
directed RNA polymerases I, II, and III subunit RPABC3  
GN=POLR2H PE=1 SV=4;Uncharacterized protein 
OS=Hom 
NaN NaN NaN NaN NaN NaN 1.099 0.689 0.881 
Uncharacterized protein  GN=OSTC PE=4 
SV=2;Oligosaccharyltransferase complex subunit OSTC  
GN=OSTC PE=1 SV=1 
NaN NaN NaN NaN NaN NaN 1.001 1.470 NaN 
UDP-glucose:glycoprotein glucosyltransferase 1  
GN=UGGT1 PE=1 SV=3;Isoform 2 of UDP-
glucose:glycoprotein glucosyltransferase 1  GN=UGGT1 
NaN NaN NaN NaN NaN NaN 0.762 NaN NaN 
Uncharacterized protein  GN=SEC61A1 PE=2 
SV=1;Protein transport protein Sec61 subunit alpha 
isoform 1  GN=SEC61A1 PE=1 SV=2 
NaN NaN NaN NaN NaN NaN 0.732 0.406 NaN 
Uncharacterized protein  GN=SSR1 PE=4 
SV=1;Uncharacterized protein  GN=SSR1 PE=4 
SV=1;Translocon-associated protein subunit alpha  
GN=SSR1 PE 
NaN NaN NaN NaN NaN NaN 0.703 0.793 0.688 
Septin-7  GN=SEPT7 PE=1 SV=2;Uncharacterized protein  
GN=SEPT7 PE=3 SV=1;Uncharacterized protein  
GN=SEPT7 PE=3 SV=2;>sp|Q16181-2|SEPT7_HUMA 
NaN NaN NaN NaN NaN NaN 0.689 0.150 0.152 
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Histone H1.4  GN=HIST1H1E PE=1 SV=2 NaN NaN NaN NaN NaN NaN 0.680 0.849 NaN 
60S ribosomal protein L30  GN=RPL30 PE=1 
SV=2;Uncharacterized protein  GN=RPL30 PE=3 SV=1 
NaN NaN NaN NaN NaN NaN 0.632 0.437 0.206 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial  GN=SDHA PE=1 
SV=2;Uncharacterized protein  GN=SDHA PE=4 
SV=1;Uncharacterized prote 
NaN NaN NaN NaN NaN NaN 0.488 0.501 0.102 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  
GN=ATP2A2 PE=1 SV=1;Isoform 4 of 
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2  
GN=ATP2A2;Isof 
NaN NaN NaN NaN NaN NaN 0.453 0.163 0.206 
V-type proton ATPase catalytic subunit A  GN=ATP6V1A 
PE=1 SV=2;Uncharacterized protein  GN=ATP6V1A PE=2 
SV=1;Uncharacterized protein  GN=ATP6 
NaN NaN NaN NaN NaN NaN 0.426 0.214 0.344 
Serine hydroxymethyltransferase, mitochondrial  
GN=SHMT2 PE=1 SV=3;Serine hydroxymethyltransferase  
GN=SHMT2 PE=2 SV=1;Serine hydroxymethyltransferase 
OS=Ho 
NaN NaN NaN NaN NaN NaN 0.390 0.855 NaN 
GPI transamidase component PIG-S  GN=PIGS PE=1 
SV=3;Isoform 2 of GPI transamidase component PIG-S  
GN=PIGS;Uncharacterized protein  GN=PIGS P 
NaN NaN NaN NaN NaN NaN 0.387 0.484 0.112 
ATP-dependent RNA helicase A  GN=DHX9 PE=1 
SV=4;Uncharacterized protein  GN=DHX9 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.382 0.343 0.197 
40S ribosomal protein S26  GN=RPS26 PE=1 
SV=3;HCG1745083  GN=RPS26 PE=2 
SV=1;Uncharacterized protein  PE=4 SV=1;Putati 
NaN NaN NaN NaN NaN NaN 0.374 3.027 0.189 
Uncharacterized protein  GN=TUBA1C PE=3 SV=1;Tubulin 
alpha-1C chain  GN=TUBA1C PE=1 SV=1;Uncharacterized 
protein  GN=TUBA1C PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.359 0.121 0.062 
Uncharacterized protein  GN=VARS PE=3 SV=1;Valyl-
tRNA synthetase  GN=VARS PE=1 SV=4;Uncharacterized 
protein  GN=VARS PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.340 0.427 NaN 
AP-2 complex subunit alpha-1  GN=AP2A1 PE=1 
SV=3;Isoform B of AP-2 complex subunit alpha-1  
GN=AP2A1;Isoform 2 of AP-2 complex subunit alpha-2 
OS=Homo sa 
NaN NaN NaN NaN NaN NaN 0.337 0.108 0.424 
Dihydropyrimidinase-related protein 2  GN=DPYSL2 PE=1 
SV=1;Uncharacterized protein  GN=DPYSL2 PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.300 NaN 0.235 
60S ribosomal protein L3  GN=RPL3 PE=1 
SV=2;Uncharacterized protein  GN=RPL3 PE=3 
SV=1;Ribosomal protein L3, isoform CRA_e  GN=RPL3 
PE=4 SV=1; 
NaN NaN NaN NaN NaN NaN 0.299 0.323 0.188 
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Uncharacterized protein  GN=TIAL1 PE=2 
SV=1;Nucleolysin TIAR  GN=TIAL1 PE=1 SV=1;TIAL1 
protein  GN=TIAL1 PE=2 SV=1;Nucl 
NaN NaN NaN NaN NaN NaN 0.276 0.763 0.329 
26S protease regulatory subunit 10B  GN=PSMC6 PE=1 
SV=1 
NaN NaN NaN NaN NaN NaN 0.253 0.122 0.080 
Uncharacterized protein  GN=ACLY PE=4 SV=2;ATP-
citrate synthase  GN=ACLY PE=1 SV=3;ATP citrate lyase, 
isoform CRA_a  GN=ACLY PE=4 SV=1;>tr|B4 
NaN NaN NaN NaN NaN NaN 0.244 NaN 0.262 
Isoform 5 of Serine/threonine-protein phosphatase 2A 
55 kDa regulatory subunit B beta isoform  
GN=PPP2R2B;Isoform 4 of Serine/threonine-protein 
phosphatase 2A 55 kDa regulatory subunit B beta i 
NaN NaN NaN NaN NaN NaN 0.242 0.225 0.073 
Phosphatidylinositol glycan anchor biosynthesis class U 
protein  GN=PIGU PE=1 SV=3;Uncharacterized protein  
GN=PIGU PE=4 SV=1;Isoform 2 of Phosphatidylinosi 
NaN NaN NaN NaN NaN NaN 0.235 NaN NaN 
26S protease regulatory subunit 8  GN=PSMC5 PE=1 
SV=1;Proteasome (Prosome, macropain) 26S subunit, 
ATPase, 5, isoform CRA_b  GN=PSMC5 PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.228 0.268 0.075 
Trifunctional purine biosynthetic protein adenosine-3  
GN=GART PE=1 SV=1;Isoform Short of Trifunctional 
purine biosynthetic protein adenosine-3  GN=GART 
NaN NaN NaN NaN NaN NaN 0.227 0.087 0.166 
26S protease regulatory subunit 4  GN=PSMC1 PE=1 
SV=1;Uncharacterized protein  GN=PSMC1 PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.218 0.179 0.095 
Uncharacterized protein  GN=DNM1L PE=3 SV=1;Isoform 
6 of Dynamin-1-like protein  GN=DNM1L;Dynamin-1-like 
protein  GN=DNM1L PE=1 SV=2;>sp|O0 
NaN NaN NaN NaN NaN NaN 0.217 0.049 0.059 
DNA replication licensing factor MCM3  GN=MCM3 PE=1 
SV=3;Uncharacterized protein  GN=MCM3 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.205 0.062 NaN 
Guanine nucleotide-binding protein subunit beta-2-like 1  
GN=GNB2L1 PE=1 SV=3;Uncharacterized protein  
GN=GNB2L1 PE=4 SV=1;Uncharacterized protein 
OS=Homo s 
NaN NaN NaN NaN NaN NaN 0.192 0.226 0.128 
Isoform 2 of General vesicular transport factor p115  
GN=USO1;Uncharacterized protein  GN=USO1 PE=4 
SV=1;General vesicular transport factor p115 OS=Homo 
sap 
NaN NaN NaN NaN NaN NaN 0.191 NaN NaN 
Coatomer subunit beta  GN=COPB2 PE=1 SV=2;Coatomer 
protein complex, subunit beta 2 (Beta prime), isoform 
CRA_b  GN=COPB2 PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.188 0.176 0.143 
AP-1 complex subunit beta-1  GN=AP1B1 PE=1 
SV=2;Isoform B of AP-1 complex subunit beta-1  
GN=AP1B1;Isoform C of AP-1 complex subunit beta-1 
OS=Homo sapie 
NaN NaN NaN NaN NaN NaN 0.183 0.216 0.286 
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40S ribosomal protein S16  GN=RPS16 PE=1 SV=2;RPS16 
protein  GN=RPS16 PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.181 0.207 0.045 
Serine/threonine-protein kinase 24  GN=STK24 PE=1 
SV=1;Uncharacterized protein  GN=STK24 PE=4 
SV=1;Isoform A of Serine/threonine-protein kinase 24 
OS=Homo 
NaN NaN NaN NaN NaN NaN 0.180 NaN NaN 
Glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing] 1  GN=GFPT1 PE=1 SV=3;Isoform 2 of 
Glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing] 1  GN=GFPT1 
NaN NaN NaN NaN NaN NaN 0.174 0.110 0.087 
Eukaryotic translation initiation factor 3, subunit E 
interacting protein  GN=EIF3EIP PE=4 SV=1;Eukaryotic 
translation initiation factor 3 subunit L  GN=EIF3L PE=1 
SV=1;>tr|C9K0Q7 
NaN NaN NaN NaN NaN NaN 0.171 0.056 NaN 
Uncharacterized protein  GN=CYFIP2 PE=4 
SV=1;Cytoplasmic FMR1-interacting protein 2  
GN=CYFIP2 PE=1 SV=2;Uncharacterized protein  
GN=CYFIP1  
NaN NaN NaN NaN NaN NaN 0.169 NaN NaN 
40S ribosomal protein S15a  GN=RPS15A PE=1 SV=2 NaN NaN NaN NaN NaN NaN 0.166 0.179 0.058 
Condensin complex subunit 3  GN=NCAPG PE=1 SV=1 NaN NaN NaN NaN NaN NaN 0.163 0.092 0.419 
Uncharacterized protein  GN=KPNA6 PE=4 SV=1;Importin 
subunit alpha-7  GN=KPNA6 PE=1 SV=1;Uncharacterized 
protein  GN=KPNA6 PE=4 SV=1;>sp|P522 
NaN NaN NaN NaN NaN NaN 0.154 NaN 0.559 
26S proteasome non-ATPase regulatory subunit 3  
GN=PSMD3 PE=1 SV=2;Uncharacterized protein  
GN=PSMD3 PE=4 SV=1;Uncharacterized protein  GN=P 
NaN NaN NaN NaN NaN NaN 0.149 0.095 0.042 
Isoform 2 of Coatomer subunit alpha  
GN=COPA;Coatomer subunit alpha  GN=COPA PE=1 SV=2 
NaN NaN NaN NaN NaN NaN 0.144 NaN 0.190 
CCR4-NOT transcription complex subunit 1  GN=CNOT1 
PE=1 SV=2;Isoform 2 of CCR4-NOT transcription complex 
subunit 1  GN=CNOT1;Isoform 3 of CCR4-NOT transc 
NaN NaN NaN NaN NaN NaN 0.142 NaN NaN 
60S ribosomal protein L7a  GN=RPL7A PE=1 
SV=2;Ribosomal protein L7a  GN=RPL7A PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.138 0.076 0.050 
26S protease regulatory subunit 6A  GN=PSMC3 PE=1 
SV=3;Uncharacterized protein  GN=PSMC3 PE=3 
SV=1;Uncharacterized protein  GN=PSMC3 PE=3 SV 
NaN NaN NaN NaN NaN NaN 0.131 0.201 0.130 
40S ribosomal protein S15  GN=RPS15 PE=1 SV=2 NaN NaN NaN NaN NaN NaN 0.127 0.162 NaN 
Uncharacterized protein  GN=RPS24 PE=4 SV=1;40S 
ribosomal protein S24  GN=RPS24 PE=1 SV=1;Isoform 3 
of 40S ribosomal protein S24  GN=RPS24;>t 
NaN NaN NaN NaN NaN NaN 0.124 NaN 0.027 
Aspartyl-tRNA synthetase, cytoplasmic  GN=DARS PE=1 NaN NaN NaN NaN NaN NaN 0.116 0.095 0.047 
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SV=2;Putative uncharacterized protein DKFZp781B11202  
GN=DKFZp781B11202 PE=2 SV=1 
Uncharacterized protein  GN=XPO7 PE=4 
SV=1;Uncharacterized protein  GN=XPO7 PE=4 
SV=1;Exportin-7  GN=XPO7 PE=1 SV=3 
NaN NaN NaN NaN NaN NaN 0.115 NaN NaN 
Nuclear cap-binding protein subunit 1  GN=NCBP1 PE=1 
SV=1;Uncharacterized protein  GN=NCBP1 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.114 NaN NaN 
Plasma membrane calcium-transporting ATPase 1  
GN=ATP2B1 PE=1 SV=3;Isoform C of Plasma membrane 
calcium-transporting ATPase 1  GN=ATP2B1;Plasma 
membrane ca 
NaN NaN NaN NaN NaN NaN 0.109 NaN NaN 
Eukaryotic translation initiation factor 3 subunit A  
GN=EIF3A PE=1 SV=1;Uncharacterized protein  GN=EIF3A 
PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.109 0.241 NaN 
Fascin  GN=FSCN1 PE=1 SV=3 NaN NaN NaN NaN NaN NaN 0.106 0.116 NaN 
Thimet oligopeptidase  GN=THOP1 PE=1 SV=2 NaN NaN NaN NaN NaN NaN 0.105 NaN NaN 
Protein diaphanous homolog 1  GN=DIAPH1 PE=1 
SV=2;Uncharacterized protein  GN=DIAPH1 PE=4 
SV=1;Uncharacterized protein  GN=DIAPH1 PE=4 SV=2; 
NaN NaN NaN NaN NaN NaN 0.103 NaN NaN 
60S ribosomal protein L4  GN=RPL4 PE=1 
SV=5;Uncharacterized protein  GN=RPL4 PE=4 
SV=1;Uncharacterized protein  GN=RPL4 PE=2 
SV=1;>tr|B4DP82|B 
NaN NaN NaN NaN NaN NaN 0.102 NaN 0.045 
Glomulin  GN=GLMN PE=1 SV=2;Uncharacterized protein  
GN=GLMN PE=2 SV=1;Isoform 2 of Glomulin  GN=GLMN 
NaN NaN NaN NaN NaN NaN 0.098 NaN NaN 
40S ribosomal protein S3a  GN=RPS3A PE=1 
SV=2;Uncharacterized protein  GN=RPS3A PE=3 
SV=1;Uncharacterized protein  GN=RPS3A PE=3 
SV=1;>tr|E9P 
NaN NaN NaN NaN NaN NaN 0.097 0.081 0.141 
V-type proton ATPase subunit H  GN=ATP6V1H PE=1 
SV=1;Isoform 2 of V-type proton ATPase subunit H  
GN=ATP6V1H;Uncharacterized protein  GN=ATP6 
NaN NaN NaN NaN NaN NaN 0.091 NaN NaN 
Uncharacterized protein  GN=AP1G1 PE=2 SV=1;Isoform 
2 of AP-1 complex subunit gamma-1  GN=AP1G1;AP-1 
complex subunit gamma-1  GN=AP1G1 PE=1 
NaN NaN NaN NaN NaN NaN 0.091 0.026 NaN 
Exportin-T  GN=XPOT PE=1 SV=2 NaN NaN NaN NaN NaN NaN 0.090 0.128 0.094 
1-acyl-sn-glycerol-3-phosphate acyltransferase alpha  
GN=AGPAT1 PE=2 SV=2;Uncharacterized protein  
GN=AGPAT1 PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.089 NaN 0.118 
Phosphoribosylformylglycinamidine synthase  GN=PFAS 
PE=1 SV=4;Uncharacterized protein  GN=PFAS PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.087 NaN NaN 
202 
 
SUMO-activating enzyme subunit 1  GN=SAE1 PE=1 
SV=1;Uncharacterized protein  GN=SAE1 PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.086 NaN NaN 
KINDLIN2 isoform 2  GN=FERMT2 PE=2 SV=1;Fermitin 
family homolog 2  GN=FERMT2 PE=1 SV=1;Isoform 2 of 
Fermitin family homolog 2  GN=FERMT2 
NaN NaN NaN NaN NaN NaN 0.085 0.097 NaN 
26S proteasome non-ATPase regulatory subunit 14  
GN=PSMD14 PE=1 SV=1;Uncharacterized protein  
GN=PSMD14 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.084 0.108 0.120 
Isoform 4 of Acetyl-CoA carboxylase 1  
GN=ACACA;Acetyl-CoA carboxylase 1  GN=ACACA PE=1 
SV=2;Isoform 2 of Acetyl-CoA carboxylase 1  GN=ACA 
NaN NaN NaN NaN NaN NaN 0.084 0.169 0.121 
Ribosomal protein S27  GN=LOC392748 PE=3 SV=1;40S 
ribosomal protein S27  GN=RPS27 PE=1 SV=3;40S 
ribosomal protein S27-like  GN=RPS27L PE=1 SV= 
NaN NaN NaN NaN NaN NaN 0.083 0.060 0.087 
Lactotransferrin  GN=LTF PE=1 SV=6;Uncharacterized 
protein  GN=LTF PE=4 SV=1;Uncharacterized protein  
GN=LTF PE=4 SV=1;>tr|B7Z4X2|B7Z4X2_HUMA 
NaN NaN NaN NaN NaN NaN 0.081 0.079 0.104 
26S protease regulatory subunit 7  GN=PSMC2 PE=1 
SV=3;Uncharacterized protein  GN=PSMC2 PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.078 0.076 0.049 
Signal recognition particle 72 kDa protein  GN=SRP72 
PE=1 SV=3;Signal recognition particle 72kDa, isoform 
CRA_c  GN=SRP72 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.078 NaN NaN 
60S ribosomal protein L14  GN=RPL14 PE=1 
SV=4;Uncharacterized protein  GN=RPL14 PE=2 
SV=1;Uncharacterized protein  GN=RPL14 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.077 0.093 NaN 
DNA replication licensing factor MCM4  GN=MCM4 PE=1 
SV=5;Uncharacterized protein  GN=MCM4 PE=3 
SV=1;Uncharacterized protein  GN=MCM4 PE=3 SV= 
NaN NaN NaN NaN NaN NaN 0.077 0.118 NaN 
ATPase ASNA1  GN=ASNA1 PE=1 SV=2;Uncharacterized 
protein  GN=ASNA1 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.075 NaN NaN 
40S ribosomal protein S4, X isoform  GN=RPS4X PE=1 
SV=2;Uncharacterized protein  GN=RPS4X PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.074 0.114 0.031 
40S ribosomal protein S11  GN=RPS11 PE=1 SV=3 NaN NaN NaN NaN NaN NaN 0.072 0.086 0.099 
Translational activator GCN1  GN=GCN1L1 PE=1 SV=6 NaN NaN NaN NaN NaN NaN 0.072 0.205 0.158 
Isoform 3 of COP9 signalosome complex subunit 7b  
GN=COPS7B;COP9 signalosome complex subunit 7b  
GN=COPS7B PE=1 SV=1;Isoform 2 of COP9 signalosome 
comple 
NaN NaN NaN NaN NaN NaN 0.070 NaN NaN 
40S ribosomal protein S13  GN=RPS13 PE=1 SV=2 NaN NaN NaN NaN NaN NaN 0.065 0.166 0.047 
Protein MON2 homolog  GN=MON2 PE=1 SV=2;Isoform 4 
of Protein MON2 homolog  GN=MON2;MON2 protein  
NaN NaN NaN NaN NaN NaN 0.064 0.162 NaN 
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GN=MON2 PE=2 SV=1;Un 
Isoleucyl-tRNA synthetase, cytoplasmic  GN=IARS PE=1 
SV=2;Uncharacterized protein  GN=IARS PE=3 SV=1 
NaN NaN NaN NaN NaN NaN 0.063 0.030 0.043 
Kappa-casein [Contains: Casoxin C; Casoxin 6; Casoxin A; 
Casoxin B; Casoplatelin]  
NaN NaN NaN NaN NaN NaN 0.063 0.110 0.087 
Cleavage and polyadenylation specificity factor subunit 2  
GN=CPSF2 PE=1 SV=2 
NaN NaN NaN NaN NaN NaN 0.061 NaN NaN 
Tubulin beta-3 chain  GN=TUBB3 PE=1 
SV=2;HCG1983504, isoform CRA_f  GN=TUBB3 PE=2 
SV=1 
NaN NaN NaN NaN NaN NaN 0.059 0.039 0.033 
Leucyl-tRNA synthetase, cytoplasmic  GN=LARS PE=1 
SV=2;Uncharacterized protein  GN=LARS PE=2 
SV=1;Uncharacterized protein  GN=LARS PE=3 SV=1; 
NaN NaN NaN NaN NaN NaN 0.056 0.086 0.080 
Pre-mRNA-processing-splicing factor 8  GN=PRPF8 PE=1 
SV=2 
NaN NaN NaN NaN NaN NaN 0.055 0.097 0.103 
STE20/SPS1-related proline-alanine-rich protein kinase  
GN=STK39 PE=1 SV=3 
NaN NaN NaN NaN NaN NaN 0.054 0.055 0.039 
Uncharacterized protein  GN=HUWE1 PE=4 SV=1;E3 
ubiquitin-protein ligase HUWE1  GN=HUWE1 PE=1 
SV=3;Isoform 3 of E3 ubiquitin-protein ligase HUWE1 
OS=Homo s 
NaN NaN NaN NaN NaN NaN 0.052 0.095 0.139 
Vacuolar protein sorting-associated protein 35  
GN=VPS35 PE=1 SV=2;Uncharacterized protein  
GN=VPS35 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.052 0.107 0.099 
Tubulin beta-2A chain  GN=TUBB2A PE=1 SV=1;Tubulin 
beta-2B chain  GN=TUBB2B PE=1 SV=1;Uncharacterized 
protein  GN=TUBB2A PE=4 SV=1;>tr|E7EX69 
NaN NaN NaN NaN NaN NaN 0.051 NaN 0.029 
Arginyl-tRNA synthetase, cytoplasmic  GN=RARS PE=1 
SV=2;Isoform Monomeric of Arginyl-tRNA synthetase, 
cytoplasmic  GN=RARS;Uncharacterized protein 
OS=Homo s 
NaN NaN NaN NaN NaN NaN 0.050 0.089 0.064 
Ras-related GTP-binding protein A  GN=RRAGA PE=1 
SV=1 
NaN NaN NaN NaN NaN NaN 0.047 NaN NaN 
Sodium/potassium-transporting ATPase subunit alpha-2  
GN=ATP1A2 PE=1 SV=1;ATPase, Na+/K+ transporting, 
alpha 2 (+) polypeptide  GN=ATP1A2 PE=3 SV=1;Unchara 
NaN NaN NaN NaN NaN NaN 0.046 NaN NaN 
Protein transport protein Sec24A  GN=SEC24A PE=1 SV=2 NaN NaN NaN NaN NaN NaN 0.044 0.096 0.066 
Probable ATP-dependent RNA helicase DHX36  
GN=DHX36 PE=1 SV=2;Uncharacterized protein  
GN=DHX36 PE=4 SV=1;Isoform 2 of Probable ATP-
dependent RNA helicase 
NaN NaN NaN NaN NaN NaN 0.044 NaN NaN 
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60S ribosomal protein L27a  GN=RPL27A PE=1 
SV=2;Uncharacterized protein  GN=RPL27A PE=3 
SV=1;Uncharacterized protein  GN=RPL27A PE=3 SV=1 
NaN NaN NaN NaN NaN NaN 0.044 0.047 0.009 
Prolactin-inducible protein  GN=PIP PE=1 SV=1 NaN NaN NaN NaN NaN NaN 0.043 0.050 0.130 
Aldehyde dehydrogenase, mitochondrial  GN=ALDH2 
PE=1 SV=2;Uncharacterized protein  GN=ALDH2 PE=3 
SV=1;Uncharacterized protein  GN=ALDH2 PE=3 
NaN NaN NaN NaN NaN NaN 0.043 0.075 0.053 
Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 1  GN=AIMP1 PE=1 
SV=2;Uncharacterized protein  GN=AIMP1 PE=2 
SV=1;Uncharacterized prote 
NaN NaN NaN NaN NaN NaN 0.043 0.066 0.040 
ADP/ATP translocase 1  GN=SLC25A4 PE=1 SV=4 NaN NaN NaN NaN NaN NaN 0.043 0.016 0.013 
Cullin-associated NEDD8-dissociated protein 2  
GN=CAND2 PE=1 SV=3;Isoform 2 of Cullin-associated 
NEDD8-dissociated protein 2  GN=CAND2 
NaN NaN NaN NaN NaN NaN 0.041 0.114 NaN 
Vitronectin  GN=VTN PE=1 SV=1 NaN NaN NaN NaN NaN NaN 0.036 NaN 0.022 
Uncharacterized protein  GN=AARS PE=3 SV=1;Alanyl-
tRNA synthetase, cytoplasmic  GN=AARS PE=1 SV=2 
NaN NaN NaN NaN NaN NaN 0.036 0.067 0.042 
6-phosphofructokinase, liver type  GN=PFKL PE=1 
SV=6;Isoform 2 of 6-phosphofructokinase, liver type  
GN=PFKL 
NaN NaN NaN NaN NaN NaN 0.036 0.031 0.038 
Zinc-alpha-2-glycoprotein  GN=AZGP1 PE=1 
SV=2;Uncharacterized protein  GN=AZGP1 PE=3 
SV=1;Uncharacterized protein  GN=AZGP1 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.036 NaN 0.033 
60S ribosomal protein L7  GN=RPL7 PE=1 
SV=1;Uncharacterized protein  GN=RPL7 PE=3 
SV=1;Uncharacterized protein  GN=RPL7 PE=4 
SV=1;>tr|C9JZ88|C 
NaN NaN NaN NaN NaN NaN 0.035 0.338 2.801 
Isoform 2 of cAMP-dependent protein kinase catalytic 
subunit beta  GN=PRKACB;Uncharacterized protein  
GN=PRKACB PE=2 SV=1;Uncharacterized protein 
OS=Homo 
NaN NaN NaN NaN NaN NaN 0.035 0.087 0.034 
Probable ubiquitin carboxyl-terminal hydrolase FAF-X  
GN=USP9X PE=1 SV=3;Isoform 2 of Probable ubiquitin 
carboxyl-terminal hydrolase FAF-X  GN=USP9X 
NaN NaN NaN NaN NaN NaN 0.034 NaN NaN 
Aminoacyl tRNA synthase complex-interacting 
multifunctional protein 2  GN=AIMP2 PE=1 
SV=2;Uncharacterized protein  GN=AIMP2 PE=4 
SV=1;Uncharacterized prote 
NaN NaN NaN NaN NaN NaN 0.033 NaN 0.032 
Long form collapsin response mediator protein 1  
GN=CRMP1 PE=2 SV=1;Dihydropyrimidinase-related 
NaN NaN NaN NaN NaN NaN 0.030 NaN 0.077 
205 
 
protein 1  GN=CRMP1 PE=1 SV=1;Uncharacterized 
protein OS=Ho 
Threonyl-tRNA synthetase, isoform CRA_a  GN=TARS 
PE=3 SV=1;Uncharacterized protein  GN=TARS PE=2 
SV=1;Threonyl-tRNA synthetase, cytoplasmic   
NaN NaN NaN NaN NaN NaN 0.029 NaN 0.030 
40S ribosomal protein S6  GN=RPS6 PE=1 SV=1;40S 
ribosomal protein S6  GN=RPS6 PE=3 SV=1;Ribosomal 
protein S6  GN=RPS6 PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.028 0.023 0.068 
Glycyl-tRNA synthetase  GN=GARS PE=1 SV=3 NaN NaN NaN NaN NaN NaN 0.028 0.054 0.186 
Uncharacterized protein  GN=TNPO3 PE=4 
SV=2;Uncharacterized protein  GN=TNPO3 PE=4 
SV=1;Isoform 1 of Transportin-3  
GN=TNPO3;>sp|Q9Y5L0|TN 
NaN NaN NaN NaN NaN NaN 0.027 NaN NaN 
Methionyl-tRNA synthetase, cytoplasmic  GN=MARS 
PE=1 SV=2;Uncharacterized protein  GN=MARS PE=3 
SV=3 
NaN NaN NaN NaN NaN NaN 0.027 0.053 0.065 
Isocitrate dehydrogenase [NADP], mitochondrial  
GN=IDH2 PE=1 SV=2;Isocitrate dehydrogenase [NADP]  
GN=IDH2 PE=2 SV=1;Uncharacterized protein  
NaN NaN NaN NaN NaN NaN 0.027 NaN NaN 
BPI fold-containing family A member 1  GN=BPIFA1 PE=1 
SV=1;Palate lung and nasal epithelium carcinoma 
associated protein  GN=BPIFA1 PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.027 0.054 0.064 
Dephospho-CoA kinase domain-containing protein  
GN=DCAKD PE=1 SV=1 
NaN NaN NaN NaN NaN NaN 0.027 0.077 0.024 
40S ribosomal protein S2  GN=RPS2 PE=1 
SV=2;Uncharacterized protein  GN=RPS2 PE=4 
SV=1;Uncharacterized protein  GN=RPS2 PE=3 
SV=1;>tr|E9PM36|E 
NaN NaN NaN NaN NaN NaN 0.026 0.074 0.027 
Bifunctional aminoacyl-tRNA synthetase  GN=EPRS PE=1 
SV=5;Uncharacterized protein  GN=EPRS PE=3 
SV=1;Uncharacterized protein  GN=EPRS PE=3 SV 
NaN NaN NaN NaN NaN NaN 0.021 0.024 0.026 
Structural maintenance of chromosomes protein 2  
GN=SMC2 PE=1 SV=2;Isoform 2 of Structural 
maintenance of chromosomes protein 2  GN=SMC2 
NaN NaN NaN NaN NaN NaN 0.017 NaN NaN 
>P02666 SWISS-PROT:P02666 Beta NaN NaN NaN NaN NaN NaN 0.017 0.033 0.021 
CTP synthase 1  GN=CTPS PE=1 SV=2;Uncharacterized 
protein  GN=CTPS PE=2 SV=1;Uncharacterized protein  
GN=CTPS PE=2 SV=1 
NaN NaN NaN NaN NaN NaN 0.016 0.023 0.038 
Myotubularin-related protein 13  GN=SBF2 PE=1 SV=1 NaN NaN NaN NaN NaN NaN 0.015 0.017 0.014 
HCG2017221, isoform CRA_b  GN=CUL2 PE=3 
SV=1;Cullin-2  GN=CUL2 PE=1 SV=2;Cullin 2  GN=CUL2 
NaN NaN NaN NaN NaN NaN 0.015 NaN NaN 
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PE=2 SV=1;Cullin 2 OS=Homo 
Protein furry homolog  GN=FRY PE=1 
SV=1;Uncharacterized protein  GN=FRY PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.014 NaN NaN 
CAP-Gly domain-containing linker protein 1  GN=CLIP1 
PE=1 SV=2;Isoform 2 of CAP-Gly domain-containing 
linker protein 1  GN=CLIP1;Isoform 3 of CAP-Gly dom 
NaN NaN NaN NaN NaN NaN 0.013 NaN NaN 
Argininosuccinate synthase  GN=ASS1 PE=1 
SV=2;Uncharacterized protein  GN=ASS1 PE=4 SV=2 
NaN NaN NaN NaN NaN NaN 0.013 0.026 0.029 
Argininosuccinate lyase  GN=ASL PE=1 
SV=4;Uncharacterized protein  GN=ASL PE=3 
SV=1;Uncharacterized protein  GN=ASL PE=4 SV=1 
NaN NaN NaN NaN NaN NaN 0.008 NaN NaN 
Uncharacterized protein  GN=ALB PE=4 
SV=2;Uncharacterized protein  GN=ALB PE=4 
SV=2;>P02768-1 SWISS-PROT:P02768-1 Tax_Id=9606 
Gene_Symbol=ALB Isoform 1 of Serum albumin 
precursor 
NaN NaN NaN NaN NaN NaN 0.008 0.009 0.008 
Leucine-rich repeat-containing protein 24  GN=LRRC24 
PE=2 SV=2;Leucine rich repeat containing 24  
GN=LRRC24 PE=4 SV=1 
NaN NaN 28.666 NaN NaN NaN 92.794 59.402 161.350 
60S ribosomal protein L13  GN=RPL13 PE=1 SV=4 NaN NaN 15.679 NaN NaN NaN 0.174 NaN NaN 
Coatomer subunit gamma  GN=COPG PE=1 
SV=1;Uncharacterized protein  GN=COPG PE=4 SV=1 
NaN NaN 11.958 NaN NaN NaN 0.571 0.619 0.440 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial  GN=PDHB PE=1 SV=3;Uncharacterized 
protein  GN=PDHB PE=2 SV=1;Isoform 2 of Pyruvate 
dehydrog 
NaN NaN 3.234 NaN NaN NaN 1.209 1.017 0.909 
ATP synthase subunit O, mitochondrial  GN=ATP5O PE=1 
SV=1 
NaN NaN 1.834 NaN NaN NaN NaN NaN NaN 
6-phosphogluconolactonase  GN=PGLS PE=1 SV=2 NaN NaN 1.533 NaN NaN NaN NaN NaN NaN 
Microtubule-actin cross-linking factor 1, isoforms 
1/2/3/5  GN=MACF1 PE=1 SV=4;Microtubule-actin cross-
linking factor 1, isoform 4  GN=MACF1 PE=1 SV=2;Uncha 
NaN NaN 1.458 NaN NaN NaN NaN NaN NaN 
Isoform 3 of Importin-5  GN=IPO5;Importin-5  GN=IPO5 
PE=1 SV=4;Uncharacterized protein  GN=IPO5 PE=2 
SV=1;Isoform 2 o 
NaN NaN 1.366 NaN NaN NaN 0.731 0.938 0.714 
Uncharacterized protein  GN=NAP1L4 PE=3 
SV=3;Nucleosome assembly protein 1-like 4b  
GN=NAP1L4b PE=2 SV=1;Nucleosome assembly protein 
1-like 4 OS=Homo sapie 
NaN NaN 0.814 NaN NaN NaN NaN NaN NaN 
Pyridoxal kinase  GN=PDXK PE=1 SV=1;Isoform 2 of 
Pyridoxal kinase  GN=PDXK;Uncharacterized protein  
NaN NaN 0.813 NaN NaN NaN NaN NaN NaN 
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GN=PDXK PE=4 SV=1;>tr|F2Z3F8|F2Z3F8_HUMAN 
Eukaryotic translation initiation factor 3 subunit E  
GN=EIF3E PE=1 SV=1;Uncharacterized protein  GN=EIF3E 
PE=4 SV=1;Uncharacterized protein OS=Homo sapien 
NaN NaN 0.258 NaN NaN NaN NaN NaN NaN 
Isoform 2 of Septin-2  GN=SEPT2;Septin-2  GN=SEPT2 
PE=1 SV=1;Uncharacterized protein  GN=SEPT2 PE=3 
SV=1;Uncharacte 
NaN NaN 0.222 NaN NaN NaN 0.365 0.847 NaN 
Importin-7  GN=IPO7 PE=1 SV=1 NaN NaN 0.197 NaN NaN NaN 0.186 0.197 0.155 
Acidic leucine-rich nuclear phosphoprotein 32 family 
member E  GN=ANP32E PE=1 SV=1;Acidic (Leucine-rich) 
nuclear phosphoprotein 32 family, member E  
GN=ANP32E PE=2 SV=1;>tr|E9PPH5 
NaN NaN 0.188 NaN NaN NaN NaN NaN NaN 
Succinyl-CoA ligase [GDP-forming] subunit beta, 
mitochondrial  GN=SUCLG2 PE=1 SV=2;Uncharacterized 
protein  GN=SUCLG2 PE=4 SV=1 
NaN 40.771 NaN NaN NaN NaN 20.170 NaN NaN 
Isoform 15 of Fibronectin  GN=FN1;Isoform 7 of 
Fibronectin  GN=FN1;Fibronectin  GN=FN1 PE=1 
SV=4;Isoform 3 of Fibron 
NaN 36.756 32.594 NaN NaN NaN 121.990 32.123 84.472 
Mitochondrial carrier homolog 2  GN=MTCH2 PE=1 
SV=1;Uncharacterized protein  GN=MTCH2 PE=3 SV=1 
NaN 7.709 11.819 NaN NaN NaN 1.850 4.524 NaN 
Neutral alpha-glucosidase AB  GN=GANAB PE=1 
SV=3;Isoform 2 of Neutral alpha-glucosidase AB  
GN=GANAB;Uncharacterized protein  GN=GANAB PE=4 
NaN 1.811 0.891 NaN NaN NaN 0.141 0.784 0.138 
Glutaminase kidney isoform, mitochondrial  GN=GLS 
PE=1 SV=1;Isoform 3 of Glutaminase kidney isoform, 
mitochondrial  GN=GLS;Isoform 2 of Glutaminase kidney 
i 
NaN 1.620 11.324 NaN NaN NaN 0.749 NaN NaN 
ATP-dependent RNA helicase DDX1  GN=DDX1 PE=1 
SV=2;Uncharacterized protein  GN=DDX1 PE=2 
SV=1;Uncharacterized protein  GN=DDX1 PE=2 SV=1 
NaN 1.549 NaN NaN NaN NaN 0.383 0.438 0.219 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 2  GN=RPN2 PE=1 
SV=3;Ribophorin II  GN=RPN2 PE=2 
SV=1;Uncharacterized protein OS=Homo 
NaN 1.548 1.739 NaN NaN NaN 3.342 3.816 3.008 
Calpain-2 catalytic subunit  GN=CAPN2 PE=1 
SV=6;Uncharacterized protein  GN=CAPN2 PE=2 SV=1 
NaN 1.536 1.443 NaN NaN NaN NaN 2.753 NaN 
60S ribosomal protein L15  GN=RPL15 PE=1 
SV=2;Ribosomal protein L15  GN=RPL15 PE=3 
SV=1;Ribosomal protein L15  GN=RPL15 PE=3 
SV=1;>tr|E7ENU7| 
NaN 1.475 1.679 NaN NaN NaN 0.129 0.336 0.165 
60S ribosomal protein L10  GN=RPL10 PE=1 SV=4;60S 
ribosomal protein L10-like  GN=RPL10L PE=1 
NaN 1.405 1.016 NaN NaN NaN 0.029 0.051 0.014 
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SV=3;Ribosomal protein L10 (Fragment)  GN=RPL10 P 
U5 small nuclear ribonucleoprotein 200 kDa helicase  
GN=SNRNP200 PE=1 SV=2;Uncharacterized protein  
GN=SNRNP200 PE=4 SV=1;Uncharacterized protein 
OS=Homo sa 
NaN 1.173 NaN NaN NaN NaN 0.316 NaN NaN 
60S ribosomal protein L18a  GN=RPL18A PE=1 
SV=2;Uncharacterized protein  GN=RPL18A PE=2 SV=1 
NaN 1.071 NaN NaN NaN NaN 0.021 0.053 0.017 
Adenine phosphoribosyltransferase  GN=APRT PE=1 
SV=2;Adenine phosphoribosyltransferase, isoform CRA_b  
GN=APRT PE=4 SV=1 
NaN 0.946 NaN NaN NaN NaN NaN NaN NaN 
Sideroflexin-1  GN=SFXN1 PE=1 SV=4;Uncharacterized 
protein  GN=SFXN1 PE=4 SV=1;Uncharacterized protein  
GN=SFXN1 PE=4 SV=1 
NaN 0.900 NaN NaN NaN NaN 1.837 1.417 NaN 
Surfeit locus protein 4  GN=SURF4 PE=1 
SV=3;Uncharacterized protein  GN=SURF4 PE=4 
SV=1;Surfeit 4  GN=SURF4 PE=2 
SV=1;>tr|Q5T8U5|Q5T8U5_HUMA 
NaN 0.889 0.755 NaN NaN NaN 0.691 0.776 0.632 
Histone H2A.x  GN=H2AFX PE=1 SV=2;Histone H2A type 
1-B/E  GN=HIST1H2AB PE=1 SV=2;Histone H2A type 1  
GN=HIST1H2AG PE=1 SV=2;>sp|P20671|H2A1D_HUM 
NaN 0.874 0.798 NaN NaN NaN NaN NaN NaN 
Putative heat shock protein HSP 90-beta 2  
GN=HSP90AB2P PE=1 SV=2 
NaN 0.831 NaN NaN NaN NaN 0.092 NaN 0.214 
Coatomer subunit beta  GN=COPB1 PE=1 
SV=3;Uncharacterized protein  GN=COPB1 PE=4 SV=1 
NaN 0.829 NaN NaN NaN NaN 0.568 0.596 0.453 
Proteasome subunit alpha type-4  GN=PSMA4 PE=1 
SV=1;PSMA4 protein  GN=PSMA4 PE=2 SV=1 
NaN 0.670 NaN NaN NaN NaN NaN NaN NaN 
Coatomer subunit epsilon  GN=COPE PE=1 
SV=3;Uncharacterized protein  GN=COPE PE=4 
SV=1;Coatomer protein complex, subunit epsilon, 
isoform CRA_b OS=Homo sapi 
NaN 0.622 0.472 NaN NaN NaN NaN NaN NaN 
Protein transport protein Sec23A  GN=SEC23A PE=1 
SV=2;Uncharacterized protein  GN=SEC23A PE=4 
SV=1;Uncharacterized protein  GN=SEC23A PE=4 S 
NaN 0.569 NaN NaN NaN NaN NaN NaN NaN 
Catechol O-methyltransferase  GN=COMT PE=1 
SV=2;Uncharacterized protein  GN=COMT PE=4 
SV=1;Isoform Soluble of Catechol O-methyltransferase  G 
NaN 0.509 0.479 NaN NaN NaN NaN NaN NaN 
Histone H1x  GN=H1FX PE=1 SV=1 NaN 0.470 NaN NaN NaN NaN 0.572 NaN NaN 
ATP-dependent RNA helicase DDX3X  GN=DDX3X PE=1 
SV=3;Uncharacterized protein  GN=DDX3X PE=2 
SV=1;Uncharacterized protein  GN=DDX3X PE=2 SV=1 
NaN 0.420 0.170 NaN NaN NaN NaN NaN NaN 
Calpain small subunit 1  GN=CAPNS1 PE=1 SV=1 NaN 0.303 NaN NaN NaN NaN NaN NaN NaN 
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Nuclear pore complex protein Nup155  GN=NUP155 
PE=1 SV=1;Uncharacterized protein  GN=NUP155 PE=2 
SV=1;Isoform 2 of Nuclear pore complex protein Nup155 
OS= 
NaN 0.173 0.351 NaN NaN NaN 0.162 NaN NaN 
Tubulin beta-4A chain  GN=TUBB4A PE=1 
SV=2;Uncharacterized protein  GN=TUBB4A PE=2 
SV=1;Uncharacterized protein  GN=TUBB4 PE=2 SV=1 
NaN 0.150 NaN NaN NaN NaN 6.325 NaN 0.057 
Eukaryotic translation initiation factor 4H  GN=EIF4H 
PE=1 SV=5;Isoform Short of Eukaryotic translation 
initiation factor 4H  GN=EIF4H 
NaN 0.144 0.131 NaN NaN NaN NaN NaN NaN 
>P05784 SWISS-PROT:P05784 Tax_Id=10090 
Gene_Symbol=Krt18 Keratin, type I cytoskeletal 18 
NaN 0.056 NaN NaN NaN NaN NaN NaN NaN 
Destrin  GN=DSTN PE=1 SV=3;Destrin (Actin 
depolymerizing factor), isoform CRA_a  GN=DSTN PE=2 
SV=1;Uncharacterized protein  GN=DSTN PE=4 SV=1 
NaN 0.037 NaN NaN NaN NaN 0.230 0.171 NaN 
Peroxiredoxin-2  GN=PRDX2 PE=1 SV=5;Peroxiredoxin 2, 
isoform CRA_a  GN=PRDX2 PE=4 SV=2 
NaN 0.035 NaN NaN NaN NaN 0.180 0.208 0.140 
Ganglioside-induced differentiation-associated protein 1  
GN=GDAP1 PE=1 SV=3;Isoform 2 of Ganglioside-induced 
differentiation-associated protein 1  GN=GDAP1 
25.188 28.194 25.353 NaN NaN NaN NaN NaN NaN 
Mitochondrial dynamin-like 120 kDa protein  GN=OPA1 
PE=3 SV=1;Isoform 2 of Dynamin-like 120 kDa protein, 
mitochondrial  GN=OPA1;Mitochondrial dynamin-like 
23.412 5.109 25.559 NaN NaN NaN NaN NaN NaN 
Fragile X mental retardation syndrome-related protein 1  
GN=FXR1 PE=1 SV=3;Uncharacterized protein  GN=FXR1 
PE=2 SV=1;Uncharacterized protein OS=Homo sapien 
13.541 1.916 1.773 NaN NaN NaN NaN NaN NaN 
ATPase family AAA domain-containing protein 1  
GN=ATAD1 PE=1 SV=1;Isoform 2 of ATPase family AAA 
domain-containing protein 1  
GN=ATAD1;Uncharacterized pro 
12.125 NaN NaN NaN NaN NaN 0.400 0.473 0.711 
Tripeptidyl-peptidase 1  GN=TPP1 PE=1 
SV=2;Uncharacterized protein  GN=TPP1 PE=4 
SV=3;Uncharacterized protein  GN=TPP1 PE=2 
SV=1;>sp|O14773-2 
10.904 2.367 2.283 NaN NaN NaN 7.089 8.326 6.797 
PRA1 family protein 3  GN=ARL6IP5 PE=1 
SV=1;Uncharacterized protein  GN=ARL6IP5 PE=4 SV=1 
10.064 2.927 2.380 NaN NaN NaN NaN NaN NaN 
ADP/ATP translocase 2  GN=SLC25A5 PE=1 SV=7 8.716 1.777 1.782 NaN NaN NaN 0.915 1.240 0.598 
Cytoplasmic dynein 1 heavy chain 1  GN=DYNC1H1 PE=1 
SV=5 
6.039 4.026 1.072 NaN NaN NaN 0.108 0.079 0.076 
Isoform 2 of Isochorismatase domain-containing protein 
2, mitochondrial  GN=ISOC2;Isochorismatase domain-
containing protein 2, mitochondrial  GN=ISOC2 PE=1 
5.021 19.755 5.515 NaN NaN NaN NaN NaN NaN 
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SV=1;>sp|Q96AB3-3|ISOC 
Tubulin beta-8 chain  GN=TUBB8 PE=1 SV=2;Novel 
protein similar to beta-tubulin 4Q (TUBB4Q) 
(LOC253936)  GN=RP11-631M21.2 PE=3 
SV=1;Uncharacterized protein O 
3.655 0.154 0.150 NaN NaN NaN 0.124 0.168 0.100 
Trifunctional enzyme subunit alpha, mitochondrial  
GN=HADHA PE=1 SV=2 
2.792 2.378 2.959 NaN NaN NaN 5.049 5.974 5.462 
ATP-dependent DNA helicase Q1  GN=RECQL PE=1 
SV=3;Uncharacterized protein  GN=RECQL PE=4 
SV=1;Uncharacterized protein  GN=RECQL PE=4 SV=1;>t 
2.684 2.797 2.910 NaN NaN NaN NaN NaN NaN 
Uncharacterized protein  GN=SLC25A10 PE=2 SV=1;39S 
ribosomal protein L12, mitochondrial  GN=MRPL12 PE=1 
SV=2;Uncharacterized protein  GN=SLC2 
2.344 2.491 1.955 NaN NaN NaN NaN NaN NaN 
26S proteasome non-ATPase regulatory subunit 2  
GN=PSMD2 PE=1 SV=3;Uncharacterized protein  
GN=PSMD2 PE=4 SV=1;Uncharacterized protein  GN=P 
2.022 2.366 2.344 NaN NaN NaN 0.361 0.384 0.130 
Major vault protein  GN=MVP PE=1 
SV=4;Uncharacterized protein  GN=MVP PE=4 SV=2 
1.936 1.906 5.665 NaN NaN NaN NaN NaN NaN 
Mitochondrial 2-oxoglutarate/malate carrier protein  
GN=SLC25A11 PE=1 SV=3;Uncharacterized protein  
GN=SLC25A11 PE=3 SV=1 
1.879 1.892 2.183 NaN NaN NaN 3.186 3.947 2.799 
Electron transfer flavoprotein subunit alpha, 
mitochondrial  GN=ETFA PE=1 SV=1;Uncharacterized 
protein  GN=ETFA PE=2 SV=1 
1.797 2.001 1.892 NaN NaN NaN NaN NaN NaN 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2  GN=GNB2 PE=1 SV=3;Uncharacterized 
protein  GN=GNB2 PE=4 SV=1;Uncharacterized protein 
OS=Ho 
1.775 8.595 11.242 NaN NaN NaN 0.279 0.490 NaN 
Uncharacterized protein  GN=TKT PE=4 
SV=1;Transketolase  GN=TKT PE=1 SV=3;Uncharacterized 
protein  GN=TKT PE=2 SV=1;Un 
1.674 4.648 0.929 NaN NaN NaN 1.444 1.292 1.305 
Importin subunit alpha-4  GN=KPNA4 PE=1 SV=1 1.627 1.787 1.351 NaN NaN NaN 1.384 0.443 NaN 
Isoform 2 of Cleavage and polyadenylation specificity 
factor subunit 6  GN=CPSF6;Cleavage and 
polyadenylation specificity factor subunit 6  GN=CPSF6 
PE=1 SV=2;>tr|C9JGC2|C9JGC2_H 
1.597 1.854 1.398 NaN NaN NaN 0.110 NaN NaN 
DNA-dependent protein kinase catalytic subunit  
GN=PRKDC PE=1 SV=3;Isoform 2 of DNA-dependent 
protein kinase catalytic subunit  
GN=PRKDC;Uncharacterized p 
1.532 1.677 1.906 NaN NaN NaN 3.114 NaN 3.631 
Delta-1-pyrroline-5-carboxylate synthase  GN=ALDH18A1 
PE=1 SV=2;Isoform Short of Delta-1-pyrroline-5-
1.464 1.547 1.604 NaN NaN NaN 0.709 0.988 0.802 
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carboxylate synthase  GN=ALDH18A1 
Calcium-binding mitochondrial carrier protein SCaMC-1  
GN=SLC25A24 PE=1 SV=2;Isoform 2 of Calcium-binding 
mitochondrial carrier protein SCaMC-1  GN=SLC25A24 
1.457 1.590 1.676 NaN NaN NaN 2.078 3.004 2.800 
Basic leucine zipper and W2 domain-containing protein 1  
GN=BZW1 PE=1 SV=1;Isoform 2 of Basic leucine zipper 
and W2 domain-containing protein 1  GN=BZW1;Unc 
1.446 NaN NaN NaN NaN NaN 0.160 0.222 NaN 
26S proteasome non-ATPase regulatory subunit 1  
GN=PSMD1 PE=1 SV=2;Isoform 2 of 26S proteasome 
non-ATPase regulatory subunit 1  GN=PSMD1 
1.435 0.990 NaN NaN NaN NaN 0.055 0.050 0.041 
Histone-binding protein RBBP4  GN=RBBP4 PE=1 
SV=3;Isoform 3 of Histone-binding protein RBBP4  
GN=RBBP4;Retinoblastoma binding protein 7  GN 
1.428 0.625 NaN NaN NaN NaN NaN NaN NaN 
Serine/arginine-rich splicing factor 7  GN=SRSF7 PE=1 
SV=1;Uncharacterized protein  GN=SRSF7 PE=4 
SV=1;Splicing factor, arginine/serine-rich 7, 35kDa, isof 
1.349 1.537 1.648 NaN NaN NaN NaN 1.371 NaN 
Catenin beta-1  GN=CTNNB1 PE=1 SV=1;Uncharacterized 
protein  GN=CTNNB1 PE=2 SV=1;Uncharacterized protein  
GN=CTNNB1 PE=4 SV=1;>sp|P35222-2|C 
1.335 7.248 NaN NaN NaN NaN NaN NaN NaN 
HCG1784554, isoform CRA_a  GN=EIF3F PE=2 
SV=1;Eukaryotic translation initiation factor 3 subunit F  
GN=EIF3F PE=1 SV=1;Uncharacterized protein OS=Homo 
sapi 
1.335 1.371 1.317 NaN NaN NaN 0.089 0.134 0.118 
Eukaryotic initiation factor 4A-III  GN=EIF4A3 PE=1 SV=4 1.287 1.217 1.430 NaN NaN NaN 0.789 1.124 NaN 
Acidic leucine-rich nuclear phosphoprotein 32 family 
member A  GN=ANP32A PE=1 SV=1;Uncharacterized 
protein  GN=ANP32A PE=4 SV=2 
1.284 NaN 1.253 NaN NaN NaN NaN NaN NaN 
Eukaryotic translation initiation factor 3 subunit M  
GN=EIF3M PE=1 SV=1;Uncharacterized protein  
GN=EIF3M PE=2 SV=1 
1.280 NaN NaN NaN NaN NaN NaN NaN NaN 
Uncharacterized protein  GN=MATR3 PE=4 SV=1;Matrin-
3  GN=MATR3 PE=1 SV=2;Uncharacterized protein  
GN=MATR3 PE=2 SV=1;>tr|B3KM87|B3KM87_HUMAN 
1.276 1.318 1.217 NaN NaN NaN NaN NaN NaN 
Apoptosis inhibitor 5  GN=API5 PE=1 
SV=3;Uncharacterized protein  GN=API5 PE=4 
SV=1;Isoform 2 of Apoptosis inhibitor 5  
GN=API5;>tr|B4DGR0|B4 
1.243 1.267 1.313 NaN NaN NaN 0.126 NaN NaN 
Isoform 2 of Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial  GN=HADH;Uncharacterized protein  
GN=HADH PE=4 SV=1;Hydroxyacyl-coenzyme A 
dehydrogenase, m 
1.230 2.074 1.418 NaN NaN NaN 3.278 4.037 3.169 
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Tropomodulin-3  GN=TMOD3 PE=1 SV=1 1.218 1.573 1.401 NaN NaN NaN NaN NaN NaN 
60S ribosomal protein L18  GN=RPL18 PE=1 
SV=2;Ribosomal protein L18  GN=RPL18 PE=3 
SV=1;Ribosomal protein L18  GN=RPL18 PE=3 
SV=1;>tr|E7EW92| 
1.208 NaN NaN NaN NaN NaN 0.139 0.033 0.044 
Tubulin alpha-1A chain  GN=TUBA1A PE=1 SV=1;Tubulin, 
alpha 3, isoform CRA_c  GN=TUBA1A PE=3 
SV=1;Uncharacterized protein  GN=TUBA1A PE=4 SV= 
1.201 1.235 1.237 NaN NaN NaN 0.004 0.091 0.114 
Actin-related protein 3  GN=ACTR3 PE=1 
SV=3;Uncharacterized protein  GN=ACTR3 PE=2 
SV=1;Uncharacterized protein  GN=ACTR3 PE=3 
SV=1;>tr|B4DTI 
1.161 1.476 1.390 NaN NaN NaN 1.573 2.069 2.135 
40S ribosomal protein S5  GN=RPS5 PE=1 SV=4 1.161 1.250 1.239 NaN NaN NaN 0.199 0.482 0.291 
Uncharacterized protein  GN=ATP1A1 PE=3 
SV=1;Sodium/potassium-transporting ATPase subunit 
alpha-1  GN=ATP1A1 PE=1 SV=1;ATPase, Na+/K+ 
transporting, alpha 1 
1.135 1.088 1.091 NaN NaN NaN 0.869 0.883 0.614 
Small nuclear ribonucleoprotein Sm D1  GN=SNRPD1 
PE=1 SV=1 
1.116 1.196 1.216 NaN NaN NaN 0.570 0.161 NaN 
60S ribosomal protein L23  GN=RPL23 PE=1 
SV=1;Uncharacterized protein  GN=RPL23 PE=3 
SV=1;Uncharacterized protein  GN=RPL23 PE=3 SV=1 
1.086 1.172 NaN NaN NaN NaN NaN NaN 0.279 
Ran GTPase-activating protein 1  GN=RANGAP1 PE=1 
SV=1;Uncharacterized protein  GN=RANGAP1 PE=4 SV=1 
1.059 11.003 NaN NaN NaN NaN NaN NaN NaN 
Coronin-1C_i2 protein  GN=CORO1C PE=2 SV=1;Coronin-
1C  GN=CORO1C PE=1 SV=1;Uncharacterized protein  
GN=CORO1C PE=2 SV=1 
1.053 1.113 1.009 NaN NaN NaN NaN NaN NaN 
40S ribosomal protein S3  GN=RPS3 PE=1 
SV=2;Uncharacterized protein  GN=RPS3 PE=3 
SV=1;Uncharacterized protein  GN=RPS3 PE=4 
SV=1;>tr|F2Z2S8|F 
1.020 1.036 0.990 NaN NaN NaN 0.171 0.178 0.063 
40S ribosomal protein S7  GN=RPS7 PE=1 
SV=1;Uncharacterized protein  GN=RPS7 PE=4 SV=1 
0.996 1.183 NaN NaN NaN NaN 0.072 0.098 0.222 
Exocyst complex component 1  GN=EXOC1 PE=1 
SV=4;Isoform 2 of Exocyst complex component 1  
GN=EXOC1 
0.973 NaN NaN NaN NaN NaN NaN NaN NaN 
Serine/threonine-protein phosphatase  GN=PPP1CA PE=3 
SV=2;Serine/threonine-protein phosphatase  
GN=PPP1CA PE=2 SV=1;Isoform Gamma-2 of 
Serine/threonine-pr 
0.973 1.024 1.019 NaN NaN NaN 0.682 0.864 0.767 
UMP-CMP kinase  GN=CMPK1 PE=1 
SV=3;Uncharacterized protein  GN=CMPK1 PE=3 
0.960 NaN NaN NaN NaN NaN NaN NaN NaN 
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SV=1;Uncharacterized protein  GN=CMPK1 PE=3 SV=1 
26S protease regulatory subunit 6B  GN=PSMC4 PE=1 
SV=2;Isoform 2 of 26S protease regulatory subunit 6B  
GN=PSMC4 
0.956 1.060 0.960 NaN NaN NaN 0.238 0.185 0.078 
Histone H3.3  GN=H3F3A PE=1 SV=2 0.955 0.757 0.917 NaN NaN NaN NaN NaN NaN 
Glutaredoxin-3  GN=GLRX3 PE=1 SV=2 0.911 0.876 0.958 NaN NaN NaN NaN NaN NaN 
Clathrin heavy chain 1  GN=CLTC PE=1 SV=5;Isoform 2 of 
Clathrin heavy chain 1  GN=CLTC 
0.909 1.157 1.323 NaN NaN NaN 0.419 0.419 0.419 
T-complex protein 1 subunit alpha  GN=TCP1 PE=1 
SV=1;T-complex protein 1 subunit alpha  GN=TCP1 PE=3 
SV=1;T-complex protein 1 subunit alpha   
0.898 0.841 0.858 NaN NaN NaN 0.086 0.065 0.082 
Isoform 2 of AP-2 complex subunit beta  GN=AP2B1;AP-2 
complex subunit beta  GN=AP2B1 PE=1 SV=1;Adaptor-
related protein complex 2, beta 1 subunit, isoform  
0.878 0.858 NaN NaN NaN NaN 0.225 0.766 0.564 
Histone H2A.Z  GN=H2AFZ PE=1 SV=2;Histone H2A.V  
GN=H2AFV PE=1 SV=3;Histone H2A  GN=H2AFV PE=3 
SV=1;Histone H2A OS=Homo 
0.750 0.739 0.342 NaN NaN NaN NaN NaN NaN 
T-complex protein 1 subunit eta  GN=CCT7 PE=1 
SV=2;Chaperonin containing TCP1, subunit 7 (Eta), 
isoform CRA_c  GN=CCT7 PE=2 SV=1;Uncharacterized 
protein OS= 
0.734 0.731 0.738 NaN NaN NaN 0.284 0.347 0.404 
Histone H3.1  GN=HIST1H3A PE=1 SV=2;Histone H3.1t  
GN=HIST3H3 PE=1 SV=3;Histone cluster 2, H3, 
pseudogene 2  GN=HIST2H3PS2 PE=3 SV=1;>sp|Q6NXT2| 
0.650 0.904 0.789 NaN NaN NaN NaN NaN NaN 
Nicotinate-nucleotide pyrophosphorylase [carboxylating]  
GN=QPRT PE=1 SV=3;Uncharacterized protein  GN=QPRT 
PE=4 SV=1 
0.610 0.516 0.512 NaN NaN NaN NaN NaN NaN 
Nicotinamide phosphoribosyltransferase  GN=NAMPT 
PE=1 SV=1;Uncharacterized protein  GN=NAMPTL PE=4 
SV=1 
0.606 0.608 NaN NaN NaN NaN NaN 4.716 4.290 
Endoplasmic reticulum resident protein 29  GN=ERP29 
PE=1 SV=4;Uncharacterized protein  GN=ERP29 PE=4 
SV=1 
0.603 0.788 0.650 NaN NaN NaN NaN NaN NaN 
Cytochrome b5 type B  GN=CYB5B PE=1 
SV=2;Uncharacterized protein  GN=CYB5B PE=3 SV=1 
0.517 0.583 0.531 NaN NaN NaN NaN NaN NaN 
ADP-ribosylation factor-like protein 1  GN=ARL1 PE=1 
SV=1;Uncharacterized protein  GN=ARL1 PE=2 
SV=1;Uncharacterized protein  GN=ARL1 PE=2 SV 
0.509 0.773 NaN NaN NaN NaN 0.166 0.053 0.109 
Actin, cytoplasmic 1  GN=ACTB PE=1 
SV=1;Uncharacterized protein  GN=ACTB PE=2 
SV=1;Uncharacteriz 
0.482 0.452 0.508 NaN NaN NaN 1.332 1.912 NaN 
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Exportin-1  GN=XPO1 PE=1 SV=1 0.442 1.052 0.946 NaN NaN NaN 0.169 0.202 0.129 
Histone H1.2  GN=HIST1H1C PE=1 SV=2;Histone H1.3  
GN=HIST1H1D PE=1 SV=2 
0.437 0.451 0.502 NaN NaN NaN 1.243 1.761 1.279 
Fatty acid synthase  GN=FASN PE=1 SV=3 0.431 0.290 0.436 NaN NaN NaN 0.123 1.211 0.676 
Prefoldin subunit 3  GN=VBP1 PE=1 
SV=3;Uncharacterized protein  GN=VBP1 PE=4 SV=1 
0.412 NaN NaN NaN NaN NaN NaN NaN NaN 
Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, 
mitochondrial  GN=OXCT1 PE=1 SV=1 
0.357 0.114 0.121 NaN NaN NaN NaN NaN NaN 
Phosphoribosyl pyrophosphate synthase-associated 
protein 2  GN=PRPSAP2 PE=1 SV=1;Uncharacterized 
protein  GN=PRPSAP2 PE=4 SV=1;Uncharacterized 
protein OS=Ho 
0.289 0.088 0.094 NaN NaN NaN NaN NaN NaN 
Isoform B of Bifunctional 3-phosphoadenosine 5-
phosphosulfate synthase 2  GN=PAPSS2;Uncharacterized 
protein  GN=PAPSS2 PE=3 SV=2;Bifunctional 3-phospho 
0.229 0.275 0.164 NaN NaN NaN 0.204 0.237 NaN 
Signal recognition particle 14 kDa protein  GN=SRP14 
PE=1 SV=2 
0.210 NaN 0.235 NaN NaN NaN NaN NaN NaN 
Aldose reductase  GN=AKR1B1 PE=1 
SV=3;Uncharacterized protein  GN=AKR1B1 PE=4 SV=1 
0.205 NaN 0.138 NaN NaN NaN NaN NaN NaN 
Copine-1  GN=CPNE1 PE=1 SV=1;Uncharacterized protein  
GN=CPNE1 PE=4 SV=1;Copine I  GN=CPNE1 PE=4 
SV=1;Uncharacterize 
0.199 0.101 0.359 NaN NaN NaN NaN NaN NaN 
Nuclear pore complex protein Nup93  GN=NUP93 PE=1 
SV=2 
0.191 0.427 1.061 NaN NaN NaN NaN NaN NaN 
Protein disulfide-isomerase TMX3  GN=TMX3 PE=1 
SV=2;Uncharacterized protein  GN=TMX3 PE=4 SV=1 
0.165 NaN NaN NaN NaN NaN NaN NaN NaN 
Importin-9  GN=IPO9 PE=1 SV=3 0.138 NaN 0.103 NaN NaN NaN 0.048 0.046 0.037 
Isoform 2 of Protein-L-isoaspartate(D-aspartate) O-
methyltransferase  GN=PCMT1;Protein-L-isoaspartate(D-
aspartate) O-methyltransferase  GN=PCMT1 PE=1 SV=4;P 
0.080 0.466 0.477 NaN NaN NaN NaN NaN NaN 
Aldehyde dehydrogenase family 1 member A3  
GN=ALDH1A3 PE=1 SV=2;Uncharacterized protein  
GN=ALDH1A3 PE=3 SV=2 
0.066 0.070 0.075 NaN NaN NaN 0.101 NaN NaN 
Uncharacterized protein  GN=MYH10 PE=4 SV=1;Isoform 
3 of Myosin-10  GN=MYH10;Uncharacterized protein  
GN=MYH10 PE=4 SV=1;>sp|P35580-2|MYH1 
0.034 0.048 0.033 NaN NaN NaN 0.035 0.109 0.121 
Pachytene checkpoint protein 2 homolog  GN=TRIP13 
PE=1 SV=2 
0.028 0.046 0.043 NaN NaN NaN 0.108 NaN NaN 
Uncharacterized protein  GN=WNK1 PE=4 SV=1;Isoform 5 
of Serine/threonine-protein kinase WNK1  
GN=WNK1;Isoform 4 of Serine/threonine-protein kinase 
0.001 0.001 0.068 NaN NaN NaN NaN NaN NaN 
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WNK1 OS 
Omega-amidase NIT2  GN=NIT2 PE=1 SV=1 NaN NaN NaN NaN NaN 20.868 NaN NaN NaN 
Heat shock protein 75 kDa, mitochondrial  GN=TRAP1 
PE=1 SV=3;Uncharacterized protein  GN=TRAP1 PE=3 
SV=1 
3.056 2.906 2.258 NaN NaN 2.295 0.193 0.520 0.114 
Protein S100-A13  GN=S100A13 PE=1 SV=1 NaN NaN NaN NaN NaN 2.074 NaN NaN NaN 
Ras GTPase-activating protein-binding protein 1  
GN=G3BP1 PE=1 SV=1;Uncharacterized protein  
GN=G3BP1 PE=4 SV=1;Uncharacterized protein  GN= 
NaN NaN NaN NaN NaN 1.825 NaN NaN NaN 
NAC-alpha domain-containing protein 1  GN=NACAD 
PE=2 SV=3 
NaN NaN NaN NaN NaN 1.722 NaN NaN NaN 
WD repeat-containing protein 65  GN=WDR65 PE=1 
SV=3;Isoform 2 of WD repeat-containing protein 65  
GN=WDR65;Uncharacterized protein  GN=WDR6 
NaN NaN NaN NaN NaN 1.554 NaN NaN NaN 
X-ray repair cross-complementing protein 5  GN=XRCC5 
PE=1 SV=3 
1.375 1.443 1.271 NaN NaN 1.480 3.672 4.287 NaN 
Thioredoxin-related transmembrane protein 1  
GN=TMX1 PE=1 SV=1;Uncharacterized protein  
GN=TMX1 PE=4 SV=1 
NaN NaN NaN NaN NaN 1.430 NaN NaN NaN 
Annexin A7  GN=ANXA7 PE=1 SV=3;Isoform 2 of Annexin 
A7  GN=ANXA7;Uncharacterized protein  GN=ANXA7 
PE=2 SV=1;Unchar 
NaN NaN NaN NaN NaN 1.211 NaN NaN NaN 
Endoplasmic reticulum resident protein 44  GN=ERP44 
PE=1 SV=1 
1.209 1.249 1.312 NaN NaN 1.165 NaN NaN NaN 
Astrocytic phosphoprotein PEA-15  GN=PEA15 PE=1 
SV=2;Phosphoprotein enriched in astrocytes 15  
GN=PEA15 PE=4 SV=1 
0.902 0.561 NaN NaN NaN 1.086 NaN NaN NaN 
SH3 domain-binding glutamic acid-rich-like protein 3  
GN=SH3BGRL3 PE=1 SV=1;SH3 domain binding glutamic 
acid-rich protein like 3  GN=SH3BGRL3 PE=2 SV=1 
NaN NaN NaN NaN NaN 1.052 NaN NaN NaN 
Transportin-1  GN=TNPO1 PE=1 SV=2;Isoform 2 of 
Transportin-1  GN=TNPO1;Isoform 3 of Transportin-1  
GN=TNPO1 
NaN 0.141 NaN NaN NaN 1.015 0.282 0.118 0.161 
40S ribosomal protein S12  GN=RPS12 PE=1 SV=3 2.371 2.873 0.995 NaN NaN 0.906 0.781 0.954 0.561 
Isoform 2 of Golgi apparatus protein 1  
GN=GLG1;Uncharacterized protein  GN=GLG1 PE=2 
SV=1;Golgi apparatus protein 1  GN=GLG1 PE=1 SV=2 
NaN NaN NaN NaN NaN 0.851 NaN NaN NaN 
Proteasome subunit beta type-3  GN=PSMB3 PE=1 SV=2 NaN NaN NaN NaN NaN 0.838 NaN NaN NaN 
Beta-actin-like protein 2  GN=ACTBL2 PE=1 SV=2 0.897 0.934 0.921 NaN NaN 0.758 0.299 3.426 0.388 
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Interleukin enhancer-binding factor 2  GN=ILF2 PE=1 
SV=2 
NaN NaN NaN NaN NaN 0.711 1.573 NaN NaN 
Eukaryotic initiation factor 4A-I  GN=EIF4A1 PE=1 SV=1 1.104 1.330 1.126 NaN NaN 0.600 0.688 0.741 NaN 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1  
GN=DDAH1 PE=1 SV=3;Uncharacterized protein  
GN=DDAH1 PE=2 SV=1;Uncharacterized protein  
NaN NaN NaN NaN NaN 0.488 NaN NaN NaN 
Isoform MBP-1 of Alpha-enolase  GN=ENO1 NaN NaN NaN NaN NaN 0.485 NaN NaN NaN 
>Q8VED5 TREMBL:Q8VED5 Tax_Id=10090 
Gene_Symbol=Krt79 Keratin 79 
0.503 NaN 0.115 NaN NaN 0.438 NaN NaN NaN 
T-complex protein 1 subunit gamma  GN=CCT3 PE=1 
SV=4;Uncharacterized protein  GN=CCT3 PE=2 
SV=1;Uncharacterized protein  GN=CCT3 PE=3 SV=1;>s 
0.484 0.806 0.963 NaN NaN 0.388 0.158 0.131 0.257 
Lon protease homolog, mitochondrial  GN=LONP1 PE=1 
SV=2;Lon protease homolog  GN=LONP1 PE=2 SV=1;Lon 
protease homolog  GN=LONP1 PE=3 SV=1 
0.282 NaN NaN NaN NaN 0.354 0.052 0.074 NaN 
Exportin-2  GN=CSE1L PE=1 SV=3;Isoform 3 of Exportin-2  
GN=CSE1L;Uncharacterized protein  GN=CSE1L PE=4 
SV=1;Uncharac 
0.697 0.672 0.623 NaN NaN 0.353 0.340 0.234 0.192 
T-complex protein 1 subunit epsilon  GN=CCT5 PE=1 
SV=1;Uncharacterized protein  GN=CCT5 PE=3 
SV=1;Uncharacterized protein  GN=CCT5 PE=2 SV=1; 
0.855 1.634 0.773 NaN NaN 0.141 0.364 0.435 0.154 
Activated RNA polymerase II transcriptional coactivator 
p15  GN=SUB1 PE=1 SV=3 
0.168 0.203 0.192 NaN NaN 0.112 NaN NaN NaN 
PRA1 family protein 2  GN=PRAF2 PE=1 
SV=1;Uncharacterized protein  GN=PRAF2 PE=4 SV=1 
NaN NaN NaN NaN NaN 0.068 NaN NaN NaN 
60S acidic ribosomal protein P1  GN=RPLP1 PE=1 SV=1 1.018 1.198 1.251 NaN NaN 0.048 NaN NaN NaN 
Uncharacterized protein  GN=APOD PE=4 
SV=1;Apolipoprotein D  GN=APOD PE=1 SV=1 
NaN NaN NaN NaN NaN 0.043 NaN NaN NaN 
Glutaminyl-tRNA synthetase  GN=QARS PE=1 
SV=1;Uncharacterized protein  GN=QARS PE=2 
SV=1;Uncharacterized protein  GN=QARS PE=2 
SV=1;>tr|C9J165 
NaN NaN NaN NaN NaN 0.040 0.142 NaN NaN 
Isoform 2 of HLA class I histocompatibility antigen, A-11 
alpha chain  GN=HLA-A;HLA class I histocompatibility 
antigen, A-11 alpha chain  GN=HLA-A PE=1 SV=1 
NaN NaN NaN NaN NaN 0.022 NaN NaN NaN 
Major histocompatibility complex, class I, A  GN=HLA-A 
PE=3 SV=2;HLA class I histocompatibility antigen, A-1 
alpha chain  GN=HLA-A PE=1 SV=1;HLA class I histo 
NaN NaN NaN NaN NaN 0.005 NaN NaN NaN 
Asparagine synthetase [glutamine-hydrolyzing]  
GN=ASNS PE=1 SV=4;Uncharacterized protein  GN=ASNS 
PE=4 SV=1;Uncharacterized protein  GN=ASNS  
NaN 0.024 NaN NaN NaN 0.000 0.021 0.011 0.008 
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14-3-3 protein sigma  GN=SFN PE=1 SV=1;Isoform 2 of 
14-3-3 protein sigma  GN=SFN 
NaN 15.918 16.984 NaN 45.541 NaN NaN NaN NaN 
Keratin, type II cytoskeletal 7  GN=KRT7 PE=1 
SV=5;>tr|E7ES34|E7 
37.304 NaN 60.926 NaN 33.685 38.857 NaN NaN NaN 
Isoform 2 of Inorganic pyrophosphatase 2, mitochondrial  
GN=PPA2;Inorganic pyrophosphatase 2, mitochondrial  
GN=PPA2 PE=1 SV=2;Uncharacterized protein OS= 
NaN NaN NaN NaN 20.742 5.196 NaN NaN NaN 
2,4-dienoyl-CoA reductase, mitochondrial  GN=DECR1 
PE=1 SV=1;Uncharacterized protein  GN=DECR1 PE=2 
SV=1;Uncharacterized protein  GN=DECR1 PE 
8.787 NaN 8.137 NaN 17.826 12.880 NaN NaN NaN 
DNA-binding protein A  GN=CSDA PE=1 SV=4;Isoform 3 of 
DNA-binding protein A  GN=CSDA;Isoform 2 of DNA-
binding protein A  GN=CSDA 
NaN NaN NaN NaN 15.031 NaN NaN NaN NaN 
Uncharacterized protein  GN=SCRN1 PE=4 
SV=2;Secernin-1  GN=SCRN1 PE=1 SV=2;Secernin 1, 
isoform CRA_a  GN=SCRN1 PE=2 
SV=1;>tr|B4DH22|B4DH22_H 
NaN NaN NaN NaN 14.139 2.803 NaN NaN NaN 
ATP synthase subunit d, mitochondrial  GN=ATP5H PE=1 
SV=3;Isoform 2 of ATP synthase subunit d, mitochondrial  
GN=ATP5H;Uncharacterized protein OS=Homo sap 
1.548 1.140 1.289 NaN 9.742 NaN NaN NaN NaN 
Torsin-1A-interacting protein 1  GN=TOR1AIP1 PE=1 
SV=2;Uncharacterized protein  GN=TOR1AIP1 PE=4 SV=1 
NaN 0.756 NaN NaN 5.318 NaN NaN NaN NaN 
Uncharacterized protein  GN=NUDT5 PE=3 SV=1;ADP-
sugar pyrophosphatase  GN=NUDT5 PE=1 
SV=1;Uncharacterized protein  GN=NUDT5 PE=3 
SV=2;>tr|A6 
NaN NaN NaN NaN 4.841 1.570 NaN NaN NaN 
Protein S100-A11  GN=S100A11 PE=1 SV=2 2.179 2.771 2.257 NaN 3.613 3.563 NaN NaN NaN 
Aspartate aminotransferase, mitochondrial  GN=GOT2 
PE=1 SV=3;Aspartate aminotransferase  GN=GOT2 PE=3 
SV=1 
NaN NaN NaN NaN 3.551 4.008 NaN NaN NaN 
Heat shock 105kDa/110kDa protein 1, isoform CRA_b  
GN=HSPH1 PE=2 SV=1;Heat shock protein 105 kDa  
GN=HSPH1 PE=1 SV=1;Isoform 3 of Heat shock protein 
105 k 
NaN NaN NaN NaN 2.824 2.634 0.824 NaN 0.745 
LETM1 and EF-hand domain-containing protein 1, 
mitochondrial  GN=LETM1 PE=1 SV=1 
NaN NaN NaN NaN 2.792 NaN NaN NaN NaN 
Mitochondrial inner membrane protein  GN=IMMT PE=1 
SV=1;Uncharacterized protein  GN=IMMT PE=4 
SV=1;Isoform 2 of Mitochondrial inner membrane 
protein OS=Homo 
NaN 2.323 1.919 NaN 2.185 1.869 3.866 NaN NaN 
Proteasome subunit beta type-2  GN=PSMB2 PE=1 SV=1 NaN NaN NaN NaN 1.983 0.819 NaN NaN NaN 
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Enoyl-CoA hydratase, mitochondrial  GN=ECHS1 PE=1 
SV=4 
1.480 1.491 1.629 NaN 1.859 NaN NaN NaN NaN 
Heterogeneous nuclear ribonucleoprotein G-like 1  
GN=RBMXL1 PE=1 SV=1 
NaN NaN NaN NaN 1.590 1.446 NaN NaN NaN 
Kinectin  GN=KTN1 PE=1 SV=1;Isoform 2 of Kinectin  
GN=KTN1;Kinectin 1 (Kinesin receptor)  GN=KTN1 PE=2 
SV=1;Uncharact 
0.223 NaN 0.342 NaN 1.333 0.528 NaN NaN NaN 
Stomatin-like protein 2  GN=STOML2 PE=1 
SV=1;Uncharacterized protein  GN=STOML2 PE=2 SV=1 
1.468 1.121 1.185 NaN 1.304 1.494 NaN NaN NaN 
Proteasomal ubiquitin receptor ADRM1  GN=ADRM1 
PE=1 SV=2;Uncharacterized protein  GN=ADRM1 PE=4 
SV=2 
1.316 1.300 1.525 NaN 1.294 NaN 1.917 2.574 NaN 
Uncharacterized protein  GN=SUMO3 PE=4 
SV=1;Uncharacterized protein  GN=SUMO3 PE=2 
SV=1;SMT3 suppressor of mif two 3 homolog 3 (Yeast), 
isoform CRA_d OS=H 
NaN NaN NaN NaN 1.212 0.267 NaN NaN NaN 
Putative nucleoside diphosphate kinase  GN=NME2P1 
PE=5 SV=1 
NaN NaN NaN NaN 1.190 NaN NaN NaN NaN 
L-lactate dehydrogenase B chain  GN=LDHB PE=1 SV=2;L-
lactate dehydrogenase  GN=LDHB PE=3 
SV=1;Uncharacterized protein  GN=LDHB PE=3 SV=1 
1.053 1.023 1.076 NaN 1.185 1.148 2.751 3.386 2.358 
Small nuclear ribonucleoprotein Sm D2  GN=SNRPD2 
PE=1 SV=1 
NaN NaN NaN NaN 1.179 1.419 NaN NaN NaN 
Mitochondrial fission 1 protein  GN=FIS1 PE=1 SV=2 0.891 0.963 1.003 NaN 1.056 NaN NaN NaN NaN 
Catenin alpha-1  GN=CTNNA1 PE=1 
SV=1;Uncharacterized protein  GN=CTNNA1 PE=2 
SV=1;Uncharacterized protein  GN=CTNNA1 PE=4 
SV=1;>tr|F5GXI1|F5 
0.698 0.669 0.853 NaN 0.904 0.927 1.358 1.251 0.224 
Radixin isoform b  GN=RDX PE=2 SV=1;Radixin  GN=RDX 
PE=1 SV=1;Uncharacterized protein  GN=RDX PE=4 SV=1 
NaN NaN NaN NaN 0.884 0.806 NaN NaN NaN 
Protein DEK  GN=DEK PE=1 SV=1;Uncharacterized 
protein  GN=DEK PE=2 SV=1;Uncharacterized protein  
GN=DEK PE=2 SV=1;Unch 
NaN NaN NaN NaN 0.863 1.086 NaN NaN NaN 
60S acidic ribosomal protein P0  GN=RPLP0 PE=1 
SV=1;60S acidic ribosomal protein P0-like  GN=RPLP0P6 
PE=5 SV=1;Uncharacterized protein  GN=RPL 
5.357 NaN NaN NaN 0.842 0.526 0.347 0.201 0.263 
Heterogeneous nuclear ribonucleoprotein F  
GN=HNRNPF PE=1 SV=3;Uncharacterized protein  
GN=HNRNPF PE=2 SV=1 
0.897 5.335 5.937 NaN 0.744 NaN 0.353 0.201 0.411 
Galectin-1  GN=LGALS1 PE=1 SV=2 0.631 0.809 0.804 NaN 0.734 0.692 1.587 2.063 1.501 
Ribonuclease inhibitor  GN=RNH1 PE=1 SV=2 0.568 0.612 0.124 NaN 0.587 NaN 1.250 1.107 0.195 
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Keratin, type II cuticular Hb4  GN=KRT8 0.745 NaN 0.847 NaN 0.587 NaN NaN 1.785 NaN 
Nucleosome assembly protein 1-like 1  GN=NAP1L1 PE=1 
SV=1;Uncharacterized protein  GN=NAP1L1 PE=3 
SV=1;Uncharacterized protein  GN=NAP1L1 PE 
0.612 0.649 0.693 NaN 0.579 NaN 0.185 0.201 0.083 
Transferrin receptor protein 1  GN=TFRC PE=1 
SV=2;Uncharacterized protein  GN=TFRC PE=4 SV=1 
NaN NaN NaN NaN 0.570 2.358 NaN NaN NaN 
T-complex protein 1 subunit zeta  GN=CCT6A PE=1 
SV=3;Uncharacterized protein  GN=CCT6A PE=2 
SV=1;Uncharacterized protein  GN=CCT6A PE=3 SV=1 
NaN NaN NaN NaN 0.565 0.343 0.070 0.100 NaN 
DNA replication licensing factor MCM6  GN=MCM6 PE=1 
SV=1 
NaN NaN NaN NaN 0.538 NaN NaN NaN NaN 
Proteasome subunit alpha type-3  GN=PSMA3 PE=1 
SV=2;Isoform 2 of Proteasome subunit alpha type-3  
GN=PSMA3;Uncharacterized protein  GN=PSMA3  
NaN NaN NaN NaN 0.534 0.488 NaN NaN NaN 
Uncharacterized protein  GN=CD81 PE=4 
SV=1;Uncharacterized protein  GN=CD81 PE=4 
SV=1;CD81 antigen  GN=CD81 PE=1 
SV=1;>tr|E9PRJ8|E9PRJ8_HUMAN 
NaN NaN NaN NaN 0.465 NaN NaN NaN NaN 
Isoform 8 of Titin  GN=TTN;Titin  GN=TTN PE=1 
SV=3;Isoform 2 of Titin  GN=TTN;Isoform 7 of Titin   
NaN 54.609 NaN NaN 0.414 0.350 NaN NaN 0.254 
Stathmin  GN=STMN2 PE=3 SV=1;Stathmin-2  GN=STMN2 
PE=1 SV=3;Stathmin  GN=STMN2 PE=2 SV=1;Stathmin  
GN 
NaN NaN NaN NaN 0.331 0.463 NaN NaN NaN 
ATP synthase subunit alpha, mitochondrial  GN=ATP5A1 
PE=1 SV=1;ATP synthase subunit alpha  GN=ATP5A1 
PE=2 SV=1 
1.702 1.860 1.760 NaN 0.307 NaN 0.479 0.503 0.210 
Proteasome subunit beta type-9  GN=PSMB9 PE=1 
SV=2;Isoform LMP2.S of Proteasome subunit beta type-9  
GN=PSMB9;Proteasome subunit beta type  G 
NaN NaN NaN NaN 0.169 0.042 NaN NaN NaN 
Poly(rC)-binding protein 1  GN=PCBP1 PE=1 SV=2 0.190 NaN NaN NaN 0.150 NaN 1.067 1.061 0.918 
Uncharacterized protein  GN=RPL28 PE=4 
SV=1;Uncharacterized protein  GN=RPL28 PE=2 SV=1;60S 
ribosomal protein L28  GN=RPL28 PE=1 SV=3;>tr|G5E 
NaN NaN NaN NaN 0.137 NaN NaN 0.070 0.057 
Kinesin-1 heavy chain  GN=KIF5B PE=1 SV=1 NaN 0.813 NaN NaN 0.118 NaN 0.066 NaN NaN 
6-phosphogluconate dehydrogenase, decarboxylating  
GN=PGD PE=1 SV=3;6-phosphogluconate 
dehydrogenase, decarboxylating  GN=PGD PE=2 SV=1;6-
phosphogluconate d 
NaN NaN NaN NaN 0.055 NaN 0.034 0.105 0.015 
Prolyl 4-hydroxylase subunit alpha-1  GN=P4HA1 PE=1 
SV=2;Isoform 2 of Prolyl 4-hydroxylase subunit alpha-1  
GN=P4HA1;Uncharacterized protein OS=Homo sapie 
NaN NaN NaN NaN 0.045 0.241 NaN NaN NaN 
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40S ribosomal protein S9  GN=RPS9 PE=1 
SV=3;Ribosomal protein S9, isoform CRA_e  GN=RPS9 
PE=3 SV=1;Ribosomal protein S9, isoform CRA_c  
GN=RPS 
NaN NaN NaN NaN 0.043 NaN 0.033 0.095 0.042 
Cullin-associated NEDD8-dissociated protein 1  
GN=CAND1 PE=1 SV=2;Isoform 2 of Cullin-associated 
NEDD8-dissociated protein 1  GN=CAND1 
NaN 0.739 NaN NaN 0.039 NaN 0.134 0.061 0.055 
D-3-phosphoglycerate dehydrogenase  GN=PHGDH PE=1 
SV=4;Phosphoglycerate dehydrogenase  GN=PHGDH 
PE=2 SV=1;Uncharacterized protein  GN=PHGDH P 
0.084 0.040 0.048 NaN 0.038 0.050 0.027 0.088 0.009 
Keratin, type I cytoskeletal 13  GN=KRT13 PE=1 
SV=4;Isoform 3 of Keratin, type I cytoskeletal 13  
GN=KRT13;> 
NaN NaN NaN NaN 0.031 NaN NaN NaN NaN 
Uncharacterized protein  GN=KIAA0586 PE=4 
SV=1;Uncharacterized protein KIAA0586  GN=KIAA0586 
PE=1 SV=4;Isoform 2 of Uncharacterized protein 
KIAA0586 OS=Ho 
NaN NaN NaN NaN 0.030 0.035 1.001 0.809 0.968 
Uncharacterized protein  GN=BST2 PE=4 SV=1;Bone 
marrow stromal antigen 2  GN=BST2 PE=1 SV=1 
NaN NaN NaN NaN 0.015 0.013 NaN NaN NaN 
Hornerin  GN=HRNR PE=1 SV=2 NaN NaN NaN NaN 0.012 0.043 0.022 0.026 NaN 
High mobility group protein HMG-I/HMG-Y  GN=HMGA1 
PE=1 SV=3;Isoform HMG-R of High mobility group 
protein HMG-I/HMG-Y  GN=HMGA1;Isoform HMG-Y of 
High mobi 
8.586 47.652 NaN 48.629 51.866 77.430 89.924 103.920 59.819 
Aminopeptidase N  GN=ANPEP PE=1 
SV=4;Uncharacterized protein  GN=ANPEP PE=2 SV=1 
22.827 28.080 32.453 36.593 22.769 35.652 NaN NaN NaN 
Protein-glutamine gamma-glutamyltransferase 2  
GN=TGM2 PE=1 SV=2;Uncharacterized protein  
GN=TGM2 PE=2 SV=1;Uncharacterized protein  
GN=TGM2  
53.410 15.492 42.327 26.264 31.110 40.665 41.743 84.405 75.453 
Signal recognition particle receptor subunit beta  
GN=SRPRB PE=1 SV=3 
0.818 9.606 1.957 13.276 2.490 NaN NaN NaN NaN 
Macrophage-capping protein  GN=CAPG PE=1 
SV=2;Uncharacterized protein  GN=CAPG PE=2 
SV=1;Uncharacterized protein  GN=CAPG PE=4 
SV=1;>tr|E7ENU 
27.962 44.087 29.468 12.639 15.890 16.062 NaN NaN NaN 
10 kDa heat shock protein, mitochondrial  GN=HSPE1 
PE=1 SV=2;Heat shock 10kDa protein 1 (Chaperonin 10), 
isoform CRA_b  GN=HSPE1 PE=3 SV=1;Heat shock 10kDa  
NaN 5.587 15.935 9.185 5.704 4.657 NaN NaN NaN 
Plectin  GN=PLEC PE=1 SV=3;Isoform 2 of Plectin  
GN=PLEC;Isoform 3 of Plectin  GN=PLEC;Isoform 6 of 
Plectin OS=Homo s 
6.706 14.219 16.137 6.044 8.207 5.928 0.034 51.083 8.817 
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DNA-(apurinic or apyrimidinic site) lyase  GN=APEX1 
PE=1 SV=2;Uncharacterized protein  GN=APEX1 PE=4 
SV=1;Uncharacterized protein  GN=APEX1  
1.443 NaN NaN 5.928 2.282 1.885 NaN NaN NaN 
Isoform 2 of Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2  GN=PLOD2;Procollagen-lysine,2-
oxoglutarate 5-dioxygenase 2  GN=PLOD2 PE=1 
SV=2;Uncharacter 
9.339 5.498 15.557 5.262 5.245 13.047 15.015 32.053 NaN 
Abhydrolase domain-containing protein 10, 
mitochondrial  GN=ABHD10 PE=1 SV=1;Uncharacterized 
protein  GN=ABHD10 PE=2 SV=1 
4.068 3.837 6.566 4.866 10.631 3.938 NaN NaN NaN 
Leucine-rich PPR motif-containing protein, mitochondrial  
GN=LRPPRC PE=1 SV=3;Uncharacterized protein  
GN=LRPPRC PE=4 SV=1 
2.133 1.757 10.387 4.415 2.816 2.978 4.812 24.730 NaN 
40S ribosomal protein S14  GN=RPS14 PE=1 
SV=3;Uncharacterized protein  GN=RPS14 PE=4 SV=1 
NaN NaN NaN 4.409 NaN NaN NaN 0.220 0.038 
Glutamate dehydrogenase 1, mitochondrial  GN=GLUD1 
PE=1 SV=2;Glutamate dehydrogenase  GN=GLUD1 PE=3 
SV=1;Glutamate dehydrogenase  GN=GLUD1 PE 
NaN 3.128 2.800 3.832 3.711 3.471 NaN NaN NaN 
Syntenin-1  GN=SDCBP PE=1 SV=1;Isoform 3 of Syntenin-
1  GN=SDCBP 
NaN NaN NaN 3.707 NaN NaN NaN NaN NaN 
60 kDa heat shock protein, mitochondrial  GN=HSPD1 
PE=1 SV=2 
4.069 4.228 4.203 3.498 3.843 3.826 7.298 8.541 7.089 
Cytochrome c  GN=CYCS PE=1 SV=2;Uncharacterized 
protein  GN=CYCS PE=3 SV=1 
2.146 2.637 2.494 3.443 3.646 3.440 NaN NaN NaN 
Glutathione S-transferase omega-1  GN=GSTO1 PE=1 
SV=2;Glutathione S-transferase omega 1, isoform CRA_a  
GN=GSTO1 PE=3 SV=1;Glutathione S-transferase omega  
6.095 NaN NaN 3.422 3.338 3.667 NaN NaN NaN 
Stress-70 protein, mitochondrial  GN=HSPA9 PE=1 
SV=2;Uncharacterized protein  GN=HSPA9 PE=2 
SV=1;Uncharacterized protein  GN=HSPA9 PE=3 SV=1 
7.096 3.212 3.019 2.941 3.259 2.879 6.455 6.462 5.395 
Caveolin-1  GN=CAV1 PE=1 SV=4;Caveolin  GN=CAV1 
PE=2 SV=1;Caveolin  GN=CAV1 PE=3 SV=1 
1.738 NaN NaN 2.681 2.118 2.162 NaN NaN NaN 
KH domain-containing, RNA-binding, signal transduction-
associated protein 1  GN=KHDRBS1 PE=1 
SV=1;Uncharacterized protein  GN=KHDRBS1 PE=4 
SV=2;Isoform 2  
7.599 1.124 1.335 2.604 2.034 2.330 NaN NaN NaN 
Superoxide dismutase [Mn], mitochondrial  GN=SOD2 
PE=1 SV=2;Superoxide dismutase  GN=SOD2 PE=2 
SV=1;Superoxide dismutase  GN=SOD2 PE=2 SV=1;> 
2.882 6.563 3.309 2.601 2.589 2.590 NaN NaN NaN 
Moesin  GN=MSN PE=1 SV=3 1.624 1.764 1.859 2.578 2.691 2.684 NaN NaN NaN 
Elongation factor Tu, mitochondrial  GN=TUFM PE=1 
SV=2 
2.156 2.391 2.430 2.541 2.308 2.263 3.578 2.502 1.510 
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Heterogeneous nuclear ribonucleoprotein A3  
GN=HNRNPA3 PE=1 SV=2;Isoform 2 of Heterogeneous 
nuclear ribonucleoprotein A3  
GN=HNRNPA3;Uncharacterized protein 
2.619 2.582 2.779 2.521 2.609 2.873 NaN NaN NaN 
Vimentin  GN=VIM PE=1 SV=4;Uncharacterized protein  
GN=VIM PE=3 SV=1;Uncharacterized protein  GN=VIM 
PE=3 SV=1;Unchar 
4.718 14.704 16.090 2.443 2.306 2.345 16.073 15.057 13.387 
Translationally-controlled tumor protein  GN=TPT1 PE=1 
SV=1;Uncharacterized protein  GN=TPT1 PE=4 SV=1;TPT1 
protein  GN=TPT1 PE=2 SV=1;>sp|Q5 
1.369 NaN NaN 2.395 2.130 2.002 NaN NaN NaN 
Filamin B  GN=FLNB PE=2 SV=1;Filamin-B  GN=FLNB PE=1 
SV=2;Filamin B  GN=FLNB PE=2 SV=1;Isoform 2 of 
Filamin-B OS=Homo 
NaN NaN 6.139 2.341 1.560 NaN 1.943 NaN NaN 
Isoform 2 of Annexin A2  GN=ANXA2;Annexin A2  
GN=ANXA2 PE=1 SV=2;Putative annexin A2-like protein  
GN=ANXA2P2 PE=5 SV=2;>tr|B3KRQ1|B3KRQ1_HU 
2.322 2.422 2.498 2.319 2.313 2.312 4.072 3.882 3.153 
Nucleophosmin  GN=NPM1 PE=1 SV=2;Isoform 2 of 
Nucleophosmin  GN=NPM1;Nucleophosmin (Nucleolar 
phosphoprotein B23, numatrin)  GN=NPM1 PE=2 SV=1 
2.261 2.388 2.432 2.241 2.582 2.482 2.175 2.103 2.437 
Isoform 1 of Voltage-dependent anion-selective channel 
protein 2  GN=VDAC2;Voltage-dependent anion-selective 
channel protein 2  GN=VDAC2 PE=1 SV=2;Isofor 
1.990 2.128 2.238 2.226 2.307 2.626 NaN NaN NaN 
Early endosome antigen 1  GN=EEA1 PE=1 SV=2 NaN NaN NaN 2.199 2.191 NaN NaN NaN NaN 
Nucleolin  GN=NCL PE=1 SV=3;Uncharacterized protein  
GN=NCL PE=4 SV=1;NCL protein  GN=NCL PE=2 SV=1 
3.241 2.798 2.975 2.094 2.622 2.035 8.398 6.157 4.538 
Adenylate kinase 2, mitochondrial  GN=AK2 PE=1 
SV=2;Uncharacterized protein  GN=AK2 PE=3 
SV=1;Isoform 2 of Adenylate kinase 2, mitochondrial  
2.011 1.617 1.743 2.041 2.070 2.805 NaN NaN NaN 
Cytochrome b-c1 complex subunit 2, mitochondrial  
GN=UQCRC2 PE=1 SV=3 
NaN NaN NaN 2.004 NaN NaN NaN NaN NaN 
Tumor protein D52-like 2  GN=TPD52L2 PE=2 
SV=1;Tumor protein D52-like 2  GN=TPD52L2 PE=2 
SV=1;Isoform 3 of Tumor protein D54  GN=TPD52L2;> 
2.218 1.903 1.678 1.918 1.430 1.869 NaN NaN NaN 
Annexin A1  GN=ANXA1 PE=1 SV=2;Annexin A1 
(Fragment)  GN=ANXA1 PE=2 SV=1 
1.838 1.867 1.884 1.917 2.002 2.078 NaN NaN NaN 
Prohibitin  GN=PHB PE=1 SV=1;Uncharacterized protein  
GN=PHB PE=4 SV=2;Uncharacterized protein  GN=PHB 
PE=4 SV=1;Uncha 
2.741 2.793 2.584 1.876 1.993 1.563 3.455 3.577 4.183 
Isoform 2 of Heat shock protein HSP 90-alpha  
GN=HSP90AA1;Heat shock protein HSP 90-alpha  
GN=HSP90AA1 PE=1 SV=5;Full-length cDNA clone 
CS0CAP007YF18 of T 
1.871 2.121 2.178 1.845 1.805 1.803 0.571 0.619 0.094 
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Isoform 2 of Heterogeneous nuclear ribonucleoprotein K  
GN=HNRNPK;Heterogeneous nuclear ribonucleoprotein 
K  GN=HNRNPK PE=1 SV=1;Uncharacterized protein O 
1.378 1.323 1.295 1.843 1.799 1.974 NaN NaN NaN 
Chloride intracellular channel protein 4  GN=CLIC4 PE=1 
SV=4;Uncharacterized protein  GN=CLIC4 PE=4 SV=1 
2.068 1.863 1.704 1.839 1.804 1.975 2.128 1.853 2.003 
Thioredoxin-dependent peroxide reductase, 
mitochondrial  GN=PRDX3 PE=1 SV=3;Uncharacterized 
protein  GN=PRDX3 PE=4 SV=1 
1.637 2.200 1.786 1.791 1.724 1.813 NaN NaN NaN 
B-cell receptor-associated protein 31  GN=BCAP31 PE=1 
SV=3;Uncharacterized protein  GN=BCAP31 PE=4 
SV=1;Uncharacterized protein  GN=BCAP31 P 
0.492 0.673 0.564 1.790 1.038 1.495 NaN NaN NaN 
Ras-related protein Rab-2A  GN=RAB2A PE=1 
SV=1;Uncharacterized protein  GN=RAB2A PE=2 
SV=1;Uncharacterized protein  GN=RAB2A PE=3 SV=1 
NaN NaN 9.976 1.778 1.660 1.539 NaN NaN NaN 
Heterogeneous nuclear ribonucleoproteins A2/B1  
GN=HNRNPA2B1 PE=1 SV=2;Isoform A2 of 
Heterogeneous nuclear ribonucleoproteins A2/B1  
GN=HNRNPA2B1 
1.731 1.534 1.868 1.765 1.795 1.842 NaN NaN NaN 
Heterogeneous nuclear ribonucleoprotein L  
GN=HNRNPL PE=1 SV=2;Uncharacterized protein  
GN=HNRNPL PE=2 SV=1 
NaN 1.637 1.435 1.723 2.020 1.894 NaN NaN NaN 
Heterogeneous nuclear ribonucleoproteins C1/C2  
GN=HNRNPC PE=1 SV=4;Uncharacterized protein  
GN=HNRNPC PE=4 SV=1;Uncharacterized protein  GN 
NaN NaN NaN 1.722 NaN NaN NaN NaN NaN 
Aspartyl/asparaginyl beta-hydroxylase  GN=ASPH PE=1 
SV=3;Uncharacterized protein  GN=ASPH PE=4 
SV=1;Uncharacterized protein  GN=ASPH PE=4 SV= 
2.580 5.910 2.709 1.697 1.904 1.538 NaN NaN NaN 
Stress-induced-phosphoprotein 1  GN=STIP1 PE=1 
SV=1;Stress-induced-phosphoprotein 1 (Hsp70/Hsp90-
organizing protein), isoform CRA_b  GN=STIP1 PE=4 
SV=1;Unc 
1.225 NaN NaN 1.691 1.453 1.665 NaN NaN NaN 
Alpha-actinin-4  GN=ACTN4 PE=1 SV=2;Alpha actinin 4 
short isoform  GN=ACTN4 PE=2 SV=1;Uncharacterized 
protein  GN=ACTN4 PE=4 SV=1 
1.415 1.654 1.521 1.683 1.722 1.742 0.810 NaN NaN 
Multifunctional protein ADE2  GN=PAICS PE=1 
SV=3;Uncharacterized protein  GN=PAICS PE=4 
SV=1;Isoform 2 of Multifunctional protein ADE2  GN=PA 
NaN NaN NaN 1.661 NaN 1.451 NaN NaN NaN 
Complement component 1 Q subcomponent-binding 
protein, mitochondrial  GN=C1QBP PE=1 SV=1 
1.919 2.427 1.869 1.659 2.624 2.023 NaN NaN NaN 
Splicing factor, proline- and glutamine-rich  GN=SFPQ 
PE=1 SV=2;Isoform Short of Splicing factor, proline- and 
glutamine-rich  GN=SFPQ 
1.364 1.607 1.674 1.636 1.687 1.550 NaN NaN NaN 
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Protein S100-A6  GN=S100A6 PE=1 SV=1 1.709 1.853 1.781 1.631 1.695 1.775 2.580 2.876 2.463 
Cathepsin D  GN=CTSD PE=1 SV=1 1.198 1.231 1.104 1.628 3.935 1.651 NaN NaN NaN 
Isoform C of Prelamin-A/C  GN=LMNA;Prelamin-A/C  
GN=LMNA PE=1 SV=1;Lamin A/C  GN=LMNA PE=2 
SV=1;Isoform ADelta10 of P 
1.530 1.575 1.718 1.627 1.618 1.650 NaN NaN NaN 
Uncharacterized protein  GN=FUBP1 PE=2 
SV=1;Uncharacterized protein  GN=FUBP1 PE=4 
SV=1;Uncharacterized protein  GN=FUBP1 PE=4 
SV=1;>sp|Q96 
5.104 5.499 NaN 1.596 1.244 1.271 53.361 12.214 NaN 
Ras-related C3 botulinum toxin substrate 1 (Rho family, 
small GTP binding protein Rac1)  GN=RAC1 PE=2 
SV=1;Isoform B of Ras-related C3 botulinum toxin 
substrate 1  GN=RAC1;>tr|A4 
NaN NaN NaN 1.596 0.910 0.314 NaN NaN NaN 
Heat shock cognate 71 kDa protein  GN=HSPA8 PE=1 
SV=1;Uncharacterized protein  GN=HSPA8 PE=3 
SV=1;Uncharacterized protein  GN=HSPA8 PE=3 SV= 
1.743 1.704 1.786 1.584 1.730 1.684 0.417 0.539 0.520 
Isoform Short of 14-3-3 protein beta/alpha  GN=YWHAB 1.307 1.406 1.379 1.574 1.645 1.723 NaN NaN 2.180 
Peroxiredoxin-5, mitochondrial  GN=PRDX5 PE=1 
SV=4;Isoform Cytoplasmic+peroxisomal of Peroxiredoxin-
5, mitochondrial  GN=PRDX5;Uncharacterized protein 
OS= 
1.499 1.400 1.744 1.559 1.654 1.583 NaN NaN NaN 
Uncharacterized protein  GN=TBCA PE=4 SV=1;Tubulin-
specific chaperone A  GN=TBCA PE=1 
SV=3;Uncharacterized protein  GN=TBCA PE=4 
SV=1;>tr|E5R 
NaN NaN NaN 1.557 NaN 1.885 NaN NaN NaN 
Dihydrolipoyl dehydrogenase, mitochondrial  GN=DLD 
PE=1 SV=2;Uncharacterized protein  GN=DLD PE=4 
SV=1;Dihydrolipoyl dehydrogenase  GN=DLD PE 
NaN NaN NaN 1.543 NaN 1.815 NaN NaN NaN 
Calcyclin-binding protein  GN=CACYBP PE=1 
SV=2;Uncharacterized protein  GN=CACYBP PE=2 
SV=1;Calcyclin binding protein  GN=CACYBP PE=2 SV=1 
NaN NaN 31.838 1.527 1.412 1.447 NaN NaN NaN 
Isoform B of Phosphate carrier protein, mitochondrial  
GN=SLC25A3;Uncharacterized protein  GN=SLC25A3 
PE=3 SV=1;Phosphate carrier protein, mitochondrial OS= 
NaN 3.210 2.861 1.523 NaN NaN 1.338 1.555 1.152 
Non-POU domain-containing octamer-binding protein  
GN=NONO PE=1 SV=4;Uncharacterized protein  
GN=NONO PE=4 SV=1;Uncharacterized protein  GN=N 
1.089 1.622 1.736 1.511 1.408 1.388 NaN NaN NaN 
Polypyrimidine tract binding protein 1  GN=PTBP1 PE=2 
SV=1;Isoform 2 of Polypyrimidine tract-binding protein 1  
GN=PTBP1;Polypyrimidine tract-binding prot 
1.485 1.530 1.579 1.466 1.656 1.602 NaN 6.379 2.533 
Transmembrane emp24 domain-containing protein 10  1.409 1.260 1.245 1.436 1.149 1.510 NaN NaN NaN 
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GN=TMED10 PE=1 SV=2;Uncharacterized protein  
GN=TMED10 PE=3 SV=1 
ATP synthase subunit b, mitochondrial  GN=ATP5F1 PE=1 
SV=2;ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit B1  GN=ATP5F1 PE=2 SV=1 
1.466 1.794 1.726 1.434 1.429 1.582 0.070 0.052 0.040 
Hypoxia up-regulated protein 1  GN=HYOU1 PE=1 
SV=1;Uncharacterized protein  GN=HYOU1 PE=3 
SV=1;Uncharacterized protein  GN=HYOU1 PE=3 SV=1;> 
0.806 1.118 0.658 1.432 1.037 1.350 NaN NaN NaN 
X-ray repair cross-complementing protein 6  GN=XRCC6 
PE=1 SV=2;Uncharacterized protein  GN=XRCC6 PE=2 
SV=1;Uncharacterized protein  GN=XRCC6 
1.298 1.433 1.282 1.427 1.233 1.143 NaN NaN NaN 
Proteasome subunit beta type-6  GN=PSMB6 PE=1 SV=4 NaN NaN NaN 1.423 6.133 1.843 NaN NaN NaN 
6-phosphofructokinase type C  GN=PFKP PE=1 SV=2;6-
phosphofructokinase  GN=PFKP PE=2 SV=1 
NaN NaN NaN 1.422 NaN NaN 0.046 0.035 0.079 
Heat shock 70 kDa protein 4  GN=HSPA4 PE=1 
SV=4;Uncharacterized protein  GN=HSPA4 PE=3 SV=1 
NaN 0.942 NaN 1.406 NaN NaN NaN NaN NaN 
Voltage-dependent anion-selective channel protein 1  
GN=VDAC1 PE=1 SV=2;Uncharacterized protein  
GN=VDAC1 PE=4 SV=1;Uncharacterized protein  
2.154 2.262 2.526 1.400 1.717 1.585 NaN NaN NaN 
Archain 1, isoform CRA_a  GN=ARCN1 PE=4 
SV=1;Coatomer subunit delta  GN=ARCN1 PE=1 
SV=1;Uncharacterized protein  GN=ARCN1 PE=4 SV=1 
NaN 0.899 NaN 1.399 1.754 NaN NaN NaN NaN 
ATP synthase subunit beta, mitochondrial  GN=ATP5B 
PE=1 SV=3;ATP synthase subunit beta  GN=ATP5B PE=3 
SV=1 
1.759 2.023 1.890 1.390 1.522 1.575 1.765 2.014 1.918 
Malate dehydrogenase, mitochondrial  GN=MDH2 PE=1 
SV=3;Uncharacterized protein  GN=MDH2 PE=3 
SV=1;Malate dehydrogenase  GN=MDH2 PE=3 SV=1 
1.581 1.440 1.380 1.345 1.615 1.491 NaN NaN NaN 
CD44 antigen  GN=CD44 PE=1 SV=3;Isoform 5 of CD44 
antigen  GN=CD44;Uncharacterized protein  GN=CD44 
PE=4 SV=2;Isoform 
1.999 1.842 NaN 1.336 1.191 1.255 NaN NaN NaN 
Heterogeneous nuclear ribonucleoprotein D0  
GN=HNRNPD PE=1 SV=1;Isoform 3 of Heterogeneous 
nuclear ribonucleoprotein D0  
GN=HNRNPD;Uncharacterized protein 
1.787 2.119 NaN 1.333 2.586 1.188 NaN NaN NaN 
Obg-like ATPase 1  GN=OLA1 PE=1 SV=2;Isoform 3 of 
Obg-like ATPase 1  GN=OLA1;Isoform 2 of Obg-like 
ATPase 1  GN=OLA1; 
1.170 1.167 1.406 1.296 1.314 3.171 NaN NaN NaN 
Isoform 2 of Vesicle-associated membrane protein-
associated protein A  GN=VAPA;Vesicle-associated 
membrane protein-associated protein A  GN=VAPA PE=1 
SV=3 
NaN 2.034 1.971 1.294 1.392 1.886 NaN NaN NaN 
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Peptidyl-prolyl cis-trans isomerase A  GN=PPIA PE=1 
SV=2;Peptidyl-prolyl cis-trans isomerase  GN=PPIA PE=2 
SV=1;Peptidylprolyl isomerase A (Cyclophilin A) O 
1.344 1.315 1.456 1.293 1.318 1.337 1.511 2.591 10.490 
78 kDa glucose-regulated protein  GN=HSPA5 PE=1 SV=2 1.211 1.243 1.327 1.283 1.368 1.291 0.788 0.876 0.704 
14-3-3 protein zeta/delta  GN=YWHAZ PE=1 
SV=1;Uncharacterized protein  GN=YWHAZ PE=3 
SV=1;Uncharacterized protein  GN=YWHAZ PE=2 
SV=1;>tr|E7 
1.443 1.488 1.410 1.261 1.525 1.404 0.604 0.453 0.428 
Prohibitin-2  GN=PHB2 PE=1 SV=2;Uncharacterized 
protein  GN=PHB2 PE=4 SV=1;Uncharacterized protein  
GN=PHB2 PE=2 SV=1;>tr|F5GWA7|F5GWA7_HUMAN 
2.727 2.849 2.704 1.258 1.382 1.286 3.289 3.742 3.970 
Heterogeneous nuclear ribonucleoprotein U  
GN=HNRNPU PE=1 SV=6;Isoform Short of Heterogeneous 
nuclear ribonucleoprotein U  
GN=HNRNPU;Uncharacterized prote 
0.584 1.111 1.412 1.255 1.424 1.267 0.182 0.190 0.052 
Peptidyl-prolyl cis-trans isomerase B  GN=PPIB PE=1 SV=2 1.196 1.294 1.265 1.248 1.261 1.235 NaN NaN NaN 
Chloride intracellular channel protein 1  GN=CLIC1 PE=1 
SV=4 
0.936 1.009 0.447 1.228 1.241 1.300 2.302 1.983 NaN 
Ras-related protein Rab-6A  GN=RAB6A PE=1 
SV=3;Isoform 2 of Ras-related protein Rab-6A  
GN=RAB6A;Ras-related protein Rab-6B  GN=RAB6B PE=1 
S 
0.958 NaN NaN 1.203 1.257 1.379 0.533 0.577 0.445 
Eukaryotic translation initiation factor 6  GN=EIF6 PE=1 
SV=1;Eukaryotic translation initiation factor 6  GN=EIF6 
PE=3 SV=1 
NaN NaN NaN 1.198 NaN 1.422 NaN NaN NaN 
Heat shock 70 kDa protein 6  GN=HSPA6 PE=1 
SV=2;Uncharacterized protein  GN=HSPA6 PE=2 
SV=1;Putative heat shock 70 kDa protein 7  GN=HSPA7 
PE 
1.191 1.232 1.302 1.197 1.213 1.293 NaN 0.917 NaN 
Nucleoside diphosphate kinase  GN=NME1-NME2 PE=2 
SV=1;Isoform 3 of Nucleoside diphosphate kinase B  
GN=NME2;Nucleoside diphosphate kinase B   
1.158 1.329 1.222 1.195 1.020 1.125 NaN NaN NaN 
Transitional endoplasmic reticulum ATPase  GN=VCP 
PE=1 SV=4 
1.304 1.385 1.422 1.186 NaN NaN 1.435 1.471 1.221 
Annexin A5  GN=ANXA5 PE=1 SV=2;Uncharacterized 
protein  GN=ANXA5 PE=3 SV=1;Uncharacterized protein  
GN=ANXA5 PE=3 SV=1;>tr|D6RBE9|D6RBE9_HUM 
1.149 1.220 1.211 1.178 1.159 1.185 NaN NaN NaN 
Uncharacterized protein  GN=GDI2 PE=4 SV=1;Rab GDP 
dissociation inhibitor beta  GN=GDI2 PE=1 SV=2;GDP 
dissociation inhibitor 2  GN=GDI2 PE=2  
0.706 0.626 0.967 1.170 0.975 0.954 NaN NaN NaN 
Tubulin beta-6 chain  GN=TUBB6 PE=1 
SV=1;Uncharacterized protein  GN=TUBB6 PE=2 
20.213 0.834 3.256 1.169 NaN NaN 1.550 NaN NaN 
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SV=1;Tubulin, beta 6, isoform CRA_a  GN=TUBB6 PE=2 
SV=1 
Heterogeneous nuclear ribonucleoprotein A1  
GN=HNRNPA1 PE=1 SV=5;Uncharacterized protein  
GN=HNRNPA1 PE=4 SV=1;Uncharacterized protein  
GN=HN 
1.149 1.164 1.210 1.156 1.151 1.161 NaN NaN NaN 
Uncharacterized protein  GN=EEF1D PE=3 SV=1;Isoform 2 
of Elongation factor 1-delta  GN=EEF1D;Elongation factor 
1-delta  GN=EEF1D PE=1 SV=5;>t 
0.480 0.274 0.051 1.143 1.163 1.279 2.638 3.446 2.404 
Ras-related protein Rab-1B  GN=RAB1B PE=1 SV=1;Ras-
related protein Rab-1A  GN=RAB1A PE=1 SV=3;Putative 
Ras-related protein Rab-1C  GN=RAB1C PE 
3.926 1.962 4.427 1.139 4.516 6.406 0.497 0.218 0.271 
Vesicle-trafficking protein SEC22b  GN=SEC22B PE=1 
SV=4 
0.893 1.166 2.299 1.132 1.159 1.211 NaN NaN NaN 
Far upstream element-binding protein 2  GN=KHSRP 
PE=1 SV=4;Isoform 2 of Far upstream element-binding 
protein 2  GN=KHSRP;Uncharacterized protein OS=Homo 
s 
NaN NaN NaN 1.099 5.458 0.480 NaN NaN NaN 
Uncharacterized protein  GN=EIF4G1 PE=4 
SV=1;Eukaryotic translation initiation factor 4 gamma 1  
GN=EIF4G1 PE=1 SV=4;Uncharacterized protein 
OS=Homo sapien 
NaN NaN NaN 1.078 NaN NaN NaN NaN NaN 
Uncharacterized protein  GN=CYB5R3 PE=2 SV=1;NADH-
cytochrome b5 reductase 3  GN=CYB5R3 PE=1 
SV=3;Isoform 2 of NADH-cytochrome b5 reductase 3 
OS=Homo sapie 
1.113 1.202 1.238 1.061 1.235 1.225 NaN NaN NaN 
Isoform 2 of Tropomyosin alpha-3 chain  
GN=TPM3;Tropomyosin 3  GN=TPM3 PE=2 
SV=1;Tropomyosin 3  GN=TPM3 PE=2 SV=1;I 
0.834 0.811 0.946 1.045 0.904 1.156 NaN NaN NaN 
Proteasome subunit beta type-1  GN=PSMB1 PE=1 SV=2 NaN NaN NaN 1.033 0.972 NaN NaN NaN NaN 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-1  GN=GNB1 PE=1 SV=3;Guanine nucleotide 
binding protein (G protein), beta polypeptide 1 
(Fragment)  GN=GNB1 PE=4 SV=1 
NaN 1.402 1.241 1.019 2.375 1.092 0.312 0.270 NaN 
Calreticulin  GN=CALR PE=1 SV=1;Uncharacterized 
protein  GN=CALR PE=2 SV=1 
0.927 0.829 0.941 1.014 1.060 0.978 NaN NaN NaN 
Adenylyl cyclase-associated protein 1  GN=CAP1 PE=1 
SV=5;Isoform 2 of Adenylyl cyclase-associated protein 1  
GN=CAP1;Adenylyl cyclase-associated protein OS= 
0.956 1.099 1.040 1.007 0.255 1.176 NaN NaN NaN 
Heat shock protein HSP 90-beta  GN=HSP90AB1 PE=1 
SV=4;Putative heat shock protein HSP 90-beta-3  
GN=HSP90AB3P PE=5 SV=1 
1.160 1.304 1.269 1.004 0.979 0.998 0.194 0.174 0.120 
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Actinin alpha 1 isoform b  GN=ACTN1 PE=2 SV=1;Alpha-
actinin-1  GN=ACTN1 PE=1 SV=2;Isoform 2 of Alpha-
actinin-1  GN=ACTN1;>tr|B7TY16|B7TY16_ 
1.052 1.100 0.695 0.993 0.956 1.007 NaN NaN NaN 
Trans-Golgi network integral membrane protein 2  
GN=TGOLN2 PE=1 SV=2;Uncharacterized protein  
GN=TGOLN2 PE=4 SV=1;Isoform TGN48 of Trans-Golgi 
network int 
0.137 0.772 NaN 0.992 0.973 1.069 NaN NaN NaN 
Ezrin  GN=EZR PE=1 SV=4;Uncharacterized protein  
GN=EZR PE=4 SV=2 
0.447 1.045 0.461 0.986 0.941 1.096 NaN NaN NaN 
Glyceraldehyde-3-phosphate dehydrogenase  
GN=GAPDH PE=1 SV=3;Glyceraldehyde-3-phosphate 
dehydrogenase  GN=GAPDH PE=3 SV=1;Glyceraldehyde-
3-phosphate dehydrog 
1.510 1.534 1.560 0.985 1.445 1.442 0.970 1.629 0.598 
Cytoskeleton-associated protein 4  GN=CKAP4 PE=1 SV=2 1.009 0.952 0.915 0.982 0.982 1.053 NaN NaN NaN 
Uncharacterized protein  GN=EEF1G PE=2 
SV=1;Elongation factor 1-gamma  GN=EEF1G PE=1 
SV=3;Uncharacterized protein  GN=EEF1G PE=2 
SV=1;>tr|E7E 
0.884 0.806 0.847 0.982 0.884 0.912 1.529 3.332 2.414 
Lysosome-associated membrane glycoprotein 1  
GN=LAMP1 PE=1 SV=3;Uncharacterized protein  
GN=LAMP1 PE=2 SV=1 
1.165 1.449 1.596 0.974 0.973 0.958 NaN NaN NaN 
Calnexin  GN=CANX PE=1 SV=2;Uncharacterized protein  
GN=CANX PE=2 SV=1 
0.708 0.726 0.701 0.969 0.768 0.773 NaN NaN 1.370 
Hepatoma-derived growth factor-related protein 2  
GN=HDGFRP2 PE=1 SV=1;Isoform 2 of Hepatoma-derived 
growth factor-related protein 2  GN=HDGFRP2 
NaN NaN NaN 0.964 0.923 NaN NaN NaN NaN 
Poly(RC) binding protein 2  GN=PCBP2 PE=2 
SV=1;Poly(rC)-binding protein 2  GN=PCBP2 PE=1 
SV=1;Poly(RC) binding protein 2, isoform CRA_b  GN= 
0.671 0.175 0.535 0.956 0.902 1.116 0.619 NaN NaN 
Putative heat shock protein HSP 90-beta 4  
GN=HSP90AB4P PE=5 SV=1 
1.531 1.563 1.549 0.941 1.022 0.967 0.475 0.638 0.438 
Uncharacterized protein  GN=CALM1 PE=4 
SV=1;Calmodulin  GN=CALM1 PE=1 
SV=2;Uncharacterized protein  GN=CALM2 PE=4 
SV=1;>tr|Q96HY3|Q96HY3_HUMA 
NaN 0.606 NaN 0.930 0.848 1.059 NaN NaN NaN 
Polyubiquitin-C  GN=UBC PE=1 SV=2;Uncharacterized 
protein  GN=UBC PE=4 SV=1;Uncharacterized protein  
GN=UBC PE=4 SV=1; 
1.192 1.284 1.277 0.923 1.069 0.951 0.644 0.442 0.464 
Peroxiredoxin-1  GN=PRDX1 PE=1 SV=1 0.864 0.865 0.911 0.917 0.964 0.974 1.373 1.600 1.244 
Talin-1  GN=TLN1 PE=1 SV=3;Talin 1  GN=TLN1 PE=2 SV=1 0.767 0.709 0.886 0.909 0.868 0.931 5.073 1.413 NaN 
Malate dehydrogenase  GN=MDH1 PE=3 SV=1;Malate 0.850 NaN 0.175 0.909 1.039 1.015 NaN NaN NaN 
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dehydrogenase, cytoplasmic  GN=MDH1 PE=1 
SV=4;Malate dehydrogenase  GN=MDH1 PE=2 
SV=1;>tr|B9A0 
Actin, cytoplasmic 2  GN=ACTG1 PE=1 
SV=1;Uncharacterized protein  GN=ACTG1 PE=3 SV=1 
0.944 0.937 0.965 0.901 0.917 0.964 1.130 1.449 1.208 
Peroxiredoxin-6  GN=PRDX6 PE=1 SV=3 0.800 0.824 0.775 0.897 0.835 0.794 NaN NaN NaN 
Nuclear migration protein nudC  GN=NUDC PE=1 SV=1 NaN NaN NaN 0.894 1.060 NaN NaN NaN NaN 
Heterogeneous nuclear ribonucleoprotein H  
GN=HNRNPH1 PE=1 SV=4;Uncharacterized protein  
GN=HNRNPH1 PE=4 SV=1;Heterogeneous nuclear 
ribonucleoprotein H2 OS= 
1.394 1.385 1.444 0.894 0.970 0.953 NaN NaN NaN 
40S ribosomal protein S8  GN=RPS8 PE=1 
SV=2;Ribosomal protein S8  GN=RPS8 PE=4 SV=1 
26.144 NaN 0.894 0.888 NaN NaN 0.144 0.031 0.019 
60S acidic ribosomal protein P2  GN=RPLP2 PE=1 SV=1 NaN NaN NaN 0.867 1.049 NaN NaN NaN NaN 
Protein SET  GN=SET PE=1 SV=3;Isoform 2 of Protein SET  
GN=SET;SET nuclear oncogene  GN=SET PE=2 
SV=2;Uncharacterized p 
0.979 0.734 1.873 0.865 0.949 0.890 NaN NaN NaN 
Rho GDP-dissociation inhibitor 1  GN=ARHGDIA PE=1 
SV=3;Uncharacterized protein  GN=ARHGDIA PE=2 SV=2 
NaN 0.782 0.790 0.861 0.773 1.106 NaN NaN NaN 
Calponin-3  GN=CNN3 PE=1 SV=1;Uncharacterized 
protein  GN=CNN3 PE=4 SV=1 
NaN 0.932 NaN 0.860 0.881 0.990 NaN NaN NaN 
Protein disulfide-isomerase A3  GN=PDIA3 PE=1 
SV=4;Protein disulfide isomerase family A, member 3, 
isoform CRA_b  GN=PDIA3 PE=4 SV=1;Uncharacterized 
protei 
0.904 0.802 0.890 0.849 0.859 0.925 4400.600 3531.000 NaN 
Phosphoglycerate kinase 1  GN=PGK1 PE=1 
SV=3;Phosphoglycerate kinase  GN=PGK1 PE=2 
SV=1;Phosphoglycerate kinase  GN=PGK1 PE=2 
SV=1;>tr|E7ERH5 
0.779 0.902 1.012 0.847 0.936 0.900 NaN NaN NaN 
Superoxide dismutase [Cu-Zn]  GN=SOD1 PE=1 
SV=2;Uncharacterized protein  GN=SOD1 PE=4 SV=1 
1.013 1.066 1.072 0.838 0.967 NaN NaN NaN NaN 
Staphylococcal nuclease domain-containing protein 1  
GN=SND1 PE=1 SV=1;Uncharacterized protein  GN=SND1 
PE=4 SV=2 
NaN 0.715 NaN 0.832 NaN 0.772 NaN NaN NaN 
Uncharacterized protein  GN=VDAC3 PE=4 SV=1;Isoform 
2 of Voltage-dependent anion-selective channel protein 
3  GN=VDAC3;Voltage-dependent anion-selective c 
NaN NaN NaN 0.825 NaN 0.801 0.112 0.133 NaN 
Thioredoxin domain-containing protein 5  GN=TXNDC5 
PE=1 SV=2;TXNDC5 protein  GN=TXNDC5 PE=2 
SV=1;HCG1811539, isoform CRA_b  GN=MUTED PE=2 SV 
0.128 0.680 NaN 0.808 0.781 0.712 NaN NaN NaN 
Hypoxanthine-guanine phosphoribosyltransferase  NaN NaN NaN 0.805 0.684 NaN NaN NaN NaN 
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GN=HPRT1 PE=1 SV=2 
Histone H3.2  GN=HIST2H3A PE=1 SV=3 0.710 0.740 0.761 0.798 0.770 0.691 NaN NaN NaN 
Uncharacterized protein  GN=CDC42 PE=3 SV=1;Cell 
division control protein 42 homolog  GN=CDC42 PE=1 
SV=2 
0.364 0.171 0.888 0.796 0.856 0.817 0.848 1.127 0.585 
Isoform 2 of Eukaryotic translation initiation factor 5A-1  
GN=EIF5A;Eukaryotic translation initiation factor 5A-1  
GN=EIF5A PE=1 SV=2;Eukaryotic translati 
0.661 0.177 NaN 0.792 0.786 0.808 NaN NaN NaN 
Uncharacterized protein  GN=CFL1 PE=4 SV=1;Cofilin-1  
GN=CFL1 PE=1 SV=3;Uncharacterized protein  GN=CFL1 
PE=4 SV=1;Co 
0.953 0.955 0.971 0.792 0.878 0.871 1.820 2.086 1.932 
60S ribosomal protein L6  GN=RPL6 PE=1 SV=3;60S 
ribosomal protein L6  GN=RPL6 PE=3 SV=1 
1.244 1.443 1.395 0.788 0.341 0.292 0.090 0.061 0.023 
Filamin-A  GN=FLNA PE=1 SV=4;Isoform 2 of Filamin-A  
GN=FLNA;Filamin A, alpha (Actin binding protein 280)  
GN=FLNA PE=2 SV=1;>tr|A6NDY9|A6NDY 
0.748 0.675 0.714 0.777 0.821 0.828 1.234 1.470 1.270 
RAN, member RAS oncogene family, isoform CRA_c  
GN=RAN PE=4 SV=1;GTP-binding nuclear protein Ran  
GN=RAN PE=1 SV=3;Uncharacterized protein  GN 
NaN 0.811 0.741 0.777 0.593 0.737 0.277 0.257 0.292 
T-complex protein 1 subunit delta  GN=CCT4 PE=1 
SV=4;T-complex protein 1 subunit delta  GN=CCT4 PE=3 
SV=1;T-complex protein 1 subunit delta   
NaN 0.895 0.953 0.770 0.753 0.719 0.192 0.263 0.097 
T-complex protein 1 subunit beta  GN=CCT2 PE=1 
SV=4;Uncharacterized protein  GN=CCT2 PE=3 
SV=2;Chaperonin containing TCP1, subunit 2 (Beta), 
isoform CRA_c O 
0.451 0.468 0.355 0.766 0.962 1.904 0.121 0.140 0.127 
Actin, alpha cardiac muscle 1  GN=ACTC1 PE=1 
SV=1;Actin, alpha skeletal muscle  GN=ACTA1 PE=1 
SV=1;Actin, aortic smooth muscle  GN=ACTA2 PE=1 SV= 
0.936 1.000 0.975 0.762 0.861 0.832 1.434 2.910 1.759 
Isoform 2 of Protein disulfide-isomerase A6  
GN=PDIA6;Uncharacterized protein  GN=PDIA6 PE=3 
SV=1;Uncharacterized protein  GN=PDIA6 PE=3 S 
0.784 0.803 0.763 0.761 0.832 0.871 1.600 NaN NaN 
Profilin-1  GN=PFN1 PE=1 SV=2 0.777 0.828 0.821 0.757 0.852 0.872 NaN NaN NaN 
Heterogeneous nuclear ribonucleoprotein Q  
GN=SYNCRIP PE=1 SV=2;Isoform 2 of Heterogeneous 
nuclear ribonucleoprotein Q  GN=SYNCRIP;Isoform 3 of 
Heterogen 
1.218 1.433 1.322 0.755 0.758 0.678 NaN 1.332 0.886 
High mobility group protein B1  GN=HMGB1 PE=1 
SV=3;High-mobility group box 1  GN=HMGB1 PE=2 
SV=1;Uncharacterized protein  GN=HMGB1 PE=4 SV=1 
0.749 0.695 0.926 0.748 0.789 0.781 NaN NaN NaN 
Protein DJ-1  GN=PARK7 PE=1 SV=2 0.706 0.684 0.727 0.733 0.770 0.913 NaN NaN NaN 
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Uncharacterized protein  PE=3 SV=1;40S ribosomal 
protein SA  GN=RPSA PE=1 SV=4;Uncharacterized protein  
GN=RPSA PE=3 SV=1 
0.198 NaN 0.199 0.729 0.804 0.920 NaN NaN NaN 
Proteasome subunit alpha type-5  GN=PSMA5 PE=1 SV=3 NaN NaN NaN 0.727 0.146 NaN NaN NaN NaN 
Lactoylglutathione lyase  GN=GLO1 PE=1 SV=4;Isoform 2 
of Lactoylglutathione lyase  GN=GLO1 
0.730 0.713 0.643 0.723 NaN NaN NaN NaN NaN 
Elongation factor 1-alpha 1  GN=EEF1A1 PE=1 
SV=1;Putative elongation factor 1-alpha-like 3  
GN=EEF1A1P5 PE=5 SV=1;EEF1A1 protein  GN=EEF1A1 P 
0.900 0.887 0.951 0.718 0.727 0.719 0.127 0.124 0.269 
Protein disulfide-isomerase  GN=P4HB PE=1 
SV=3;Uncharacterized protein  GN=P4HB PE=3 
SV=2;Uncharacterized protein  GN=P4HB PE=2 
SV=1;>tr|F5H 
0.651 0.609 0.682 0.702 0.702 0.713 0.139 0.116 0.148 
Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform  GN=PPP2R1A PE=1 
SV=4;Uncharacterized protein  GN=PPP2R1A PE=2 
SV=1;Unchar 
0.724 0.831 0.777 0.691 0.725 0.334 0.582 0.653 0.507 
Histone H4  GN=HIST1H4A PE=1 SV=2 0.767 0.890 0.876 0.690 0.653 0.734 NaN NaN NaN 
Ras-related protein Rap-1b  GN=RAP1B PE=1 
SV=1;Uncharacterized protein  GN=RAP1B PE=2 
SV=1;Uncharacterized protein  GN=RAP1B PE=2 
SV=1;>sp|A 
0.726 0.759 0.699 0.686 0.675 0.699 0.209 0.077 0.231 
Triosephosphate isomerase  GN=TPI1 PE=1 SV=3;Isoform 
2 of Triosephosphate isomerase  
GN=TPI1;Triosephosphate isomerase  GN=TPI1 PE=2 
SV=1 
0.687 0.634 0.639 0.679 0.723 0.716 NaN NaN NaN 
Uncharacterized protein  GN=CAPZB PE=4 SV=1;Capping 
protein (Actin filament) muscle Z-line, beta  GN=CAPZB 
PE=4 SV=1;Isoform 2 of F-actin-capping protein 
0.623 0.693 0.632 0.674 0.779 0.656 NaN NaN NaN 
>P07744 SWISS-PROT:P07744 Tax_Id=10090 
Gene_Symbol=Krt4 Keratin, type II cytoskeletal 4 
0.745 NaN 0.847 0.668 0.587 0.608 1.623 1.785 NaN 
F-actin-capping protein subunit alpha-1  GN=CAPZA1 
PE=1 SV=3 
0.577 NaN NaN 0.650 0.641 0.642 NaN NaN NaN 
Endoplasmin  GN=HSP90B1 PE=1 SV=1;Uncharacterized 
protein  GN=HSP90B1 PE=4 SV=1 
0.757 0.737 0.682 0.639 0.693 0.719 0.272 0.347 0.278 
Keratin, type I cytoskeletal 18  GN=KRT18 PE=1 
SV=2;Uncharacterized protein  GN=KRT18 PE=3 SV=1 
0.722 0.773 0.802 0.635 0.587 0.575 1.650 1.744 0.346 
Phosphoglycerate mutase  PE=3 SV=1;Phosphoglycerate 
mutase 1  GN=PGAM1 PE=1 SV=2 
0.598 0.742 0.661 0.625 0.688 0.714 NaN NaN NaN 
Thioredoxin  GN=TXN PE=1 SV=3;Thioredoxin  GN=TXN 
PE=4 SV=1 
NaN NaN NaN 0.614 NaN 0.612 NaN NaN NaN 
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Adipocyte plasma membrane-associated protein  
GN=APMAP PE=1 SV=2;Isoform 2 of Adipocyte plasma 
membrane-associated protein  GN=APMAP 
0.510 0.517 0.697 0.611 0.835 0.851 NaN NaN NaN 
Ras-related protein Rab-10  GN=RAB10 PE=1 SV=1 NaN 1.116 1.251 0.598 NaN 1.116 NaN 0.370 NaN 
Isocitrate dehydrogenase [NADP] cytoplasmic  GN=IDH1 
PE=1 SV=2 
NaN NaN NaN 0.552 0.483 NaN NaN NaN NaN 
14-3-3 protein theta  GN=YWHAQ PE=1 
SV=1;Uncharacterized protein  GN=YWHAQ PE=2 SV=1 
0.724 0.644 0.751 0.550 0.625 0.644 4.034 44.483 43.599 
Ubiquitin-like modifier-activating enzyme 1  GN=UBA1 
PE=1 SV=3;Uncharacterized protein  GN=UBA1 PE=3 
SV=1;Uncharacterized protein  GN=UBA1 PE 
0.604 0.560 0.519 0.540 0.540 0.557 NaN NaN NaN 
Filamin-C  GN=FLNC PE=1 SV=3;Isoform 2 of Filamin-C  
GN=FLNC 
0.377 0.691 0.705 0.538 NaN NaN 1.132 0.529 NaN 
Elongation factor 2  GN=EEF2 PE=1 SV=4;Uncharacterized 
protein  GN=EEF2 PE=2 SV=1;Uncharacterized protein  
GN=EEF2 PE=4 SV=1;>tr|F5GZG3|F5GZG3 
0.602 0.641 0.624 0.538 0.651 0.654 0.096 0.186 0.191 
Enoyl-CoA delta isomerase 1, mitochondrial  GN=ECI1 
PE=1 SV=1;Isoform 2 of Enoyl-CoA delta isomerase 1, 
mitochondrial  GN=ECI1 
NaN NaN NaN 0.536 0.596 NaN NaN NaN NaN 
Calponin-2  GN=CNN2 PE=1 SV=4;Calponin 2, isoform 
CRA_a  GN=CNN2 PE=2 SV=1;Uncharacterized protein  
GN=CNN2 PE=4 SV=1 
0.688 NaN NaN 0.534 0.568 NaN NaN NaN NaN 
Fructose-bisphosphate aldolase A  GN=ALDOA PE=1 SV=2 0.460 0.524 0.602 0.527 0.535 0.552 NaN NaN NaN 
Histone H2B  GN=HIST2H2BF PE=2 SV=1;Histone H2B  
GN=HIST2H2BF PE=2 SV=1;Histone H2B type 1-K   
0.770 0.739 0.698 0.513 0.588 NaN NaN 0.735 0.568 
Uncharacterized protein  GN=PSME2 PE=4 
SV=1;Uncharacterized protein  GN=PSME2 PE=4 
SV=1;Proteasome activator complex subunit 2   
0.615 0.562 0.281 0.501 0.545 0.570 NaN NaN NaN 
Peptidyl-prolyl cis-trans isomerase FKBP4  GN=FKBP4 
PE=1  
0.543 0.504 NaN 0.498 0.505 0.490 NaN NaN NaN 
Isoform 2 of Heterogeneous nuclear ribonucleoprotein 
A/B  GN=HNRNPAB;Uncharacterized protein  
GN=HNRNPAB PE=4 SV=1;Isoform 3 of Heterogeneous 
nuclear ribo 
0.787 0.849 NaN 0.497 0.635 NaN NaN NaN NaN 
Spectrin alpha chain, brain  GN=SPTAN1 PE=1 
SV=3;Uncharacterized protein  GN=SPTAN1 PE=4 
SV=1;Isoform 3 of Spectrin alpha chain, brain  GN= 
0.226 0.552 0.556 0.493 0.480 0.460 NaN NaN NaN 
14-3-3 protein gamma  GN=YWHAG PE=1 
SV=2;Uncharacterized protein  GN=YWHAG PE=2 
SV=1;Uncharacterized protein  GN=YWHAG PE=2 SV=1 
0.468 0.459 0.506 0.485 0.464 0.407 0.047 0.035 0.033 
Tubulin alpha-1B chain  GN=TUBA1B PE=1 SV=1;Tubulin 
alpha-4A chain  GN=TUBA4A PE=1 
0.682 0.739 0.727 0.479 0.516 0.398 0.182 0.210 0.126 
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SV=1;>tr|A8MUB1|A8M 
Nuclease-sensitive element-binding protein 1  GN=YBX1 
PE=1 SV=3;Uncharacterized protein  GN=YBX1 PE=4 
SV=1;Y-box-binding protein 2  GN=YBX2 P 
NaN NaN NaN 0.471 0.462 NaN NaN NaN NaN 
Tropomyosin 1 (Alpha) isoform 5  GN=TPM1 PE=3 
SV=1;Isoform 3 of Tropomyosin alpha-1 chain  
GN=TPM1;Isoform 4 of Tropomyosin alpha-1 chain   
NaN NaN NaN 0.469 NaN 0.376 NaN NaN NaN 
GTP-binding protein SAR1a  GN=SAR1A PE=1 SV=1;GTP-
binding protein SAR1b  GN=SAR1B PE=1 
SV=1;Uncharacterized protein  GN=SAR1B PE=3 
SV=1;>tr|B 
NaN NaN NaN 0.456 0.452 NaN NaN NaN NaN 
Glucose-6-phosphate isomerase  GN=GPI PE=1 
SV=4;Glucose-6-phosphate isomerase  GN=GPI PE=2 
SV=1 
0.441 0.421 0.288 0.450 0.403 0.388 NaN NaN NaN 
Brain acid soluble protein 1  GN=BASP1 PE=1 
SV=2;Isoform 2 of Brain acid soluble protein 1  
GN=BASP1 
0.520 0.513 0.526 0.450 0.567 0.508 NaN NaN NaN 
Alpha-enolase  GN=ENO1 PE=1 SV=2 0.345 0.263 0.434 0.444 0.456 0.486 3.209 4.855 4.346 
Uncharacterized protein  GN=KRT8 PE=3 SV=1;Keratin, 
type II cytoskeletal 8  GN=KRT8 PE=1 SV=7 
0.539 0.562 0.567 0.415 0.307 0.384 1.484 1.834 0.253 
Pyruvate kinase isozymes M1/M2  GN=PKM2 PE=1 
SV=4;Isoform M1 of Pyruvate kinase isozymes M1/M2  
GN=PKM2;Pyruvate kinase  GN=PKM2 PE=3 SV=1;>t 
0.578 0.620 0.629 0.403 0.339 0.460 0.539 0.670 0.528 
Macrophage migration inhibitory factor  GN=MIF PE=1 
SV=4 
NaN 0.089 0.093 0.388 0.400 0.437 NaN NaN NaN 
Isoform 2 of Stathmin  GN=STMN1;Stathmin  GN=STMN1 
PE=1 SV=3;Stathmin (Fragment)  GN=STMN1 PE=3 SV=1 
NaN NaN 0.492 0.382 0.334 NaN NaN NaN NaN 
Transgelin-2  GN=TAGLN2 PE=1 SV=3 0.342 0.369 0.373 0.380 0.401 0.260 NaN NaN NaN 
Tubulin beta-4B chain  GN=TUBB4B PE=1 SV=1 0.726 0.744 0.788 0.377 0.324 0.267 0.269 0.228 0.169 
Lamina-associated polypeptide 2, isoform alpha  
GN=TMPO PE=1 SV=2;Lamina-associated polypeptide 2, 
isoforms beta/gamma  GN=TMPO PE=1 
SV=2;Thymopoietin, isof 
0.311 NaN NaN 0.368 0.187 0.354 NaN NaN NaN 
Heat shock 70 kDa protein 1A/1B  GN=HSPA1A PE=1 
SV=5;Uncharacterized protein  GN=HSPA1B PE=3 
SV=1;Uncharacterized protein  GN=HSPA1A PE=3 SV 
0.250 0.119 0.367 0.368 0.340 0.350 NaN NaN NaN 
Lamin-B1  GN=LMNB1 PE=1 SV=2;Uncharacterized 
protein   
0.345 0.322 0.082 0.364 0.367 0.415 0.103 NaN NaN 
Vinculin  GN=VCL PE=1 SV=4;Isoform 1 of Vinculin  
GN=VCL;Uncharacterized protein  GN=VCL PE=4 SV=1 
0.380 0.374 0.364 0.362 0.376 0.370 NaN NaN NaN 
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Uncharacterized protein  GN=MYL6 PE=2 SV=1;Myosin, 
light polypeptide 6, alkali, smooth muscle and non-
muscle, isoform CRA_c  GN=MYL6 PE=4 SV=1;Myosin 
light  
0.475 0.525 0.509 0.360 0.400 0.375 0.958 0.996 0.152 
UV excision repair protein RAD23 homolog B  
GN=RAD23B PE=1 SV=1;RAD23 homolog B (S. cerevisiae), 
isoform CRA_a  GN=RAD23B PE=4 SV=1;Uncharacterized 
protein 
0.667 NaN 0.726 0.343 0.828 0.802 NaN NaN NaN 
Tubulin beta chain  GN=TUBB PE=1 
SV=2;Uncharacterized protein  GN=TUBB PE=3 
SV=1;Uncharacterized protein  GN=TUBB PE=3 
SV=1;>tr|Q5JP53|Q5JP53 
0.660 0.649 0.673 0.294 0.528 NaN 0.243 0.312 0.187 
Histone H2A type 2-A  GN=HIST2H2AA3 PE=1 
SV=3;Histone H2A type 2-C  GN=HIST2H2AC PE=1 SV=4 
0.661 0.744 0.662 0.293 0.120 NaN NaN NaN NaN 
Protein disulfide-isomerase A4  GN=PDIA4 PE=1 SV=2 0.319 0.270 0.320 0.287 0.283 0.285 NaN NaN NaN 
L-lactate dehydrogenase A chain  GN=LDHA PE=1 SV=2;L-
lactate dehydrogenase  GN=LDHA PE=3 SV=2;Isoform 2 
of L-lactate dehydrogenase A chain  G 
0.655 0.701 0.820 0.282 0.507 0.124 0.463 0.394 0.236 
Proliferating cell nuclear antigen  GN=PCNA PE=1 SV=1 0.381 0.523 0.630 0.249 0.129 0.533 0.543 NaN NaN 
Vigilin  GN=HDLBP PE=1 SV=2;Uncharacterized protein  
GN=HDLBP PE=4 SV=1;Uncharacterized protein  
GN=HDLBP PE=4 SV=1 
NaN NaN NaN 0.223 0.195 NaN NaN NaN NaN 
Glutathione S-transferase P  GN=GSTP1 PE=1 
SV=2;Uncharacterized protein  GN=GSTP1 PE=3 SV=1 
0.214 0.261 0.267 0.212 0.272 0.075 NaN NaN NaN 
Ribonucleoside-diphosphate reductase large subunit  
GN=RRM1 PE=1 SV=1;Ribonucleoside-diphosphate 
reductase  GN=RRM1 PE=3 SV=2;Uncharacterized 
protein OS=Hom 
NaN NaN NaN 0.211 NaN NaN NaN NaN NaN 
Spectrin beta chain, brain 1  GN=SPTBN1 PE=1 
SV=2;Isoform Short of Spectrin beta chain, brain 1  
GN=SPTBN1;Isoform 2 of Spectrin beta chain, brain 1 
OS=H 
0.237 0.131 0.599 0.198 0.387 0.315 NaN NaN NaN 
Na(+)/H(+) exchange regulatory cofactor NHE-RF1  
GN=SLC9A3R1 PE=1 SV=4;Uncharacterized protein  
GN=SLC9A3R1 PE=4 SV=1 
NaN NaN NaN 0.196 0.215 NaN NaN NaN NaN 
Isoform 3 of Nuclear autoantigenic sperm protein  
GN=NASP;Nuclear autoantigenic sperm protein  
GN=NASP PE=1 SV=2;Uncharacterized protein  GN= 
NaN 0.130 NaN 0.182 0.242 0.366 NaN NaN NaN 
Peptidyl-prolyl cis-trans isomerase FKBP1A  GN=FKBP1A 
PE=1 SV=2;FK506 binding protein 1A, 12kDa  GN=FKBP1A 
PE=2 SV=1;FK506 binding protein12 OS=Homo sapien 
NaN NaN NaN 0.172 NaN 0.209 NaN NaN NaN 
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Caldesmon  GN=CALD1 PE=1 SV=3;Isoform 2 of 
Caldesmon  GN=CALD1;Uncharacterized protein  
GN=CALD1 PE=2 SV=1;Isoform 
NaN NaN NaN 0.159 NaN 0.102 NaN NaN NaN 
14-3-3 protein epsilon  GN=YWHAE PE=1 SV=1;Isoform 
SV of 14-3-3 protein epsilon  GN=YWHAE 
0.047 0.065 0.113 0.147 0.150 0.155 0.024 0.031 0.041 
Myosin-9  GN=MYH9 PE=1 SV=4;Isoform 2 of Myosin-9  
GN=MYH9 
0.550 0.521 0.585 0.134 0.306 0.134 0.444 0.239 0.084 
Uncharacterized protein  PE=4 SV=1;Protein canopy 
homolog 2  GN=CNPY2 PE=1 SV=1;Uncharacterized 
protein  GN=CNPY2 PE=4 SV=1;>tr|F8VP03|F8VP0 
NaN 0.535 0.145 0.133 0.589 NaN NaN NaN NaN 
Ras GTPase-activating-like protein IQGAP1  GN=IQGAP1 
PE=1  
0.435 0.152 0.475 0.102 0.413 0.431 0.102 0.554 0.113 
ADP-ribosylation factor 3  GN=ARF3 PE=1 SV=2;ADP-
ribosylation factor 1  GN=ARF1 PE=1 
SV=2;Uncharacterized protein  GN=ARF3 PE=3 
SV=1;>tr|F5H3A6 
0.663 0.604 NaN 0.102 0.106 0.146 0.223 0.176 0.112 
Lysozyme C  GN=LYZ PE=1 SV=1 NaN NaN NaN 0.095 0.075 NaN 0.073 0.060 0.034 
Uncharacterized protein  GN=B2M PE=3 SV=1;Beta-2-
microglobulin  GN=B2M PE=1 SV=1 
0.093 0.088 0.052 0.091 0.038 0.110 NaN NaN NaN 
Isoform Long of Glucose-6-phosphate 1-dehydrogenase  
GN=G6PD;Isoform 3 of Glucose-6-phosphate 1-
dehydrogenase  GN=G6PD;Glucose-6-phosphate 1-
dehydrogenase O 
NaN NaN NaN 0.089 NaN NaN NaN NaN NaN 
Annexin A11  GN=ANXA11 PE=1 SV=1;Uncharacterized 
protein  GN=ANXA11 PE=2 SV=1;Uncharacterized protein  
GN=ANXA11  
0.362 NaN 0.308 0.089 0.022 0.027 NaN NaN NaN 
Importin subunit beta-1  GN=KPNB1 PE=1 
SV=2;Uncharacterized protein  GN=KPNB1 PE=2 
SV=1;Uncharacterized protein  GN=KPNB1 PE=4 SV=1 
0.551 0.611 0.625 0.088 0.388 0.395 0.490 0.405 0.415 
Serine/arginine-rich splicing factor 2  GN=SRSF2 PE=1 
SV=4;Uncharacterized protein  GN=SRSF2 PE=2 
SV=1;Uncharacterized protein  GN=SRSF2 PE= 
NaN NaN NaN 0.087 0.516 NaN NaN NaN NaN 
Protein FAM3C  GN=FAM3C PE=1 SV=1;Uncharacterized 
protein  GN=FAM3C PE=4 SV=1;Uncharacterized protein   
0.215 0.083 0.094 0.053 NaN NaN NaN NaN NaN 
Uncharacterized protein  GN=HLA-C PE=3 
SV=1;Uncharacterized protein  GN=HLA-C PE=3 
SV=1;Uncharacterized protein  GN=HLA-C PE=3 
SV=1;>tr|A2A 
NaN 0.021 NaN 0.038 0.011 0.013 0.022 NaN NaN 
Glutathione S-transferase Mu 3  GN=GSTM3 PE=1 SV=3 0.132 0.073 NaN 0.028 0.013 0.005 NaN NaN NaN 
Isoform 2 of Tropomyosin beta chain  GN=TPM2;Isoform 
3 of Tropomyosin beta chain  GN=TPM2 
0.025 0.027 0.015 0.026 0.020 0.024 NaN NaN NaN 
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Keratin, type II cytoskeletal 6A  GN=KRT NaN NaN NaN 0.025 NaN NaN NaN 0.050 0.014 
Serpin H1  GN=SERPINH1 PE=1 SV=2;Uncharacterized 
protein  GN=SERPINH1 PE=2 SV=1;Uncharacterized 
protein  GN=SERPINH1 PE=3 SV=1;>tr|E9PR70|E9 
0.020 0.027 0.025 0.025 0.024 0.029 0.129 0.192 0.175 
HLA class I histocompatibility antigen, B-42 alpha chain  
GN=HLA-B PE=1 SV=1;HLA class I histocompatibility 
antigen, B-7 alpha chain  GN=HLA-B PE=1 SV=3;HLA cla 
0.021 0.032 0.016 0.023 0.035 0.052 0.050 NaN NaN 
Keratin, type II cytoskeletal 2 epidermal  GN=KRT2 PE=1 
SV=2;>P35908 SWISS-PROT:P35908 Tax_Id=9606 
Gene_Symbol=KRT2 Keratin, type II cytoskeletal 2 
epidermal 
0.551 0.029 0.631 0.020 0.019 0.013 0.021 0.023 0.020 
Keratin, type I cytoskeletal 16  GN=KRT16 PE=1 SV=4 NaN NaN NaN 0.020 NaN NaN 0.097 0.010 0.036 
60S ribosomal protein L22  GN=RPL22 PE=1 SV=2 1.080 1.220 1.154 0.019 0.014 NaN 0.081 0.090 0.091 
Keratin, type I cytoskeletal 14  GN=KRT14 PE=1 SV=4 0.629 NaN NaN 0.019 0.028 0.136 0.019 0.040 0.015 
Heat shock protein beta-1  GN=HSPB1 PE=1 
SV=2;Uncharacterized protein  GN=HSPB1 PE=2 SV=1 
0.013 0.022 0.026 0.017 0.010 0.017 NaN NaN NaN 
Uncharacterized protein  GN=HLA-A PE=3 SV=2;HLA class 
I histocompatibility antigen, A-3 alpha chain  GN=HLA-A 
PE=1 SV=2;Uncharacterized protein  
0.072 0.038 0.031 0.015 0.020 0.010 0.036 0.044 NaN 
Bovine serum albumin precursor 0.037 0.021 0.024 0.009 0.008 0.011 0.057 0.058 0.046 
Alpha-2-HS-glycoprotein precursor 0.033 0.043 0.067 0.007 0.008 0.004 NaN 0.020 NaN 
Keratin, type II cytoskeletal 1  GN=KRT1 PE=1 
SV=6;>P04264 SWISS-PROT:P04264 Tax_Id=9606 
Gene_Symbol=KRT1 Keratin, type II cytoskeletal 1 
0.021 0.019 0.028 0.006 0.007 0.006 0.011 0.008 0.006 
HLA class I histocompatibility antigen, A-34 alpha chain  
GN=HLA-A PE=1 SV=1;HLA class I histocompatibility 
antigen, A-66 alpha chain  GN=HLA-A PE=2 SV=1;Majo 
NaN NaN NaN 0.006 NaN NaN NaN NaN NaN 
Uncharacterized protein  GN=PRSS1 PE=3 SV=1;Trypsin-1  
GN=PRSS1 PE=1 SV=1;Protea 
0.003 0.010 0.005 0.006 0.002 0.006 0.008 0.028 0.006 
Keratin, type I cytoskeletal 9  GN=KRT9 PE=1 SV=3 0.095 0.034 0.158 0.005 0.007 0.008 0.019 0.029 0.017 
HLA class I histocompatibility antigen, Cw-12 alpha chain  
GN=HLA-C PE=1 SV=2;HLA class I histocompatibility 
antigen, Cw-15 alpha chain  GN=HLA-C PE=1 SV=1;Ma 
NaN 0.064 NaN 0.005 0.017 0.052 NaN NaN NaN 
Cytoplasmic aconitate hydratase  GN=ACO1 PE=1 
SV=3;Iron regulatory protein 1  GN=IRP1 PE=2 SV=1 
NaN NaN NaN 0.004 NaN NaN 0.016 NaN NaN 
Keratin, type I cytoskeletal 10  GN=KRT10 PE=1 SV=6 0.034 0.022 0.006 0.003 0.003 0.004 0.011 0.012 0.009 
Alpha-S1-casein  NaN NaN NaN 0.003 0.026 NaN 0.012 0.013 0.006 
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Ras-related protein Rab-13  GN=RAB13 PE=1 SV=1 NaN NaN NaN 0.003 NaN 0.001 NaN NaN NaN 
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